{"asset": "drug-shortage-duration-tracker", "asset_type": "duration-tracking", "body": "For every package FDA currently lists as in shortage: how long that shortage entry has been open (from openFDA's own `initial_posting_date` to today), what FDA says the package's supply is right now, and any recovery estimate FDA has given. What FDA itself publishes, checked directly on 2026-09-01 rather than assumed: the shortage list page (accessdata.fda.gov/scripts/drugshortages) shows which drugs are short and why and carries no date at all, while each per-drug detail page adds a single 'Date first posted' for the whole drug. Neither prints an elapsed duration, and neither gives the date per manufacturer. openFDA does \u2014 where several manufacturers report a shortage of the same drug, each carries its own posting date, and FDA's page shows only the earliest of them. Cross-checked across 30 drugs against those detail pages: 30 of 30 agreed, and in all 10 multi-manufacturer cases FDA's single date was exactly the earliest of ours. The underlying facts are FDA's own public-domain data; the duration is a computation over them that nobody publishes maintained, because it changes every day and hand-updating it was never worth the effort. A scheduled refetch of the same public API keeps it current for free. Read the duration next to `availability`, and do not read it alone: a shortage entry stays 'Current' until FDA resolves the whole shortage, so 63.8% of listed packages (746 of 1,169, measured 2026-09-01) are marked 'Available' even while their entry has been open for years \u2014 the median entry has been open 1,721 days and 1,118 of 1,169 have been open more than 1,000. Records cite a per-drug, per-manufacturer API query rather than a page offset, because openFDA's result ordering rotates daily and an offset URL stops containing its own record \u2014 see sources.txt. Source: https://api.fda.gov/drug/shortages.json (openFDA, no API key required at this volume). This is a monitored dataset, not a static page \u2014 stale_after_days is short and a build should re-run the fetch on a schedule rather than once.\n", "description": "For every package FDA currently lists as in shortage: how long that shortage entry has been open (from openFDA's own `initial_posting_date` to today), what FDA says the package's supply is right now, and any recovery estimate FDA has given. What FDA itself publishes, checked directly on 2026-09-01 rather than assumed: the shortage list page (accessdata.fda.gov/scripts/drugshortages) shows which drugs are short and why and carries no date at all, while each per-drug detail page adds a single 'Date first posted' for the whole drug. Neither prints an elapsed duration, and neither gives the date per manufacturer. openFDA does \u2014 where several manufacturers report a shortage of the same drug, each carries its own posting date, and FDA's page shows only the earliest of them. Cross-checked across 30 drugs against those detail pages: 30 of 30 agreed, and in all 10 multi-manufacturer cases FDA's single date was exactly the earliest of ours. The underlying facts are FDA's own public-domain data; the duration is a computation over them that nobody publishes maintained, because it changes every day and hand-updating it was never worth the effort. A scheduled refetch of the same public API keeps it current for free. Read the duration next to `availability`, and do not read it alone: a shortage entry stays 'Current' until FDA resolves the whole shortage, so 63.8% of listed packages (746 of 1,169, measured 2026-09-01) are marked 'Available' even while their entry has been open for years \u2014 the median entry has been open 1,721 days and 1,118 of 1,169 have been open more than 1,000. Records cite a per-drug, per-manufacturer API query rather than a page offset, because openFDA's result ordering rotates daily and an offset URL stops containing its own record \u2014 see sources.txt. Source: https://api.fda.gov/drug/shortages.json (openFDA, no API key required at this volume). This is a monitored dataset, not a static page \u2014 stale_after_days is short and a build should re-run the fetch on a schedule rather than once.", "file": "index.md", "generated": true, "harvested": "2026-09-16", "key_field": "package_ndc", "licence": "openFDA drug shortage data is a U.S. government work and is in the public domain. No source-licence question arises; each record still cites the specific API query and retrieval date it came from.", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Ailex%20Pharmaceuticals%22+AND+generic_name%3A%22Cromolyn%20Sodium%20Concentrate%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alembic%20Pharmaceuticals%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22American%20Regent,%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2050%25%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Anthea%20Pharma%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Desmopressin%20Acetate%20Spray%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Armas%20Pharmaceuticals%20Inc%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aspiro%20Pharma%20Limited%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avyxa%20Pharma,%20LLC%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Azurity%20Pharmaceuticals,%20Inc%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2070%25%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2070%25%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Metronidazole%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Bristol%20Myers%20Squibb%20Co.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22BTG%20International%20Inc.%22+AND+generic_name%3A%22Hydroxocobalamin%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Flurazepam%20Hydrochloride%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Cheplapharm%20Arzneimittel%20GmbH%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Cumberland%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Conivaptan%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Curium%20US%20LLC%22+AND+generic_name%3A%22Technetium%20TC-99M%20Pyrophosphate%20Kit%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Dr.%20Reddy%27s%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22EDW%20Pharma,%20Inc.%20(formerly%20Italfarmaco%20Pharma,%20Inc.)%22+AND+generic_name%3A%22Riluzole%20Oral%20Suspension%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22ESTEVE%20PHARMACEUTICALS,%20S.A.%22+AND+generic_name%3A%22Streptozocin%20Powder,%20For%20Solution%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Exela%20Pharma%20Sciences,%20LLC%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fera%20Pharmaceuticals%22+AND+generic_name%3A%22Echothiophate%20Iodide%20Ophthalmic%20Solution%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Ferring%22+AND+generic_name%3A%22Desmopressin%20Acetate%20Spray%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Propranolol%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rifampin%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Valproate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Metronidazole%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Granules%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hainan%20Poly%20Pharm.%20Co.,%20Ltd.%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Cefotaxime%20Sodium%20Powder,%20for%20Solution%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Oral%20Solution%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Propranolol%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Sufentanil%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Valproate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2050%25%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Pentostatin%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sufentanil%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22HQ%20Specialty%20Pharma%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Huons%20Co.,%20Ltd%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Huons%20Co.,%20Ltd.%20(South%20Korea)%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Metronidazole%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Janssen%20Pharmaceuticals%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Jiangsu%20Hengrui%20Pharmaceuticals%20Co.,%20Ltd.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Jiangsu%20Hengrui%20Pharmaceuticals%20Co.%20(US%20Agent%20eVenus%20Pharmaceutical%20Laboratories,%20Inc.)%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Kindos%20Pharmaceuticals%20Co.%20Ltd.%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Laboratorios%20Atral%22+AND+generic_name%3A%22Penicillin%20G%20Benzathine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lifsa%20Drugs%20LLC%22+AND+generic_name%3A%22Isocarboxazid%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Long%20Grove%20Pharmaceuticals%20LLC%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lupin%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lupin%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Medefil,%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Medefil,%20Inc.%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Medexus%22+AND+generic_name%3A%22Triamcinolone%20Hexacetonide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Micro%20Labs%20LTD%22+AND+generic_name%3A%22Cromolyn%20Sodium%20Concentrate%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Milla%20Pharmaceuticals%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mullan%20Pharmaceutical%20Inc.%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Rifampin%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Pharmaceuticals%20Inc.,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Specialty,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Cromolyn%20Sodium%20Concentrate%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Nephron%20Pharmaceuticals%20Corporation%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novadoz%20Pharmaceuticals%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novo%20Nordisk,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22ONESOURCE%20SPECIALTY%20PTE%20LTD%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Oryza%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2070%25%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Padagis%20US%20LLC%22+AND+generic_name%3A%22Bacitracin%20Ophthalmic%20Ointment%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Par%20Health,%20USA%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Par%20Health,%20USA%20LLC%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Penicillin%20G%20Benzathine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Piramal%20Critical%20Care%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Piramal%20Critical%20Care%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rhodes%20Pharmaceuticals%20L.P.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rising%20Pharma%20Holdings,%20Inc.%22+AND+generic_name%3A%22Cromolyn%20Sodium%20Concentrate%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rising%20Pharma%20Holdings,%20Inc.%22+AND+generic_name%3A%22Flurazepam%20Hydrochloride%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sanofi-Aventis%20U.S.%20LLC%22+AND+generic_name%3A%22Rifampin%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Spectra%20Medical%20Devices,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SteriMax,%20Inc.%22+AND+generic_name%3A%22Cefotaxime%20Sodium%20Powder,%20for%20Solution%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SteriMax,%20Inc.%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Technetium%20TC-99M%20Pyrophosphate%20Kit%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sunrise%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydroxocobalamin%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Streptozocin%20Powder,%20For%20Solution%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teyro%20Labs%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Trigen%20Laboratories,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22WG%20Critical%20Care%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22XGen%20Pharmaceuticals%20DJB,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000", "https://api.fda.gov/drug/shortages.json?search=company_name%3A%22XGen%20Pharmaceuticals%20DJB,%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "title": "FDA drug shortage duration tracker", "type": "dataset", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-483-03\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/01/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2435\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2020\", \"package_ndc\": \"16729-483-03\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2435", "dosage_form": "Injection", "file": "accord-healthcare-inc-atropine-sulfate-injection-16729-483-03.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-atropine-sulfate-injection-16729-483-03", "initial_posting_date": "01/01/2020", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-483-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/01/2020\", \"package_ndc\": \"16729-483-03\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "16729-483-03 \u00b7 Atropine Sulfate Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 16729-484-45\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/01/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2435\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2020\", \"package_ndc\": \"16729-484-45\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2435", "dosage_form": "Injection", "file": "accord-healthcare-inc-atropine-sulfate-injection-16729-484-45.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-atropine-sulfate-injection-16729-484-45", "initial_posting_date": "01/01/2020", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-484-45", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"01/01/2020\", \"package_ndc\": \"16729-484-45\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "16729-484-45 \u00b7 Atropine Sulfate Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-484-90\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/01/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2435\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2020\", \"package_ndc\": \"16729-484-90\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2435", "dosage_form": "Injection", "file": "accord-healthcare-inc-atropine-sulfate-injection-16729-484-90.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-atropine-sulfate-injection-16729-484-90", "initial_posting_date": "01/01/2020", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-484-90", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/01/2020\", \"package_ndc\": \"16729-484-90\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "16729-484-90 \u00b7 Atropine Sulfate Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-512-43\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"16729-512-43\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "accord-healthcare-inc-atropine-sulfate-injection-16729-512-43.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-atropine-sulfate-injection-16729-512-43", "initial_posting_date": "01/01/2012", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-512-43", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: TBD", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"16729-512-43\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "16729-512-43 \u00b7 Atropine Sulfate Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-525-08\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: mid-September 2026\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 5366\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"16729-525-08\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: mid-September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5366", "dosage_form": "Injection", "file": "accord-healthcare-inc-atropine-sulfate-injection-16729-525-08-2.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-10", "id": "accord-healthcare-inc-atropine-sulfate-injection-16729-525-08-2", "initial_posting_date": "01/01/2012", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-525-08", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "related_info": "Estimated recovery: mid-September 2026", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"16729-525-08\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: mid-September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "16729-525-08 \u00b7 Atropine Sulfate Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-525-08\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: September 2026\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"16729-525-08\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "accord-healthcare-inc-atropine-sulfate-injection-16729-525-08.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-atropine-sulfate-injection-16729-525-08", "initial_posting_date": "01/01/2012", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-525-08", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "related_info": "Estimated recovery: September 2026", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"16729-525-08\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "16729-525-08 \u00b7 Atropine Sulfate Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-526-08\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"16729-526-08\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "accord-healthcare-inc-atropine-sulfate-injection-16729-526-08.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-atropine-sulfate-injection-16729-526-08", "initial_posting_date": "01/01/2012", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-526-08", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: TBD", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"16729-526-08\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "16729-526-08 \u00b7 Atropine Sulfate Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 16729-306-10\n\n**Generic name:** Azacitidine Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 16729-306-10)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 16729-306-10)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/21/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 16729-306-10)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2080\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 16729-306-10)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 16729-306-10)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/21/2020\", \"package_ndc\": \"16729-306-10\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2080", "dosage_form": "Injection", "file": "accord-healthcare-inc-azacitidine-injection-16729-306-10.md", "generated": true, "generic_name": "Azacitidine Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-azacitidine-injection-16729-306-10", "initial_posting_date": "12/21/2020", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-306-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 16729-306-10)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 16729-306-10)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 16729-306-10)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 16729-306-10)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 16729-306-10)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"12/21/2020\", \"package_ndc\": \"16729-306-10\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "16729-306-10 \u00b7 Azacitidine Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-295-12\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD; NDC is non-exempt\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"16729-295-12\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; NDC is non-exempt\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "accord-healthcare-inc-carboplatin-injection-16729-295-12.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-carboplatin-injection-16729-295-12", "initial_posting_date": "04/28/2023", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-295-12", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD; NDC is non-exempt", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"16729-295-12\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; NDC is non-exempt\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Oncology", "title": "16729-295-12 \u00b7 Carboplatin Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-295-31\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD; NDC is non-exempt\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1228\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"16729-295-31\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; NDC is non-exempt\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1228", "dosage_form": "Injection", "file": "accord-healthcare-inc-carboplatin-injection-16729-295-31-2.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-07", "id": "accord-healthcare-inc-carboplatin-injection-16729-295-31-2", "initial_posting_date": "04/28/2023", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-295-31", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD; NDC is non-exempt", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"16729-295-31\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; NDC is non-exempt\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Oncology", "title": "16729-295-31 \u00b7 Carboplatin Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-295-31\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"16729-295-31\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "accord-healthcare-inc-carboplatin-injection-16729-295-31.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-carboplatin-injection-16729-295-31", "initial_posting_date": "04/28/2023", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-295-31", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"16729-295-31\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "16729-295-31 \u00b7 Carboplatin Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-295-33\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD; NDC is non-exempt\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"16729-295-33\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; NDC is non-exempt\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "accord-healthcare-inc-carboplatin-injection-16729-295-33.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-carboplatin-injection-16729-295-33", "initial_posting_date": "04/28/2023", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-295-33", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD; NDC is non-exempt", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"16729-295-33\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; NDC is non-exempt\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Oncology", "title": "16729-295-33 \u00b7 Carboplatin Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-295-34\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD; NDC is non-exempt\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"16729-295-34\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; NDC is non-exempt\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "accord-healthcare-inc-carboplatin-injection-16729-295-34.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-carboplatin-injection-16729-295-34", "initial_posting_date": "04/28/2023", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-295-34", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD; NDC is non-exempt", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"16729-295-34\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; NDC is non-exempt\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Oncology", "title": "16729-295-34 \u00b7 Carboplatin Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 16729-136-00\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"16729-136-00\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "accord-healthcare-inc-clonazepam-tablet-16729-136-00.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "accord-healthcare-inc-clonazepam-tablet-16729-136-00", "initial_posting_date": "03/10/2023", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-136-00", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"16729-136-00\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "16729-136-00 \u00b7 Clonazepam Tablet \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 16729-136-16\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"16729-136-16\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "accord-healthcare-inc-clonazepam-tablet-16729-136-16.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "accord-healthcare-inc-clonazepam-tablet-16729-136-16", "initial_posting_date": "03/10/2023", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-136-16", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 16729-136-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"16729-136-16\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "16729-136-16 \u00b7 Clonazepam Tablet \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 16729-137-00\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"16729-137-00\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "accord-healthcare-inc-clonazepam-tablet-16729-137-00.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "accord-healthcare-inc-clonazepam-tablet-16729-137-00", "initial_posting_date": "03/10/2023", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-137-00", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"16729-137-00\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "16729-137-00 \u00b7 Clonazepam Tablet \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 16729-137-16\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"16729-137-16\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "accord-healthcare-inc-clonazepam-tablet-16729-137-16.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "accord-healthcare-inc-clonazepam-tablet-16729-137-16", "initial_posting_date": "03/10/2023", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-137-16", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 16729-137-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"16729-137-16\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "16729-137-16 \u00b7 Clonazepam Tablet \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 16729-138-00\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"16729-138-00\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "accord-healthcare-inc-clonazepam-tablet-16729-138-00.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "accord-healthcare-inc-clonazepam-tablet-16729-138-00", "initial_posting_date": "03/10/2023", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-138-00", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-00)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"16729-138-00\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "16729-138-00 \u00b7 Clonazepam Tablet \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 16729-138-16\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"16729-138-16\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "accord-healthcare-inc-clonazepam-tablet-16729-138-16.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "accord-healthcare-inc-clonazepam-tablet-16729-138-16", "initial_posting_date": "03/10/2023", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-138-16", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 16729-138-16)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"16729-138-16\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "16729-138-16 \u00b7 Clonazepam Tablet \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-239-93\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"16729-239-93\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dexmedetomidine%20Hydrochloride%20Injection&st=d\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "accord-healthcare-inc-dexmedetomidine-hydrochloride-injection-16729-239-93.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-dexmedetomidine-hydrochloride-injection-16729-239-93", "initial_posting_date": "04/10/2020", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-239-93", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"16729-239-93\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dexmedetomidine%20Hydrochloride%20Injection&st=d\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "16729-239-93 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-432-93\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"16729-432-93\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "accord-healthcare-inc-dexmedetomidine-hydrochloride-injection-16729-432-93.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-dexmedetomidine-hydrochloride-injection-16729-432-93", "initial_posting_date": "04/10/2020", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-432-93", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"16729-432-93\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "16729-432-93 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-500-08\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD; NDC is non-exempt\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"16729-500-08\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"866-941-7875\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; NDC is non-exempt\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "accord-healthcare-inc-furosemide-injection-16729-500-08.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-furosemide-injection-16729-500-08", "initial_posting_date": "04/07/2020", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-500-08", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD; NDC is non-exempt", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"16729-500-08\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"866-941-7875\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; NDC is non-exempt\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "16729-500-08 \u00b7 Furosemide Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-501-43\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD; NDC is non-exempt\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"16729-501-43\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"866-941-7875\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; NDC is non-exempt\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "accord-healthcare-inc-furosemide-injection-16729-501-43.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-furosemide-injection-16729-501-43", "initial_posting_date": "04/07/2020", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-501-43", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD; NDC is non-exempt", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"16729-501-43\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"866-941-7875\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; NDC is non-exempt\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "16729-501-43 \u00b7 Furosemide Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-502-43\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD; NDC is non-exempt\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"16729-502-43\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"866-941-7875\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; NDC is non-exempt\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "accord-healthcare-inc-furosemide-injection-16729-502-43.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-furosemide-injection-16729-502-43", "initial_posting_date": "04/07/2020", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-502-43", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD; NDC is non-exempt", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"16729-502-43\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"866-941-7875\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; NDC is non-exempt\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "16729-502-43 \u00b7 Furosemide Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-277-30\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Fresh batch est avail Sep Week 3; ACC has short dated inventory with expiry of 09/30/27\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1270\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"16729-277-30\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Fresh batch est avail Sep Week 3; ACC has short dated inventory with expiry of 09/30/27\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1270", "dosage_form": "Injection", "file": "accord-healthcare-inc-methotrexate-sodium-injection-16729-277-30-2.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-03", "id": "accord-healthcare-inc-methotrexate-sodium-injection-16729-277-30-2", "initial_posting_date": "03/13/2023", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-277-30", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Fresh batch est avail Sep Week 3; ACC has short dated inventory with expiry of 09/30/27", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"16729-277-30\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"Fresh batch est avail Sep Week 3; ACC has short dated inventory with expiry of 09/30/27\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Rheumatology", "title": "16729-277-30 \u00b7 Methotrexate Sodium Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 16729-277-30\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1268\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"16729-277-30\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1268", "dosage_form": "Injection", "file": "accord-healthcare-inc-methotrexate-sodium-injection-16729-277-30.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-methotrexate-sodium-injection-16729-277-30", "initial_posting_date": "03/13/2023", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-277-30", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"16729-277-30\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "16729-277-30 \u00b7 Methotrexate Sodium Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 16729-277-35\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** ACC has short dated inventory with expiry of 08/31/27; Fresh inventory plan TBD\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1270\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"16729-277-35\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"ACC has short dated inventory with expiry of 08/31/27; Fresh inventory plan TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1270", "dosage_form": "Injection", "file": "accord-healthcare-inc-methotrexate-sodium-injection-16729-277-35-2.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-03", "id": "accord-healthcare-inc-methotrexate-sodium-injection-16729-277-35-2", "initial_posting_date": "03/13/2023", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-277-35", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "ACC has short dated inventory with expiry of 08/31/27; Fresh inventory plan TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"16729-277-35\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Unavailable\", \"related_info\": \"ACC has short dated inventory with expiry of 08/31/27; Fresh inventory plan TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Rheumatology", "title": "16729-277-35 \u00b7 Methotrexate Sodium Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 16729-277-35\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Accord Healthcare Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1268\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"16729-277-35\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1268", "dosage_form": "Injection", "file": "accord-healthcare-inc-methotrexate-sodium-injection-16729-277-35.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-01", "id": "accord-healthcare-inc-methotrexate-sodium-injection-16729-277-35", "initial_posting_date": "03/13/2023", "manufacturer_name": "Accord Healthcare Inc.", "package_ndc": "16729-277-35", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)\", \"company_name\": \"Accord Healthcare Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"16729-277-35\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"866-941-7875, option 2\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Accord%20Healthcare%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "16729-277-35 \u00b7 Methotrexate Sodium Injection \u00b7 Accord Healthcare Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 69784-200-96\n\n**Generic name:** Cromolyn Sodium Concentrate\n\n**Manufacturer:** Ailex Pharmaceuticals\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** No longer manufactured, some supplies still available in supply chain. Distributed by Woodward Pharma Services LLC (248) 308-1120 Ext 2\n\n**Initial posting date:** 11/03/2023\n\n**Last update date:** 07/17/2026\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1033\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Concentrate\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Pulmonary/Allergy\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/03/2023\", \"package_ndc\": \"69784-200-96\", \"generic_name\": \"Cromolyn Sodium Concentrate\", \"contact_info\": \"Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com\", \"availability\": \"Limited Availability\", \"related_info\": \"No longer manufactured, some supplies still available in supply chain. Distributed by Woodward Pharma Services LLC (248) 308-1120 Ext 2\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Ailex%20Pharmaceuticals%22+AND+generic_name%3A%22Cromolyn%20Sodium%20Concentrate%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1033", "dosage_form": "Concentrate", "file": "ailex-pharmaceuticals-cromolyn-sodium-concentrate-69784-200-96.md", "generated": true, "generic_name": "Cromolyn Sodium Concentrate", "harvested": "2026-09-01", "id": "ailex-pharmaceuticals-cromolyn-sodium-concentrate-69784-200-96", "initial_posting_date": "11/03/2023", "manufacturer_name": "Ailex Pharmaceuticals", "package_ndc": "69784-200-96", "quote_dosage_form": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "No longer manufactured, some supplies still available in supply chain. Distributed by Woodward Pharma Services LLC (248) 308-1120 Ext 2", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/03/2023\", \"package_ndc\": \"69784-200-96\", \"generic_name\": \"Cromolyn Sodium Concentrate\", \"contact_info\": \"Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com\", \"availability\": \"Limited Availability\", \"related_info\": \"No longer manufactured, some supplies still available in supply chain. Distributed by Woodward Pharma Services LLC (248) 308-1120 Ext 2\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Ailex%20Pharmaceuticals%22+AND+generic_name%3A%22Cromolyn%20Sodium%20Concentrate%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Pulmonary/Allergy", "title": "69784-200-96 \u00b7 Cromolyn Sodium Concentrate \u00b7 Ailex Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 76204-025-96\n\n**Generic name:** Cromolyn Sodium Concentrate\n\n**Manufacturer:** Ailex Pharmaceuticals\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** No longer manufactured, some supplies still available in supply chain. Distributed by Ritedose Pharmaceuticals, LLC (855) 806 3300\n\n**Initial posting date:** 11/03/2023\n\n**Last update date:** 07/17/2026\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1033\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Concentrate\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Pulmonary/Allergy\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/03/2023\", \"package_ndc\": \"76204-025-96\", \"generic_name\": \"Cromolyn Sodium Concentrate\", \"contact_info\": \"Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com\", \"availability\": \"Limited Availability\", \"related_info\": \"No longer manufactured, some supplies still available in supply chain. Distributed by Ritedose Pharmaceuticals, LLC (855) 806 3300\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Ailex%20Pharmaceuticals%22+AND+generic_name%3A%22Cromolyn%20Sodium%20Concentrate%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1033", "dosage_form": "Concentrate", "file": "ailex-pharmaceuticals-cromolyn-sodium-concentrate-76204-025-96.md", "generated": true, "generic_name": "Cromolyn Sodium Concentrate", "harvested": "2026-09-01", "id": "ailex-pharmaceuticals-cromolyn-sodium-concentrate-76204-025-96", "initial_posting_date": "11/03/2023", "manufacturer_name": "Ailex Pharmaceuticals", "package_ndc": "76204-025-96", "quote_dosage_form": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "No longer manufactured, some supplies still available in supply chain. Distributed by Ritedose Pharmaceuticals, LLC (855) 806 3300", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/03/2023\", \"package_ndc\": \"76204-025-96\", \"generic_name\": \"Cromolyn Sodium Concentrate\", \"contact_info\": \"Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com\", \"availability\": \"Limited Availability\", \"related_info\": \"No longer manufactured, some supplies still available in supply chain. Distributed by Ritedose Pharmaceuticals, LLC (855) 806 3300\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Ailex%20Pharmaceuticals%22+AND+generic_name%3A%22Cromolyn%20Sodium%20Concentrate%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Pulmonary/Allergy", "title": "76204-025-96 \u00b7 Cromolyn Sodium Concentrate \u00b7 Ailex Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 81665-104-96\n\n**Generic name:** Cromolyn Sodium Concentrate\n\n**Manufacturer:** Ailex Pharmaceuticals\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195\n\n**Initial posting date:** 11/03/2023\n\n**Last update date:** 07/17/2026\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 1033\n\n**Dosage form:** Concentrate\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Pulmonary/Allergy\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/03/2023\", \"package_ndc\": \"81665-104-96\", \"generic_name\": \"Cromolyn Sodium Concentrate\", \"contact_info\": \"Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com\", \"availability\": \"Available\", \"related_info\": \"Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Ailex%20Pharmaceuticals%22+AND+generic_name%3A%22Cromolyn%20Sodium%20Concentrate%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1033", "dosage_form": "Concentrate", "file": "ailex-pharmaceuticals-cromolyn-sodium-concentrate-81665-104-96.md", "generated": true, "generic_name": "Cromolyn Sodium Concentrate", "harvested": "2026-09-01", "id": "ailex-pharmaceuticals-cromolyn-sodium-concentrate-81665-104-96", "initial_posting_date": "11/03/2023", "manufacturer_name": "Ailex Pharmaceuticals", "package_ndc": "81665-104-96", "quote_dosage_form": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)\", \"company_name\": \"Ailex Pharmaceuticals\", \"status\": \"Current\"", "related_info": "Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195", "source_quote": "\"initial_posting_date\": \"11/03/2023\", \"package_ndc\": \"81665-104-96\", \"generic_name\": \"Cromolyn Sodium Concentrate\", \"contact_info\": \"Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com\", \"availability\": \"Available\", \"related_info\": \"Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Ailex%20Pharmaceuticals%22+AND+generic_name%3A%22Cromolyn%20Sodium%20Concentrate%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Pulmonary/Allergy", "title": "81665-104-96 \u00b7 Cromolyn Sodium Concentrate \u00b7 Ailex Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62332-599-25\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Alembic Pharmaceuticals\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 05/15/2026\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"62332-599-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"908-393-9604\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alembic%20Pharmaceuticals%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "alembic-pharmaceuticals-ketorolac-tromethamine-injection-62332-599-25.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "alembic-pharmaceuticals-ketorolac-tromethamine-injection-62332-599-25", "initial_posting_date": "03/23/2018", "manufacturer_name": "Alembic Pharmaceuticals", "package_ndc": "62332-599-25", "quote_dosage_form": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"62332-599-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"908-393-9604\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alembic%20Pharmaceuticals%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "62332-599-25 \u00b7 Ketorolac Tromethamine Injection \u00b7 Alembic Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "05/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62332-600-25\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Alembic Pharmaceuticals\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 05/15/2026\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"62332-600-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"908-393-9604\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alembic%20Pharmaceuticals%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "alembic-pharmaceuticals-ketorolac-tromethamine-injection-62332-600-25.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "alembic-pharmaceuticals-ketorolac-tromethamine-injection-62332-600-25", "initial_posting_date": "03/23/2018", "manufacturer_name": "Alembic Pharmaceuticals", "package_ndc": "62332-600-25", "quote_dosage_form": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"62332-600-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"908-393-9604\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alembic%20Pharmaceuticals%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "62332-600-25 \u00b7 Ketorolac Tromethamine Injection \u00b7 Alembic Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "05/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62332-601-25\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Alembic Pharmaceuticals\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 05/15/2026\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"62332-601-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"908-393-9604\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alembic%20Pharmaceuticals%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "alembic-pharmaceuticals-ketorolac-tromethamine-injection-62332-601-25.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "alembic-pharmaceuticals-ketorolac-tromethamine-injection-62332-601-25", "initial_posting_date": "03/23/2018", "manufacturer_name": "Alembic Pharmaceuticals", "package_ndc": "62332-601-25", "quote_dosage_form": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)\", \"company_name\": \"Alembic Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"62332-601-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"908-393-9604\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alembic%20Pharmaceuticals%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "62332-601-25 \u00b7 Ketorolac Tromethamine Injection \u00b7 Alembic Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "05/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 47781-174-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Alvogen\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5mg (NDC 47781-174-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5mg (NDC 47781-174-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5mg (NDC 47781-174-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5mg (NDC 47781-174-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5mg (NDC 47781-174-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"47781-174-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "alvogen-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-47781-174-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "alvogen-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-47781-174-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Alvogen", "package_ndc": "47781-174-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5mg (NDC 47781-174-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5mg (NDC 47781-174-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5mg (NDC 47781-174-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5mg (NDC 47781-174-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5mg (NDC 47781-174-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"47781-174-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "47781-174-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Alvogen \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 47781-176-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Alvogen\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 10mg (NDC 47781-176-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 10mg (NDC 47781-176-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 10mg (NDC 47781-176-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 10mg (NDC 47781-176-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 10mg (NDC 47781-176-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"47781-176-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "alvogen-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-47781-176-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "alvogen-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-47781-176-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Alvogen", "package_ndc": "47781-176-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 10mg (NDC 47781-176-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 10mg (NDC 47781-176-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 10mg (NDC 47781-176-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 10mg (NDC 47781-176-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 10mg (NDC 47781-176-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"47781-176-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "47781-176-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Alvogen \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 47781-178-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Alvogen\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 15mg (NDC 47781-178-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 15mg (NDC 47781-178-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 15mg (NDC 47781-178-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 15mg (NDC 47781-178-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 15mg (NDC 47781-178-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"47781-178-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "alvogen-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-47781-178-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "alvogen-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-47781-178-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Alvogen", "package_ndc": "47781-178-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 15mg (NDC 47781-178-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 15mg (NDC 47781-178-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 15mg (NDC 47781-178-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 15mg (NDC 47781-178-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 15mg (NDC 47781-178-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"47781-178-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "47781-178-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Alvogen \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 47781-179-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Alvogen\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 20mg (NDC 47781-179-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 20mg (NDC 47781-179-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 20mg (NDC 47781-179-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 20mg (NDC 47781-179-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 20mg (NDC 47781-179-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"47781-179-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "alvogen-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-47781-179-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "alvogen-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-47781-179-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Alvogen", "package_ndc": "47781-179-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 20mg (NDC 47781-179-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 20mg (NDC 47781-179-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 20mg (NDC 47781-179-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 20mg (NDC 47781-179-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 20mg (NDC 47781-179-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"47781-179-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "47781-179-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Alvogen \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 47781-180-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Alvogen\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 30mg (NDC 47781-180-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 30mg (NDC 47781-180-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 30mg (NDC 47781-180-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 30mg (NDC 47781-180-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 30mg (NDC 47781-180-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"47781-180-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "alvogen-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-47781-180-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "alvogen-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-47781-180-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Alvogen", "package_ndc": "47781-180-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 30mg (NDC 47781-180-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 30mg (NDC 47781-180-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 30mg (NDC 47781-180-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 30mg (NDC 47781-180-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 30mg (NDC 47781-180-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"47781-180-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "47781-180-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Alvogen \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 47781-562-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Alvogen\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"47781-562-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "alvogen-lisdexamfetamine-dimesylate-capsule-47781-562-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "alvogen-lisdexamfetamine-dimesylate-capsule-47781-562-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Alvogen", "package_ndc": "47781-562-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"47781-562-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "47781-562-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Alvogen \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 47781-563-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Alvogen\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"47781-563-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "alvogen-lisdexamfetamine-dimesylate-capsule-47781-563-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "alvogen-lisdexamfetamine-dimesylate-capsule-47781-563-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Alvogen", "package_ndc": "47781-563-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"47781-563-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "47781-563-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Alvogen \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 47781-564-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Alvogen\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"47781-564-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "alvogen-lisdexamfetamine-dimesylate-capsule-47781-564-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "alvogen-lisdexamfetamine-dimesylate-capsule-47781-564-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Alvogen", "package_ndc": "47781-564-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"47781-564-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "47781-564-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Alvogen \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 47781-565-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Alvogen\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"47781-565-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "alvogen-lisdexamfetamine-dimesylate-capsule-47781-565-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "alvogen-lisdexamfetamine-dimesylate-capsule-47781-565-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Alvogen", "package_ndc": "47781-565-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"47781-565-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "47781-565-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Alvogen \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 47781-566-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Alvogen\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"47781-566-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "alvogen-lisdexamfetamine-dimesylate-capsule-47781-566-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "alvogen-lisdexamfetamine-dimesylate-capsule-47781-566-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Alvogen", "package_ndc": "47781-566-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"47781-566-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "47781-566-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Alvogen \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 47781-567-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Alvogen\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"47781-567-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "alvogen-lisdexamfetamine-dimesylate-capsule-47781-567-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "alvogen-lisdexamfetamine-dimesylate-capsule-47781-567-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Alvogen", "package_ndc": "47781-567-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"47781-567-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "47781-567-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Alvogen \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 47781-568-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Alvogen\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"47781-568-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "alvogen-lisdexamfetamine-dimesylate-capsule-47781-568-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "alvogen-lisdexamfetamine-dimesylate-capsule-47781-568-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Alvogen", "package_ndc": "47781-568-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)\", \"company_name\": \"Alvogen\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"47781-568-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-842-8672 and email: CustomerService-US@alvogen.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Alvogen%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "47781-568-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Alvogen \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0517-1001-25\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** American Regent, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0517-1001-25\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"800-645-1706\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22American%20Regent,%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "american-regent-inc-atropine-sulfate-injection-0517-1001-25.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "american-regent-inc-atropine-sulfate-injection-0517-1001-25", "initial_posting_date": "01/01/2012", "manufacturer_name": "American Regent, Inc.", "package_ndc": "0517-1001-25", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0517-1001-25\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"800-645-1706\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22American%20Regent,%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0517-1001-25 \u00b7 Atropine Sulfate Injection \u00b7 American Regent, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0517-1004-25\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** American Regent, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0517-1004-25\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"800-645-1706\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22American%20Regent,%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "american-regent-inc-atropine-sulfate-injection-0517-1004-25.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "american-regent-inc-atropine-sulfate-injection-0517-1004-25", "initial_posting_date": "01/01/2012", "manufacturer_name": "American Regent, Inc.", "package_ndc": "0517-1004-25", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)\", \"company_name\": \"American Regent, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0517-1004-25\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"800-645-1706\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22American%20Regent,%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0517-1004-25 \u00b7 Atropine Sulfate Injection \u00b7 American Regent, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70121-1388-1\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Amneal Pharmaceuticals\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 06/17/2026\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"70121-1388-1\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"877-835-5472\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "amneal-pharmaceuticals-dexmedetomidine-hydrochloride-injection-70121-1388-1.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "amneal-pharmaceuticals-dexmedetomidine-hydrochloride-injection-70121-1388-1", "initial_posting_date": "04/10/2020", "manufacturer_name": "Amneal Pharmaceuticals", "package_ndc": "70121-1388-1", "quote_dosage_form": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"70121-1388-1\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"877-835-5472\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70121-1388-1 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Amneal Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70121-1388-8\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Amneal Pharmaceuticals\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Inventory available 4 to 5 month as per current demand. Next supply: week of 06/29/2026\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 06/17/2026\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"70121-1388-8\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\", \"related_info\": \"Inventory available 4 to 5 month as per current demand. Next supply: week of 06/29/2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "amneal-pharmaceuticals-dexmedetomidine-hydrochloride-injection-70121-1388-8.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "amneal-pharmaceuticals-dexmedetomidine-hydrochloride-injection-70121-1388-8", "initial_posting_date": "04/10/2020", "manufacturer_name": "Amneal Pharmaceuticals", "package_ndc": "70121-1388-8", "quote_dosage_form": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "related_info": "Inventory available 4 to 5 month as per current demand. Next supply: week of 06/29/2026", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"70121-1388-8\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\", \"related_info\": \"Inventory available 4 to 5 month as per current demand. Next supply: week of 06/29/2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70121-1388-8 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Amneal Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70121-1389-1\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Amneal Pharmaceuticals\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 06/17/2026\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"70121-1389-1\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "amneal-pharmaceuticals-dexmedetomidine-hydrochloride-injection-70121-1389-1.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "amneal-pharmaceuticals-dexmedetomidine-hydrochloride-injection-70121-1389-1", "initial_posting_date": "04/10/2020", "manufacturer_name": "Amneal Pharmaceuticals", "package_ndc": "70121-1389-1", "quote_dosage_form": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"70121-1389-1\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70121-1389-1 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Amneal Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70121-1389-7\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Amneal Pharmaceuticals\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 06/17/2026\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"70121-1389-7\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "amneal-pharmaceuticals-dexmedetomidine-hydrochloride-injection-70121-1389-7.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "amneal-pharmaceuticals-dexmedetomidine-hydrochloride-injection-70121-1389-7", "initial_posting_date": "04/10/2020", "manufacturer_name": "Amneal Pharmaceuticals", "package_ndc": "70121-1389-7", "quote_dosage_form": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"70121-1389-7\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70121-1389-7 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Amneal Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65162-023-09\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Amneal Pharmaceuticals\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/17/2026\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"65162-023-09\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "amneal-pharmaceuticals-lisdexamfetamine-dimesylate-capsule-65162-023-09.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "amneal-pharmaceuticals-lisdexamfetamine-dimesylate-capsule-65162-023-09", "initial_posting_date": "07/14/2023", "manufacturer_name": "Amneal Pharmaceuticals", "package_ndc": "65162-023-09", "quote_dosage_form": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"65162-023-09\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "65162-023-09 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Amneal Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65162-024-09\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Amneal Pharmaceuticals\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/17/2026\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"65162-024-09\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "amneal-pharmaceuticals-lisdexamfetamine-dimesylate-capsule-65162-024-09.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "amneal-pharmaceuticals-lisdexamfetamine-dimesylate-capsule-65162-024-09", "initial_posting_date": "07/14/2023", "manufacturer_name": "Amneal Pharmaceuticals", "package_ndc": "65162-024-09", "quote_dosage_form": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"65162-024-09\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "65162-024-09 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Amneal Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65162-025-09\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Amneal Pharmaceuticals\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/17/2026\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"65162-025-09\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "amneal-pharmaceuticals-lisdexamfetamine-dimesylate-capsule-65162-025-09.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "amneal-pharmaceuticals-lisdexamfetamine-dimesylate-capsule-65162-025-09", "initial_posting_date": "07/14/2023", "manufacturer_name": "Amneal Pharmaceuticals", "package_ndc": "65162-025-09", "quote_dosage_form": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"65162-025-09\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "65162-025-09 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Amneal Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65162-026-09\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Amneal Pharmaceuticals\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/17/2026\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"65162-026-09\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "amneal-pharmaceuticals-lisdexamfetamine-dimesylate-capsule-65162-026-09.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "amneal-pharmaceuticals-lisdexamfetamine-dimesylate-capsule-65162-026-09", "initial_posting_date": "07/14/2023", "manufacturer_name": "Amneal Pharmaceuticals", "package_ndc": "65162-026-09", "quote_dosage_form": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"65162-026-09\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "65162-026-09 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Amneal Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65162-027-09\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Amneal Pharmaceuticals\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/17/2026\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"65162-027-09\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "amneal-pharmaceuticals-lisdexamfetamine-dimesylate-capsule-65162-027-09.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "amneal-pharmaceuticals-lisdexamfetamine-dimesylate-capsule-65162-027-09", "initial_posting_date": "07/14/2023", "manufacturer_name": "Amneal Pharmaceuticals", "package_ndc": "65162-027-09", "quote_dosage_form": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"65162-027-09\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "65162-027-09 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Amneal Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65162-028-09\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Amneal Pharmaceuticals\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/17/2026\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"65162-028-09\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "amneal-pharmaceuticals-lisdexamfetamine-dimesylate-capsule-65162-028-09.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "amneal-pharmaceuticals-lisdexamfetamine-dimesylate-capsule-65162-028-09", "initial_posting_date": "07/14/2023", "manufacturer_name": "Amneal Pharmaceuticals", "package_ndc": "65162-028-09", "quote_dosage_form": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"65162-028-09\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "65162-028-09 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Amneal Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 70121-1573-1\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Amneal Pharmaceuticals\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** On backorder. Estimated recovery: late July\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 06/17/2026\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"70121-1573-1\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"866-525-7270\", \"availability\": \"Limited Availability\", \"related_info\": \"On backorder. Estimated recovery: late July\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "amneal-pharmaceuticals-methylprednisolone-acetate-injection-70121-1573-1.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "amneal-pharmaceuticals-methylprednisolone-acetate-injection-70121-1573-1", "initial_posting_date": "12/15/2021", "manufacturer_name": "Amneal Pharmaceuticals", "package_ndc": "70121-1573-1", "quote_dosage_form": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "On backorder. Estimated recovery: late July", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"70121-1573-1\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"866-525-7270\", \"availability\": \"Limited Availability\", \"related_info\": \"On backorder. Estimated recovery: late July\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "70121-1573-1 \u00b7 Methylprednisolone Acetate Injection \u00b7 Amneal Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70121-1573-5\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Amneal Pharmaceuticals\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 06/17/2026\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"70121-1573-5\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "amneal-pharmaceuticals-methylprednisolone-acetate-injection-70121-1573-5.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "amneal-pharmaceuticals-methylprednisolone-acetate-injection-70121-1573-5", "initial_posting_date": "12/15/2021", "manufacturer_name": "Amneal Pharmaceuticals", "package_ndc": "70121-1573-5", "quote_dosage_form": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"70121-1573-5\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "70121-1573-5 \u00b7 Methylprednisolone Acetate Injection \u00b7 Amneal Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70121-1574-1\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Amneal Pharmaceuticals\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 06/17/2026\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"70121-1574-1\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "amneal-pharmaceuticals-methylprednisolone-acetate-injection-70121-1574-1.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "amneal-pharmaceuticals-methylprednisolone-acetate-injection-70121-1574-1", "initial_posting_date": "12/15/2021", "manufacturer_name": "Amneal Pharmaceuticals", "package_ndc": "70121-1574-1", "quote_dosage_form": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"70121-1574-1\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "70121-1574-1 \u00b7 Methylprednisolone Acetate Injection \u00b7 Amneal Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70121-1574-5\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Amneal Pharmaceuticals\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 06/17/2026\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"70121-1574-5\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "amneal-pharmaceuticals-methylprednisolone-acetate-injection-70121-1574-5.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "amneal-pharmaceuticals-methylprednisolone-acetate-injection-70121-1574-5", "initial_posting_date": "12/15/2021", "manufacturer_name": "Amneal Pharmaceuticals", "package_ndc": "70121-1574-5", "quote_dosage_form": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/17/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)\", \"company_name\": \"Amneal Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"70121-1574-5\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"866-525-7270\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amneal%20Pharmaceuticals%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "70121-1574-5 \u00b7 Methylprednisolone Acetate Injection \u00b7 Amneal Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 76329-3340-1\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Amphastar Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/01/2020\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2435\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2020\", \"package_ndc\": \"76329-3340-1\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"800-423-4136\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2435", "dosage_form": "Injection", "file": "amphastar-pharmaceuticals-inc-atropine-sulfate-injection-76329-3340-1.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "amphastar-pharmaceuticals-inc-atropine-sulfate-injection-76329-3340-1", "initial_posting_date": "01/01/2020", "manufacturer_name": "Amphastar Pharmaceuticals, Inc.", "package_ndc": "76329-3340-1", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"01/01/2020\", \"package_ndc\": \"76329-3340-1\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"800-423-4136\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "76329-3340-1 \u00b7 Atropine Sulfate Injection \u00b7 Amphastar Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 76329-3302-1\n\n**Generic name:** Dextrose Monohydrate 50% Injection\n\n**Manufacturer:** Amphastar Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/13/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1692\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/13/2022\", \"package_ndc\": \"76329-3302-1\", \"generic_name\": \"Dextrose Monohydrate 50% Injection\", \"contact_info\": \"800-423-4136\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2050%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1692", "dosage_form": "Injection", "file": "amphastar-pharmaceuticals-inc-dextrose-monohydrate-50-injection-76329-3302-1.md", "generated": true, "generic_name": "Dextrose Monohydrate 50% Injection", "harvested": "2026-09-01", "id": "amphastar-pharmaceuticals-inc-dextrose-monohydrate-50-injection-76329-3302-1", "initial_posting_date": "01/13/2022", "manufacturer_name": "Amphastar Pharmaceuticals, Inc.", "package_ndc": "76329-3302-1", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"01/13/2022\", \"package_ndc\": \"76329-3302-1\", \"generic_name\": \"Dextrose Monohydrate 50% Injection\", \"contact_info\": \"800-423-4136\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2050%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "76329-3302-1 \u00b7 Dextrose Monohydrate 50% Injection \u00b7 Amphastar Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 76329-3390-1\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Amphastar Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Available on allocation\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"76329-3390-1\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"800-423-4136\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "amphastar-pharmaceuticals-inc-lidocaine-hydrochloride-injection-76329-3390-1.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "amphastar-pharmaceuticals-inc-lidocaine-hydrochloride-injection-76329-3390-1", "initial_posting_date": "02/22/2012", "manufacturer_name": "Amphastar Pharmaceuticals, Inc.", "package_ndc": "76329-3390-1", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Available on allocation", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"76329-3390-1\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"800-423-4136\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "76329-3390-1 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Amphastar Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 76329-8261-1\n\n**Generic name:** Lorazepam Injection\n\n**Manufacturer:** Amphastar Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 05/03/2018\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3043\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/03/2018\", \"package_ndc\": \"76329-8261-1\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-423-4136\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3043", "dosage_form": "Injection", "file": "amphastar-pharmaceuticals-inc-lorazepam-injection-76329-8261-1.md", "generated": true, "generic_name": "Lorazepam Injection", "harvested": "2026-09-01", "id": "amphastar-pharmaceuticals-inc-lorazepam-injection-76329-8261-1", "initial_posting_date": "05/03/2018", "manufacturer_name": "Amphastar Pharmaceuticals, Inc.", "package_ndc": "76329-8261-1", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"05/03/2018\", \"package_ndc\": \"76329-8261-1\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-423-4136\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Neurology", "title": "76329-8261-1 \u00b7 Lorazepam Injection \u00b7 Amphastar Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 76329-1912-1\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Amphastar Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/06/2018\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2826\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/06/2018\", \"package_ndc\": \"76329-1912-1\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-423-4136\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2826", "dosage_form": "Injection", "file": "amphastar-pharmaceuticals-inc-morphine-sulfate-injection-76329-1912-1.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "amphastar-pharmaceuticals-inc-morphine-sulfate-injection-76329-1912-1", "initial_posting_date": "12/06/2018", "manufacturer_name": "Amphastar Pharmaceuticals, Inc.", "package_ndc": "76329-1912-1", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"12/06/2018\", \"package_ndc\": \"76329-1912-1\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-423-4136\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "76329-1912-1 \u00b7 Morphine Sulfate Injection \u00b7 Amphastar Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 76329-3352-1\n\n**Generic name:** Sodium Bicarbonate Injection\n\n**Manufacturer:** Amphastar Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Available on allocation\n\n**Initial posting date:** 03/01/2017\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3471\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"76329-3352-1\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"800-423-4136\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3471", "dosage_form": "Injection", "file": "amphastar-pharmaceuticals-inc-sodium-bicarbonate-injection-76329-3352-1.md", "generated": true, "generic_name": "Sodium Bicarbonate Injection", "harvested": "2026-09-01", "id": "amphastar-pharmaceuticals-inc-sodium-bicarbonate-injection-76329-3352-1", "initial_posting_date": "03/01/2017", "manufacturer_name": "Amphastar Pharmaceuticals, Inc.", "package_ndc": "76329-3352-1", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)\", \"company_name\": \"Amphastar Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Available on allocation", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"76329-3352-1\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"800-423-4136\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Amphastar%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "76329-3352-1 \u00b7 Sodium Bicarbonate Injection \u00b7 Amphastar Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 83634-651-10\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Anthea Pharma\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/10 mL (NDC 83634-651-10)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/10 mL (NDC 83634-651-10)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Avenacy, LLC\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/10 mL (NDC 83634-651-10)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/10 mL (NDC 83634-651-10)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/10 mL (NDC 83634-651-10)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"83634-651-10\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"Avenacy, LLC: 877-283-6229\", \"availability\": \"Available\", \"related_info\": \"Distributed by Avenacy, LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Anthea%20Pharma%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "anthea-pharma-lidocaine-hydrochloride-injection-83634-651-10.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "anthea-pharma-lidocaine-hydrochloride-injection-83634-651-10", "initial_posting_date": "02/22/2012", "manufacturer_name": "Anthea Pharma", "package_ndc": "83634-651-10", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/10 mL (NDC 83634-651-10)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/10 mL (NDC 83634-651-10)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/10 mL (NDC 83634-651-10)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/10 mL (NDC 83634-651-10)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/10 mL (NDC 83634-651-10)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Distributed by Avenacy, LLC", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"83634-651-10\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"Avenacy, LLC: 877-283-6229\", \"availability\": \"Available\", \"related_info\": \"Distributed by Avenacy, LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Anthea%20Pharma%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "83634-651-10 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Anthea Pharma \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 83634-651-20\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Anthea Pharma\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/20 mL (NDC 83634-651-20)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/20 mL (NDC 83634-651-20)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Avenacy, LLC\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/20 mL (NDC 83634-651-20)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/20 mL (NDC 83634-651-20)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/20 mL (NDC 83634-651-20)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"83634-651-20\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"Avenacy, LLC: 877-283-6229\", \"availability\": \"Available\", \"related_info\": \"Distributed by Avenacy, LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Anthea%20Pharma%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "anthea-pharma-lidocaine-hydrochloride-injection-83634-651-20.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "anthea-pharma-lidocaine-hydrochloride-injection-83634-651-20", "initial_posting_date": "02/22/2012", "manufacturer_name": "Anthea Pharma", "package_ndc": "83634-651-20", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/20 mL (NDC 83634-651-20)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/20 mL (NDC 83634-651-20)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/20 mL (NDC 83634-651-20)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/20 mL (NDC 83634-651-20)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/20 mL (NDC 83634-651-20)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Distributed by Avenacy, LLC", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"83634-651-20\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"Avenacy, LLC: 877-283-6229\", \"availability\": \"Available\", \"related_info\": \"Distributed by Avenacy, LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Anthea%20Pharma%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "83634-651-20 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Anthea Pharma \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 83634-651-50\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Anthea Pharma\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 500 mg/50 mL (NDC 83634-651-50)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 500 mg/50 mL (NDC 83634-651-50)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Avenacy, LLC\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 500 mg/50 mL (NDC 83634-651-50)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 500 mg/50 mL (NDC 83634-651-50)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 500 mg/50 mL (NDC 83634-651-50)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"83634-651-50\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"Avenacy, LLC: 877-283-6229\", \"availability\": \"Available\", \"related_info\": \"Distributed by Avenacy, LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Anthea%20Pharma%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "anthea-pharma-lidocaine-hydrochloride-injection-83634-651-50.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "anthea-pharma-lidocaine-hydrochloride-injection-83634-651-50", "initial_posting_date": "02/22/2012", "manufacturer_name": "Anthea Pharma", "package_ndc": "83634-651-50", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 500 mg/50 mL (NDC 83634-651-50)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 500 mg/50 mL (NDC 83634-651-50)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 500 mg/50 mL (NDC 83634-651-50)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 500 mg/50 mL (NDC 83634-651-50)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 500 mg/50 mL (NDC 83634-651-50)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Distributed by Avenacy, LLC", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"83634-651-50\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"Avenacy, LLC: 877-283-6229\", \"availability\": \"Available\", \"related_info\": \"Distributed by Avenacy, LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Anthea%20Pharma%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "83634-651-50 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Anthea Pharma \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 83634-653-02\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Anthea Pharma\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/2 mL (NDC 83634-653-02)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/2 mL (NDC 83634-653-02)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Avenacy, LLC\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/2 mL (NDC 83634-653-02)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/2 mL (NDC 83634-653-02)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/2 mL (NDC 83634-653-02)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"83634-653-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"Avenacy, LLC: 877-283-6229\", \"availability\": \"Available\", \"related_info\": \"Distributed by Avenacy, LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Anthea%20Pharma%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "anthea-pharma-lidocaine-hydrochloride-injection-83634-653-02.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "anthea-pharma-lidocaine-hydrochloride-injection-83634-653-02", "initial_posting_date": "02/22/2012", "manufacturer_name": "Anthea Pharma", "package_ndc": "83634-653-02", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/2 mL (NDC 83634-653-02)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/2 mL (NDC 83634-653-02)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/2 mL (NDC 83634-653-02)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/2 mL (NDC 83634-653-02)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/2 mL (NDC 83634-653-02)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Distributed by Avenacy, LLC", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"83634-653-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"Avenacy, LLC: 877-283-6229\", \"availability\": \"Available\", \"related_info\": \"Distributed by Avenacy, LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Anthea%20Pharma%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "83634-653-02 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Anthea Pharma \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 83634-653-05\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Anthea Pharma\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydochloride, Injection, 50 mg/5 mL (NDC 83634-653-05)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydochloride, Injection, 50 mg/5 mL (NDC 83634-653-05)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Avenacy, LLC\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydochloride, Injection, 50 mg/5 mL (NDC 83634-653-05)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydochloride, Injection, 50 mg/5 mL (NDC 83634-653-05)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydochloride, Injection, 50 mg/5 mL (NDC 83634-653-05)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"83634-653-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"Avenacy, LLC: 877-283-6229\", \"availability\": \"Available\", \"related_info\": \"Distributed by Avenacy, LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Anthea%20Pharma%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "anthea-pharma-lidocaine-hydrochloride-injection-83634-653-05.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "anthea-pharma-lidocaine-hydrochloride-injection-83634-653-05", "initial_posting_date": "02/22/2012", "manufacturer_name": "Anthea Pharma", "package_ndc": "83634-653-05", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydochloride, Injection, 50 mg/5 mL (NDC 83634-653-05)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydochloride, Injection, 50 mg/5 mL (NDC 83634-653-05)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydochloride, Injection, 50 mg/5 mL (NDC 83634-653-05)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydochloride, Injection, 50 mg/5 mL (NDC 83634-653-05)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydochloride, Injection, 50 mg/5 mL (NDC 83634-653-05)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Distributed by Avenacy, LLC", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"83634-653-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"Avenacy, LLC: 877-283-6229\", \"availability\": \"Available\", \"related_info\": \"Distributed by Avenacy, LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Anthea%20Pharma%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "83634-653-05 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Anthea Pharma \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 83634-653-30\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Anthea Pharma\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (NDC 83634-653-30)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (NDC 83634-653-30)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Avenacy, LLC\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (NDC 83634-653-30)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (NDC 83634-653-30)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (NDC 83634-653-30)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"83634-653-30\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"Avenacy, LLC: 877-283-6229\", \"availability\": \"Available\", \"related_info\": \"Distributed by Avenacy, LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Anthea%20Pharma%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "anthea-pharma-lidocaine-hydrochloride-injection-83634-653-30.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "anthea-pharma-lidocaine-hydrochloride-injection-83634-653-30", "initial_posting_date": "02/22/2012", "manufacturer_name": "Anthea Pharma", "package_ndc": "83634-653-30", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (NDC 83634-653-30)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (NDC 83634-653-30)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (NDC 83634-653-30)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (NDC 83634-653-30)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (NDC 83634-653-30)\", \"company_name\": \"Anthea Pharma\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Distributed by Avenacy, LLC", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"83634-653-30\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"Avenacy, LLC: 877-283-6229\", \"availability\": \"Available\", \"related_info\": \"Distributed by Avenacy, LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Anthea%20Pharma%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "83634-653-30 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Anthea Pharma \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 60505-0815-0\n\n**Generic name:** Desmopressin Acetate Spray\n\n**Manufacturer:** Apotex Corp.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: 9/7/26\n\n**Initial posting date:** 03/12/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1999\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Spray\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Hematology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/12/2021\", \"package_ndc\": \"60505-0815-0\", \"generic_name\": \"Desmopressin Acetate Spray\", \"contact_info\": \"800-706-5575\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: 9/7/26\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Desmopressin%20Acetate%20Spray%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1999", "dosage_form": "Spray", "file": "apotex-corp-desmopressin-acetate-spray-60505-0815-0.md", "generated": true, "generic_name": "Desmopressin Acetate Spray", "harvested": "2026-09-01", "id": "apotex-corp-desmopressin-acetate-spray-60505-0815-0", "initial_posting_date": "03/12/2021", "manufacturer_name": "Apotex Corp.", "package_ndc": "60505-0815-0", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: 9/7/26", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"03/12/2021\", \"package_ndc\": \"60505-0815-0\", \"generic_name\": \"Desmopressin Acetate Spray\", \"contact_info\": \"800-706-5575\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: 9/7/26\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Desmopressin%20Acetate%20Spray%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Hematology", "title": "60505-0815-0 \u00b7 Desmopressin Acetate Spray \u00b7 Apotex Corp. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 60505-4739-1\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Apotex Corp.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/01/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Days in shortage:** 1035\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4739-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1035", "dosage_form": "Capsule", "file": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4739-1.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4739-1", "initial_posting_date": "11/01/2023", "manufacturer_name": "Apotex Corp.", "package_ndc": "60505-4739-1", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4739-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Psychiatry", "title": "60505-4739-1 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Apotex Corp. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 60505-4740-1\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Apotex Corp.\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: 10/12/26\n\n**Initial posting date:** 11/01/2023\n\n**Last update date:** 09/08/2026\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1044\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4740-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: 10/12/26\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1044", "dosage_form": "Capsule", "file": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4740-1-2.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-10", "id": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4740-1-2", "initial_posting_date": "11/01/2023", "manufacturer_name": "Apotex Corp.", "package_ndc": "60505-4740-1", "quote_dosage_form": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: 10/12/26", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4740-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: 10/12/26\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Psychiatry", "title": "60505-4740-1 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Apotex Corp. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/08/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 60505-4740-1\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Apotex Corp.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: 10/20/26\n\n**Initial posting date:** 11/01/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1035\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4740-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: 10/20/26\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1035", "dosage_form": "Capsule", "file": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4740-1.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4740-1", "initial_posting_date": "11/01/2023", "manufacturer_name": "Apotex Corp.", "package_ndc": "60505-4740-1", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: 10/20/26", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4740-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: 10/20/26\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "60505-4740-1 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Apotex Corp. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 60505-4741-1\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Apotex Corp.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/01/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Days in shortage:** 1035\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4741-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1035", "dosage_form": "Capsule", "file": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4741-1.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4741-1", "initial_posting_date": "11/01/2023", "manufacturer_name": "Apotex Corp.", "package_ndc": "60505-4741-1", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4741-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Psychiatry", "title": "60505-4741-1 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Apotex Corp. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 60505-4742-1\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Apotex Corp.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/01/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Days in shortage:** 1035\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4742-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1035", "dosage_form": "Capsule", "file": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4742-1.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4742-1", "initial_posting_date": "11/01/2023", "manufacturer_name": "Apotex Corp.", "package_ndc": "60505-4742-1", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4742-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Psychiatry", "title": "60505-4742-1 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Apotex Corp. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 60505-4743-1\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Apotex Corp.\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/01/2023\n\n**Last update date:** 09/08/2026\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Days in shortage:** 1044\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4743-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1044", "dosage_form": "Capsule", "file": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4743-1-2.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-10", "id": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4743-1-2", "initial_posting_date": "11/01/2023", "manufacturer_name": "Apotex Corp.", "package_ndc": "60505-4743-1", "quote_dosage_form": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4743-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Psychiatry", "title": "60505-4743-1 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Apotex Corp. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/08/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 60505-4743-1\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Apotex Corp.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: Week of 8/24/26\n\n**Initial posting date:** 11/01/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1035\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4743-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: Week of 8/24/26\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1035", "dosage_form": "Capsule", "file": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4743-1.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4743-1", "initial_posting_date": "11/01/2023", "manufacturer_name": "Apotex Corp.", "package_ndc": "60505-4743-1", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)\", \"company_name\": \"Apotex Corp.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: Week of 8/24/26", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4743-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: Week of 8/24/26\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "60505-4743-1 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Apotex Corp. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 60505-4744-1\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Apotex Corp.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/01/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Days in shortage:** 1035\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4744-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1035", "dosage_form": "Capsule", "file": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4744-1.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4744-1", "initial_posting_date": "11/01/2023", "manufacturer_name": "Apotex Corp.", "package_ndc": "60505-4744-1", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4744-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Psychiatry", "title": "60505-4744-1 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Apotex Corp. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 60505-4745-1\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Apotex Corp.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/01/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Days in shortage:** 1035\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4745-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1035", "dosage_form": "Capsule", "file": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4745-1.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "apotex-corp-lisdexamfetamine-dimesylate-capsule-60505-4745-1", "initial_posting_date": "11/01/2023", "manufacturer_name": "Apotex Corp.", "package_ndc": "60505-4745-1", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)\", \"company_name\": \"Apotex Corp.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"11/01/2023\", \"package_ndc\": \"60505-4745-1\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-706-5575\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Apotex%20Corp.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Psychiatry", "title": "60505-4745-1 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Apotex Corp. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 72485-201-01\n\n**Generic name:** Azacitidine Injection\n\n**Manufacturer:** Armas Pharmaceuticals Inc\n\n> \"update_date\": \"06/08/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 72485-201-01)\", \"company_name\": \"Armas Pharmaceuticals Inc\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/08/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 72485-201-01)\", \"company_name\": \"Armas Pharmaceuticals Inc\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 12/18/2020\n\n**Last update date:** 06/08/2026\n\n> \"update_date\": \"06/08/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 72485-201-01)\", \"company_name\": \"Armas Pharmaceuticals Inc\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2083\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"06/08/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 72485-201-01)\", \"company_name\": \"Armas Pharmaceuticals Inc\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/08/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 72485-201-01)\", \"company_name\": \"Armas Pharmaceuticals Inc\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"06/08/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 72485-201-01)\", \"company_name\": \"Armas Pharmaceuticals Inc\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/18/2020\", \"package_ndc\": \"72485-201-01\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"732-637-1971\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Armas%20Pharmaceuticals%20Inc%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2083", "dosage_form": "Injection", "file": "armas-pharmaceuticals-inc-azacitidine-injection-72485-201-01.md", "generated": true, "generic_name": "Azacitidine Injection", "harvested": "2026-09-01", "id": "armas-pharmaceuticals-inc-azacitidine-injection-72485-201-01", "initial_posting_date": "12/18/2020", "manufacturer_name": "Armas Pharmaceuticals Inc", "package_ndc": "72485-201-01", "quote_dosage_form": "\"update_date\": \"06/08/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 72485-201-01)\", \"company_name\": \"Armas Pharmaceuticals Inc\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/08/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 72485-201-01)\", \"company_name\": \"Armas Pharmaceuticals Inc\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/08/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 72485-201-01)\", \"company_name\": \"Armas Pharmaceuticals Inc\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/08/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 72485-201-01)\", \"company_name\": \"Armas Pharmaceuticals Inc\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/08/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 72485-201-01)\", \"company_name\": \"Armas Pharmaceuticals Inc\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/08/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 72485-201-01)\", \"company_name\": \"Armas Pharmaceuticals Inc\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"12/18/2020\", \"package_ndc\": \"72485-201-01\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"732-637-1971\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Armas%20Pharmaceuticals%20Inc%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "72485-201-01 \u00b7 Azacitidine Injection \u00b7 Armas Pharmaceuticals Inc \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/08/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 31722-275-32\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Aspiro Pharma Limited\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 07/17/2026\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"31722-275-32\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-529-0430, customerservice@camberpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aspiro%20Pharma%20Limited%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "aspiro-pharma-limited-bupivacaine-hydrochloride-injection-31722-275-32.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "aspiro-pharma-limited-bupivacaine-hydrochloride-injection-31722-275-32", "initial_posting_date": "02/20/2018", "manufacturer_name": "Aspiro Pharma Limited", "package_ndc": "31722-275-32", "quote_dosage_form": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"31722-275-32\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-529-0430, customerservice@camberpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aspiro%20Pharma%20Limited%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "31722-275-32 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Aspiro Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 31722-275-34\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Aspiro Pharma Limited\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 07/17/2026\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"31722-275-34\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-529-0430, customerservice@camberpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aspiro%20Pharma%20Limited%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "aspiro-pharma-limited-bupivacaine-hydrochloride-injection-31722-275-34.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "aspiro-pharma-limited-bupivacaine-hydrochloride-injection-31722-275-34", "initial_posting_date": "02/20/2018", "manufacturer_name": "Aspiro Pharma Limited", "package_ndc": "31722-275-34", "quote_dosage_form": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"31722-275-34\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-529-0430, customerservice@camberpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aspiro%20Pharma%20Limited%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "31722-275-34 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Aspiro Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 31722-276-32\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Aspiro Pharma Limited\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 07/17/2026\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"31722-276-32\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-529-0430, customerservice@camberpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aspiro%20Pharma%20Limited%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "aspiro-pharma-limited-bupivacaine-hydrochloride-injection-31722-276-32.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "aspiro-pharma-limited-bupivacaine-hydrochloride-injection-31722-276-32", "initial_posting_date": "02/20/2018", "manufacturer_name": "Aspiro Pharma Limited", "package_ndc": "31722-276-32", "quote_dosage_form": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"31722-276-32\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-529-0430, customerservice@camberpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aspiro%20Pharma%20Limited%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "31722-276-32 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Aspiro Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 31722-276-34\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Aspiro Pharma Limited\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 07/17/2026\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"31722-276-34\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-529-0430, customerservice@camberpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aspiro%20Pharma%20Limited%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "aspiro-pharma-limited-bupivacaine-hydrochloride-injection-31722-276-34.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "aspiro-pharma-limited-bupivacaine-hydrochloride-injection-31722-276-34", "initial_posting_date": "02/20/2018", "manufacturer_name": "Aspiro Pharma Limited", "package_ndc": "31722-276-34", "quote_dosage_form": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"31722-276-34\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-529-0430, customerservice@camberpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aspiro%20Pharma%20Limited%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "31722-276-34 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Aspiro Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 31722-277-32\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Aspiro Pharma Limited\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 07/17/2026\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"31722-277-32\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-529-0430, customerservice@camberpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aspiro%20Pharma%20Limited%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "aspiro-pharma-limited-bupivacaine-hydrochloride-injection-31722-277-32.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "aspiro-pharma-limited-bupivacaine-hydrochloride-injection-31722-277-32", "initial_posting_date": "02/20/2018", "manufacturer_name": "Aspiro Pharma Limited", "package_ndc": "31722-277-32", "quote_dosage_form": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-32)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"31722-277-32\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-529-0430, customerservice@camberpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aspiro%20Pharma%20Limited%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "31722-277-32 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Aspiro Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 31722-277-34\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Aspiro Pharma Limited\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 07/17/2026\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"31722-277-34\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-529-0430, customerservice@camberpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aspiro%20Pharma%20Limited%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "aspiro-pharma-limited-bupivacaine-hydrochloride-injection-31722-277-34.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "aspiro-pharma-limited-bupivacaine-hydrochloride-injection-31722-277-34", "initial_posting_date": "02/20/2018", "manufacturer_name": "Aspiro Pharma Limited", "package_ndc": "31722-277-34", "quote_dosage_form": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-34)\", \"company_name\": \"Aspiro Pharma Limited\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"31722-277-34\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-529-0430, customerservice@camberpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aspiro%20Pharma%20Limited%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "31722-277-34 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Aspiro Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 13107-068-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated availability: October 2026\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 07/21/2026\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"13107-068-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(866) 850-2876 or CustomerService@AurobindoUSA.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-13107-068-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-13107-068-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "13107-068-01", "quote_dosage_form": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated availability: October 2026", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"13107-068-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(866) 850-2876 or CustomerService@AurobindoUSA.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "13107-068-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 13107-069-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated availability: October 2026\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 07/21/2026\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"13107-069-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(866) 850-2876 or CustomerService@AurobindoUSA.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-13107-069-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-13107-069-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "13107-069-01", "quote_dosage_form": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated availability: October 2026", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"13107-069-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(866) 850-2876 or CustomerService@AurobindoUSA.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "13107-069-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 13107-070-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated availability: October 2026\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 07/21/2026\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"13107-070-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(866) 850-2876 or CustomerService@AurobindoUSA.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-13107-070-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-13107-070-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "13107-070-01", "quote_dosage_form": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated availability: October 2026", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"13107-070-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(866) 850-2876 or CustomerService@AurobindoUSA.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "13107-070-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 13107-072-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated availability: October 2026\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 07/21/2026\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"13107-072-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(866) 850-2876 OR CustomerService@AurobindoUSA.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-13107-072-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-13107-072-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "13107-072-01", "quote_dosage_form": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated availability: October 2026", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"13107-072-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(866) 850-2876 OR CustomerService@AurobindoUSA.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "13107-072-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 13107-073-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated availability: October 2026\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 07/21/2026\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"13107-073-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(866) 850-2876 or CustomerService@AurobindoUSA.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-13107-073-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-13107-073-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "13107-073-01", "quote_dosage_form": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated availability: October 2026", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"13107-073-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(866) 850-2876 or CustomerService@AurobindoUSA.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "13107-073-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 13107-074-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated availability: October 2026\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 07/21/2026\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"13107-074-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(866) 850-2876 OR CustomerService@AurobindoUSA.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-13107-074-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-13107-074-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "13107-074-01", "quote_dosage_form": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/21/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated availability: October 2026", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"13107-074-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(866) 850-2876 OR CustomerService@AurobindoUSA.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "13107-074-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59651-722-01\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 06/02/2026\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"59651-722-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-clonazepam-tablet-59651-722-01.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-clonazepam-tablet-59651-722-01", "initial_posting_date": "03/10/2023", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "59651-722-01", "quote_dosage_form": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"59651-722-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "59651-722-01 \u00b7 Clonazepam Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/02/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59651-722-99\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 06/02/2026\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"59651-722-99\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-clonazepam-tablet-59651-722-99.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-clonazepam-tablet-59651-722-99", "initial_posting_date": "03/10/2023", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "59651-722-99", "quote_dosage_form": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 59651-722-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"59651-722-99\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "59651-722-99 \u00b7 Clonazepam Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/02/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59651-723-01\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 06/02/2026\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"59651-723-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-clonazepam-tablet-59651-723-01.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-clonazepam-tablet-59651-723-01", "initial_posting_date": "03/10/2023", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "59651-723-01", "quote_dosage_form": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"59651-723-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "59651-723-01 \u00b7 Clonazepam Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/02/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59651-723-99\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 06/02/2026\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"59651-723-99\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-clonazepam-tablet-59651-723-99.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-clonazepam-tablet-59651-723-99", "initial_posting_date": "03/10/2023", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "59651-723-99", "quote_dosage_form": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 59651-723-99)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"59651-723-99\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "59651-723-99 \u00b7 Clonazepam Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/02/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59651-724-01\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 06/02/2026\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"59651-724-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-clonazepam-tablet-59651-724-01.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-clonazepam-tablet-59651-724-01", "initial_posting_date": "03/10/2023", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "59651-724-01", "quote_dosage_form": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-01)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"59651-724-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "59651-724-01 \u00b7 Clonazepam Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/02/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59651-724-05\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-05)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-05)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 06/02/2026\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-05)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-05)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-05)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"59651-724-05\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-clonazepam-tablet-59651-724-05.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-clonazepam-tablet-59651-724-05", "initial_posting_date": "03/10/2023", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "59651-724-05", "quote_dosage_form": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-05)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-05)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-05)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-05)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 59651-724-05)\", \"company_name\": \"Aurobindo Pharma USA\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"59651-724-05\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "59651-724-05 \u00b7 Clonazepam Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/02/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 65862-617-90\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 06/02/2026\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"65862-617-90\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-quinapril-hydrochloride-tablet-65862-617-90.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-quinapril-hydrochloride-tablet-65862-617-90", "initial_posting_date": "01/19/2023", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "65862-617-90", "quote_dosage_form": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"65862-617-90\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "65862-617-90 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/02/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 65862-618-90\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 06/02/2026\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"65862-618-90\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-quinapril-hydrochloride-tablet-65862-618-90.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-quinapril-hydrochloride-tablet-65862-618-90", "initial_posting_date": "01/19/2023", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "65862-618-90", "quote_dosage_form": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"65862-618-90\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "65862-618-90 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/02/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 65862-620-90\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 06/02/2026\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"65862-620-90\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-quinapril-hydrochloride-tablet-65862-620-90.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-quinapril-hydrochloride-tablet-65862-620-90", "initial_posting_date": "01/19/2023", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "65862-620-90", "quote_dosage_form": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"65862-620-90\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "65862-620-90 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/02/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 65862-161-90\n\n**Generic name:** Quinapril/Hydrochlorothiazide Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 06/02/2026\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"65862-161-90\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-quinapril-hydrochlorothiazide-tablet-65862-161-90.md", "generated": true, "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-quinapril-hydrochlorothiazide-tablet-65862-161-90", "initial_posting_date": "01/19/2023", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "65862-161-90", "quote_dosage_form": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"65862-161-90\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "65862-161-90 \u00b7 Quinapril/Hydrochlorothiazide Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/02/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 65862-162-90\n\n**Generic name:** Quinapril/Hydrochlorothiazide Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 06/02/2026\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"65862-162-90\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-quinapril-hydrochlorothiazide-tablet-65862-162-90.md", "generated": true, "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-quinapril-hydrochlorothiazide-tablet-65862-162-90", "initial_posting_date": "01/19/2023", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "65862-162-90", "quote_dosage_form": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"65862-162-90\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "65862-162-90 \u00b7 Quinapril/Hydrochlorothiazide Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/02/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 65862-163-90\n\n**Generic name:** Quinapril/Hydrochlorothiazide Tablet\n\n**Manufacturer:** Aurobindo Pharma USA\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 06/02/2026\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"65862-163-90\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "aurobindo-pharma-usa-quinapril-hydrochlorothiazide-tablet-65862-163-90.md", "generated": true, "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "harvested": "2026-09-01", "id": "aurobindo-pharma-usa-quinapril-hydrochlorothiazide-tablet-65862-163-90", "initial_posting_date": "01/19/2023", "manufacturer_name": "Aurobindo Pharma USA", "package_ndc": "65862-163-90", "quote_dosage_form": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/02/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)\", \"company_name\": \"Aurobindo Pharma USA\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"65862-163-90\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"866-850-2876\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Aurobindo%20Pharma%20USA%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "65862-163-90 \u00b7 Quinapril/Hydrochlorothiazide Tablet \u00b7 Aurobindo Pharma USA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/02/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 23155-473-41\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Avet Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"23155-473-41\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "avet-pharmaceuticals-inc-furosemide-injection-23155-473-41.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "avet-pharmaceuticals-inc-furosemide-injection-23155-473-41", "initial_posting_date": "04/07/2020", "manufacturer_name": "Avet Pharmaceuticals, Inc.", "package_ndc": "23155-473-41", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"23155-473-41\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "23155-473-41 \u00b7 Furosemide Injection \u00b7 Avet Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 23155-473-42\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Avet Pharmaceuticals, Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: End October 2026; Manufacturing delay\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2344\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"23155-473-42\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: End October 2026; Manufacturing delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2344", "dosage_form": "Injection", "file": "avet-pharmaceuticals-inc-furosemide-injection-23155-473-42-2.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-07", "id": "avet-pharmaceuticals-inc-furosemide-injection-23155-473-42-2", "initial_posting_date": "04/07/2020", "manufacturer_name": "Avet Pharmaceuticals, Inc.", "package_ndc": "23155-473-42", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: End October 2026; Manufacturing delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"23155-473-42\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: End October 2026; Manufacturing delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "23155-473-42 \u00b7 Furosemide Injection \u00b7 Avet Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 23155-473-42\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Avet Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: late October 2026; Manufacturing delay\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"23155-473-42\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: late October 2026; Manufacturing delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "avet-pharmaceuticals-inc-furosemide-injection-23155-473-42.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "avet-pharmaceuticals-inc-furosemide-injection-23155-473-42", "initial_posting_date": "04/07/2020", "manufacturer_name": "Avet Pharmaceuticals, Inc.", "package_ndc": "23155-473-42", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: late October 2026; Manufacturing delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"23155-473-42\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: late October 2026; Manufacturing delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "23155-473-42 \u00b7 Furosemide Injection \u00b7 Avet Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 23155-473-44\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Avet Pharmaceuticals, Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: End October 2026; Manufacturing delay\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2344\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"23155-473-44\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: End October 2026; Manufacturing delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2344", "dosage_form": "Injection", "file": "avet-pharmaceuticals-inc-furosemide-injection-23155-473-44-2.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-07", "id": "avet-pharmaceuticals-inc-furosemide-injection-23155-473-44-2", "initial_posting_date": "04/07/2020", "manufacturer_name": "Avet Pharmaceuticals, Inc.", "package_ndc": "23155-473-44", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: End October 2026; Manufacturing delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"23155-473-44\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: End October 2026; Manufacturing delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "23155-473-44 \u00b7 Furosemide Injection \u00b7 Avet Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 23155-473-44\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Avet Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: late October 2026; Manufacturing delay\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"23155-473-44\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: late October 2026; Manufacturing delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "avet-pharmaceuticals-inc-furosemide-injection-23155-473-44.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "avet-pharmaceuticals-inc-furosemide-injection-23155-473-44", "initial_posting_date": "04/07/2020", "manufacturer_name": "Avet Pharmaceuticals, Inc.", "package_ndc": "23155-473-44", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: late October 2026; Manufacturing delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"23155-473-44\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: late October 2026; Manufacturing delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "23155-473-44 \u00b7 Furosemide Injection \u00b7 Avet Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 23155-600-41\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Avet Pharmaceuticals, Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: 9/25/2026\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2345\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"23155-600-41\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: 9/25/2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2345", "dosage_form": "Injection", "file": "avet-pharmaceuticals-inc-midazolam-hydrochloride-injection-23155-600-41-2.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-03", "id": "avet-pharmaceuticals-inc-midazolam-hydrochloride-injection-23155-600-41-2", "initial_posting_date": "04/02/2020", "manufacturer_name": "Avet Pharmaceuticals, Inc.", "package_ndc": "23155-600-41", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: 9/25/2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"23155-600-41\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: 9/25/2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Anesthesia", "title": "23155-600-41 \u00b7 Midazolam Hydrochloride Injection \u00b7 Avet Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 23155-600-41\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Avet Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: 8/25/2026\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"23155-600-41\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: 8/25/2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "avet-pharmaceuticals-inc-midazolam-hydrochloride-injection-23155-600-41.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "avet-pharmaceuticals-inc-midazolam-hydrochloride-injection-23155-600-41", "initial_posting_date": "04/02/2020", "manufacturer_name": "Avet Pharmaceuticals, Inc.", "package_ndc": "23155-600-41", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: 8/25/2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"23155-600-41\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: 8/25/2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "23155-600-41 \u00b7 Midazolam Hydrochloride Injection \u00b7 Avet Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 23155-601-41\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Avet Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"23155-601-41\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "avet-pharmaceuticals-inc-midazolam-hydrochloride-injection-23155-601-41.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "avet-pharmaceuticals-inc-midazolam-hydrochloride-injection-23155-601-41", "initial_posting_date": "04/02/2020", "manufacturer_name": "Avet Pharmaceuticals, Inc.", "package_ndc": "23155-601-41", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"23155-601-41\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "23155-601-41 \u00b7 Midazolam Hydrochloride Injection \u00b7 Avet Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 23155-601-42\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Avet Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"23155-601-42\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "avet-pharmaceuticals-inc-midazolam-hydrochloride-injection-23155-601-42.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "avet-pharmaceuticals-inc-midazolam-hydrochloride-injection-23155-601-42", "initial_posting_date": "04/02/2020", "manufacturer_name": "Avet Pharmaceuticals, Inc.", "package_ndc": "23155-601-42", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)\", \"company_name\": \"Avet Pharmaceuticals, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"23155-601-42\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"855-228-9470\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avet%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "23155-601-42 \u00b7 Midazolam Hydrochloride Injection \u00b7 Avet Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 83831-141-08\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Avyxa Pharma, LLC\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"83831-141-08\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"877-595-7337; customerservice@avyxa.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avyxa%20Pharma,%20LLC%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "avyxa-pharma-llc-carboplatin-injection-83831-141-08.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "avyxa-pharma-llc-carboplatin-injection-83831-141-08", "initial_posting_date": "04/28/2023", "manufacturer_name": "Avyxa Pharma, LLC", "package_ndc": "83831-141-08", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"83831-141-08\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"877-595-7337; customerservice@avyxa.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avyxa%20Pharma,%20LLC%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "83831-141-08 \u00b7 Carboplatin Injection \u00b7 Avyxa Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 83831-142-50\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Avyxa Pharma, LLC\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"83831-142-50\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"877-595-7337; customerservice@avyxa.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avyxa%20Pharma,%20LLC%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "avyxa-pharma-llc-carboplatin-injection-83831-142-50.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "avyxa-pharma-llc-carboplatin-injection-83831-142-50", "initial_posting_date": "04/28/2023", "manufacturer_name": "Avyxa Pharma, LLC", "package_ndc": "83831-142-50", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50)\", \"company_name\": \"Avyxa Pharma, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"83831-142-50\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"877-595-7337; customerservice@avyxa.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Avyxa%20Pharma,%20LLC%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "83831-142-50 \u00b7 Carboplatin Injection \u00b7 Avyxa Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 52536-125-10\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Azurity Pharmaceuticals, Inc\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 52536-125-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 52536-125-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Wilshire Pharmaceuticals, Inc.\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 52536-125-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 52536-125-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 52536-125-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"52536-125-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"877-495-6856\", \"availability\": \"Available\", \"related_info\": \"Distributed by Wilshire Pharmaceuticals, Inc.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Azurity%20Pharmaceuticals,%20Inc%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "azurity-pharmaceuticals-inc-dexmedetomidine-hydrochloride-injection-52536-125-10.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "azurity-pharmaceuticals-inc-dexmedetomidine-hydrochloride-injection-52536-125-10", "initial_posting_date": "04/10/2020", "manufacturer_name": "Azurity Pharmaceuticals, Inc", "package_ndc": "52536-125-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 52536-125-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 52536-125-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 52536-125-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 52536-125-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 52536-125-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Distributed by Wilshire Pharmaceuticals, Inc.", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"52536-125-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"877-495-6856\", \"availability\": \"Available\", \"related_info\": \"Distributed by Wilshire Pharmaceuticals, Inc.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Azurity%20Pharmaceuticals,%20Inc%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "52536-125-10 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Azurity Pharmaceuticals, Inc \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 52536-126-08\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Azurity Pharmaceuticals, Inc\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 52536-126-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 52536-126-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Wilshire Pharmaceuticals, Inc.\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 52536-126-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 52536-126-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 52536-126-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"52536-126-08\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"877-495-6856\", \"availability\": \"Available\", \"related_info\": \"Distributed by Wilshire Pharmaceuticals, Inc.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Azurity%20Pharmaceuticals,%20Inc%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "azurity-pharmaceuticals-inc-dexmedetomidine-hydrochloride-injection-52536-126-08.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "azurity-pharmaceuticals-inc-dexmedetomidine-hydrochloride-injection-52536-126-08", "initial_posting_date": "04/10/2020", "manufacturer_name": "Azurity Pharmaceuticals, Inc", "package_ndc": "52536-126-08", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 52536-126-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 52536-126-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 52536-126-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 52536-126-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 52536-126-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Distributed by Wilshire Pharmaceuticals, Inc.", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"52536-126-08\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"877-495-6856\", \"availability\": \"Available\", \"related_info\": \"Distributed by Wilshire Pharmaceuticals, Inc.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Azurity%20Pharmaceuticals,%20Inc%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "52536-126-08 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Azurity Pharmaceuticals, Inc \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72572-127-10\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Azurity Pharmaceuticals, Inc\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 72572-127-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 72572-127-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Civica\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 72572-127-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 72572-127-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 72572-127-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"72572-127-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"877-495-6856\", \"availability\": \"Available\", \"related_info\": \"Distributed by Civica\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Azurity%20Pharmaceuticals,%20Inc%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "azurity-pharmaceuticals-inc-dexmedetomidine-hydrochloride-injection-72572-127-10.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "azurity-pharmaceuticals-inc-dexmedetomidine-hydrochloride-injection-72572-127-10", "initial_posting_date": "04/10/2020", "manufacturer_name": "Azurity Pharmaceuticals, Inc", "package_ndc": "72572-127-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 72572-127-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 72572-127-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 72572-127-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 72572-127-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 72572-127-10)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Distributed by Civica", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"72572-127-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"877-495-6856\", \"availability\": \"Available\", \"related_info\": \"Distributed by Civica\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Azurity%20Pharmaceuticals,%20Inc%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "72572-127-10 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Azurity Pharmaceuticals, Inc \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72572-128-08\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Azurity Pharmaceuticals, Inc\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 72572-128-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 72572-128-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Civica\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 72572-128-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 72572-128-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 72572-128-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"72572-128-08\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"877-495-6856\", \"availability\": \"Available\", \"related_info\": \"Distributed by Civica\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Azurity%20Pharmaceuticals,%20Inc%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "azurity-pharmaceuticals-inc-dexmedetomidine-hydrochloride-injection-72572-128-08.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "azurity-pharmaceuticals-inc-dexmedetomidine-hydrochloride-injection-72572-128-08", "initial_posting_date": "04/10/2020", "manufacturer_name": "Azurity Pharmaceuticals, Inc", "package_ndc": "72572-128-08", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 72572-128-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 72572-128-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 72572-128-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 72572-128-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 72572-128-08)\", \"company_name\": \"Azurity Pharmaceuticals, Inc\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Distributed by Civica", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"72572-128-08\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"877-495-6856\", \"availability\": \"Available\", \"related_info\": \"Distributed by Civica\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Azurity%20Pharmaceuticals,%20Inc%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "72572-128-08 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Azurity Pharmaceuticals, Inc \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-1933-10\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2093\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0264-1933-10\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2093", "dosage_form": "Injection", "file": "b-braun-medical-inc-amino-acid-injection-0264-1933-10.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-amino-acid-injection-0264-1933-10", "initial_posting_date": "12/08/2020", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-1933-10", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0264-1933-10\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0264-1933-10 \u00b7 Amino Acid Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-4500-00\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2093\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0264-4500-00\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2093", "dosage_form": "Injection", "file": "b-braun-medical-inc-amino-acid-injection-0264-4500-00.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-amino-acid-injection-0264-4500-00", "initial_posting_date": "12/08/2020", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-4500-00", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0264-4500-00\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0264-4500-00 \u00b7 Amino Acid Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-4500-05\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-05)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-05)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-05)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2093\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-05)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-05)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0264-4500-05\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2093", "dosage_form": "Injection", "file": "b-braun-medical-inc-amino-acid-injection-0264-4500-05.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-amino-acid-injection-0264-4500-05", "initial_posting_date": "12/08/2020", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-4500-05", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-05)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-05)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-05)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-05)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Plenamine, Injection, 0.15 (NDC 0264-4500-05)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0264-4500-05\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0264-4500-05 \u00b7 Amino Acid Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-7520-00\n\n**Generic name:** Dextrose Monohydrate 10% Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/01/2022\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1645\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0264-7520-00\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1645", "dosage_form": "Injection", "file": "b-braun-medical-inc-dextrose-monohydrate-10-injection-0264-7520-00.md", "generated": true, "generic_name": "Dextrose Monohydrate 10% Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-dextrose-monohydrate-10-injection-0264-7520-00", "initial_posting_date": "03/01/2022", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-7520-00", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0264-7520-00\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0264-7520-00 \u00b7 Dextrose Monohydrate 10% Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-7520-10\n\n**Generic name:** Dextrose Monohydrate 10% Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/01/2022\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1645\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0264-7520-10\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1645", "dosage_form": "Injection", "file": "b-braun-medical-inc-dextrose-monohydrate-10-injection-0264-7520-10.md", "generated": true, "generic_name": "Dextrose Monohydrate 10% Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-dextrose-monohydrate-10-injection-0264-7520-10", "initial_posting_date": "03/01/2022", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-7520-10", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0264-7520-10\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0264-7520-10 \u00b7 Dextrose Monohydrate 10% Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-7520-20\n\n**Generic name:** Dextrose Monohydrate 10% Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/01/2022\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1645\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0264-7520-20\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1645", "dosage_form": "Injection", "file": "b-braun-medical-inc-dextrose-monohydrate-10-injection-0264-7520-20.md", "generated": true, "generic_name": "Dextrose Monohydrate 10% Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-dextrose-monohydrate-10-injection-0264-7520-20", "initial_posting_date": "03/01/2022", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-7520-20", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0264-7520-20\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0264-7520-20 \u00b7 Dextrose Monohydrate 10% Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-1510-31\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0264-1510-31\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "b-braun-medical-inc-dextrose-monohydrate-5-injection-0264-1510-31.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-dextrose-monohydrate-5-injection-0264-1510-31", "initial_posting_date": "02/14/2022", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-1510-31", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0264-1510-31\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0264-1510-31 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-1510-32\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0264-1510-32\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "b-braun-medical-inc-dextrose-monohydrate-5-injection-0264-1510-32.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-dextrose-monohydrate-5-injection-0264-1510-32", "initial_posting_date": "02/14/2022", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-1510-32", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0264-1510-32\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0264-1510-32 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-7510-00\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0264-7510-00\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "b-braun-medical-inc-dextrose-monohydrate-5-injection-0264-7510-00.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-dextrose-monohydrate-5-injection-0264-7510-00", "initial_posting_date": "02/14/2022", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-7510-00", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0264-7510-00\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0264-7510-00 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-7510-10\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0264-7510-10\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "b-braun-medical-inc-dextrose-monohydrate-5-injection-0264-7510-10.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-dextrose-monohydrate-5-injection-0264-7510-10", "initial_posting_date": "02/14/2022", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-7510-10", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0264-7510-10\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0264-7510-10 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-7510-20\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0264-7510-20\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "b-braun-medical-inc-dextrose-monohydrate-5-injection-0264-7510-20.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-dextrose-monohydrate-5-injection-0264-7510-20", "initial_posting_date": "02/14/2022", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-7510-20", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0264-7510-20\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0264-7510-20 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-7387-50\n\n**Generic name:** Dextrose Monohydrate 70% Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/11/2024\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 690\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/11/2024\", \"package_ndc\": \"0264-7387-50\", \"generic_name\": \"Dextrose Monohydrate 70% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2070%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "690", "dosage_form": "Injection", "file": "b-braun-medical-inc-dextrose-monohydrate-70-injection-0264-7387-50.md", "generated": true, "generic_name": "Dextrose Monohydrate 70% Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-dextrose-monohydrate-70-injection-0264-7387-50", "initial_posting_date": "10/11/2024", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-7387-50", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"10/11/2024\", \"package_ndc\": \"0264-7387-50\", \"generic_name\": \"Dextrose Monohydrate 70% Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2070%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0264-7387-50 \u00b7 Dextrose Monohydrate 70% Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0264-9872-00\n\n**Generic name:** Heparin Sodium Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD; Manufacturing delays\n\n**Initial posting date:** 11/14/2017\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Hematology\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0264-9872-00\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD; Manufacturing delays\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "b-braun-medical-inc-heparin-sodium-injection-0264-9872-00-2.md", "generated": true, "generic_name": "Heparin Sodium Injection", "harvested": "2026-09-15", "id": "b-braun-medical-inc-heparin-sodium-injection-0264-9872-00-2", "initial_posting_date": "11/14/2017", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-9872-00", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD; Manufacturing delays", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0264-9872-00\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD; Manufacturing delays\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Hematology", "title": "0264-9872-00 \u00b7 Heparin Sodium Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-9872-00\n\n**Generic name:** Heparin Sodium Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/14/2017\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3213\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Hematology\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0264-9872-00\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3213", "dosage_form": "Injection", "file": "b-braun-medical-inc-heparin-sodium-injection-0264-9872-00.md", "generated": true, "generic_name": "Heparin Sodium Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-heparin-sodium-injection-0264-9872-00", "initial_posting_date": "11/14/2017", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-9872-00", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0264-9872-00\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Hematology", "title": "0264-9872-00 \u00b7 Heparin Sodium Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0264-9872-10\n\n**Generic name:** Heparin Sodium Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD; Manufacturing delays\n\n**Initial posting date:** 11/14/2017\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Hematology\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0264-9872-10\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD; Manufacturing delays\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "b-braun-medical-inc-heparin-sodium-injection-0264-9872-10-2.md", "generated": true, "generic_name": "Heparin Sodium Injection", "harvested": "2026-09-15", "id": "b-braun-medical-inc-heparin-sodium-injection-0264-9872-10-2", "initial_posting_date": "11/14/2017", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-9872-10", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD; Manufacturing delays", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0264-9872-10\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD; Manufacturing delays\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Hematology", "title": "0264-9872-10 \u00b7 Heparin Sodium Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-9872-10\n\n**Generic name:** Heparin Sodium Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/14/2017\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3213\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Hematology\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0264-9872-10\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3213", "dosage_form": "Injection", "file": "b-braun-medical-inc-heparin-sodium-injection-0264-9872-10.md", "generated": true, "generic_name": "Heparin Sodium Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-heparin-sodium-injection-0264-9872-10", "initial_posting_date": "11/14/2017", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-9872-10", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0264-9872-10\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Hematology", "title": "0264-9872-10 \u00b7 Heparin Sodium Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-9594-10\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/25/2017\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3233\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/25/2017\", \"package_ndc\": \"0264-9594-10\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3233", "dosage_form": "Injection", "file": "b-braun-medical-inc-lidocaine-hydrochloride-injection-0264-9594-10.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-lidocaine-hydrochloride-injection-0264-9594-10", "initial_posting_date": "10/25/2017", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-9594-10", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"10/25/2017\", \"package_ndc\": \"0264-9594-10\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0264-9594-10 \u00b7 Lidocaine Hydrochloride Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-9594-20\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/25/2017\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3233\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/25/2017\", \"package_ndc\": \"0264-9594-20\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3233", "dosage_form": "Injection", "file": "b-braun-medical-inc-lidocaine-hydrochloride-injection-0264-9594-20.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-lidocaine-hydrochloride-injection-0264-9594-20", "initial_posting_date": "10/25/2017", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-9594-20", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"10/25/2017\", \"package_ndc\": \"0264-9594-20\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0264-9594-20 \u00b7 Lidocaine Hydrochloride Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-9598-20\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/25/2017\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3233\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/25/2017\", \"package_ndc\": \"0264-9598-20\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3233", "dosage_form": "Injection", "file": "b-braun-medical-inc-lidocaine-hydrochloride-injection-0264-9598-20.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "b-braun-medical-inc-lidocaine-hydrochloride-injection-0264-9598-20", "initial_posting_date": "10/25/2017", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-9598-20", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"10/25/2017\", \"package_ndc\": \"0264-9598-20\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0264-9598-20 \u00b7 Lidocaine Hydrochloride Injection \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-2101-00\n\n**Generic name:** Sterile Water Irrigant\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Dosage form:** Irrigant\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0264-2101-00\", \"generic_name\": \"Sterile Water Irrigant\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Irrigant", "file": "b-braun-medical-inc-sterile-water-irrigant-0264-2101-00.md", "generated": true, "generic_name": "Sterile Water Irrigant", "harvested": "2026-09-01", "id": "b-braun-medical-inc-sterile-water-irrigant-0264-2101-00", "initial_posting_date": "04/28/2023", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-2101-00", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0264-2101-00\", \"generic_name\": \"Sterile Water Irrigant\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0264-2101-00 \u00b7 Sterile Water Irrigant \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0264-2101-10\n\n**Generic name:** Sterile Water Irrigant\n\n**Manufacturer:** B. Braun Medical Inc.\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Dosage form:** Irrigant\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0264-2101-10\", \"generic_name\": \"Sterile Water Irrigant\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Irrigant", "file": "b-braun-medical-inc-sterile-water-irrigant-0264-2101-10.md", "generated": true, "generic_name": "Sterile Water Irrigant", "harvested": "2026-09-01", "id": "b-braun-medical-inc-sterile-water-irrigant-0264-2101-10", "initial_posting_date": "04/28/2023", "manufacturer_name": "B. Braun Medical Inc.", "package_ndc": "0264-2101-10", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)\", \"company_name\": \"B. Braun Medical Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0264-2101-10\", \"generic_name\": \"Sterile Water Irrigant\", \"contact_info\": \"800-227-2862\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22B.%20Braun%20Medical%20Inc.%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0264-2101-10 \u00b7 Sterile Water Irrigant \u00b7 B. Braun Medical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0499-06\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 2093\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0499-06\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2093", "dosage_form": "Injection", "file": "baxter-healthcare-amino-acid-injection-0338-0499-06.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-amino-acid-injection-0338-0499-06", "initial_posting_date": "12/08/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0499-06", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0499-06\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0338-0499-06 \u00b7 Amino Acid Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0502-03\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-03\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Status:** Current\n\n> \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-03\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 09/04/2026\n\n> \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-03\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Days in shortage:** 2107\n\n**Dosage form:** Injection\n\n> \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-03\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-03\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-03\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2107", "dosage_form": "Injection", "file": "baxter-healthcare-amino-acid-injection-0338-0502-03-2.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-15", "id": "baxter-healthcare-amino-acid-injection-0338-0502-03-2", "initial_posting_date": "12/08/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0502-03", "quote_dosage_form": "\"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-03\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_manufacturer_name": "\"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-03\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_status": "\"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-03\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_therapeutic_category": "\"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-03\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_update_date": "\"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-03\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-03\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0338-0502-03 \u00b7 Amino Acid Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0502-03\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 2093\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-03\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2093", "dosage_form": "Injection", "file": "baxter-healthcare-amino-acid-injection-0338-0502-03.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-amino-acid-injection-0338-0502-03", "initial_posting_date": "12/08/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0502-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-03\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0338-0502-03 \u00b7 Amino Acid Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0502-06\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-06\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Status:** Current\n\n> \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-06\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 09/04/2026\n\n> \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-06\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Days in shortage:** 2107\n\n**Dosage form:** Injection\n\n> \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-06\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-06\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-06\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2107", "dosage_form": "Injection", "file": "baxter-healthcare-amino-acid-injection-0338-0502-06-2.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-15", "id": "baxter-healthcare-amino-acid-injection-0338-0502-06-2", "initial_posting_date": "12/08/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0502-06", "quote_dosage_form": "\"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-06\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_manufacturer_name": "\"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-06\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_status": "\"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-06\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_therapeutic_category": "\"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-06\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_update_date": "\"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-06\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-06\", \"generic_name\": \"Amino Acid Injection\", \"company_name\": \"Baxter Healthcare\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0338-0502-06 \u00b7 Amino Acid Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0502-06\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 2093\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-06\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2093", "dosage_form": "Injection", "file": "baxter-healthcare-amino-acid-injection-0338-0502-06.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-amino-acid-injection-0338-0502-06", "initial_posting_date": "12/08/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0502-06", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0502-06\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0338-0502-06 \u00b7 Amino Acid Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0338-0644-03\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: December 2026\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 09/04/2026\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Days in shortage:** 2102\n\n**Reason for shortage:** Shortage of an inactive ingredient component\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0644-03\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: December 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2102", "dosage_form": "Injection", "file": "baxter-healthcare-amino-acid-injection-0338-0644-03-2.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-10", "id": "baxter-healthcare-amino-acid-injection-0338-0644-03-2", "initial_posting_date": "12/08/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0644-03", "quote_dosage_form": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Estimated recovery: December 2026", "shortage_reason": "Shortage of an inactive ingredient component", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0644-03\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: December 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0338-0644-03 \u00b7 Amino Acid Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0338-0644-03\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Days in shortage:** 2093\n\n**Reason for shortage:** Shortage of an inactive ingredient component\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0644-03\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2093", "dosage_form": "Injection", "file": "baxter-healthcare-amino-acid-injection-0338-0644-03.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-amino-acid-injection-0338-0644-03", "initial_posting_date": "12/08/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0644-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an inactive ingredient component", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0644-03\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0338-0644-03 \u00b7 Amino Acid Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0644-04\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 2093\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0644-04\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2093", "dosage_form": "Injection", "file": "baxter-healthcare-amino-acid-injection-0338-0644-04.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-amino-acid-injection-0338-0644-04", "initial_posting_date": "12/08/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0644-04", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0644-04\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0338-0644-04 \u00b7 Amino Acid Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0644-06\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 2093\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0644-06\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2093", "dosage_form": "Injection", "file": "baxter-healthcare-amino-acid-injection-0338-0644-06.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-amino-acid-injection-0338-0644-06", "initial_posting_date": "12/08/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0644-06", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-0644-06\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0338-0644-06 \u00b7 Amino Acid Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-1130-03\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 2093\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-1130-03\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2093", "dosage_form": "Injection", "file": "baxter-healthcare-amino-acid-injection-0338-1130-03.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-amino-acid-injection-0338-1130-03", "initial_posting_date": "12/08/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-1130-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-1130-03\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0338-1130-03 \u00b7 Amino Acid Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-1130-04\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 2093\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-1130-04\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2093", "dosage_form": "Injection", "file": "baxter-healthcare-amino-acid-injection-0338-1130-04.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-amino-acid-injection-0338-1130-04", "initial_posting_date": "12/08/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-1130-04", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-1130-04\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0338-1130-04 \u00b7 Amino Acid Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-1130-06\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 2093\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-1130-06\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2093", "dosage_form": "Injection", "file": "baxter-healthcare-amino-acid-injection-0338-1130-06.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-amino-acid-injection-0338-1130-06", "initial_posting_date": "12/08/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-1130-06", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0338-1130-06\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0338-1130-06 \u00b7 Amino Acid Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-3410-50\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0338-3410-50\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "baxter-healthcare-clindamycin-phosphate-injection-0338-3410-50.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-clindamycin-phosphate-injection-0338-3410-50", "initial_posting_date": "03/21/2023", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-3410-50", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0338-3410-50\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0338-3410-50 \u00b7 Clindamycin Phosphate Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0338-3612-50\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0338-3612-50\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "baxter-healthcare-clindamycin-phosphate-injection-0338-3612-50.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-clindamycin-phosphate-injection-0338-3612-50", "initial_posting_date": "03/21/2023", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-3612-50", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0338-3612-50\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0338-3612-50 \u00b7 Clindamycin Phosphate Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-3814-50\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 09/04/2026\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1269\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0338-3814-50\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1269", "dosage_form": "Injection", "file": "baxter-healthcare-clindamycin-phosphate-injection-0338-3814-50-2.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-10", "id": "baxter-healthcare-clindamycin-phosphate-injection-0338-3814-50-2", "initial_posting_date": "03/21/2023", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-3814-50", "quote_dosage_form": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0338-3814-50\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0338-3814-50 \u00b7 Clindamycin Phosphate Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0338-3814-50\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0338-3814-50\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "baxter-healthcare-clindamycin-phosphate-injection-0338-3814-50.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-clindamycin-phosphate-injection-0338-3814-50", "initial_posting_date": "03/21/2023", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-3814-50", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0338-3814-50\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0338-3814-50 \u00b7 Clindamycin Phosphate Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-9545-50\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0338-9545-50\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "baxter-healthcare-clindamycin-phosphate-injection-0338-9545-50.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-clindamycin-phosphate-injection-0338-9545-50", "initial_posting_date": "03/21/2023", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-9545-50", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0338-9545-50\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0338-9545-50 \u00b7 Clindamycin Phosphate Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-9549-50\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0338-9549-50\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "baxter-healthcare-clindamycin-phosphate-injection-0338-9549-50.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-clindamycin-phosphate-injection-0338-9549-50", "initial_posting_date": "03/21/2023", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-9549-50", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0338-9549-50\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0338-9549-50 \u00b7 Clindamycin Phosphate Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-9553-50\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0338-9553-50\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "baxter-healthcare-clindamycin-phosphate-injection-0338-9553-50.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-clindamycin-phosphate-injection-0338-9553-50", "initial_posting_date": "03/21/2023", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-9553-50", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0338-9553-50\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0338-9553-50 \u00b7 Clindamycin Phosphate Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0338-9555-24\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: September 2026\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0338-9555-24\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "baxter-healthcare-dexmedetomidine-hydrochloride-injection-0338-9555-24.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dexmedetomidine-hydrochloride-injection-0338-9555-24", "initial_posting_date": "04/10/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-9555-24", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: September 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0338-9555-24\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0338-9555-24 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-9557-12\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0338-9557-12\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "baxter-healthcare-dexmedetomidine-hydrochloride-injection-0338-9557-12.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dexmedetomidine-hydrochloride-injection-0338-9557-12", "initial_posting_date": "04/10/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-9557-12", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0338-9557-12\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0338-9557-12 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43066-555-24\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"43066-555-24\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "baxter-healthcare-dexmedetomidine-hydrochloride-injection-43066-555-24.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dexmedetomidine-hydrochloride-injection-43066-555-24", "initial_posting_date": "04/10/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "43066-555-24", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"43066-555-24\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "43066-555-24 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43066-557-12\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"43066-557-12\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "baxter-healthcare-dexmedetomidine-hydrochloride-injection-43066-557-12.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dexmedetomidine-hydrochloride-injection-43066-557-12", "initial_posting_date": "04/10/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "43066-557-12", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"43066-557-12\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "43066-557-12 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0338-0023-02\n\n**Generic name:** Dextrose Monohydrate 10% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: September 2026\n\n**Initial posting date:** 03/01/2022\n\n**Last update date:** 09/04/2026\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1654\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0338-0023-02\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1654", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-10-injection-0338-0023-02-2.md", "generated": true, "generic_name": "Dextrose Monohydrate 10% Injection", "harvested": "2026-09-10", "id": "baxter-healthcare-dextrose-monohydrate-10-injection-0338-0023-02-2", "initial_posting_date": "03/01/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0023-02", "quote_dosage_form": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: September 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0338-0023-02\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0023-02 \u00b7 Dextrose Monohydrate 10% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0023-02\n\n**Generic name:** Dextrose Monohydrate 10% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/01/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1645\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0338-0023-02\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1645", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-10-injection-0338-0023-02.md", "generated": true, "generic_name": "Dextrose Monohydrate 10% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-10-injection-0338-0023-02", "initial_posting_date": "03/01/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0023-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0338-0023-02\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0023-02 \u00b7 Dextrose Monohydrate 10% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0023-03\n\n**Generic name:** Dextrose Monohydrate 10% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/01/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1645\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0338-0023-03\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1645", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-10-injection-0338-0023-03.md", "generated": true, "generic_name": "Dextrose Monohydrate 10% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-10-injection-0338-0023-03", "initial_posting_date": "03/01/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0023-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0338-0023-03\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0023-03 \u00b7 Dextrose Monohydrate 10% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0023-04\n\n**Generic name:** Dextrose Monohydrate 10% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/01/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1645\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0338-0023-04\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1645", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-10-injection-0338-0023-04.md", "generated": true, "generic_name": "Dextrose Monohydrate 10% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-10-injection-0338-0023-04", "initial_posting_date": "03/01/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0023-04", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0338-0023-04\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0023-04 \u00b7 Dextrose Monohydrate 10% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0017-02\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-02\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-02.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-02", "initial_posting_date": "02/14/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0017-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-02\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0017-02 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0017-03\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-03\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-03.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-03", "initial_posting_date": "02/14/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0017-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-03\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0017-03 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0017-10\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-10\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-10.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-10", "initial_posting_date": "02/14/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0017-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-10\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0017-10 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0017-11\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-11\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-11.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-11", "initial_posting_date": "02/14/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0017-11", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-11\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0017-11 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0017-18\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-18\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-18.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-18", "initial_posting_date": "02/14/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0017-18", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-18\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0017-18 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0017-31\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-31\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-31.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-31", "initial_posting_date": "02/14/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0017-31", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-31\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0017-31 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0017-38\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-38\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-38.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-38", "initial_posting_date": "02/14/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0017-38", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-38\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0017-38 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0017-41\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-41\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-41.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-41", "initial_posting_date": "02/14/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0017-41", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-41\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0017-41 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0017-48\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-48\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-48.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0017-48", "initial_posting_date": "02/14/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0017-48", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0017-48\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0017-48 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0070-10\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0070-10\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0070-10.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0070-10", "initial_posting_date": "02/14/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0070-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0070-10\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0070-10 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0074-30\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0074-30)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0074-30)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/20/2026\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0074-30)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 43\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0074-30)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0074-30)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/20/2026\", \"package_ndc\": \"0338-0074-30\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "43", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0074-30.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0074-30", "initial_posting_date": "07/20/2026", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0074-30", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0074-30)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0074-30)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0074-30)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0074-30)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0074-30)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"07/20/2026\", \"package_ndc\": \"0338-0074-30\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0074-30 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0078-20\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0078-20)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0078-20)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0078-20)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0078-20)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0078-20)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0078-20\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0078-20.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0078-20", "initial_posting_date": "02/14/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0078-20", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0078-20)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0078-20)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0078-20)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0078-20)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0078-20)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0078-20\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0078-20 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0551-11\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0551-11\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0551-11.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0551-11", "initial_posting_date": "02/14/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0551-11", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0551-11\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0551-11 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0551-18\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0551-18\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0551-18.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-0551-18", "initial_posting_date": "02/14/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0551-18", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-0551-18\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0551-18 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-9664-40\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9664-40)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9664-40)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9664-40)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9664-40)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9664-40)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-9664-40\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-9664-40.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-9664-40", "initial_posting_date": "02/14/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-9664-40", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9664-40)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9664-40)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9664-40)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9664-40)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9664-40)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-9664-40\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-9664-40 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-9666-35\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9666-35)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9666-35)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9666-35)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9666-35)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9666-35)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-9666-35\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-9666-35.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-5-injection-0338-9666-35", "initial_posting_date": "02/14/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-9666-35", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9666-35)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9666-35)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9666-35)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9666-35)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9666-35)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0338-9666-35\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-9666-35 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0338-0719-06\n\n**Generic name:** Dextrose Monohydrate 70% Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: September 2026\n\n**Initial posting date:** 10/11/2024\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 690\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/11/2024\", \"package_ndc\": \"0338-0719-06\", \"generic_name\": \"Dextrose Monohydrate 70% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2070%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "690", "dosage_form": "Injection", "file": "baxter-healthcare-dextrose-monohydrate-70-injection-0338-0719-06.md", "generated": true, "generic_name": "Dextrose Monohydrate 70% Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dextrose-monohydrate-70-injection-0338-0719-06", "initial_posting_date": "10/11/2024", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0719-06", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: September 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/11/2024\", \"package_ndc\": \"0338-0719-06\", \"generic_name\": \"Dextrose Monohydrate 70% Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2070%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0338-0719-06 \u00b7 Dextrose Monohydrate 70% Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-1073-02\n\n**Generic name:** Dobutamine Hydrochloride Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0338-1073-02\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "baxter-healthcare-dobutamine-hydrochloride-injection-0338-1073-02.md", "generated": true, "generic_name": "Dobutamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dobutamine-hydrochloride-injection-0338-1073-02", "initial_posting_date": "11/06/2017", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-1073-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0338-1073-02\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0338-1073-02 \u00b7 Dobutamine Hydrochloride Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-1075-02\n\n**Generic name:** Dobutamine Hydrochloride Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0338-1075-02\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "baxter-healthcare-dobutamine-hydrochloride-injection-0338-1075-02.md", "generated": true, "generic_name": "Dobutamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dobutamine-hydrochloride-injection-0338-1075-02", "initial_posting_date": "11/06/2017", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-1075-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0338-1075-02\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0338-1075-02 \u00b7 Dobutamine Hydrochloride Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-1077-02\n\n**Generic name:** Dobutamine Hydrochloride Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0338-1077-02\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "baxter-healthcare-dobutamine-hydrochloride-injection-0338-1077-02.md", "generated": true, "generic_name": "Dobutamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dobutamine-hydrochloride-injection-0338-1077-02", "initial_posting_date": "11/06/2017", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-1077-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0338-1077-02\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0338-1077-02 \u00b7 Dobutamine Hydrochloride Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-1005-02\n\n**Generic name:** Dopamine Hydrochloride Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0338-1005-02\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "baxter-healthcare-dopamine-hydrochloride-injection-0338-1005-02.md", "generated": true, "generic_name": "Dopamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dopamine-hydrochloride-injection-0338-1005-02", "initial_posting_date": "11/06/2017", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-1005-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0338-1005-02\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0338-1005-02 \u00b7 Dopamine Hydrochloride Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-1005-03\n\n**Generic name:** Dopamine Hydrochloride Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0338-1005-03\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "baxter-healthcare-dopamine-hydrochloride-injection-0338-1005-03.md", "generated": true, "generic_name": "Dopamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dopamine-hydrochloride-injection-0338-1005-03", "initial_posting_date": "11/06/2017", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-1005-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0338-1005-03\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0338-1005-03 \u00b7 Dopamine Hydrochloride Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-1007-02\n\n**Generic name:** Dopamine Hydrochloride Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0338-1007-02\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "baxter-healthcare-dopamine-hydrochloride-injection-0338-1007-02.md", "generated": true, "generic_name": "Dopamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dopamine-hydrochloride-injection-0338-1007-02", "initial_posting_date": "11/06/2017", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-1007-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0338-1007-02\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0338-1007-02 \u00b7 Dopamine Hydrochloride Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-1007-03\n\n**Generic name:** Dopamine Hydrochloride Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0338-1007-03\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "baxter-healthcare-dopamine-hydrochloride-injection-0338-1007-03.md", "generated": true, "generic_name": "Dopamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-dopamine-hydrochloride-injection-0338-1007-03", "initial_posting_date": "11/06/2017", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-1007-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0338-1007-03\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0338-1007-03 \u00b7 Dopamine Hydrochloride Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 36000-282-25\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"36000-282-25\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "baxter-healthcare-furosemide-injection-36000-282-25.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-furosemide-injection-36000-282-25", "initial_posting_date": "04/07/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "36000-282-25", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"36000-282-25\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "36000-282-25 \u00b7 Furosemide Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 36000-283-25\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"36000-283-25\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "baxter-healthcare-furosemide-injection-36000-283-25.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-furosemide-injection-36000-283-25", "initial_posting_date": "04/07/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "36000-283-25", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"36000-283-25\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "36000-283-25 \u00b7 Furosemide Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 36000-284-25\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"36000-284-25\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "baxter-healthcare-furosemide-injection-36000-284-25.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-furosemide-injection-36000-284-25", "initial_posting_date": "04/07/2020", "manufacturer_name": "Baxter Healthcare", "package_ndc": "36000-284-25", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"36000-284-25\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "36000-284-25 \u00b7 Furosemide Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0431-03\n\n**Generic name:** Heparin Sodium Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/14/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 3213\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Hematology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0338-0431-03\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3213", "dosage_form": "Injection", "file": "baxter-healthcare-heparin-sodium-injection-0338-0431-03.md", "generated": true, "generic_name": "Heparin Sodium Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-heparin-sodium-injection-0338-0431-03", "initial_posting_date": "11/14/2017", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0431-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0338-0431-03\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Hematology", "title": "0338-0431-03 \u00b7 Heparin Sodium Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0433-04\n\n**Generic name:** Heparin Sodium Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/14/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 3213\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Hematology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0338-0433-04\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3213", "dosage_form": "Injection", "file": "baxter-healthcare-heparin-sodium-injection-0338-0433-04.md", "generated": true, "generic_name": "Heparin Sodium Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-heparin-sodium-injection-0338-0433-04", "initial_posting_date": "11/14/2017", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0433-04", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0338-0433-04\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Hematology", "title": "0338-0433-04 \u00b7 Heparin Sodium Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0338-3991-01\n\n**Generic name:** Ifosfamide Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 06/12/2026\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 81\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"0338-3991-01\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "81", "dosage_form": "Injection", "file": "baxter-healthcare-ifosfamide-injection-0338-3991-01.md", "generated": true, "generic_name": "Ifosfamide Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-ifosfamide-injection-0338-3991-01", "initial_posting_date": "06/12/2026", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-3991-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"0338-3991-01\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Oncology", "title": "0338-3991-01 \u00b7 Ifosfamide Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0338-3993-01\n\n**Generic name:** Ifosfamide Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 06/12/2026\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 81\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"0338-3993-01\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "81", "dosage_form": "Injection", "file": "baxter-healthcare-ifosfamide-injection-0338-3993-01.md", "generated": true, "generic_name": "Ifosfamide Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-ifosfamide-injection-0338-3993-01", "initial_posting_date": "06/12/2026", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-3993-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"0338-3993-01\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Oncology", "title": "0338-3993-01 \u00b7 Ifosfamide Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 10019-925-01\n\n**Generic name:** Ifosfamide Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 06/12/2026\n\n**Last update date:** 09/04/2026\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 90\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"10019-925-01\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "90", "dosage_form": "Injection", "file": "baxter-healthcare-ifosfamide-injection-10019-925-01-2.md", "generated": true, "generic_name": "Ifosfamide Injection", "harvested": "2026-09-10", "id": "baxter-healthcare-ifosfamide-injection-10019-925-01-2", "initial_posting_date": "06/12/2026", "manufacturer_name": "Baxter Healthcare", "package_ndc": "10019-925-01", "quote_dosage_form": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"10019-925-01\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Oncology", "title": "10019-925-01 \u00b7 Ifosfamide Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 10019-925-01\n\n**Generic name:** Ifosfamide Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: September 2026\n\n**Initial posting date:** 06/12/2026\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 81\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"10019-925-01\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "81", "dosage_form": "Injection", "file": "baxter-healthcare-ifosfamide-injection-10019-925-01.md", "generated": true, "generic_name": "Ifosfamide Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-ifosfamide-injection-10019-925-01", "initial_posting_date": "06/12/2026", "manufacturer_name": "Baxter Healthcare", "package_ndc": "10019-925-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: September 2026", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"10019-925-01\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Oncology", "title": "10019-925-01 \u00b7 Ifosfamide Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 10019-926-02\n\n**Generic name:** Ifosfamide Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 06/12/2026\n\n**Last update date:** 09/04/2026\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 90\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"10019-926-02\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "90", "dosage_form": "Injection", "file": "baxter-healthcare-ifosfamide-injection-10019-926-02-2.md", "generated": true, "generic_name": "Ifosfamide Injection", "harvested": "2026-09-10", "id": "baxter-healthcare-ifosfamide-injection-10019-926-02-2", "initial_posting_date": "06/12/2026", "manufacturer_name": "Baxter Healthcare", "package_ndc": "10019-926-02", "quote_dosage_form": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"10019-926-02\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Oncology", "title": "10019-926-02 \u00b7 Ifosfamide Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 10019-926-02\n\n**Generic name:** Ifosfamide Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: September 2026\n\n**Initial posting date:** 06/12/2026\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 81\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"10019-926-02\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "81", "dosage_form": "Injection", "file": "baxter-healthcare-ifosfamide-injection-10019-926-02.md", "generated": true, "generic_name": "Ifosfamide Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-ifosfamide-injection-10019-926-02", "initial_posting_date": "06/12/2026", "manufacturer_name": "Baxter Healthcare", "package_ndc": "10019-926-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: September 2026", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"10019-926-02\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Oncology", "title": "10019-926-02 \u00b7 Ifosfamide Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0338-0069-10\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: November 2026\n\n**Initial posting date:** 06/06/2018\n\n**Last update date:** 09/04/2026\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3018\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"0338-0069-10\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: November 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3018", "dosage_form": "Injection", "file": "baxter-healthcare-ketorolac-tromethamine-injection-0338-0069-10-2.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-10", "id": "baxter-healthcare-ketorolac-tromethamine-injection-0338-0069-10-2", "initial_posting_date": "06/06/2018", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0069-10", "quote_dosage_form": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: November 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"0338-0069-10\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: November 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0338-0069-10 \u00b7 Ketorolac Tromethamine Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0338-0069-10\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: January 2027\n\n**Initial posting date:** 06/06/2018\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3009\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"0338-0069-10\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: January 2027\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3009", "dosage_form": "Injection", "file": "baxter-healthcare-ketorolac-tromethamine-injection-0338-0069-10.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-ketorolac-tromethamine-injection-0338-0069-10", "initial_posting_date": "06/06/2018", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0069-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: January 2027", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"0338-0069-10\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: January 2027\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0338-0069-10 \u00b7 Ketorolac Tromethamine Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0338-0072-25\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: November 2026\n\n**Initial posting date:** 06/06/2018\n\n**Last update date:** 09/04/2026\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3018\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"0338-0072-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: November 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3018", "dosage_form": "Injection", "file": "baxter-healthcare-ketorolac-tromethamine-injection-0338-0072-25-2.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-10", "id": "baxter-healthcare-ketorolac-tromethamine-injection-0338-0072-25-2", "initial_posting_date": "06/06/2018", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0072-25", "quote_dosage_form": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: November 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"0338-0072-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: November 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0338-0072-25 \u00b7 Ketorolac Tromethamine Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0338-0072-25\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 06/06/2018\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3009\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"0338-0072-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3009", "dosage_form": "Injection", "file": "baxter-healthcare-ketorolac-tromethamine-injection-0338-0072-25.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-ketorolac-tromethamine-injection-0338-0072-25", "initial_posting_date": "06/06/2018", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0072-25", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"0338-0072-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0338-0072-25 \u00b7 Ketorolac Tromethamine Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0409-03\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/25/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 3233\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/25/2017\", \"package_ndc\": \"0338-0409-03\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3233", "dosage_form": "Injection", "file": "baxter-healthcare-lidocaine-hydrochloride-injection-0338-0409-03.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-lidocaine-hydrochloride-injection-0338-0409-03", "initial_posting_date": "10/25/2017", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0409-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"10/25/2017\", \"package_ndc\": \"0338-0409-03\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0338-0409-03 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0411-02\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/25/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 3233\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/25/2017\", \"package_ndc\": \"0338-0411-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3233", "dosage_form": "Injection", "file": "baxter-healthcare-lidocaine-hydrochloride-injection-0338-0411-02.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-lidocaine-hydrochloride-injection-0338-0411-02", "initial_posting_date": "10/25/2017", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0411-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"10/25/2017\", \"package_ndc\": \"0338-0411-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0338-0411-02 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-1055-48\n\n**Generic name:** Metronidazole Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/13/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1692\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/13/2022\", \"package_ndc\": \"0338-1055-48\", \"generic_name\": \"Metronidazole Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Metronidazole%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1692", "dosage_form": "Injection", "file": "baxter-healthcare-metronidazole-injection-0338-1055-48.md", "generated": true, "generic_name": "Metronidazole Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-metronidazole-injection-0338-1055-48", "initial_posting_date": "01/13/2022", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-1055-48", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"01/13/2022\", \"package_ndc\": \"0338-1055-48\", \"generic_name\": \"Metronidazole Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Metronidazole%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0338-1055-48 \u00b7 Metronidazole Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43066-007-10\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"43066-007-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "baxter-healthcare-rocuronium-bromide-injection-43066-007-10.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-rocuronium-bromide-injection-43066-007-10", "initial_posting_date": "02/15/2023", "manufacturer_name": "Baxter Healthcare", "package_ndc": "43066-007-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"43066-007-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "43066-007-10 \u00b7 Rocuronium Bromide Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43066-013-10\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"43066-013-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "baxter-healthcare-rocuronium-bromide-injection-43066-013-10.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "baxter-healthcare-rocuronium-bromide-injection-43066-013-10", "initial_posting_date": "02/15/2023", "manufacturer_name": "Baxter Healthcare", "package_ndc": "43066-013-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"43066-013-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "43066-013-10 \u00b7 Rocuronium Bromide Injection \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0004-02\n\n**Generic name:** Sterile Water Irrigant\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Dosage form:** Irrigant\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0338-0004-02\", \"generic_name\": \"Sterile Water Irrigant\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Irrigant", "file": "baxter-healthcare-sterile-water-irrigant-0338-0004-02.md", "generated": true, "generic_name": "Sterile Water Irrigant", "harvested": "2026-09-01", "id": "baxter-healthcare-sterile-water-irrigant-0338-0004-02", "initial_posting_date": "04/28/2023", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0004-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0338-0004-02\", \"generic_name\": \"Sterile Water Irrigant\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0338-0004-02 \u00b7 Sterile Water Irrigant \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0338-0004-03\n\n**Generic name:** Sterile Water Irrigant\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 09/04/2026\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Days in shortage:** 1231\n\n**Dosage form:** Irrigant\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0338-0004-03\", \"generic_name\": \"Sterile Water Irrigant\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1231", "dosage_form": "Irrigant", "file": "baxter-healthcare-sterile-water-irrigant-0338-0004-03-2.md", "generated": true, "generic_name": "Sterile Water Irrigant", "harvested": "2026-09-10", "id": "baxter-healthcare-sterile-water-irrigant-0338-0004-03-2", "initial_posting_date": "04/28/2023", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0004-03", "quote_dosage_form": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/04/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0338-0004-03\", \"generic_name\": \"Sterile Water Irrigant\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0338-0004-03 \u00b7 Sterile Water Irrigant \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0338-0004-03\n\n**Generic name:** Sterile Water Irrigant\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: August 2026\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Irrigant\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0338-0004-03\", \"generic_name\": \"Sterile Water Irrigant\", \"contact_info\": \"888-229-0001\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: August 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Irrigant", "file": "baxter-healthcare-sterile-water-irrigant-0338-0004-03.md", "generated": true, "generic_name": "Sterile Water Irrigant", "harvested": "2026-09-01", "id": "baxter-healthcare-sterile-water-irrigant-0338-0004-03", "initial_posting_date": "04/28/2023", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0004-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: August 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0338-0004-03\", \"generic_name\": \"Sterile Water Irrigant\", \"contact_info\": \"888-229-0001\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: August 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0338-0004-03 \u00b7 Sterile Water Irrigant \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0338-0004-04\n\n**Generic name:** Sterile Water Irrigant\n\n**Manufacturer:** Baxter Healthcare\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: September 2026\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Irrigant\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0338-0004-04\", \"generic_name\": \"Sterile Water Irrigant\", \"contact_info\": \"888-229-0001\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Irrigant", "file": "baxter-healthcare-sterile-water-irrigant-0338-0004-04.md", "generated": true, "generic_name": "Sterile Water Irrigant", "harvested": "2026-09-01", "id": "baxter-healthcare-sterile-water-irrigant-0338-0004-04", "initial_posting_date": "04/28/2023", "manufacturer_name": "Baxter Healthcare", "package_ndc": "0338-0004-04", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)\", \"company_name\": \"Baxter Healthcare\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: September 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0338-0004-04\", \"generic_name\": \"Sterile Water Irrigant\", \"contact_info\": \"888-229-0001\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Baxter%20Healthcare%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0338-0004-04 \u00b7 Sterile Water Irrigant \u00b7 Baxter Healthcare \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59572-102-01\n\n**Generic name:** Azacitidine Injection\n\n**Manufacturer:** Bristol Myers Squibb Co.\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vidaza, Injection, 100 mg (NDC 59572-102-01)\", \"company_name\": \"Bristol Myers Squibb Co.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vidaza, Injection, 100 mg (NDC 59572-102-01)\", \"company_name\": \"Bristol Myers Squibb Co.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/18/2020\n\n**Last update date:** 08/16/2026\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vidaza, Injection, 100 mg (NDC 59572-102-01)\", \"company_name\": \"Bristol Myers Squibb Co.\", \"status\": \"Current\"\n\n**Days in shortage:** 2083\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vidaza, Injection, 100 mg (NDC 59572-102-01)\", \"company_name\": \"Bristol Myers Squibb Co.\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vidaza, Injection, 100 mg (NDC 59572-102-01)\", \"company_name\": \"Bristol Myers Squibb Co.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/18/2020\", \"package_ndc\": \"59572-102-01\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"1-888-423-5436\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Bristol%20Myers%20Squibb%20Co.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2083", "dosage_form": "Injection", "file": "bristol-myers-squibb-co-azacitidine-injection-59572-102-01.md", "generated": true, "generic_name": "Azacitidine Injection", "harvested": "2026-09-01", "id": "bristol-myers-squibb-co-azacitidine-injection-59572-102-01", "initial_posting_date": "12/18/2020", "manufacturer_name": "Bristol Myers Squibb Co.", "package_ndc": "59572-102-01", "quote_dosage_form": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vidaza, Injection, 100 mg (NDC 59572-102-01)\", \"company_name\": \"Bristol Myers Squibb Co.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vidaza, Injection, 100 mg (NDC 59572-102-01)\", \"company_name\": \"Bristol Myers Squibb Co.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vidaza, Injection, 100 mg (NDC 59572-102-01)\", \"company_name\": \"Bristol Myers Squibb Co.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vidaza, Injection, 100 mg (NDC 59572-102-01)\", \"company_name\": \"Bristol Myers Squibb Co.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vidaza, Injection, 100 mg (NDC 59572-102-01)\", \"company_name\": \"Bristol Myers Squibb Co.\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"12/18/2020\", \"package_ndc\": \"59572-102-01\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"1-888-423-5436\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Bristol%20Myers%20Squibb%20Co.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Oncology", "title": "59572-102-01 \u00b7 Azacitidine Injection \u00b7 Bristol Myers Squibb Co. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/16/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 50633-310-11\n\n**Generic name:** Hydroxocobalamin Injection\n\n**Manufacturer:** BTG International Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)\", \"company_name\": \"BTG International Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)\", \"company_name\": \"BTG International Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Cyanokit is available to order. To address the drug shortage, BTG International Inc (a SERB Pharmaceuticals company) coordinated with the U.S. Food and Drug Administration (FDA) to make the following impacted batches available to U.S. patients during this period of shortage.\n\n**Initial posting date:** 11/04/2024\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)\", \"company_name\": \"BTG International Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 666\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)\", \"company_name\": \"BTG International Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)\", \"company_name\": \"BTG International Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)\", \"company_name\": \"BTG International Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/04/2024\", \"package_ndc\": \"50633-310-11\", \"generic_name\": \"Hydroxocobalamin Injection\", \"related_info_link\": \"https://www.fda.gov/media/185400/download\", \"contact_info\": \"1 877 377 3784\", \"availability\": \"Limited Availability\", \"related_info\": \"Cyanokit is available to order. To address the drug shortage, BTG International Inc (a SERB Pharmaceuticals company) coordinated with the U.S. Food and Drug Administration (FDA) to make the following impacted batches available to U.S. patients during this period of shortage.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22BTG%20International%20Inc.%22+AND+generic_name%3A%22Hydroxocobalamin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "666", "dosage_form": "Injection", "file": "btg-international-inc-hydroxocobalamin-injection-50633-310-11.md", "generated": true, "generic_name": "Hydroxocobalamin Injection", "harvested": "2026-09-01", "id": "btg-international-inc-hydroxocobalamin-injection-50633-310-11", "initial_posting_date": "11/04/2024", "manufacturer_name": "BTG International Inc.", "package_ndc": "50633-310-11", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)\", \"company_name\": \"BTG International Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)\", \"company_name\": \"BTG International Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)\", \"company_name\": \"BTG International Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)\", \"company_name\": \"BTG International Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)\", \"company_name\": \"BTG International Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)\", \"company_name\": \"BTG International Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Cyanokit is available to order. To address the drug shortage, BTG International Inc (a SERB Pharmaceuticals company) coordinated with the U.S. Food and Drug Administration (FDA) to make the following impacted batches available to U.S. patients during this period of shortage.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/04/2024\", \"package_ndc\": \"50633-310-11\", \"generic_name\": \"Hydroxocobalamin Injection\", \"related_info_link\": \"https://www.fda.gov/media/185400/download\", \"contact_info\": \"1 877 377 3784\", \"availability\": \"Limited Availability\", \"related_info\": \"Cyanokit is available to order. To address the drug shortage, BTG International Inc (a SERB Pharmaceuticals company) coordinated with the U.S. Food and Drug Administration (FDA) to make the following impacted batches available to U.S. patients during this period of shortage.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22BTG%20International%20Inc.%22+AND+generic_name%3A%22Hydroxocobalamin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Other", "title": "50633-310-11 \u00b7 Hydroxocobalamin Injection \u00b7 BTG International Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65219-445-10\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Caplin Steriles, Ltd.\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/1 mL (NDC 65219-445-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/1 mL (NDC 65219-445-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory; Marketed by Fresenius Kabi\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 06/16/2026\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/1 mL (NDC 65219-445-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/1 mL (NDC 65219-445-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/1 mL (NDC 65219-445-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"65219-445-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-551-7176\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory; Marketed by Fresenius Kabi\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "caplin-steriles-ltd-etomidate-injection-65219-445-10.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "caplin-steriles-ltd-etomidate-injection-65219-445-10", "initial_posting_date": "10/05/2022", "manufacturer_name": "Caplin Steriles, Ltd.", "package_ndc": "65219-445-10", "quote_dosage_form": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/1 mL (NDC 65219-445-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/1 mL (NDC 65219-445-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/1 mL (NDC 65219-445-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/1 mL (NDC 65219-445-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/1 mL (NDC 65219-445-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory; Marketed by Fresenius Kabi", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"65219-445-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-551-7176\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory; Marketed by Fresenius Kabi\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "65219-445-10 \u00b7 Etomidate Injection \u00b7 Caplin Steriles, Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/16/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65219-447-20\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Caplin Steriles, Ltd.\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/mL (NDC 65219-447-20)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/mL (NDC 65219-447-20)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory; Marketed by Fresenius Kabi\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 06/16/2026\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/mL (NDC 65219-447-20)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/mL (NDC 65219-447-20)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/mL (NDC 65219-447-20)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"65219-447-20\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-551-7176\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory; Marketed by Fresenius Kabi\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "caplin-steriles-ltd-etomidate-injection-65219-447-20.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "caplin-steriles-ltd-etomidate-injection-65219-447-20", "initial_posting_date": "10/05/2022", "manufacturer_name": "Caplin Steriles, Ltd.", "package_ndc": "65219-447-20", "quote_dosage_form": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/mL (NDC 65219-447-20)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/mL (NDC 65219-447-20)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/mL (NDC 65219-447-20)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/mL (NDC 65219-447-20)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2mg/mL (NDC 65219-447-20)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory; Marketed by Fresenius Kabi", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"65219-447-20\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-551-7176\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory; Marketed by Fresenius Kabi\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "65219-447-20 \u00b7 Etomidate Injection \u00b7 Caplin Steriles, Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/16/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72485-508-10\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Caplin Steriles, Ltd.\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 06/16/2026\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"72485-508-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"908-803-2586\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "caplin-steriles-ltd-etomidate-injection-72485-508-10.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "caplin-steriles-ltd-etomidate-injection-72485-508-10", "initial_posting_date": "10/05/2022", "manufacturer_name": "Caplin Steriles, Ltd.", "package_ndc": "72485-508-10", "quote_dosage_form": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"72485-508-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"908-803-2586\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "72485-508-10 \u00b7 Etomidate Injection \u00b7 Caplin Steriles, Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/16/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72485-509-10\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Caplin Steriles, Ltd.\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 06/16/2026\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"72485-509-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"908-803-2586\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "caplin-steriles-ltd-etomidate-injection-72485-509-10.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "caplin-steriles-ltd-etomidate-injection-72485-509-10", "initial_posting_date": "10/05/2022", "manufacturer_name": "Caplin Steriles, Ltd.", "package_ndc": "72485-509-10", "quote_dosage_form": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/16/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"72485-509-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"908-803-2586\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "72485-509-10 \u00b7 Etomidate Injection \u00b7 Caplin Steriles, Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/16/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 43066-015-10\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Caplin Steriles, Ltd.\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Check wholesalers for inventory; Marketed by Baxter\n\n**Initial posting date:** 12/22/2020\n\n**Last update date:** 06/10/2026\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2079\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/22/2020\", \"package_ndc\": \"43066-015-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Limited Availability\", \"related_info\": \"Check wholesalers for inventory; Marketed by Baxter\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2079", "dosage_form": "Injection", "file": "caplin-steriles-ltd-ropivacaine-hydrochloride-injection-43066-015-10.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "caplin-steriles-ltd-ropivacaine-hydrochloride-injection-43066-015-10", "initial_posting_date": "12/22/2020", "manufacturer_name": "Caplin Steriles, Ltd.", "package_ndc": "43066-015-10", "quote_dosage_form": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory; Marketed by Baxter", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"12/22/2020\", \"package_ndc\": \"43066-015-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Limited Availability\", \"related_info\": \"Check wholesalers for inventory; Marketed by Baxter\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "43066-015-10 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Caplin Steriles, Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/10/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43066-019-10\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Caplin Steriles, Ltd.\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory; Marketed by Baxter\n\n**Initial posting date:** 12/22/2020\n\n**Last update date:** 06/10/2026\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Days in shortage:** 2079\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/22/2020\", \"package_ndc\": \"43066-019-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory; Marketed by Baxter\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2079", "dosage_form": "Injection", "file": "caplin-steriles-ltd-ropivacaine-hydrochloride-injection-43066-019-10.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "caplin-steriles-ltd-ropivacaine-hydrochloride-injection-43066-019-10", "initial_posting_date": "12/22/2020", "manufacturer_name": "Caplin Steriles, Ltd.", "package_ndc": "43066-019-10", "quote_dosage_form": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory; Marketed by Baxter", "source_quote": "\"initial_posting_date\": \"12/22/2020\", \"package_ndc\": \"43066-019-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory; Marketed by Baxter\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "43066-019-10 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Caplin Steriles, Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/10/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 43066-023-10\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Caplin Steriles, Ltd.\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited supply; Check wholesalers for inventory; Marketed by Baxter\n\n**Initial posting date:** 12/22/2020\n\n**Last update date:** 06/10/2026\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2079\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/22/2020\", \"package_ndc\": \"43066-023-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited supply; Check wholesalers for inventory; Marketed by Baxter\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2079", "dosage_form": "Injection", "file": "caplin-steriles-ltd-ropivacaine-hydrochloride-injection-43066-023-10.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "caplin-steriles-ltd-ropivacaine-hydrochloride-injection-43066-023-10", "initial_posting_date": "12/22/2020", "manufacturer_name": "Caplin Steriles, Ltd.", "package_ndc": "43066-023-10", "quote_dosage_form": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Limited supply; Check wholesalers for inventory; Marketed by Baxter", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"12/22/2020\", \"package_ndc\": \"43066-023-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited supply; Check wholesalers for inventory; Marketed by Baxter\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "43066-023-10 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Caplin Steriles, Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/10/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43066-027-10\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Caplin Steriles, Ltd.\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory; Marketed by Baxter\n\n**Initial posting date:** 12/22/2020\n\n**Last update date:** 06/10/2026\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Days in shortage:** 2079\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/22/2020\", \"package_ndc\": \"43066-027-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory; Marketed by Baxter\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2079", "dosage_form": "Injection", "file": "caplin-steriles-ltd-ropivacaine-hydrochloride-injection-43066-027-10.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "caplin-steriles-ltd-ropivacaine-hydrochloride-injection-43066-027-10", "initial_posting_date": "12/22/2020", "manufacturer_name": "Caplin Steriles, Ltd.", "package_ndc": "43066-027-10", "quote_dosage_form": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/10/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)\", \"company_name\": \"Caplin Steriles, Ltd.\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory; Marketed by Baxter", "source_quote": "\"initial_posting_date\": \"12/22/2020\", \"package_ndc\": \"43066-027-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-229-0001\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory; Marketed by Baxter\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Caplin%20Steriles,%20Ltd.%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "43066-027-10 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Caplin Steriles, Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/10/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62135-736-30\n\n**Generic name:** Flurazepam Hydrochloride Capsule\n\n**Manufacturer:** Chartwell Molecular Holdings LLC\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 08/03/2022\n\n**Last update date:** 08/26/2026\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1490\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"08/03/2022\", \"package_ndc\": \"62135-736-30\", \"generic_name\": \"Flurazepam Hydrochloride Capsule\", \"contact_info\": \"845-268-5000 Ext. 510\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Flurazepam%20Hydrochloride%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1490", "dosage_form": "Capsule", "file": "chartwell-molecular-holdings-llc-flurazepam-hydrochloride-capsule-62135-736-30.md", "generated": true, "generic_name": "Flurazepam Hydrochloride Capsule", "harvested": "2026-09-01", "id": "chartwell-molecular-holdings-llc-flurazepam-hydrochloride-capsule-62135-736-30", "initial_posting_date": "08/03/2022", "manufacturer_name": "Chartwell Molecular Holdings LLC", "package_ndc": "62135-736-30", "quote_dosage_form": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "rechecked": "2026-09-09", "source_quote": "\"initial_posting_date\": \"08/03/2022\", \"package_ndc\": \"62135-736-30\", \"generic_name\": \"Flurazepam Hydrochloride Capsule\", \"contact_info\": \"845-268-5000 Ext. 510\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Flurazepam%20Hydrochloride%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-12", "status": "Current", "therapeutic_category": "Neurology", "title": "62135-736-30 \u00b7 Flurazepam Hydrochloride Capsule \u00b7 Chartwell Molecular Holdings LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/26/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62135-736-90\n\n**Generic name:** Flurazepam Hydrochloride Capsule\n\n**Manufacturer:** Chartwell Molecular Holdings LLC\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Oncology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Oncology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 08/03/2022\n\n**Last update date:** 08/26/2026\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Oncology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1490\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Oncology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Oncology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"08/03/2022\", \"package_ndc\": \"62135-736-90\", \"generic_name\": \"Flurazepam Hydrochloride Capsule\", \"contact_info\": \"845-268-5000 Ext. 510\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Flurazepam%20Hydrochloride%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1490", "dosage_form": "Capsule", "file": "chartwell-molecular-holdings-llc-flurazepam-hydrochloride-capsule-62135-736-90.md", "generated": true, "generic_name": "Flurazepam Hydrochloride Capsule", "harvested": "2026-09-01", "id": "chartwell-molecular-holdings-llc-flurazepam-hydrochloride-capsule-62135-736-90", "initial_posting_date": "08/03/2022", "manufacturer_name": "Chartwell Molecular Holdings LLC", "package_ndc": "62135-736-90", "quote_dosage_form": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Oncology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Oncology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Oncology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Oncology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Oncology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "rechecked": "2026-09-09", "source_quote": "\"initial_posting_date\": \"08/03/2022\", \"package_ndc\": \"62135-736-90\", \"generic_name\": \"Flurazepam Hydrochloride Capsule\", \"contact_info\": \"845-268-5000 Ext. 510\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Flurazepam%20Hydrochloride%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-12", "status": "Current", "therapeutic_category": "Oncology", "title": "62135-736-90 \u00b7 Flurazepam Hydrochloride Capsule \u00b7 Chartwell Molecular Holdings LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/26/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62135-737-30\n\n**Generic name:** Flurazepam Hydrochloride Capsule\n\n**Manufacturer:** Chartwell Molecular Holdings LLC\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 08/03/2022\n\n**Last update date:** 08/26/2026\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1490\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"08/03/2022\", \"package_ndc\": \"62135-737-30\", \"generic_name\": \"Flurazepam Hydrochloride Capsule\", \"contact_info\": \"845-268-5000 Ext. 510\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Flurazepam%20Hydrochloride%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1490", "dosage_form": "Capsule", "file": "chartwell-molecular-holdings-llc-flurazepam-hydrochloride-capsule-62135-737-30.md", "generated": true, "generic_name": "Flurazepam Hydrochloride Capsule", "harvested": "2026-09-01", "id": "chartwell-molecular-holdings-llc-flurazepam-hydrochloride-capsule-62135-737-30", "initial_posting_date": "08/03/2022", "manufacturer_name": "Chartwell Molecular Holdings LLC", "package_ndc": "62135-737-30", "quote_dosage_form": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "rechecked": "2026-09-09", "source_quote": "\"initial_posting_date\": \"08/03/2022\", \"package_ndc\": \"62135-737-30\", \"generic_name\": \"Flurazepam Hydrochloride Capsule\", \"contact_info\": \"845-268-5000 Ext. 510\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Flurazepam%20Hydrochloride%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-12", "status": "Current", "therapeutic_category": "Neurology", "title": "62135-737-30 \u00b7 Flurazepam Hydrochloride Capsule \u00b7 Chartwell Molecular Holdings LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/26/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62135-737-90\n\n**Generic name:** Flurazepam Hydrochloride Capsule\n\n**Manufacturer:** Chartwell Molecular Holdings LLC\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 08/03/2022\n\n**Last update date:** 08/26/2026\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1490\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"08/03/2022\", \"package_ndc\": \"62135-737-90\", \"generic_name\": \"Flurazepam Hydrochloride Capsule\", \"contact_info\": \"845-268-5000 Ext. 510\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Flurazepam%20Hydrochloride%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1490", "dosage_form": "Capsule", "file": "chartwell-molecular-holdings-llc-flurazepam-hydrochloride-capsule-62135-737-90.md", "generated": true, "generic_name": "Flurazepam Hydrochloride Capsule", "harvested": "2026-09-01", "id": "chartwell-molecular-holdings-llc-flurazepam-hydrochloride-capsule-62135-737-90", "initial_posting_date": "08/03/2022", "manufacturer_name": "Chartwell Molecular Holdings LLC", "package_ndc": "62135-737-90", "quote_dosage_form": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "rechecked": "2026-09-09", "source_quote": "\"initial_posting_date\": \"08/03/2022\", \"package_ndc\": \"62135-737-90\", \"generic_name\": \"Flurazepam Hydrochloride Capsule\", \"contact_info\": \"845-268-5000 Ext. 510\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Flurazepam%20Hydrochloride%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-12", "status": "Current", "therapeutic_category": "Neurology", "title": "62135-737-90 \u00b7 Flurazepam Hydrochloride Capsule \u00b7 Chartwell Molecular Holdings LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/26/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62135-484-60\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Chartwell Molecular Holdings LLC\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/26/2026\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"62135-484-60\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "chartwell-molecular-holdings-llc-quinapril-hydrochloride-tablet-62135-484-60.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "chartwell-molecular-holdings-llc-quinapril-hydrochloride-tablet-62135-484-60", "initial_posting_date": "01/19/2023", "manufacturer_name": "Chartwell Molecular Holdings LLC", "package_ndc": "62135-484-60", "quote_dosage_form": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "rechecked": "2026-09-09", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"62135-484-60\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-12", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "62135-484-60 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Chartwell Molecular Holdings LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/26/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62135-485-90\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Chartwell Molecular Holdings LLC\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/26/2026\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"62135-485-90\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "chartwell-molecular-holdings-llc-quinapril-hydrochloride-tablet-62135-485-90.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "chartwell-molecular-holdings-llc-quinapril-hydrochloride-tablet-62135-485-90", "initial_posting_date": "01/19/2023", "manufacturer_name": "Chartwell Molecular Holdings LLC", "package_ndc": "62135-485-90", "quote_dosage_form": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "rechecked": "2026-09-09", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"62135-485-90\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-12", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "62135-485-90 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Chartwell Molecular Holdings LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/26/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62135-486-90\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Chartwell Molecular Holdings LLC\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/26/2026\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"62135-486-90\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "chartwell-molecular-holdings-llc-quinapril-hydrochloride-tablet-62135-486-90.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "chartwell-molecular-holdings-llc-quinapril-hydrochloride-tablet-62135-486-90", "initial_posting_date": "01/19/2023", "manufacturer_name": "Chartwell Molecular Holdings LLC", "package_ndc": "62135-486-90", "quote_dosage_form": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "rechecked": "2026-09-09", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"62135-486-90\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-12", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "62135-486-90 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Chartwell Molecular Holdings LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/26/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62135-487-90\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Chartwell Molecular Holdings LLC\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/26/2026\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"62135-487-90\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "chartwell-molecular-holdings-llc-quinapril-hydrochloride-tablet-62135-487-90.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "chartwell-molecular-holdings-llc-quinapril-hydrochloride-tablet-62135-487-90", "initial_posting_date": "01/19/2023", "manufacturer_name": "Chartwell Molecular Holdings LLC", "package_ndc": "62135-487-90", "quote_dosage_form": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "rechecked": "2026-09-09", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"62135-487-90\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-12", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "62135-487-90 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Chartwell Molecular Holdings LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/26/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62135-667-90\n\n**Generic name:** Quinapril/Hydrochlorothiazide Tablet\n\n**Manufacturer:** Chartwell Molecular Holdings LLC\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/26/2026\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"62135-667-90\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "chartwell-molecular-holdings-llc-quinapril-hydrochlorothiazide-tablet-62135-667-90.md", "generated": true, "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "harvested": "2026-09-01", "id": "chartwell-molecular-holdings-llc-quinapril-hydrochlorothiazide-tablet-62135-667-90", "initial_posting_date": "01/19/2023", "manufacturer_name": "Chartwell Molecular Holdings LLC", "package_ndc": "62135-667-90", "quote_dosage_form": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "rechecked": "2026-09-09", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"62135-667-90\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-12", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "62135-667-90 \u00b7 Quinapril/Hydrochlorothiazide Tablet \u00b7 Chartwell Molecular Holdings LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/26/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62135-668-90\n\n**Generic name:** Quinapril/Hydrochlorothiazide Tablet\n\n**Manufacturer:** Chartwell Molecular Holdings LLC\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/26/2026\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"62135-668-90\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "chartwell-molecular-holdings-llc-quinapril-hydrochlorothiazide-tablet-62135-668-90.md", "generated": true, "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "harvested": "2026-09-01", "id": "chartwell-molecular-holdings-llc-quinapril-hydrochlorothiazide-tablet-62135-668-90", "initial_posting_date": "01/19/2023", "manufacturer_name": "Chartwell Molecular Holdings LLC", "package_ndc": "62135-668-90", "quote_dosage_form": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "rechecked": "2026-09-09", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"62135-668-90\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-12", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "62135-668-90 \u00b7 Quinapril/Hydrochlorothiazide Tablet \u00b7 Chartwell Molecular Holdings LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/26/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62135-669-90\n\n**Generic name:** Quinapril/Hydrochlorothiazide Tablet\n\n**Manufacturer:** Chartwell Molecular Holdings LLC\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/26/2026\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"62135-669-90\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "chartwell-molecular-holdings-llc-quinapril-hydrochlorothiazide-tablet-62135-669-90.md", "generated": true, "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "harvested": "2026-09-01", "id": "chartwell-molecular-holdings-llc-quinapril-hydrochlorothiazide-tablet-62135-669-90", "initial_posting_date": "01/19/2023", "manufacturer_name": "Chartwell Molecular Holdings LLC", "package_ndc": "62135-669-90", "quote_dosage_form": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/26/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)\", \"company_name\": \"Chartwell Molecular Holdings LLC\", \"status\": \"Current\"", "rechecked": "2026-09-09", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"62135-669-90\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Chartwell%20Molecular%20Holdings%20LLC%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-12", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "62135-669-90 \u00b7 Quinapril/Hydrochlorothiazide Tablet \u00b7 Chartwell Molecular Holdings LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/26/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 61269-605-10\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Cheplapharm Arzneimittel GmbH\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, .5 mg (NDC 61269-605-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, .5 mg (NDC 61269-605-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by H2-Pharma\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, .5 mg (NDC 61269-605-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, .5 mg (NDC 61269-605-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, .5 mg (NDC 61269-605-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"61269-605-10\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"orders@h2-pharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by H2-Pharma\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Cheplapharm%20Arzneimittel%20GmbH%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "cheplapharm-arzneimittel-gmbh-clonazepam-tablet-61269-605-10.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "cheplapharm-arzneimittel-gmbh-clonazepam-tablet-61269-605-10", "initial_posting_date": "03/10/2023", "manufacturer_name": "Cheplapharm Arzneimittel GmbH", "package_ndc": "61269-605-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, .5 mg (NDC 61269-605-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, .5 mg (NDC 61269-605-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, .5 mg (NDC 61269-605-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, .5 mg (NDC 61269-605-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, .5 mg (NDC 61269-605-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"", "related_info": "Marketed by H2-Pharma", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"61269-605-10\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"orders@h2-pharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by H2-Pharma\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Cheplapharm%20Arzneimittel%20GmbH%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "61269-605-10 \u00b7 Clonazepam Tablet \u00b7 Cheplapharm Arzneimittel GmbH \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 61269-610-10\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Cheplapharm Arzneimittel GmbH\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 1 mg (NDC 61269-610-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 1 mg (NDC 61269-610-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by H2-Pharma\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 1 mg (NDC 61269-610-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 1 mg (NDC 61269-610-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 1 mg (NDC 61269-610-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"61269-610-10\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"orders@h2-pharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by H2-Pharma\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Cheplapharm%20Arzneimittel%20GmbH%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "cheplapharm-arzneimittel-gmbh-clonazepam-tablet-61269-610-10.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "cheplapharm-arzneimittel-gmbh-clonazepam-tablet-61269-610-10", "initial_posting_date": "03/10/2023", "manufacturer_name": "Cheplapharm Arzneimittel GmbH", "package_ndc": "61269-610-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 1 mg (NDC 61269-610-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 1 mg (NDC 61269-610-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 1 mg (NDC 61269-610-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 1 mg (NDC 61269-610-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 1 mg (NDC 61269-610-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"", "related_info": "Marketed by H2-Pharma", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"61269-610-10\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"orders@h2-pharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by H2-Pharma\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Cheplapharm%20Arzneimittel%20GmbH%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "61269-610-10 \u00b7 Clonazepam Tablet \u00b7 Cheplapharm Arzneimittel GmbH \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 61269-620-10\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Cheplapharm Arzneimittel GmbH\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 2 mg (NDC 61269-620-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 2 mg (NDC 61269-620-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by H2-Pharma\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 2 mg (NDC 61269-620-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 2 mg (NDC 61269-620-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 2 mg (NDC 61269-620-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"61269-620-10\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"orders@h2-pharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by H2-Pharma\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Cheplapharm%20Arzneimittel%20GmbH%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "cheplapharm-arzneimittel-gmbh-clonazepam-tablet-61269-620-10.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "cheplapharm-arzneimittel-gmbh-clonazepam-tablet-61269-620-10", "initial_posting_date": "03/10/2023", "manufacturer_name": "Cheplapharm Arzneimittel GmbH", "package_ndc": "61269-620-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 2 mg (NDC 61269-620-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 2 mg (NDC 61269-620-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 2 mg (NDC 61269-620-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 2 mg (NDC 61269-620-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Klonopin, Tablet, 2 mg (NDC 61269-620-10)\", \"company_name\": \"Cheplapharm Arzneimittel GmbH\", \"status\": \"Current\"", "related_info": "Marketed by H2-Pharma", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"61269-620-10\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"orders@h2-pharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by H2-Pharma\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Cheplapharm%20Arzneimittel%20GmbH%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "61269-620-10 \u00b7 Clonazepam Tablet \u00b7 Cheplapharm Arzneimittel GmbH \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 66220-160-10\n\n**Generic name:** Conivaptan Hydrochloride Injection\n\n**Manufacturer:** Cumberland Pharmaceuticals Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)\", \"company_name\": \"Cumberland Pharmaceuticals Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)\", \"company_name\": \"Cumberland Pharmaceuticals Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 03/14/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)\", \"company_name\": \"Cumberland Pharmaceuticals Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1632\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)\", \"company_name\": \"Cumberland Pharmaceuticals Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)\", \"company_name\": \"Cumberland Pharmaceuticals Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)\", \"company_name\": \"Cumberland Pharmaceuticals Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/14/2022\", \"package_ndc\": \"66220-160-10\", \"generic_name\": \"Conivaptan Hydrochloride Injection\", \"contact_info\": \"800-706-5575\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Cumberland%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Conivaptan%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1632", "dosage_form": "Injection", "file": "cumberland-pharmaceuticals-inc-conivaptan-hydrochloride-injection-66220-160-10.md", "generated": true, "generic_name": "Conivaptan Hydrochloride Injection", "harvested": "2026-09-01", "id": "cumberland-pharmaceuticals-inc-conivaptan-hydrochloride-injection-66220-160-10", "initial_posting_date": "03/14/2022", "manufacturer_name": "Cumberland Pharmaceuticals Inc.", "package_ndc": "66220-160-10", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)\", \"company_name\": \"Cumberland Pharmaceuticals Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)\", \"company_name\": \"Cumberland Pharmaceuticals Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)\", \"company_name\": \"Cumberland Pharmaceuticals Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)\", \"company_name\": \"Cumberland Pharmaceuticals Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)\", \"company_name\": \"Cumberland Pharmaceuticals Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)\", \"company_name\": \"Cumberland Pharmaceuticals Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"03/14/2022\", \"package_ndc\": \"66220-160-10\", \"generic_name\": \"Conivaptan Hydrochloride Injection\", \"contact_info\": \"800-706-5575\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Cumberland%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Conivaptan%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "66220-160-10 \u00b7 Conivaptan Hydrochloride Injection \u00b7 Cumberland Pharmaceuticals Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 69945-094-20\n\n**Generic name:** Technetium TC-99M Pyrophosphate Kit Injection\n\n**Manufacturer:** Curium US LLC\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)\", \"company_name\": \"Curium US LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)\", \"company_name\": \"Curium US LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Available via allocation\n\n**Initial posting date:** 12/27/2023\n\n**Last update date:** 08/19/2026\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)\", \"company_name\": \"Curium US LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 979\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)\", \"company_name\": \"Curium US LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)\", \"company_name\": \"Curium US LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Medical Imaging\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)\", \"company_name\": \"Curium US LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/27/2023\", \"package_ndc\": \"69945-094-20\", \"generic_name\": \"Technetium TC-99M Pyrophosphate Kit Injection\", \"contact_info\": \"888-744-1414\", \"availability\": \"Limited Availability\", \"related_info\": \"Available via allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Curium%20US%20LLC%22+AND+generic_name%3A%22Technetium%20TC-99M%20Pyrophosphate%20Kit%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "979", "dosage_form": "Injection", "file": "curium-us-llc-technetium-tc-99m-pyrophosphate-kit-injection-69945-094-20.md", "generated": true, "generic_name": "Technetium TC-99M Pyrophosphate Kit Injection", "harvested": "2026-09-01", "id": "curium-us-llc-technetium-tc-99m-pyrophosphate-kit-injection-69945-094-20", "initial_posting_date": "12/27/2023", "manufacturer_name": "Curium US LLC", "package_ndc": "69945-094-20", "quote_dosage_form": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)\", \"company_name\": \"Curium US LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)\", \"company_name\": \"Curium US LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)\", \"company_name\": \"Curium US LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)\", \"company_name\": \"Curium US LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)\", \"company_name\": \"Curium US LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)\", \"company_name\": \"Curium US LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Available via allocation", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"12/27/2023\", \"package_ndc\": \"69945-094-20\", \"generic_name\": \"Technetium TC-99M Pyrophosphate Kit Injection\", \"contact_info\": \"888-744-1414\", \"availability\": \"Limited Availability\", \"related_info\": \"Available via allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Curium%20US%20LLC%22+AND+generic_name%3A%22Technetium%20TC-99M%20Pyrophosphate%20Kit%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Medical Imaging", "title": "69945-094-20 \u00b7 Technetium TC-99M Pyrophosphate Kit Injection \u00b7 Curium US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/19/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43598-305-62\n\n**Generic name:** Azacitidine Injection\n\n**Manufacturer:** Dr. Reddy's Laboratories, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 43598-305-62)\", \"company_name\": \"Dr. Reddy's Laboratories, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 43598-305-62)\", \"company_name\": \"Dr. Reddy's Laboratories, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Available to existing customers\n\n**Initial posting date:** 12/18/2020\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 43598-305-62)\", \"company_name\": \"Dr. Reddy's Laboratories, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2083\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 43598-305-62)\", \"company_name\": \"Dr. Reddy's Laboratories, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 43598-305-62)\", \"company_name\": \"Dr. Reddy's Laboratories, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/18/2020\", \"package_ndc\": \"43598-305-62\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"866-732-3952\", \"availability\": \"Available\", \"related_info\": \"Available to existing customers\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Dr.%20Reddy%27s%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2083", "dosage_form": "Injection", "file": "dr-reddy-s-laboratories-inc-azacitidine-injection-43598-305-62.md", "generated": true, "generic_name": "Azacitidine Injection", "harvested": "2026-09-01", "id": "dr-reddy-s-laboratories-inc-azacitidine-injection-43598-305-62", "initial_posting_date": "12/18/2020", "manufacturer_name": "Dr. Reddy's Laboratories, Inc.", "package_ndc": "43598-305-62", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 43598-305-62)\", \"company_name\": \"Dr. Reddy's Laboratories, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 43598-305-62)\", \"company_name\": \"Dr. Reddy's Laboratories, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 43598-305-62)\", \"company_name\": \"Dr. Reddy's Laboratories, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 43598-305-62)\", \"company_name\": \"Dr. Reddy's Laboratories, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 43598-305-62)\", \"company_name\": \"Dr. Reddy's Laboratories, Inc.\", \"status\": \"Current\"", "related_info": "Available to existing customers", "source_quote": "\"initial_posting_date\": \"12/18/2020\", \"package_ndc\": \"43598-305-62\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"866-732-3952\", \"availability\": \"Available\", \"related_info\": \"Available to existing customers\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Dr.%20Reddy%27s%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "43598-305-62 \u00b7 Azacitidine Injection \u00b7 Dr. Reddy's Laboratories, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 70726-0303-1\n\n**Generic name:** Riluzole Oral Suspension\n\n**Manufacturer:** EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release not available at this time; Shortage per Manufacturer: Product manufacturing interrupted due to testing\n\n**Initial posting date:** 01/26/2024\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 949\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Oral Suspension\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/26/2024\", \"package_ndc\": \"70726-0303-1\", \"generic_name\": \"Riluzole Oral Suspension\", \"contact_info\": \"610-937-6172\", \"availability\": \"Unavailable\", \"related_info\": \"Next release not available at this time; Shortage per Manufacturer: Product manufacturing interrupted due to testing\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22EDW%20Pharma,%20Inc.%20(formerly%20Italfarmaco%20Pharma,%20Inc.)%22+AND+generic_name%3A%22Riluzole%20Oral%20Suspension%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "949", "dosage_form": "Oral Suspension", "file": "edw-pharma-inc-formerly-italfarmaco-pharma-inc-riluzole-oral-suspension-70726-0303-1.md", "generated": true, "generic_name": "Riluzole Oral Suspension", "harvested": "2026-09-01", "id": "edw-pharma-inc-formerly-italfarmaco-pharma-inc-riluzole-oral-suspension-70726-0303-1", "initial_posting_date": "01/26/2024", "manufacturer_name": "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)", "package_ndc": "70726-0303-1", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "related_info": "Next release not available at this time; Shortage per Manufacturer: Product manufacturing interrupted due to testing", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"01/26/2024\", \"package_ndc\": \"70726-0303-1\", \"generic_name\": \"Riluzole Oral Suspension\", \"contact_info\": \"610-937-6172\", \"availability\": \"Unavailable\", \"related_info\": \"Next release not available at this time; Shortage per Manufacturer: Product manufacturing interrupted due to testing\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22EDW%20Pharma,%20Inc.%20(formerly%20Italfarmaco%20Pharma,%20Inc.)%22+AND+generic_name%3A%22Riluzole%20Oral%20Suspension%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "70726-0303-1 \u00b7 Riluzole Oral Suspension \u00b7 EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70726-0304-1\n\n**Generic name:** Riluzole Oral Suspension\n\n**Manufacturer:** EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/26/2024\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"\n\n**Days in shortage:** 949\n\n**Dosage form:** Oral Suspension\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/26/2024\", \"package_ndc\": \"70726-0304-1\", \"generic_name\": \"Riluzole Oral Suspension\", \"related_info_link\": \"https://www.fda.gov/media/185611/download?attachment\", \"contact_info\": \"610-937-6172\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22EDW%20Pharma,%20Inc.%20(formerly%20Italfarmaco%20Pharma,%20Inc.)%22+AND+generic_name%3A%22Riluzole%20Oral%20Suspension%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "949", "dosage_form": "Oral Suspension", "file": "edw-pharma-inc-formerly-italfarmaco-pharma-inc-riluzole-oral-suspension-70726-0304-1.md", "generated": true, "generic_name": "Riluzole Oral Suspension", "harvested": "2026-09-01", "id": "edw-pharma-inc-formerly-italfarmaco-pharma-inc-riluzole-oral-suspension-70726-0304-1", "initial_posting_date": "01/26/2024", "manufacturer_name": "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)", "package_ndc": "70726-0304-1", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"01/26/2024\", \"package_ndc\": \"70726-0304-1\", \"generic_name\": \"Riluzole Oral Suspension\", \"related_info_link\": \"https://www.fda.gov/media/185611/download?attachment\", \"contact_info\": \"610-937-6172\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22EDW%20Pharma,%20Inc.%20(formerly%20Italfarmaco%20Pharma,%20Inc.)%22+AND+generic_name%3A%22Riluzole%20Oral%20Suspension%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "70726-0304-1 \u00b7 Riluzole Oral Suspension \u00b7 EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70726-0305-1\n\n**Generic name:** Riluzole Oral Suspension\n\n**Manufacturer:** EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/26/2024\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"\n\n**Days in shortage:** 949\n\n**Dosage form:** Oral Suspension\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/26/2024\", \"package_ndc\": \"70726-0305-1\", \"generic_name\": \"Riluzole Oral Suspension\", \"related_info_link\": \"https://www.fda.gov/media/177206/download\", \"contact_info\": \"610-937-6172\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22EDW%20Pharma,%20Inc.%20(formerly%20Italfarmaco%20Pharma,%20Inc.)%22+AND+generic_name%3A%22Riluzole%20Oral%20Suspension%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "949", "dosage_form": "Oral Suspension", "file": "edw-pharma-inc-formerly-italfarmaco-pharma-inc-riluzole-oral-suspension-70726-0305-1.md", "generated": true, "generic_name": "Riluzole Oral Suspension", "harvested": "2026-09-01", "id": "edw-pharma-inc-formerly-italfarmaco-pharma-inc-riluzole-oral-suspension-70726-0305-1", "initial_posting_date": "01/26/2024", "manufacturer_name": "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)", "package_ndc": "70726-0305-1", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"01/26/2024\", \"package_ndc\": \"70726-0305-1\", \"generic_name\": \"Riluzole Oral Suspension\", \"related_info_link\": \"https://www.fda.gov/media/177206/download\", \"contact_info\": \"610-937-6172\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22EDW%20Pharma,%20Inc.%20(formerly%20Italfarmaco%20Pharma,%20Inc.)%22+AND+generic_name%3A%22Riluzole%20Oral%20Suspension%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "70726-0305-1 \u00b7 Riluzole Oral Suspension \u00b7 EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70726-0306-1\n\n**Generic name:** Riluzole Oral Suspension\n\n**Manufacturer:** EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/26/2024\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"\n\n**Days in shortage:** 949\n\n**Dosage form:** Oral Suspension\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/26/2024\", \"package_ndc\": \"70726-0306-1\", \"generic_name\": \"Riluzole Oral Suspension\", \"related_info_link\": \"https://www.fda.gov/media/185612/download?attachment\", \"contact_info\": \"610-937-6172\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22EDW%20Pharma,%20Inc.%20(formerly%20Italfarmaco%20Pharma,%20Inc.)%22+AND+generic_name%3A%22Riluzole%20Oral%20Suspension%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "949", "dosage_form": "Oral Suspension", "file": "edw-pharma-inc-formerly-italfarmaco-pharma-inc-riluzole-oral-suspension-70726-0306-1.md", "generated": true, "generic_name": "Riluzole Oral Suspension", "harvested": "2026-09-01", "id": "edw-pharma-inc-formerly-italfarmaco-pharma-inc-riluzole-oral-suspension-70726-0306-1", "initial_posting_date": "01/26/2024", "manufacturer_name": "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)", "package_ndc": "70726-0306-1", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Oral Suspension\", \"presentation\": \"Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)\", \"company_name\": \"EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"01/26/2024\", \"package_ndc\": \"70726-0306-1\", \"generic_name\": \"Riluzole Oral Suspension\", \"related_info_link\": \"https://www.fda.gov/media/185612/download?attachment\", \"contact_info\": \"610-937-6172\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22EDW%20Pharma,%20Inc.%20(formerly%20Italfarmaco%20Pharma,%20Inc.)%22+AND+generic_name%3A%22Riluzole%20Oral%20Suspension%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "70726-0306-1 \u00b7 Riluzole Oral Suspension \u00b7 EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.) \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 64850-500-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Elite Laboratories, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"64850-500-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"888-852-6657\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "elite-laboratories-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-64850-500-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "elite-laboratories-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-64850-500-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Elite Laboratories, Inc.", "package_ndc": "64850-500-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"64850-500-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"888-852-6657\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "64850-500-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Elite Laboratories, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 64850-501-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Elite Laboratories, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"64850-501-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"888-852-6657\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "elite-laboratories-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-64850-501-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "elite-laboratories-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-64850-501-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Elite Laboratories, Inc.", "package_ndc": "64850-501-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"64850-501-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"888-852-6657\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "64850-501-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Elite Laboratories, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 64850-502-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Elite Laboratories, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"64850-502-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"888-852-6657\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "elite-laboratories-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-64850-502-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "elite-laboratories-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-64850-502-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Elite Laboratories, Inc.", "package_ndc": "64850-502-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"64850-502-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"888-852-6657\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "64850-502-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Elite Laboratories, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 64850-503-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Elite Laboratories, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"64850-503-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"888-852-6657\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "elite-laboratories-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-64850-503-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "elite-laboratories-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-64850-503-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Elite Laboratories, Inc.", "package_ndc": "64850-503-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"64850-503-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"888-852-6657\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "64850-503-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Elite Laboratories, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 64850-504-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Elite Laboratories, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"64850-504-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"888-852-6657\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "elite-laboratories-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-64850-504-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "elite-laboratories-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-64850-504-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Elite Laboratories, Inc.", "package_ndc": "64850-504-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"64850-504-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"888-852-6657\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "64850-504-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Elite Laboratories, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 64850-505-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Elite Laboratories, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"64850-505-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"888-852-6657\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "elite-laboratories-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-64850-505-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "elite-laboratories-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-64850-505-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Elite Laboratories, Inc.", "package_ndc": "64850-505-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"64850-505-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"888-852-6657\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "64850-505-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Elite Laboratories, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 64850-506-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Elite Laboratories, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 08/15/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1113\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"08/15/2023\", \"package_ndc\": \"64850-506-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"888-852-6657\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1113", "dosage_form": "Tablet", "file": "elite-laboratories-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-64850-506-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "elite-laboratories-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-64850-506-01", "initial_posting_date": "08/15/2023", "manufacturer_name": "Elite Laboratories, Inc.", "package_ndc": "64850-506-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"08/15/2023\", \"package_ndc\": \"64850-506-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"888-852-6657\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "64850-506-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Elite Laboratories, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 64850-550-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Elite Laboratories, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"64850-550-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-852-6657\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "elite-laboratories-inc-lisdexamfetamine-dimesylate-capsule-64850-550-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "elite-laboratories-inc-lisdexamfetamine-dimesylate-capsule-64850-550-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Elite Laboratories, Inc.", "package_ndc": "64850-550-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"64850-550-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-852-6657\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "64850-550-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Elite Laboratories, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 64850-551-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Elite Laboratories, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"64850-551-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-852-6657\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "elite-laboratories-inc-lisdexamfetamine-dimesylate-capsule-64850-551-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "elite-laboratories-inc-lisdexamfetamine-dimesylate-capsule-64850-551-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Elite Laboratories, Inc.", "package_ndc": "64850-551-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"64850-551-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-852-6657\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "64850-551-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Elite Laboratories, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 64850-552-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Elite Laboratories, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"64850-552-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-852-6657\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "elite-laboratories-inc-lisdexamfetamine-dimesylate-capsule-64850-552-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "elite-laboratories-inc-lisdexamfetamine-dimesylate-capsule-64850-552-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Elite Laboratories, Inc.", "package_ndc": "64850-552-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"64850-552-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-852-6657\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "64850-552-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Elite Laboratories, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 64850-553-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Elite Laboratories, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"64850-553-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-852-6657\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "elite-laboratories-inc-lisdexamfetamine-dimesylate-capsule-64850-553-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "elite-laboratories-inc-lisdexamfetamine-dimesylate-capsule-64850-553-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Elite Laboratories, Inc.", "package_ndc": "64850-553-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"64850-553-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-852-6657\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "64850-553-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Elite Laboratories, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 64850-554-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Elite Laboratories, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"64850-554-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-852-6657\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "elite-laboratories-inc-lisdexamfetamine-dimesylate-capsule-64850-554-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "elite-laboratories-inc-lisdexamfetamine-dimesylate-capsule-64850-554-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Elite Laboratories, Inc.", "package_ndc": "64850-554-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"64850-554-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-852-6657\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "64850-554-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Elite Laboratories, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 64850-555-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Elite Laboratories, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"64850-555-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-852-6657\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "elite-laboratories-inc-lisdexamfetamine-dimesylate-capsule-64850-555-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "elite-laboratories-inc-lisdexamfetamine-dimesylate-capsule-64850-555-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Elite Laboratories, Inc.", "package_ndc": "64850-555-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"64850-555-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-852-6657\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "64850-555-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Elite Laboratories, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 64850-556-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Elite Laboratories, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"64850-556-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-852-6657\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "elite-laboratories-inc-lisdexamfetamine-dimesylate-capsule-64850-556-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "elite-laboratories-inc-lisdexamfetamine-dimesylate-capsule-64850-556-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Elite Laboratories, Inc.", "package_ndc": "64850-556-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)\", \"company_name\": \"Elite Laboratories, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"64850-556-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-852-6657\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Elite%20Laboratories,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "64850-556-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Elite Laboratories, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 42806-339-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Epic Pharma, LLC\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1426\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-339-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1426", "dosage_form": "Tablet", "file": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-339-01-2.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-07", "id": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-339-01-2", "initial_posting_date": "10/12/2022", "manufacturer_name": "Epic Pharma, LLC", "package_ndc": "42806-339-01", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-339-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "42806-339-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Epic Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 42806-339-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Epic Pharma, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-339-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-339-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-339-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Epic Pharma, LLC", "package_ndc": "42806-339-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-339-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "42806-339-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Epic Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 42806-341-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Epic Pharma, LLC\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1426\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-341-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1426", "dosage_form": "Tablet", "file": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-341-01-2.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-07", "id": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-341-01-2", "initial_posting_date": "10/12/2022", "manufacturer_name": "Epic Pharma, LLC", "package_ndc": "42806-341-01", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-341-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "42806-341-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Epic Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 42806-341-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Epic Pharma, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-341-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-341-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-341-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Epic Pharma, LLC", "package_ndc": "42806-341-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-341-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "42806-341-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Epic Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 42806-343-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Epic Pharma, LLC\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1426\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-343-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1426", "dosage_form": "Tablet", "file": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-343-01-2.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-07", "id": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-343-01-2", "initial_posting_date": "10/12/2022", "manufacturer_name": "Epic Pharma, LLC", "package_ndc": "42806-343-01", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-343-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "42806-343-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Epic Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 42806-343-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Epic Pharma, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-343-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-343-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-343-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Epic Pharma, LLC", "package_ndc": "42806-343-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-343-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "42806-343-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Epic Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 42806-344-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Epic Pharma, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-344-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-344-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-344-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Epic Pharma, LLC", "package_ndc": "42806-344-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-344-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "42806-344-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Epic Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 42806-345-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Epic Pharma, LLC\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1426\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-345-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1426", "dosage_form": "Tablet", "file": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-345-01-2.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-07", "id": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-345-01-2", "initial_posting_date": "10/12/2022", "manufacturer_name": "Epic Pharma, LLC", "package_ndc": "42806-345-01", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-345-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "42806-345-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Epic Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 42806-345-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Epic Pharma, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-345-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-345-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "epic-pharma-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-42806-345-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Epic Pharma, LLC", "package_ndc": "42806-345-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"42806-345-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "42806-345-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Epic Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 42806-799-01\n\n**Generic name:** Rifampin Capsule\n\n**Manufacturer:** Epic Pharma, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 12/22/2021\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1714\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"42806-799-01\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1714", "dosage_form": "Capsule", "file": "epic-pharma-llc-rifampin-capsule-42806-799-01.md", "generated": true, "generic_name": "Rifampin Capsule", "harvested": "2026-09-01", "id": "epic-pharma-llc-rifampin-capsule-42806-799-01", "initial_posting_date": "12/22/2021", "manufacturer_name": "Epic Pharma, LLC", "package_ndc": "42806-799-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"42806-799-01\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "42806-799-01 \u00b7 Rifampin Capsule \u00b7 Epic Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 42806-799-05\n\n**Generic name:** Rifampin Capsule\n\n**Manufacturer:** Epic Pharma, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-05)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-05)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 12/22/2021\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-05)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1714\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-05)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-05)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-05)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"42806-799-05\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1714", "dosage_form": "Capsule", "file": "epic-pharma-llc-rifampin-capsule-42806-799-05.md", "generated": true, "generic_name": "Rifampin Capsule", "harvested": "2026-09-01", "id": "epic-pharma-llc-rifampin-capsule-42806-799-05", "initial_posting_date": "12/22/2021", "manufacturer_name": "Epic Pharma, LLC", "package_ndc": "42806-799-05", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-05)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-05)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-05)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-05)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-05)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-05)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"42806-799-05\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "42806-799-05 \u00b7 Rifampin Capsule \u00b7 Epic Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 42806-799-30\n\n**Generic name:** Rifampin Capsule\n\n**Manufacturer:** Epic Pharma, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-30)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-30)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 12/22/2021\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-30)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1714\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-30)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-30)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-30)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"42806-799-30\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1714", "dosage_form": "Capsule", "file": "epic-pharma-llc-rifampin-capsule-42806-799-30.md", "generated": true, "generic_name": "Rifampin Capsule", "harvested": "2026-09-01", "id": "epic-pharma-llc-rifampin-capsule-42806-799-30", "initial_posting_date": "12/22/2021", "manufacturer_name": "Epic Pharma, LLC", "package_ndc": "42806-799-30", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-30)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-30)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-30)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-30)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-30)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-30)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"42806-799-30\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "42806-799-30 \u00b7 Rifampin Capsule \u00b7 Epic Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 42806-799-60\n\n**Generic name:** Rifampin Capsule\n\n**Manufacturer:** Epic Pharma, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-60)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-60)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/22/2021\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-60)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1714\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-60)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-60)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"42806-799-60\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1714", "dosage_form": "Capsule", "file": "epic-pharma-llc-rifampin-capsule-42806-799-60.md", "generated": true, "generic_name": "Rifampin Capsule", "harvested": "2026-09-01", "id": "epic-pharma-llc-rifampin-capsule-42806-799-60", "initial_posting_date": "12/22/2021", "manufacturer_name": "Epic Pharma, LLC", "package_ndc": "42806-799-60", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-60)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-60)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-60)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-60)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 42806-799-60)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"42806-799-60\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "42806-799-60 \u00b7 Rifampin Capsule \u00b7 Epic Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 42806-801-01\n\n**Generic name:** Rifampin Capsule\n\n**Manufacturer:** Epic Pharma, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 12/22/2021\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1714\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"42806-801-01\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1714", "dosage_form": "Capsule", "file": "epic-pharma-llc-rifampin-capsule-42806-801-01.md", "generated": true, "generic_name": "Rifampin Capsule", "harvested": "2026-09-01", "id": "epic-pharma-llc-rifampin-capsule-42806-801-01", "initial_posting_date": "12/22/2021", "manufacturer_name": "Epic Pharma, LLC", "package_ndc": "42806-801-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-01)\", \"company_name\": \"Epic Pharma, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"42806-801-01\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "42806-801-01 \u00b7 Rifampin Capsule \u00b7 Epic Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 42806-801-30\n\n**Generic name:** Rifampin Capsule\n\n**Manufacturer:** Epic Pharma, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-30)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-30)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/22/2021\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-30)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1714\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-30)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-30)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"42806-801-30\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1714", "dosage_form": "Capsule", "file": "epic-pharma-llc-rifampin-capsule-42806-801-30.md", "generated": true, "generic_name": "Rifampin Capsule", "harvested": "2026-09-01", "id": "epic-pharma-llc-rifampin-capsule-42806-801-30", "initial_posting_date": "12/22/2021", "manufacturer_name": "Epic Pharma, LLC", "package_ndc": "42806-801-30", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-30)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-30)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-30)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-30)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 42806-801-30)\", \"company_name\": \"Epic Pharma, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"42806-801-30\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"(718) 276-8600 ext. 3\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Epic%20Pharma,%20LLC%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "42806-801-30 \u00b7 Rifampin Capsule \u00b7 Epic Pharma, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 68118-100-01\n\n**Generic name:** Streptozocin Powder, For Solution\n\n**Manufacturer:** ESTEVE PHARMACEUTICALS, S.A.\n\n> \"update_date\": \"05/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)\", \"company_name\": \"ESTEVE PHARMACEUTICALS, S.A.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"05/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)\", \"company_name\": \"ESTEVE PHARMACEUTICALS, S.A.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/12/2022\n\n**Last update date:** 05/06/2026\n\n> \"update_date\": \"05/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)\", \"company_name\": \"ESTEVE PHARMACEUTICALS, S.A.\", \"status\": \"Current\"\n\n**Days in shortage:** 1512\n\n**Dosage form:** Powder, For Solution\n\n> \"update_date\": \"05/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)\", \"company_name\": \"ESTEVE PHARMACEUTICALS, S.A.\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"05/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)\", \"company_name\": \"ESTEVE PHARMACEUTICALS, S.A.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/12/2022\", \"package_ndc\": \"68118-100-01\", \"generic_name\": \"Streptozocin Powder, For Solution\", \"related_info_link\": \"https://www.fda.gov/media/187353/download?attachment\", \"contact_info\": \"USSZTOrders@esteve.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22ESTEVE%20PHARMACEUTICALS,%20S.A.%22+AND+generic_name%3A%22Streptozocin%20Powder,%20For%20Solution%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1512", "dosage_form": "Powder, For Solution", "file": "esteve-pharmaceuticals-s-a-streptozocin-powder-for-solution-68118-100-01.md", "generated": true, "generic_name": "Streptozocin Powder, For Solution", "harvested": "2026-09-01", "id": "esteve-pharmaceuticals-s-a-streptozocin-powder-for-solution-68118-100-01", "initial_posting_date": "07/12/2022", "manufacturer_name": "ESTEVE PHARMACEUTICALS, S.A.", "package_ndc": "68118-100-01", "quote_dosage_form": "\"update_date\": \"05/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)\", \"company_name\": \"ESTEVE PHARMACEUTICALS, S.A.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"05/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)\", \"company_name\": \"ESTEVE PHARMACEUTICALS, S.A.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"05/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)\", \"company_name\": \"ESTEVE PHARMACEUTICALS, S.A.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"05/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)\", \"company_name\": \"ESTEVE PHARMACEUTICALS, S.A.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"05/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)\", \"company_name\": \"ESTEVE PHARMACEUTICALS, S.A.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/12/2022\", \"package_ndc\": \"68118-100-01\", \"generic_name\": \"Streptozocin Powder, For Solution\", \"related_info_link\": \"https://www.fda.gov/media/187353/download?attachment\", \"contact_info\": \"USSZTOrders@esteve.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22ESTEVE%20PHARMACEUTICALS,%20S.A.%22+AND+generic_name%3A%22Streptozocin%20Powder,%20For%20Solution%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "68118-100-01 \u00b7 Streptozocin Powder, For Solution \u00b7 ESTEVE PHARMACEUTICALS, S.A. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "05/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-393-01\n\n**Generic name:** Azacitidine Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: TBD. Check wholesalers for inventory\n\n**Initial posting date:** 12/22/2020\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2079\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/22/2020\", \"package_ndc\": \"55150-393-01\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2079", "dosage_form": "Injection", "file": "eugia-us-llc-azacitidine-injection-55150-393-01.md", "generated": true, "generic_name": "Azacitidine Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-azacitidine-injection-55150-393-01", "initial_posting_date": "12/22/2020", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-393-01", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"12/22/2020\", \"package_ndc\": \"55150-393-01\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Oncology", "title": "55150-393-01 \u00b7 Azacitidine Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-167-10\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-167-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "eugia-us-llc-bupivacaine-hydrochloride-injection-55150-167-10.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-bupivacaine-hydrochloride-injection-55150-167-10", "initial_posting_date": "02/20/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-167-10", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-167-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-167-10 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-168-30\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-168-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "eugia-us-llc-bupivacaine-hydrochloride-injection-55150-168-30.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-bupivacaine-hydrochloride-injection-55150-168-30", "initial_posting_date": "02/20/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-168-30", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-168-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-168-30 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-169-10\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-169-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "eugia-us-llc-bupivacaine-hydrochloride-injection-55150-169-10.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-bupivacaine-hydrochloride-injection-55150-169-10", "initial_posting_date": "02/20/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-169-10", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-169-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-169-10 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-170-30\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-170-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "eugia-us-llc-bupivacaine-hydrochloride-injection-55150-170-30.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-bupivacaine-hydrochloride-injection-55150-170-30", "initial_posting_date": "02/20/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-170-30", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-170-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-170-30 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-171-10\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-171-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "eugia-us-llc-bupivacaine-hydrochloride-injection-55150-171-10.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-bupivacaine-hydrochloride-injection-55150-171-10", "initial_posting_date": "02/20/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-171-10", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-171-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-171-10 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-172-30\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-172-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "eugia-us-llc-bupivacaine-hydrochloride-injection-55150-172-30.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-bupivacaine-hydrochloride-injection-55150-172-30", "initial_posting_date": "02/20/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-172-30", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-172-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-172-30 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-249-50\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-249-50\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "eugia-us-llc-bupivacaine-hydrochloride-injection-55150-249-50.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-bupivacaine-hydrochloride-injection-55150-249-50", "initial_posting_date": "02/20/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-249-50", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-249-50\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-249-50 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-250-50\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-250-50\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "eugia-us-llc-bupivacaine-hydrochloride-injection-55150-250-50.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-bupivacaine-hydrochloride-injection-55150-250-50", "initial_posting_date": "02/20/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-250-50", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-250-50\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-250-50 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-335-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: late September 2026. Check wholesalers for inventory\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1228\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"55150-335-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: late September 2026. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1228", "dosage_form": "Injection", "file": "eugia-us-llc-carboplatin-injection-55150-335-01-2.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-07", "id": "eugia-us-llc-carboplatin-injection-55150-335-01-2", "initial_posting_date": "04/28/2023", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-335-01", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "On backorder. Recovery: late September 2026. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"55150-335-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: late September 2026. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Oncology", "title": "55150-335-01 \u00b7 Carboplatin Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-335-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: TBD. Check wholesalers for inventory\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"55150-335-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "eugia-us-llc-carboplatin-injection-55150-335-01.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-carboplatin-injection-55150-335-01", "initial_posting_date": "04/28/2023", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-335-01", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"55150-335-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "55150-335-01 \u00b7 Carboplatin Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-386-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"55150-386-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "eugia-us-llc-carboplatin-injection-55150-386-01.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-carboplatin-injection-55150-386-01", "initial_posting_date": "04/28/2023", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-386-01", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"55150-386-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Oncology", "title": "55150-386-01 \u00b7 Carboplatin Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-304-25\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"55150-304-25\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "eugia-us-llc-dexamethasone-sodium-phosphate-injection-55150-304-25.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-dexamethasone-sodium-phosphate-injection-55150-304-25", "initial_posting_date": "02/08/2019", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-304-25", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"55150-304-25\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Dermatology", "title": "55150-304-25 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-209-02\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"55150-209-02\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "eugia-us-llc-dexmedetomidine-hydrochloride-injection-55150-209-02.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-dexmedetomidine-hydrochloride-injection-55150-209-02", "initial_posting_date": "04/10/2020", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-209-02", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"55150-209-02\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-209-02 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-296-10\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"55150-296-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "eugia-us-llc-dexmedetomidine-hydrochloride-injection-55150-296-10.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-dexmedetomidine-hydrochloride-injection-55150-296-10", "initial_posting_date": "04/10/2020", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-296-10", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"55150-296-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-296-10 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-297-10\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"55150-297-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "eugia-us-llc-dexmedetomidine-hydrochloride-injection-55150-297-10.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-dexmedetomidine-hydrochloride-injection-55150-297-10", "initial_posting_date": "04/10/2020", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-297-10", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"55150-297-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-297-10 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-221-10\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: TBD. Check wholesalers for inventory\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"55150-221-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "eugia-us-llc-etomidate-injection-55150-221-10.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-etomidate-injection-55150-221-10", "initial_posting_date": "10/05/2022", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-221-10", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"55150-221-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-221-10 \u00b7 Etomidate Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-222-20\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: TBD. Check wholesalers for inventory\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"55150-222-20\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "eugia-us-llc-etomidate-injection-55150-222-20.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-etomidate-injection-55150-222-20", "initial_posting_date": "10/05/2022", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-222-20", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"55150-222-20\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-222-20 \u00b7 Etomidate Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-322-25\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: TBD. Check wholesalers for inventory\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"55150-322-25\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "eugia-us-llc-furosemide-injection-55150-322-25.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-furosemide-injection-55150-322-25", "initial_posting_date": "04/07/2020", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-322-25", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"55150-322-25\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "55150-322-25 \u00b7 Furosemide Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-323-25\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"55150-323-25\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "eugia-us-llc-furosemide-injection-55150-323-25.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-furosemide-injection-55150-323-25", "initial_posting_date": "04/07/2020", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-323-25", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"55150-323-25\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "55150-323-25 \u00b7 Furosemide Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-324-25\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"55150-324-25\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "eugia-us-llc-furosemide-injection-55150-324-25.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-furosemide-injection-55150-324-25", "initial_posting_date": "04/07/2020", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-324-25", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"55150-324-25\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "55150-324-25 \u00b7 Furosemide Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-159-74\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: TBD. Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-159-74\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-159-74.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-159-74", "initial_posting_date": "02/20/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-159-74", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-159-74\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-159-74 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-161-02\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: late September 2026. Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3121\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-161-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: late September 2026. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3121", "dosage_form": "Injection", "file": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-161-02-2.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-07", "id": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-161-02-2", "initial_posting_date": "02/20/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-161-02", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "On backorder. Recovery: late September 2026. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-161-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: late September 2026. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-161-02 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-161-02\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-161-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-161-02.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-161-02", "initial_posting_date": "02/20/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-161-02", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-161-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-161-02 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-162-05\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-162-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-162-05.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-162-05", "initial_posting_date": "02/20/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-162-05", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-162-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-162-05 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-163-30\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-163-30\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-163-30.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-163-30", "initial_posting_date": "02/20/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-163-30", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-163-30\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-163-30 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-164-02\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-164-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-164-02.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-164-02", "initial_posting_date": "02/20/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-164-02", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-164-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-164-02 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-165-05\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: October 2026. Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3121\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-165-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: October 2026. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3121", "dosage_form": "Injection", "file": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-165-05-2.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-07", "id": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-165-05-2", "initial_posting_date": "02/20/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-165-05", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "On backorder. Recovery: October 2026. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-165-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: October 2026. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-165-05 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-165-05\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-165-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-165-05.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-165-05", "initial_posting_date": "02/20/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-165-05", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"55150-165-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-165-05 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-251-10\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 06/13/2018\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3008\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"55150-251-10\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3008", "dosage_form": "Injection", "file": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-251-10-2.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-07", "id": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-251-10-2", "initial_posting_date": "06/13/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-251-10", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"55150-251-10\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-251-10 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-251-10\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: end-August 2026. Check wholesalers for inventory\n\n**Initial posting date:** 06/13/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3002\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"55150-251-10\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: end-August 2026. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3002", "dosage_form": "Injection", "file": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-251-10.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-251-10", "initial_posting_date": "06/13/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-251-10", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "On backorder. Recovery: end-August 2026. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"55150-251-10\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: end-August 2026. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-251-10 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-252-20\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: TBD. Check wholesalers for inventory\n\n**Initial posting date:** 06/13/2018\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3008\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"55150-252-20\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3008", "dosage_form": "Injection", "file": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-252-20-2.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-07", "id": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-252-20-2", "initial_posting_date": "06/13/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-252-20", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"55150-252-20\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-252-20 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-252-20\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 06/13/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3002\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"55150-252-20\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3002", "dosage_form": "Injection", "file": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-252-20.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-252-20", "initial_posting_date": "06/13/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-252-20", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"55150-252-20\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-252-20 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-254-10\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: TBD. Check wholesalers for inventory\n\n**Initial posting date:** 06/13/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3002\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"55150-254-10\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3002", "dosage_form": "Injection", "file": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-254-10.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-254-10", "initial_posting_date": "06/13/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-254-10", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"55150-254-10\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-254-10 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-255-20\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 06/13/2018\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3008\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"55150-255-20\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3008", "dosage_form": "Injection", "file": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-255-20-2.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-07", "id": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-255-20-2", "initial_posting_date": "06/13/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-255-20", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"55150-255-20\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-255-20 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-255-20\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: mid-August 2026. Check wholesalers for inventory\n\n**Initial posting date:** 06/13/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3002\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"55150-255-20\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: mid-August 2026. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3002", "dosage_form": "Injection", "file": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-255-20.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-255-20", "initial_posting_date": "06/13/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-255-20", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "On backorder. Recovery: mid-August 2026. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"55150-255-20\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: mid-August 2026. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-255-20 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-256-50\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: TBD. Check wholesalers for inventory\n\n**Initial posting date:** 06/13/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3002\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"55150-256-50\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3002", "dosage_form": "Injection", "file": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-256-50.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-lidocaine-hydrochloride-injection-55150-256-50", "initial_posting_date": "06/13/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-256-50", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"55150-256-50\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-256-50 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-313-01\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: TBD. Check wholesalers for inventory\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"55150-313-01\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "eugia-us-llc-methylprednisolone-acetate-injection-55150-313-01.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-methylprednisolone-acetate-injection-55150-313-01", "initial_posting_date": "12/15/2021", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-313-01", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"55150-313-01\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Rheumatology", "title": "55150-313-01 \u00b7 Methylprednisolone Acetate Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-314-01\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: TBD. Check wholesalers for inventory\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"55150-314-01\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "eugia-us-llc-methylprednisolone-acetate-injection-55150-314-01.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-methylprednisolone-acetate-injection-55150-314-01", "initial_posting_date": "12/15/2021", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-314-01", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"55150-314-01\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Rheumatology", "title": "55150-314-01 \u00b7 Methylprednisolone Acetate Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-225-05\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"55150-225-05\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "eugia-us-llc-rocuronium-bromide-injection-55150-225-05.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-rocuronium-bromide-injection-55150-225-05", "initial_posting_date": "02/15/2023", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-225-05", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"55150-225-05\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-225-05 \u00b7 Rocuronium Bromide Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-226-10\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"55150-226-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "eugia-us-llc-rocuronium-bromide-injection-55150-226-10.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-rocuronium-bromide-injection-55150-226-10", "initial_posting_date": "02/15/2023", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-226-10", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"55150-226-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-226-10 \u00b7 Rocuronium Bromide Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-195-20\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: TBD. Check wholesalers for inventory\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-195-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-195-20.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-195-20", "initial_posting_date": "03/23/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-195-20", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-195-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-195-20 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-196-99\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-196-99\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-196-99.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-196-99", "initial_posting_date": "03/23/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-196-99", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-196-99\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-196-99 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-197-20\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-197-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-197-20.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-197-20", "initial_posting_date": "03/23/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-197-20", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-197-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-197-20 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-198-30\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-198-30\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-198-30.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-198-30", "initial_posting_date": "03/23/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-198-30", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-198-30\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-198-30 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-199-20\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: TBD. Check wholesalers for inventory\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3090\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-199-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3090", "dosage_form": "Injection", "file": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-199-20-2.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-07", "id": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-199-20-2", "initial_posting_date": "03/23/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-199-20", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-199-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: TBD. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-199-20 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-199-20\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: end-August 2026. Check wholesalers for inventory\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-199-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: end-August 2026. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-199-20.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-199-20", "initial_posting_date": "03/23/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-199-20", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "On backorder. Recovery: end-August 2026. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-199-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: end-August 2026. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-199-20 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-200-10\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3090\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-200-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3090", "dosage_form": "Injection", "file": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-200-10-2.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-07", "id": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-200-10-2", "initial_posting_date": "03/23/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-200-10", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-200-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-200-10 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55150-200-10\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** On backorder. Recovery: end-August 2026. Check wholesalers for inventory\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-200-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: end-August 2026. Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-200-10.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-200-10", "initial_posting_date": "03/23/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-200-10", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)\", \"company_name\": \"Eugia US LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "On backorder. Recovery: end-August 2026. Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-200-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Unavailable\", \"related_info\": \"On backorder. Recovery: end-August 2026. Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-200-10 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 55150-201-20\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Eugia US LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-201-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-201-20.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "eugia-us-llc-ropivacaine-hydrochloride-injection-55150-201-20", "initial_posting_date": "03/23/2018", "manufacturer_name": "Eugia US LLC", "package_ndc": "55150-201-20", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)\", \"company_name\": \"Eugia US LLC\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"55150-201-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-238-7880\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Eugia%20US%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "55150-201-20 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Eugia US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 51754-5001-5\n\n**Generic name:** Sodium Bicarbonate Injection\n\n**Manufacturer:** Exela Pharma Sciences, LLC\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/24/2017\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3326\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/24/2017\", \"package_ndc\": \"51754-5001-5\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"828-758-5474 ext. 154\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Exela%20Pharma%20Sciences,%20LLC%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3326", "dosage_form": "Injection", "file": "exela-pharma-sciences-llc-sodium-bicarbonate-injection-51754-5001-5.md", "generated": true, "generic_name": "Sodium Bicarbonate Injection", "harvested": "2026-09-01", "id": "exela-pharma-sciences-llc-sodium-bicarbonate-injection-51754-5001-5", "initial_posting_date": "07/24/2017", "manufacturer_name": "Exela Pharma Sciences, LLC", "package_ndc": "51754-5001-5", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"07/24/2017\", \"package_ndc\": \"51754-5001-5\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"828-758-5474 ext. 154\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Exela%20Pharma%20Sciences,%20LLC%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "51754-5001-5 \u00b7 Sodium Bicarbonate Injection \u00b7 Exela Pharma Sciences, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 51754-5011-4\n\n**Generic name:** Sodium Bicarbonate Injection\n\n**Manufacturer:** Exela Pharma Sciences, LLC\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/24/2017\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3326\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/24/2017\", \"package_ndc\": \"51754-5011-4\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"828-758-5474 ext. 154\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Exela%20Pharma%20Sciences,%20LLC%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3326", "dosage_form": "Injection", "file": "exela-pharma-sciences-llc-sodium-bicarbonate-injection-51754-5011-4.md", "generated": true, "generic_name": "Sodium Bicarbonate Injection", "harvested": "2026-09-01", "id": "exela-pharma-sciences-llc-sodium-bicarbonate-injection-51754-5011-4", "initial_posting_date": "07/24/2017", "manufacturer_name": "Exela Pharma Sciences, LLC", "package_ndc": "51754-5011-4", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"07/24/2017\", \"package_ndc\": \"51754-5011-4\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"828-758-5474 ext. 154\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Exela%20Pharma%20Sciences,%20LLC%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "51754-5011-4 \u00b7 Sodium Bicarbonate Injection \u00b7 Exela Pharma Sciences, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 51754-5012-4\n\n**Generic name:** Sodium Bicarbonate Injection\n\n**Manufacturer:** Exela Pharma Sciences, LLC\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/24/2017\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3326\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/24/2017\", \"package_ndc\": \"51754-5012-4\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"828-758-5474 ext. 154\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Exela%20Pharma%20Sciences,%20LLC%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3326", "dosage_form": "Injection", "file": "exela-pharma-sciences-llc-sodium-bicarbonate-injection-51754-5012-4.md", "generated": true, "generic_name": "Sodium Bicarbonate Injection", "harvested": "2026-09-01", "id": "exela-pharma-sciences-llc-sodium-bicarbonate-injection-51754-5012-4", "initial_posting_date": "07/24/2017", "manufacturer_name": "Exela Pharma Sciences, LLC", "package_ndc": "51754-5012-4", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)\", \"company_name\": \"Exela Pharma Sciences, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"07/24/2017\", \"package_ndc\": \"51754-5012-4\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"828-758-5474 ext. 154\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Exela%20Pharma%20Sciences,%20LLC%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "51754-5012-4 \u00b7 Sodium Bicarbonate Injection \u00b7 Exela Pharma Sciences, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 48102-053-05\n\n**Generic name:** Echothiophate Iodide Ophthalmic Solution\n\n**Manufacturer:** Fera Pharmaceuticals\n\n> \"update_date\": \"08/10/2026\", \"therapeutic_category\": [ \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Solution\", \"presentation\": \"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)\", \"company_name\": \"Fera Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/10/2026\", \"therapeutic_category\": [ \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Solution\", \"presentation\": \"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)\", \"company_name\": \"Fera Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Available through limited distribution by Walgreens Specialty Pharmacy.\n\n**Initial posting date:** 09/24/2019\n\n**Last update date:** 08/10/2026\n\n> \"update_date\": \"08/10/2026\", \"therapeutic_category\": [ \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Solution\", \"presentation\": \"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)\", \"company_name\": \"Fera Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2534\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/10/2026\", \"therapeutic_category\": [ \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Solution\", \"presentation\": \"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)\", \"company_name\": \"Fera Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Ophthalmic Solution\n\n> \"update_date\": \"08/10/2026\", \"therapeutic_category\": [ \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Solution\", \"presentation\": \"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)\", \"company_name\": \"Fera Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Ophthalmology\n\n> \"update_date\": \"08/10/2026\", \"therapeutic_category\": [ \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Solution\", \"presentation\": \"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)\", \"company_name\": \"Fera Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"09/24/2019\", \"package_ndc\": \"48102-053-05\", \"generic_name\": \"Echothiophate Iodide Ophthalmic Solution\", \"contact_info\": \"516-277-1449\", \"availability\": \"Available\", \"related_info\": \"Available through limited distribution by Walgreens Specialty Pharmacy.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fera%20Pharmaceuticals%22+AND+generic_name%3A%22Echothiophate%20Iodide%20Ophthalmic%20Solution%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2534", "dosage_form": "Ophthalmic Solution", "file": "fera-pharmaceuticals-echothiophate-iodide-ophthalmic-solution-48102-053-05.md", "generated": true, "generic_name": "Echothiophate Iodide Ophthalmic Solution", "harvested": "2026-09-01", "id": "fera-pharmaceuticals-echothiophate-iodide-ophthalmic-solution-48102-053-05", "initial_posting_date": "09/24/2019", "manufacturer_name": "Fera Pharmaceuticals", "package_ndc": "48102-053-05", "quote_dosage_form": "\"update_date\": \"08/10/2026\", \"therapeutic_category\": [ \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Solution\", \"presentation\": \"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)\", \"company_name\": \"Fera Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/10/2026\", \"therapeutic_category\": [ \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Solution\", \"presentation\": \"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)\", \"company_name\": \"Fera Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/10/2026\", \"therapeutic_category\": [ \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Solution\", \"presentation\": \"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)\", \"company_name\": \"Fera Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/10/2026\", \"therapeutic_category\": [ \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Solution\", \"presentation\": \"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)\", \"company_name\": \"Fera Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/10/2026\", \"therapeutic_category\": [ \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Solution\", \"presentation\": \"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)\", \"company_name\": \"Fera Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/10/2026\", \"therapeutic_category\": [ \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Solution\", \"presentation\": \"Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)\", \"company_name\": \"Fera Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Available through limited distribution by Walgreens Specialty Pharmacy.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"09/24/2019\", \"package_ndc\": \"48102-053-05\", \"generic_name\": \"Echothiophate Iodide Ophthalmic Solution\", \"contact_info\": \"516-277-1449\", \"availability\": \"Available\", \"related_info\": \"Available through limited distribution by Walgreens Specialty Pharmacy.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fera%20Pharmaceuticals%22+AND+generic_name%3A%22Echothiophate%20Iodide%20Ophthalmic%20Solution%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Ophthalmology", "title": "48102-053-05 \u00b7 Echothiophate Iodide Ophthalmic Solution \u00b7 Fera Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/10/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0053-6871-00\n\n**Generic name:** Desmopressin Acetate Spray\n\n**Manufacturer:** Ferring\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 03/12/2021\n\n**Last update date:** 05/01/2026\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 1999\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Spray\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Hematology\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/12/2021\", \"package_ndc\": \"0053-6871-00\", \"generic_name\": \"Desmopressin Acetate Spray\", \"contact_info\": \"888-337-7464\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Ferring%22+AND+generic_name%3A%22Desmopressin%20Acetate%20Spray%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1999", "dosage_form": "Spray", "file": "ferring-desmopressin-acetate-spray-0053-6871-00.md", "generated": true, "generic_name": "Desmopressin Acetate Spray", "harvested": "2026-09-01", "id": "ferring-desmopressin-acetate-spray-0053-6871-00", "initial_posting_date": "03/12/2021", "manufacturer_name": "Ferring", "package_ndc": "0053-6871-00", "quote_dosage_form": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"03/12/2021\", \"package_ndc\": \"0053-6871-00\", \"generic_name\": \"Desmopressin Acetate Spray\", \"contact_info\": \"888-337-7464\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Ferring%22+AND+generic_name%3A%22Desmopressin%20Acetate%20Spray%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Hematology", "title": "0053-6871-00 \u00b7 Desmopressin Acetate Spray \u00b7 Ferring \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "05/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 55566-2500-0\n\n**Generic name:** Desmopressin Acetate Spray\n\n**Manufacturer:** Ferring\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 03/12/2021\n\n**Last update date:** 05/01/2026\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 1999\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Spray\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Hematology\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/12/2021\", \"package_ndc\": \"55566-2500-0\", \"generic_name\": \"Desmopressin Acetate Spray\", \"contact_info\": \"888-337-7464\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Ferring%22+AND+generic_name%3A%22Desmopressin%20Acetate%20Spray%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1999", "dosage_form": "Spray", "file": "ferring-desmopressin-acetate-spray-55566-2500-0.md", "generated": true, "generic_name": "Desmopressin Acetate Spray", "harvested": "2026-09-01", "id": "ferring-desmopressin-acetate-spray-55566-2500-0", "initial_posting_date": "03/12/2021", "manufacturer_name": "Ferring", "package_ndc": "55566-2500-0", "quote_dosage_form": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"03/12/2021\", \"package_ndc\": \"55566-2500-0\", \"generic_name\": \"Desmopressin Acetate Spray\", \"contact_info\": \"888-337-7464\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Ferring%22+AND+generic_name%3A%22Desmopressin%20Acetate%20Spray%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Hematology", "title": "55566-2500-0 \u00b7 Desmopressin Acetate Spray \u00b7 Ferring \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "05/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 69918-501-05\n\n**Generic name:** Desmopressin Acetate Spray\n\n**Manufacturer:** Ferring\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 03/12/2021\n\n**Last update date:** 05/01/2026\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 1999\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Spray\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Hematology\n\n> \"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/12/2021\", \"package_ndc\": \"69918-501-05\", \"generic_name\": \"Desmopressin Acetate Spray\", \"contact_info\": \"888-337-7464\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Ferring%22+AND+generic_name%3A%22Desmopressin%20Acetate%20Spray%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1999", "dosage_form": "Spray", "file": "ferring-desmopressin-acetate-spray-69918-501-05.md", "generated": true, "generic_name": "Desmopressin Acetate Spray", "harvested": "2026-09-01", "id": "ferring-desmopressin-acetate-spray-69918-501-05", "initial_posting_date": "03/12/2021", "manufacturer_name": "Ferring", "package_ndc": "69918-501-05", "quote_dosage_form": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"05/01/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Spray\", \"presentation\": \"Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)\", \"company_name\": \"Ferring\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"03/12/2021\", \"package_ndc\": \"69918-501-05\", \"generic_name\": \"Desmopressin Acetate Spray\", \"contact_info\": \"888-337-7464\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Ferring%22+AND+generic_name%3A%22Desmopressin%20Acetate%20Spray%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Hematology", "title": "69918-501-05 \u00b7 Desmopressin Acetate Spray \u00b7 Ferring \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "05/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-580-20\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"63323-580-20\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-atropine-sulfate-injection-63323-580-20.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-atropine-sulfate-injection-63323-580-20", "initial_posting_date": "01/01/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-580-20", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"63323-580-20\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-580-20 \u00b7 Atropine Sulfate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-771-39\n\n**Generic name:** Azacitidine Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 12/18/2020\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2085\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/18/2020\", \"package_ndc\": \"63323-771-39\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"1-888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2085", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-azacitidine-injection-63323-771-39-2.md", "generated": true, "generic_name": "Azacitidine Injection", "harvested": "2026-09-03", "id": "fresenius-kabi-usa-llc-azacitidine-injection-63323-771-39-2", "initial_posting_date": "12/18/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-771-39", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"12/18/2020\", \"package_ndc\": \"63323-771-39\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"1-888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Oncology", "title": "63323-771-39 \u00b7 Azacitidine Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-771-39\n\n**Generic name:** Azacitidine Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 12/18/2020\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2083\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/18/2020\", \"package_ndc\": \"63323-771-39\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"1-888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2083", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-azacitidine-injection-63323-771-39.md", "generated": true, "generic_name": "Azacitidine Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-azacitidine-injection-63323-771-39", "initial_posting_date": "12/18/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-771-39", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"12/18/2020\", \"package_ndc\": \"63323-771-39\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"1-888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "63323-771-39 \u00b7 Azacitidine Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65219-570-04\n\n**Generic name:** Bumetanide Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 01/31/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3135\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/31/2018\", \"package_ndc\": \"65219-570-04\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3135", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bumetanide-injection-65219-570-04.md", "generated": true, "generic_name": "Bumetanide Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bumetanide-injection-65219-570-04", "initial_posting_date": "01/31/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "65219-570-04", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"01/31/2018\", \"package_ndc\": \"65219-570-04\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "65219-570-04 \u00b7 Bumetanide Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65219-572-10\n\n**Generic name:** Bumetanide Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 01/31/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3135\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/31/2018\", \"package_ndc\": \"65219-572-10\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3135", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bumetanide-injection-65219-572-10.md", "generated": true, "generic_name": "Bumetanide Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bumetanide-injection-65219-572-10", "initial_posting_date": "01/31/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "65219-572-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"01/31/2018\", \"package_ndc\": \"65219-572-10\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "65219-572-10 \u00b7 Bumetanide Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-460-37\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesaler for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-460-37\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesaler for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-460-37.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-460-37", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-460-37", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesaler for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-460-37\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesaler for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-460-37 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-461-57\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesaler for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-461-57\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesaler for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-461-57.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-461-57", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-461-57", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesaler for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-461-57\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesaler for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-461-57 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-462-17\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3117\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-462-17\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3117", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-462-17-2.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-03", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-462-17-2", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-462-17", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-462-17\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-462-17 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-462-17\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** 7 month dating available on request. Check wholesalers for inventory.\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-462-17\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"7 month dating available on request. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-462-17.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-462-17", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-462-17", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "7 month dating available on request. Check wholesalers for inventory.", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-462-17\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"7 month dating available on request. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-462-17 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-462-31\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-462-31\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-462-31.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-462-31", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-462-31", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-462-31\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-462-31 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-462-37\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-462-37\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-462-37.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-462-37", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-462-37", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-462-37\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-462-37 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-463-57\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesaler for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-463-57\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesaler for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-463-57.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-463-57", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-463-57", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesaler for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-463-57\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesaler for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-463-57 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-468-17\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-468-17\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-468-17.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-468-17", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-468-17", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-468-17\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-468-17 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-468-37\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesaler for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-468-37\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesaler for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-468-37.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-63323-468-37", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-468-37", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Check wholesaler for inventory", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-468-37\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesaler for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-468-37 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-464-17\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-464-17\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-464-17.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-464-17", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-464-17", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-464-17\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-464-17 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-464-31\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-464-31\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-464-31.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-464-31", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-464-31", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-464-31\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-464-31 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-464-37\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-464-37\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-464-37.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-464-37", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-464-37", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-464-37\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-464-37 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-465-57\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-465-57\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-465-57.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-465-57", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-465-57", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-465-57\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-465-57 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-466-17\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-466-17\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-466-17.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-466-17", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-466-17", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-466-17\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-466-17 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-466-31\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-466-31\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-466-31.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-466-31", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-466-31", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-466-31\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-466-31 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-466-37\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-466-37\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-466-37.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-466-37", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-466-37", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-466-37\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-466-37 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-467-57\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-467-57\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-467-57.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-467-57", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-467-57", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-467-57\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-467-57 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-472-17\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-472-17\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-472-17.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-472-17", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-472-17", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-472-17\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-472-17 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-472-37\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-472-37\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-472-37.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-bupivacaine-hydrochloride-injection-63323-472-37", "initial_posting_date": "02/20/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-472-37", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"63323-472-37\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-472-37 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-172-60\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release November 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"63323-172-60\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release November 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-carboplatin-injection-63323-172-60.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-carboplatin-injection-63323-172-60", "initial_posting_date": "04/28/2023", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-172-60", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Next release November 2026. Check wholesalers for inventory.", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"63323-172-60\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release November 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "63323-172-60 \u00b7 Carboplatin Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-165-01\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"63323-165-01\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-63323-165-01.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-63323-165-01", "initial_posting_date": "02/08/2019", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-165-01", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"63323-165-01\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Dermatology", "title": "63323-165-01 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-165-05\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"63323-165-05\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-63323-165-05.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-63323-165-05", "initial_posting_date": "02/08/2019", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-165-05", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"63323-165-05\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Dermatology", "title": "63323-165-05 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-165-30\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"63323-165-30\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-63323-165-30.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-63323-165-30", "initial_posting_date": "02/08/2019", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-165-30", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"63323-165-30\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Dermatology", "title": "63323-165-30 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-506-01\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"63323-506-01\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-63323-506-01.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-63323-506-01", "initial_posting_date": "02/08/2019", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-506-01", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"63323-506-01\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Dermatology", "title": "63323-506-01 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-516-10\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"63323-516-10\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-63323-516-10.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-63323-516-10", "initial_posting_date": "02/08/2019", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-516-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"63323-516-10\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Dermatology", "title": "63323-516-10 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 76045-0210-10\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Checkwholesalers for inventory\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"76045-0210-10\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Checkwholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-76045-0210-10.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-76045-0210-10", "initial_posting_date": "02/08/2019", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "76045-0210-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Checkwholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"76045-0210-10\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Checkwholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Dermatology", "title": "76045-0210-10 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 76045-0212-10\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** 4 month expiry available on request. Next release not available at this time.\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"76045-0212-10\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Limited Availability\", \"related_info\": \"4 month expiry available on request. Next release not available at this time.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-76045-0212-10.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-76045-0212-10", "initial_posting_date": "02/08/2019", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "76045-0212-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "4 month expiry available on request. Next release not available at this time.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"76045-0212-10\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Limited Availability\", \"related_info\": \"4 month expiry available on request. Next release not available at this time.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Dermatology", "title": "76045-0212-10 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 76045-210-10\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"76045-210-10\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-76045-210-10.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-76045-210-10", "initial_posting_date": "02/08/2019", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "76045-210-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"76045-210-10\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Dermatology", "title": "76045-210-10 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 76045-212-10\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** 4 month expiry available on request. Next release not available at this time.\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"76045-212-10\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Limited Availability\", \"related_info\": \"4 month expiry available on request. Next release not available at this time.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-76045-212-10.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dexamethasone-sodium-phosphate-injection-76045-212-10", "initial_posting_date": "02/08/2019", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "76045-212-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "4 month expiry available on request. Next release not available at this time.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"76045-212-10\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Limited Availability\", \"related_info\": \"4 month expiry available on request. Next release not available at this time.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Dermatology", "title": "76045-212-10 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-421-02\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"63323-421-02\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dexmedetomidine-hydrochloride-injection-63323-421-02.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dexmedetomidine-hydrochloride-injection-63323-421-02", "initial_posting_date": "04/10/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-421-02", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"63323-421-02\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-421-02 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-671-00\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Expected recovery: TBD\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"63323-671-00\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Expected recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dexmedetomidine-hydrochloride-injection-63323-671-00.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dexmedetomidine-hydrochloride-injection-63323-671-00", "initial_posting_date": "04/10/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-671-00", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Expected recovery: TBD", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"63323-671-00\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Expected recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-671-00 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-671-20\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Expected recovery: TBD\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"63323-671-20\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Expected recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dexmedetomidine-hydrochloride-injection-63323-671-20.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dexmedetomidine-hydrochloride-injection-63323-671-20", "initial_posting_date": "04/10/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-671-20", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Expected recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"63323-671-20\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Expected recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-671-20 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-671-50\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"63323-671-50\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dexmedetomidine-hydrochloride-injection-63323-671-50.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dexmedetomidine-hydrochloride-injection-63323-671-50", "initial_posting_date": "04/10/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-671-50", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"63323-671-50\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-671-50 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-824-74\n\n**Generic name:** Dextrose Monohydrate 10% Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 03/01/2022\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1645\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"63323-824-74\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1645", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dextrose-monohydrate-10-injection-63323-824-74.md", "generated": true, "generic_name": "Dextrose Monohydrate 10% Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dextrose-monohydrate-10-injection-63323-824-74", "initial_posting_date": "03/01/2022", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-824-74", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"63323-824-74\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "63323-824-74 \u00b7 Dextrose Monohydrate 10% Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-824-75\n\n**Generic name:** Dextrose Monohydrate 10% Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 03/01/2022\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1645\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"63323-824-75\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1645", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dextrose-monohydrate-10-injection-63323-824-75.md", "generated": true, "generic_name": "Dextrose Monohydrate 10% Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dextrose-monohydrate-10-injection-63323-824-75", "initial_posting_date": "03/01/2022", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-824-75", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"63323-824-75\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "63323-824-75 \u00b7 Dextrose Monohydrate 10% Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-824-76\n\n**Generic name:** Dextrose Monohydrate 10% Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 03/01/2022\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1645\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"63323-824-76\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1645", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dextrose-monohydrate-10-injection-63323-824-76.md", "generated": true, "generic_name": "Dextrose Monohydrate 10% Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dextrose-monohydrate-10-injection-63323-824-76", "initial_posting_date": "03/01/2022", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-824-76", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"63323-824-76\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "63323-824-76 \u00b7 Dextrose Monohydrate 10% Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65219-456-60\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholealers for inventory\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"65219-456-60\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholealers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dextrose-monohydrate-5-injection-65219-456-60.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dextrose-monohydrate-5-injection-65219-456-60", "initial_posting_date": "02/14/2022", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "65219-456-60", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholealers for inventory", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"65219-456-60\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholealers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "65219-456-60 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65219-458-30\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"65219-458-30\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dextrose-monohydrate-5-injection-65219-458-30.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dextrose-monohydrate-5-injection-65219-458-30", "initial_posting_date": "02/14/2022", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "65219-458-30", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"65219-458-30\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "65219-458-30 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65219-460-20\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"65219-460-20\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dextrose-monohydrate-5-injection-65219-460-20.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dextrose-monohydrate-5-injection-65219-460-20", "initial_posting_date": "02/14/2022", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "65219-460-20", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"65219-460-20\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "65219-460-20 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 65219-462-10\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"65219-462-10\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dextrose-monohydrate-5-injection-65219-462-10.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dextrose-monohydrate-5-injection-65219-462-10", "initial_posting_date": "02/14/2022", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "65219-462-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"65219-462-10\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "65219-462-10 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65219-464-50\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"65219-464-50\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-dextrose-monohydrate-5-injection-65219-464-50.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-dextrose-monohydrate-5-injection-65219-464-50", "initial_posting_date": "02/14/2022", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "65219-464-50", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"65219-464-50\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "65219-464-50 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-481-57\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 10/14/2016\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3609\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-481-57\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3609", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-481-57.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-481-57", "initial_posting_date": "10/14/2016", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-481-57", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-481-57\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-481-57 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-482-17\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 10/14/2016\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3609\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-482-17\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3609", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-482-17.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-482-17", "initial_posting_date": "10/14/2016", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-482-17", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-482-17\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-482-17 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-482-27\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 10/14/2016\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3609\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-482-27\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3609", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-482-27.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-482-27", "initial_posting_date": "10/14/2016", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-482-27", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-482-27\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-482-27 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-482-57\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 10/14/2016\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3611\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-482-57\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3611", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-482-57-2.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-03", "id": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-482-57-2", "initial_posting_date": "10/14/2016", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-482-57", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-482-57\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-482-57 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-482-57\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release August 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 10/14/2016\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3609\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-482-57\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release August 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3609", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-482-57.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-482-57", "initial_posting_date": "10/14/2016", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-482-57", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release August 2026. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-482-57\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release August 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-482-57 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-483-27\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 10/14/2016\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3609\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-483-27\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3609", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-483-27.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-483-27", "initial_posting_date": "10/14/2016", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-483-27", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-483-27\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-483-27 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-483-57\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 10/14/2016\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3609\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-483-57\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3609", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-483-57.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-483-57", "initial_posting_date": "10/14/2016", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-483-57", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-483-57\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-483-57 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-487-17\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 10/14/2016\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3609\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-487-17\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3609", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-487-17.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-487-17", "initial_posting_date": "10/14/2016", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-487-17", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-487-17\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-487-17 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-487-37\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 10/14/2016\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3609\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-487-37\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3609", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-487-37.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-487-37", "initial_posting_date": "10/14/2016", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-487-37", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-487-37\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-487-37 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-488-17\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 10/14/2016\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3609\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-488-17\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3609", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-488-17.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-488-17", "initial_posting_date": "10/14/2016", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-488-17", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-488-17\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-488-17 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-488-37\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 10/14/2016\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3609\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-488-37\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3609", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-488-37.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-488-37", "initial_posting_date": "10/14/2016", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-488-37", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-488-37\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-488-37 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-489-17\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 10/14/2016\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3609\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-489-17\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3609", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-489-17.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-489-17", "initial_posting_date": "10/14/2016", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-489-17", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-489-17\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-489-17 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-489-27\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 10/14/2016\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3609\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-489-27\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3609", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-489-27.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-epinephrine-bitartrate-lidocaine-hydrochloride-injection-63323-489-27", "initial_posting_date": "10/14/2016", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-489-27", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/14/2016\", \"package_ndc\": \"63323-489-27\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-489-27 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-806-01\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"63323-806-01\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-fentanyl-citrate-injection-63323-806-01.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-fentanyl-citrate-injection-63323-806-01", "initial_posting_date": "01/01/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-806-01", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"63323-806-01\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-806-01 \u00b7 Fentanyl Citrate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-806-02\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"63323-806-02\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-fentanyl-citrate-injection-63323-806-02.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-fentanyl-citrate-injection-63323-806-02", "initial_posting_date": "01/01/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-806-02", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"63323-806-02\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-806-02 \u00b7 Fentanyl Citrate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-806-05\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"63323-806-05\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-fentanyl-citrate-injection-63323-806-05.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-fentanyl-citrate-injection-63323-806-05", "initial_posting_date": "01/01/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-806-05", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"63323-806-05\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-806-05 \u00b7 Fentanyl Citrate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-806-20\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"63323-806-20\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-fentanyl-citrate-injection-63323-806-20.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-fentanyl-citrate-injection-63323-806-20", "initial_posting_date": "01/01/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-806-20", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"63323-806-20\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-806-20 \u00b7 Fentanyl Citrate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-806-50\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5359\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"63323-806-50\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5359", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-fentanyl-citrate-injection-63323-806-50-2.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-03", "id": "fresenius-kabi-usa-llc-fentanyl-citrate-injection-63323-806-50-2", "initial_posting_date": "01/01/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-806-50", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"63323-806-50\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-806-50 \u00b7 Fentanyl Citrate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-806-50\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"63323-806-50\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-fentanyl-citrate-injection-63323-806-50.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-fentanyl-citrate-injection-63323-806-50", "initial_posting_date": "01/01/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-806-50", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"63323-806-50\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-806-50 \u00b7 Fentanyl Citrate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-808-11\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"63323-808-11\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-fentanyl-citrate-injection-63323-808-11.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-fentanyl-citrate-injection-63323-808-11", "initial_posting_date": "01/01/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-808-11", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"63323-808-11\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-808-11 \u00b7 Fentanyl Citrate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-280-02\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"63323-280-02\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-furosemide-injection-63323-280-02.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-furosemide-injection-63323-280-02", "initial_posting_date": "04/07/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-280-02", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"63323-280-02\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "63323-280-02 \u00b7 Furosemide Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-280-04\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"63323-280-04\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-furosemide-injection-63323-280-04.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-furosemide-injection-63323-280-04", "initial_posting_date": "04/07/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-280-04", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"63323-280-04\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "63323-280-04 \u00b7 Furosemide Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-280-10\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"63323-280-10\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-furosemide-injection-63323-280-10.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-furosemide-injection-63323-280-10", "initial_posting_date": "04/07/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-280-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"63323-280-10\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "63323-280-10 \u00b7 Furosemide Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-519-10\n\n**Generic name:** Heparin Sodium Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 11/14/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3213\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Hematology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"63323-519-10\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3213", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-heparin-sodium-injection-63323-519-10.md", "generated": true, "generic_name": "Heparin Sodium Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-heparin-sodium-injection-63323-519-10", "initial_posting_date": "11/14/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-519-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"63323-519-10\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Hematology", "title": "63323-519-10 \u00b7 Heparin Sodium Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-519-77\n\n**Generic name:** Heparin Sodium Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 11/14/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3213\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Hematology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"63323-519-77\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3213", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-heparin-sodium-injection-63323-519-77.md", "generated": true, "generic_name": "Heparin Sodium Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-heparin-sodium-injection-63323-519-77", "initial_posting_date": "11/14/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-519-77", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"63323-519-77\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Hematology", "title": "63323-519-77 \u00b7 Heparin Sodium Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-851-10\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-851-10\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-63323-851-10.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-63323-851-10", "initial_posting_date": "10/31/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-851-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-851-10\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-851-10 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-851-15\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesaler for inventory\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-851-15\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesaler for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-63323-851-15.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-63323-851-15", "initial_posting_date": "10/31/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-851-15", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesaler for inventory", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-851-15\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesaler for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-851-15 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-851-50\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-851-50\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-63323-851-50.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-63323-851-50", "initial_posting_date": "10/31/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-851-50", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-851-50\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-851-50 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-852-25\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-852-25\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-63323-852-25.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-63323-852-25", "initial_posting_date": "10/31/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-852-25", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-852-25\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-852-25 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-853-25\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3229\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-853-25\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3229", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-63323-853-25-2.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-03", "id": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-63323-853-25-2", "initial_posting_date": "10/31/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-853-25", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-853-25\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-853-25 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-853-25\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release October 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-853-25\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release October 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-63323-853-25.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-63323-853-25", "initial_posting_date": "10/31/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-853-25", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release October 2026. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-853-25\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release October 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-853-25 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-854-10\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 11/01/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3226\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"63323-854-10\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3226", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-63323-854-10.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-63323-854-10", "initial_posting_date": "11/01/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-854-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"63323-854-10\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-854-10 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 76045-009-06\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3229\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"76045-009-06\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3229", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-76045-009-06-2.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-03", "id": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-76045-009-06-2", "initial_posting_date": "10/31/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "76045-009-06", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"76045-009-06\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "76045-009-06 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 76045-009-06\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release August 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"76045-009-06\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release August 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-76045-009-06.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-76045-009-06", "initial_posting_date": "10/31/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "76045-009-06", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release August 2026. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"76045-009-06\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release August 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "76045-009-06 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 76045-009-11\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release October 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"76045-009-11\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release October 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-76045-009-11.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-76045-009-11", "initial_posting_date": "10/31/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "76045-009-11", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release October 2026. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"76045-009-11\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release October 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "76045-009-11 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 76045-010-11\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release not available at this time. Check wholesalers for inventory.\n\n**Initial posting date:** 11/01/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3226\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"76045-010-11\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release not available at this time. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3226", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-76045-010-11.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-76045-010-11", "initial_posting_date": "11/01/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "76045-010-11", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release not available at this time. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"76045-010-11\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release not available at this time. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "76045-010-11 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 76045-121-11\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD; Check wholesalers for inventory.\n\n**Initial posting date:** 11/01/2017\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3228\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"76045-121-11\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3228", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-76045-121-11-2.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-03", "id": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-76045-121-11-2", "initial_posting_date": "11/01/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "76045-121-11", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD; Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"76045-121-11\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "76045-121-11 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 76045-121-11\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 11/01/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3226\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"76045-121-11\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3226", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-76045-121-11.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-hydromorphone-hydrochloride-injection-76045-121-11", "initial_posting_date": "11/01/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "76045-121-11", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"76045-121-11\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "76045-121-11 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 63323-142-10\n\n**Generic name:** Ifosfamide Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 06/12/2026\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 83\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"63323-142-10\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Limited Availability\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "83", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ifosfamide-injection-63323-142-10-2.md", "generated": true, "generic_name": "Ifosfamide Injection", "harvested": "2026-09-03", "id": "fresenius-kabi-usa-llc-ifosfamide-injection-63323-142-10-2", "initial_posting_date": "06/12/2026", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-142-10", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Check wholesalers for inventory", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"63323-142-10\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Limited Availability\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Oncology", "title": "63323-142-10 \u00b7 Ifosfamide Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-142-10\n\n**Generic name:** Ifosfamide Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release August 2026\n\n**Initial posting date:** 06/12/2026\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 81\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"63323-142-10\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release August 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "81", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ifosfamide-injection-63323-142-10.md", "generated": true, "generic_name": "Ifosfamide Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ifosfamide-injection-63323-142-10", "initial_posting_date": "06/12/2026", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-142-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g (NDC 63323-142-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next release August 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"63323-142-10\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release August 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "63323-142-10 \u00b7 Ifosfamide Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-161-01\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-161-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ketorolac-tromethamine-injection-63323-161-01.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ketorolac-tromethamine-injection-63323-161-01", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-161-01", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-161-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-161-01 \u00b7 Ketorolac Tromethamine Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-162-01\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-162-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ketorolac-tromethamine-injection-63323-162-01.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ketorolac-tromethamine-injection-63323-162-01", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-162-01", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-162-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-162-01 \u00b7 Ketorolac Tromethamine Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-162-02\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-162-02\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ketorolac-tromethamine-injection-63323-162-02.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ketorolac-tromethamine-injection-63323-162-02", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-162-02", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-162-02\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-162-02 \u00b7 Ketorolac Tromethamine Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 76045-104-10\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"76045-104-10\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ketorolac-tromethamine-injection-76045-104-10.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ketorolac-tromethamine-injection-76045-104-10", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "76045-104-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"76045-104-10\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "76045-104-10 \u00b7 Ketorolac Tromethamine Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 76045-105-20\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"76045-105-20\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ketorolac-tromethamine-injection-76045-105-20.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ketorolac-tromethamine-injection-76045-105-20", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "76045-105-20", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"76045-105-20\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "76045-105-20 \u00b7 Ketorolac Tromethamine Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 76045-107-10\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3086\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"76045-107-10\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3086", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ketorolac-tromethamine-injection-76045-107-10.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-03", "id": "fresenius-kabi-usa-llc-ketorolac-tromethamine-injection-76045-107-10", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "76045-107-10", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"76045-107-10\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "76045-107-10 \u00b7 Ketorolac Tromethamine Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-201-02\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-201-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-201-02.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-201-02", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-201-02", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-201-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-201-02 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-201-10\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release October 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-201-10\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release October 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-201-10.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-201-10", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-201-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next release October 2026. Check wholesalers for inventory.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-201-10\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release October 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-201-10 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-202-02\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-202-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-202-02.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-202-02", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-202-02", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-202-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-202-02 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-208-05\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release October 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 5307\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-208-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release October 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5307", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-208-05-2.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-03", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-208-05-2", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-208-05", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next release October 2026. Check wholesalers for inventory.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-208-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release October 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-208-05 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-208-05\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-208-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-208-05.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-208-05", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-208-05", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-208-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-208-05 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-484-57\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-484-57\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-484-57.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-484-57", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-484-57", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-484-57\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-484-57 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-485-27\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-485-27\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-485-27.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-485-27", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-485-27", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-485-27\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-485-27 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-485-57\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-485-57\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-485-57.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-485-57", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-485-57", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-485-57\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-485-57 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-486-17\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-486-17\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-486-17.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-486-17", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-486-17", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-486-17\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-486-17 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-486-27\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-486-27\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-486-27.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-486-27", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-486-27", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-486-27\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-486-27 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-486-57\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-486-57\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-486-57.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-486-57", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-486-57", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-486-57\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-486-57 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-491-57\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-491-57\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-491-57.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-491-57", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-491-57", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-491-57\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-491-57 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-492-27\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-492-27\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-492-27.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-492-27", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-492-27", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-492-27\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-492-27 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-492-31\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-492-31\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-492-31.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-492-31", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-492-31", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-492-31\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-492-31 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-492-37\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-492-37\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-492-37.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-492-37", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-492-37", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-492-37\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-492-37 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-492-57\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-492-57\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-492-57.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-492-57", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-492-57", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-492-57\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-492-57 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-493-91\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-493-91\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-493-91.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-493-91", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-493-91", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-493-91\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-493-91 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-493-97\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-493-97\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-493-97.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-493-97", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-493-97", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-493-97\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-493-97 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-495-07\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-495-07\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-495-07.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-495-07", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-495-07", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-495-07\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-495-07 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-495-27\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-495-27\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-495-27.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-495-27", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-495-27", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-495-27\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-495-27 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-496-97\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-496-97\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-496-97.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lidocaine-hydrochloride-injection-63323-496-97", "initial_posting_date": "02/22/2012", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-496-97", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"63323-496-97\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-496-97 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 65219-368-02\n\n**Generic name:** Lorazepam Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 05/03/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3043\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/03/2018\", \"package_ndc\": \"65219-368-02\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3043", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-lorazepam-injection-65219-368-02.md", "generated": true, "generic_name": "Lorazepam Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-lorazepam-injection-65219-368-02", "initial_posting_date": "05/03/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "65219-368-02", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"05/03/2018\", \"package_ndc\": \"65219-368-02\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "65219-368-02 \u00b7 Lorazepam Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-122-50\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesaler for inventory\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1268\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"63323-122-50\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesaler for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1268", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-methotrexate-sodium-injection-63323-122-50.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-methotrexate-sodium-injection-63323-122-50", "initial_posting_date": "03/13/2023", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-122-50", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesaler for inventory", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"63323-122-50\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesaler for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "63323-122-50 \u00b7 Methotrexate Sodium Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-123-10\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesaler for inventory\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1268\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"63323-123-10\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesaler for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1268", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-methotrexate-sodium-injection-63323-123-10.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-methotrexate-sodium-injection-63323-123-10", "initial_posting_date": "03/13/2023", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-123-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesaler for inventory", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"63323-123-10\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesaler for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "63323-123-10 \u00b7 Methotrexate Sodium Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-411-10\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"63323-411-10\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-midazolam-hydrochloride-injection-63323-411-10.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-midazolam-hydrochloride-injection-63323-411-10", "initial_posting_date": "04/02/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-411-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"63323-411-10\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-411-10 \u00b7 Midazolam Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-411-12\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"63323-411-12\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-midazolam-hydrochloride-injection-63323-411-12.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-midazolam-hydrochloride-injection-63323-411-12", "initial_posting_date": "04/02/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-411-12", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"63323-411-12\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-411-12 \u00b7 Midazolam Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-411-25\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2345\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"63323-411-25\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2345", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-midazolam-hydrochloride-injection-63323-411-25-2.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-03", "id": "fresenius-kabi-usa-llc-midazolam-hydrochloride-injection-63323-411-25-2", "initial_posting_date": "04/02/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-411-25", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"63323-411-25\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-411-25 \u00b7 Midazolam Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-411-25\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"63323-411-25\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-midazolam-hydrochloride-injection-63323-411-25.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-midazolam-hydrochloride-injection-63323-411-25", "initial_posting_date": "04/02/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-411-25", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"63323-411-25\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-411-25 \u00b7 Midazolam Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-412-02\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"63323-412-02\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-midazolam-hydrochloride-injection-63323-412-02.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-midazolam-hydrochloride-injection-63323-412-02", "initial_posting_date": "04/02/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-412-02", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"63323-412-02\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-412-02 \u00b7 Midazolam Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-412-10\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"63323-412-10\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-midazolam-hydrochloride-injection-63323-412-10.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-midazolam-hydrochloride-injection-63323-412-10", "initial_posting_date": "04/02/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-412-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"63323-412-10\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-412-10 \u00b7 Midazolam Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-412-25\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"63323-412-25\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-midazolam-hydrochloride-injection-63323-412-25.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-midazolam-hydrochloride-injection-63323-412-25", "initial_posting_date": "04/02/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-412-25", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"63323-412-25\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-412-25 \u00b7 Midazolam Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 76045-211-20\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release October 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"76045-211-20\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release October 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-midazolam-hydrochloride-injection-76045-211-20.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-midazolam-hydrochloride-injection-76045-211-20", "initial_posting_date": "04/02/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "76045-211-20", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next release October 2026. Check wholesalers for inventory.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"76045-211-20\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release October 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "76045-211-20 \u00b7 Midazolam Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-451-01\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-451-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-morphine-sulfate-injection-63323-451-01.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-morphine-sulfate-injection-63323-451-01", "initial_posting_date": "10/31/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-451-01", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-451-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-451-01 \u00b7 Morphine Sulfate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-452-01\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-452-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-morphine-sulfate-injection-63323-452-01.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-morphine-sulfate-injection-63323-452-01", "initial_posting_date": "10/31/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-452-01", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-452-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-452-01 \u00b7 Morphine Sulfate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-454-01\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release October 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-454-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release October 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-morphine-sulfate-injection-63323-454-01.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-morphine-sulfate-injection-63323-454-01", "initial_posting_date": "10/31/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-454-01", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release October 2026. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-454-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release October 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-454-01 \u00b7 Morphine Sulfate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-455-01\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-455-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-morphine-sulfate-injection-63323-455-01.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-morphine-sulfate-injection-63323-455-01", "initial_posting_date": "10/31/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-455-01", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"63323-455-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-455-01 \u00b7 Morphine Sulfate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 76045-004-11\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"76045-004-11\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-morphine-sulfate-injection-76045-004-11.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-morphine-sulfate-injection-76045-004-11", "initial_posting_date": "10/31/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "76045-004-11", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"76045-004-11\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "76045-004-11 \u00b7 Morphine Sulfate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 76045-005-11\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"76045-005-11\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-morphine-sulfate-injection-76045-005-11.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-morphine-sulfate-injection-76045-005-11", "initial_posting_date": "10/31/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "76045-005-11", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"76045-005-11\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "76045-005-11 \u00b7 Morphine Sulfate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-604-01\n\n**Generic name:** Propranolol Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 10/31/2023\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1036\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2023\", \"package_ndc\": \"63323-604-01\", \"generic_name\": \"Propranolol Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Propranolol%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1036", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-propranolol-hydrochloride-injection-63323-604-01.md", "generated": true, "generic_name": "Propranolol Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-propranolol-hydrochloride-injection-63323-604-01", "initial_posting_date": "10/31/2023", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-604-01", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"10/31/2023\", \"package_ndc\": \"63323-604-01\", \"generic_name\": \"Propranolol Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Propranolol%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "63323-604-01 \u00b7 Propranolol Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-723-03\n\n**Generic name:** Remifentanil Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 06/28/2022\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1526\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"63323-723-03\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1526", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-remifentanil-hydrochloride-injection-63323-723-03.md", "generated": true, "generic_name": "Remifentanil Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-remifentanil-hydrochloride-injection-63323-723-03", "initial_posting_date": "06/28/2022", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-723-03", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"63323-723-03\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-723-03 \u00b7 Remifentanil Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-724-05\n\n**Generic name:** Remifentanil Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 06/28/2022\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1526\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"63323-724-05\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1526", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-remifentanil-hydrochloride-injection-63323-724-05.md", "generated": true, "generic_name": "Remifentanil Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-remifentanil-hydrochloride-injection-63323-724-05", "initial_posting_date": "06/28/2022", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-724-05", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"63323-724-05\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-724-05 \u00b7 Remifentanil Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-725-10\n\n**Generic name:** Remifentanil Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 06/28/2022\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1526\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"63323-725-10\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1526", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-remifentanil-hydrochloride-injection-63323-725-10.md", "generated": true, "generic_name": "Remifentanil Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-remifentanil-hydrochloride-injection-63323-725-10", "initial_posting_date": "06/28/2022", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-725-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"63323-725-10\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "63323-725-10 \u00b7 Remifentanil Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 63323-351-20\n\n**Generic name:** Rifampin Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/17/2021\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2031\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/17/2021\", \"package_ndc\": \"63323-351-20\", \"generic_name\": \"Rifampin Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Limited Availability\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rifampin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2031", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-rifampin-injection-63323-351-20-2.md", "generated": true, "generic_name": "Rifampin Injection", "harvested": "2026-09-10", "id": "fresenius-kabi-usa-llc-rifampin-injection-63323-351-20-2", "initial_posting_date": "02/17/2021", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-351-20", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/17/2021\", \"package_ndc\": \"63323-351-20\", \"generic_name\": \"Rifampin Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Limited Availability\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rifampin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "63323-351-20 \u00b7 Rifampin Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-351-20\n\n**Generic name:** Rifampin Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/17/2021\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2022\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/17/2021\", \"package_ndc\": \"63323-351-20\", \"generic_name\": \"Rifampin Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rifampin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2022", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-rifampin-injection-63323-351-20.md", "generated": true, "generic_name": "Rifampin Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-rifampin-injection-63323-351-20", "initial_posting_date": "02/17/2021", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-351-20", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 63323-351-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/17/2021\", \"package_ndc\": \"63323-351-20\", \"generic_name\": \"Rifampin Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rifampin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "63323-351-20 \u00b7 Rifampin Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-426-05\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release October 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1296\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"63323-426-05\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release October 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1296", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-rocuronium-bromide-injection-63323-426-05-2.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-03", "id": "fresenius-kabi-usa-llc-rocuronium-bromide-injection-63323-426-05-2", "initial_posting_date": "02/15/2023", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-426-05", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Next release October 2026. Check wholesalers for inventory.", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"63323-426-05\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release October 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-426-05 \u00b7 Rocuronium Bromide Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-426-05\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"63323-426-05\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-rocuronium-bromide-injection-63323-426-05.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-rocuronium-bromide-injection-63323-426-05", "initial_posting_date": "02/15/2023", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-426-05", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"63323-426-05\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-426-05 \u00b7 Rocuronium Bromide Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-426-10\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1296\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"63323-426-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1296", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-rocuronium-bromide-injection-63323-426-10-2.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-03", "id": "fresenius-kabi-usa-llc-rocuronium-bromide-injection-63323-426-10-2", "initial_posting_date": "02/15/2023", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-426-10", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"63323-426-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-426-10 \u00b7 Rocuronium Bromide Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-426-10\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"63323-426-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-rocuronium-bromide-injection-63323-426-10.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-rocuronium-bromide-injection-63323-426-10", "initial_posting_date": "02/15/2023", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-426-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"63323-426-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-426-10 \u00b7 Rocuronium Bromide Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 65219-065-05\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"65219-065-05\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-rocuronium-bromide-injection-65219-065-05.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-rocuronium-bromide-injection-65219-065-05", "initial_posting_date": "02/15/2023", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "65219-065-05", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"65219-065-05\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "65219-065-05 \u00b7 Rocuronium Bromide Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65219-442-05\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1296\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"65219-442-05\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1296", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-rocuronium-bromide-injection-65219-442-05-2.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-03", "id": "fresenius-kabi-usa-llc-rocuronium-bromide-injection-65219-442-05-2", "initial_posting_date": "02/15/2023", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "65219-442-05", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"65219-442-05\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Anesthesia", "title": "65219-442-05 \u00b7 Rocuronium Bromide Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 65219-442-05\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release August 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"65219-442-05\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release August 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-rocuronium-bromide-injection-65219-442-05.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-rocuronium-bromide-injection-65219-442-05", "initial_posting_date": "02/15/2023", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "65219-442-05", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Next release August 2026. Check wholesalers for inventory.", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"65219-442-05\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release August 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "65219-442-05 \u00b7 Rocuronium Bromide Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65219-444-10\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"65219-444-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-rocuronium-bromide-injection-65219-444-10.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-rocuronium-bromide-injection-65219-444-10", "initial_posting_date": "02/15/2023", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "65219-444-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"65219-444-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "65219-444-10 \u00b7 Rocuronium Bromide Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-285-10\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-285-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-285-10.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-285-10", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-285-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-285-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-285-10 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-285-13\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesaler for inventory\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-285-13\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesaler for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-285-13.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-285-13", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-285-13", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesaler for inventory", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-285-13\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesaler for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-285-13 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-285-20\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-285-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-285-20.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-285-20", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-285-20", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-285-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-285-20 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-285-23\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-285-23\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-285-23.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-285-23", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-285-23", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-285-23\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-285-23 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-285-61\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-285-61\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-285-61.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-285-61", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-285-61", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-285-61\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-285-61 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-285-63\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-285-63\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-285-63.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-285-63", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-285-63", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-285-63\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-285-63 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-285-64\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-285-64\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-285-64.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-285-64", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-285-64", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-285-64\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-285-64 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-285-65\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-285-65\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-285-65.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-285-65", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-285-65", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-285-65\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-285-65 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-286-00\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-286-00\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-286-00.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-286-00", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-286-00", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-286-00\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-286-00 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-286-20\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-286-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-286-20.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-286-20", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-286-20", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-286-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-286-20 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-286-23\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-286-23\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-286-23.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-286-23", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-286-23", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-286-23\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-286-23 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-286-31\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-286-31\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-286-31.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-286-31", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-286-31", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-286-31\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-286-31 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-286-35\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-286-35\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-286-35.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-286-35", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-286-35", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-286-35\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-286-35 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-286-63\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-286-63\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-286-63.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-286-63", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-286-63", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-286-63\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-286-63 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-287-20\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-287-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-287-20.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-287-20", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-287-20", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-287-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-287-20 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-287-21\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-287-21\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-287-21.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-287-21", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-287-21", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-287-21\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-287-21 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-288-10\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-288-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-288-10.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-288-10", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-288-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-288-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-288-10 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-288-11\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-288-11\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-288-11.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-288-11", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-288-11", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-288-11\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-288-11 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-288-20\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-288-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-288-20.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-288-20", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-288-20", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-288-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-288-20 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-288-21\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-288-21\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-288-21.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-63323-288-21", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-288-21", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"63323-288-21\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "63323-288-21 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65219-632-10\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"65219-632-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-65219-632-10.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-65219-632-10", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "65219-632-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"65219-632-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "65219-632-10 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 65219-632-20\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"65219-632-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-65219-632-20.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-ropivacaine-hydrochloride-injection-65219-632-20", "initial_posting_date": "03/23/2018", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "65219-632-20", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"65219-632-20\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "65219-632-20 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-032-00\n\n**Generic name:** Sodium Acetate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 03/23/2016\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3814\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Total Parenteral Nutrition\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2016\", \"package_ndc\": \"63323-032-00\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3814", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-sodium-acetate-injection-63323-032-00.md", "generated": true, "generic_name": "Sodium Acetate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-sodium-acetate-injection-63323-032-00", "initial_posting_date": "03/23/2016", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-032-00", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"03/23/2016\", \"package_ndc\": \"63323-032-00\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Total Parenteral Nutrition", "title": "63323-032-00 \u00b7 Sodium Acetate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-083-05\n\n**Generic name:** Sodium Bicarbonate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory.\n\n**Initial posting date:** 07/24/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3326\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/24/2017\", \"package_ndc\": \"63323-083-05\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3326", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-sodium-bicarbonate-injection-63323-083-05.md", "generated": true, "generic_name": "Sodium Bicarbonate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-sodium-bicarbonate-injection-63323-083-05", "initial_posting_date": "07/24/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-083-05", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory.", "source_quote": "\"initial_posting_date\": \"07/24/2017\", \"package_ndc\": \"63323-083-05\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "63323-083-05 \u00b7 Sodium Bicarbonate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-089-50\n\n**Generic name:** Sodium Bicarbonate Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 07/24/2017\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3326\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/24/2017\", \"package_ndc\": \"63323-089-50\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3326", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-sodium-bicarbonate-injection-63323-089-50.md", "generated": true, "generic_name": "Sodium Bicarbonate Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-sodium-bicarbonate-injection-63323-089-50", "initial_posting_date": "07/24/2017", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-089-50", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"07/24/2017\", \"package_ndc\": \"63323-089-50\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "63323-089-50 \u00b7 Sodium Bicarbonate Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-178-76\n\n**Generic name:** Sterile Water Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 11/23/2021\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1743\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"63323-178-76\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1743", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-sterile-water-injection-63323-178-76.md", "generated": true, "generic_name": "Sterile Water Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-sterile-water-injection-63323-178-76", "initial_posting_date": "11/23/2021", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-178-76", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"63323-178-76\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Other", "title": "63323-178-76 \u00b7 Sterile Water Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 63323-185-10\n\n**Generic name:** Sterile Water Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next release September 2026. Check wholesalers for inventory.\n\n**Initial posting date:** 11/23/2021\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1743\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"63323-185-10\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1743", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-sterile-water-injection-63323-185-10.md", "generated": true, "generic_name": "Sterile Water Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-sterile-water-injection-63323-185-10", "initial_posting_date": "11/23/2021", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-185-10", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next release September 2026. Check wholesalers for inventory.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"63323-185-10\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Unavailable\", \"related_info\": \"Next release September 2026. Check wholesalers for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Other", "title": "63323-185-10 \u00b7 Sterile Water Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-185-20\n\n**Generic name:** Sterile Water Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 11/23/2021\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1743\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"63323-185-20\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1743", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-sterile-water-injection-63323-185-20.md", "generated": true, "generic_name": "Sterile Water Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-sterile-water-injection-63323-185-20", "initial_posting_date": "11/23/2021", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-185-20", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"63323-185-20\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Other", "title": "63323-185-20 \u00b7 Sterile Water Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-185-50\n\n**Generic name:** Sterile Water Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 11/23/2021\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1743\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Other\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"63323-185-50\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1743", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-sterile-water-injection-63323-185-50.md", "generated": true, "generic_name": "Sterile Water Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-sterile-water-injection-63323-185-50", "initial_posting_date": "11/23/2021", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-185-50", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"63323-185-50\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Other", "title": "63323-185-50 \u00b7 Sterile Water Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 63323-494-05\n\n**Generic name:** Valproate Sodium Injection\n\n**Manufacturer:** Fresenius Kabi USA, LLC\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Checkwholesalers for inventory\n\n**Initial posting date:** 12/30/2020\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2071\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/30/2020\", \"package_ndc\": \"63323-494-05\", \"generic_name\": \"Valproate Sodium Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Checkwholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Valproate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2071", "dosage_form": "Injection", "file": "fresenius-kabi-usa-llc-valproate-sodium-injection-63323-494-05.md", "generated": true, "generic_name": "Valproate Sodium Injection", "harvested": "2026-09-01", "id": "fresenius-kabi-usa-llc-valproate-sodium-injection-63323-494-05", "initial_posting_date": "12/30/2020", "manufacturer_name": "Fresenius Kabi USA, LLC", "package_ndc": "63323-494-05", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)\", \"company_name\": \"Fresenius Kabi USA, LLC\", \"status\": \"Current\"", "related_info": "Checkwholesalers for inventory", "source_quote": "\"initial_posting_date\": \"12/30/2020\", \"package_ndc\": \"63323-494-05\", \"generic_name\": \"Valproate Sodium Injection\", \"contact_info\": \"888-386-1300\", \"availability\": \"Available\", \"related_info\": \"Checkwholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Fresenius%20Kabi%20USA,%20LLC%22+AND+generic_name%3A%22Valproate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "63323-494-05 \u00b7 Valproate Sodium Injection \u00b7 Fresenius Kabi USA, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 54288-164-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinued; Distributed by BPI Labs, LLC\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"54288-164-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinued; Distributed by BPI Labs, LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "gland-pharma-limited-carboplatin-injection-54288-164-01.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-carboplatin-injection-54288-164-01", "initial_posting_date": "04/28/2023", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "54288-164-01", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-16", "related_info": "Discontinued; Distributed by BPI Labs, LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"54288-164-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinued; Distributed by BPI Labs, LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Oncology", "title": "54288-164-01 \u00b7 Carboplatin Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 54288-165-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by BPI Labs, LLC\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 09/15/2026\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 1237\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"54288-165-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270\", \"availability\": \"Available\", \"related_info\": \"Distributed by BPI Labs, LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1237", "dosage_form": "Injection", "file": "gland-pharma-limited-carboplatin-injection-54288-165-01-2.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-16", "id": "gland-pharma-limited-carboplatin-injection-54288-165-01-2", "initial_posting_date": "04/28/2023", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "54288-165-01", "quote_dosage_form": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "related_info": "Distributed by BPI Labs, LLC", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"54288-165-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270\", \"availability\": \"Available\", \"related_info\": \"Distributed by BPI Labs, LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Oncology", "title": "54288-165-01 \u00b7 Carboplatin Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 54288-165-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: end of August 2026; Distributed by BPI Labs, LLC\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"54288-165-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: end of August 2026; Distributed by BPI Labs, LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "gland-pharma-limited-carboplatin-injection-54288-165-01.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-carboplatin-injection-54288-165-01", "initial_posting_date": "04/28/2023", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "54288-165-01", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: end of August 2026; Distributed by BPI Labs, LLC", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"54288-165-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: end of August 2026; Distributed by BPI Labs, LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "54288-165-01 \u00b7 Carboplatin Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 54288-166-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 09/15/2026\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1237\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"54288-166-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270\", \"availability\": \"Limited Availability\", \"related_info\": \"Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1237", "dosage_form": "Injection", "file": "gland-pharma-limited-carboplatin-injection-54288-166-01-2.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-16", "id": "gland-pharma-limited-carboplatin-injection-54288-166-01-2", "initial_posting_date": "04/28/2023", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "54288-166-01", "quote_dosage_form": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"54288-166-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270\", \"availability\": \"Limited Availability\", \"related_info\": \"Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Oncology", "title": "54288-166-01 \u00b7 Carboplatin Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 54288-166-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: end of June 2026; Distributed by BPI Labs, LLC\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"54288-166-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: end of June 2026; Distributed by BPI Labs, LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "gland-pharma-limited-carboplatin-injection-54288-166-01.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-carboplatin-injection-54288-166-01", "initial_posting_date": "04/28/2023", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "54288-166-01", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: end of June 2026; Distributed by BPI Labs, LLC", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"54288-166-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: end of June 2026; Distributed by BPI Labs, LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "54288-166-01 \u00b7 Carboplatin Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 54288-167-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 09/15/2026\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1237\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"54288-167-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270\", \"availability\": \"Limited Availability\", \"related_info\": \"Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1237", "dosage_form": "Injection", "file": "gland-pharma-limited-carboplatin-injection-54288-167-01-2.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-16", "id": "gland-pharma-limited-carboplatin-injection-54288-167-01-2", "initial_posting_date": "04/28/2023", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "54288-167-01", "quote_dosage_form": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/15/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"54288-167-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270\", \"availability\": \"Limited Availability\", \"related_info\": \"Recovery estimated in late Q4 2026; Distributed by BPI Labs, LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Oncology", "title": "54288-167-01 \u00b7 Carboplatin Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 54288-167-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Distributed by BPI Labs, LLC\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"54288-167-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270\", \"availability\": \"Limited Availability\", \"related_info\": \"Distributed by BPI Labs, LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "gland-pharma-limited-carboplatin-injection-54288-167-01.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-carboplatin-injection-54288-167-01", "initial_posting_date": "04/28/2023", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "54288-167-01", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Distributed by BPI Labs, LLC", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"54288-167-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270\", \"availability\": \"Limited Availability\", \"related_info\": \"Distributed by BPI Labs, LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "54288-167-01 \u00b7 Carboplatin Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43598-975-58\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by DRL\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"43598-975-58\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"Distributed by DRL\", \"availability\": \"Available\", \"related_info\": \"Distributed by DRL\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "gland-pharma-limited-dexmedetomidine-hydrochloride-injection-43598-975-58.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-dexmedetomidine-hydrochloride-injection-43598-975-58", "initial_posting_date": "04/10/2020", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "43598-975-58", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "related_info": "Distributed by DRL", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"43598-975-58\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"Distributed by DRL\", \"availability\": \"Available\", \"related_info\": \"Distributed by DRL\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "43598-975-58 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43598-976-58\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by DRL\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"43598-976-58\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"Distributed by DRL\", \"availability\": \"Available\", \"related_info\": \"Distributed by DRL\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "gland-pharma-limited-dexmedetomidine-hydrochloride-injection-43598-976-58.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-dexmedetomidine-hydrochloride-injection-43598-976-58", "initial_posting_date": "04/10/2020", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "43598-976-58", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "related_info": "Distributed by DRL", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"43598-976-58\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"Distributed by DRL\", \"availability\": \"Available\", \"related_info\": \"Distributed by DRL\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "43598-976-58 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 66794-230-42\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Piramal Critical Care Inc.: 800-414-1901\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"66794-230-42\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"855-273-0154\", \"availability\": \"Available\", \"related_info\": \"Marketed by Piramal Critical Care Inc.: 800-414-1901\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "gland-pharma-limited-dexmedetomidine-hydrochloride-injection-66794-230-42.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-dexmedetomidine-hydrochloride-injection-66794-230-42", "initial_posting_date": "04/10/2020", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "66794-230-42", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "related_info": "Marketed by Piramal Critical Care Inc.: 800-414-1901", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"66794-230-42\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"855-273-0154\", \"availability\": \"Available\", \"related_info\": \"Marketed by Piramal Critical Care Inc.: 800-414-1901\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "66794-230-42 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72266-146-10\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"72266-146-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"833-291-9645\", \"availability\": \"Available\", \"related_info\": \"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "gland-pharma-limited-etomidate-injection-72266-146-10.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-etomidate-injection-72266-146-10", "initial_posting_date": "10/05/2022", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "72266-146-10", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "related_info": "Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"72266-146-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"833-291-9645\", \"availability\": \"Available\", \"related_info\": \"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "72266-146-10 \u00b7 Etomidate Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72266-147-10\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"72266-147-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"833-291-9645\", \"availability\": \"Available\", \"related_info\": \"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "gland-pharma-limited-etomidate-injection-72266-147-10.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-etomidate-injection-72266-147-10", "initial_posting_date": "10/05/2022", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "72266-147-10", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "related_info": "Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"72266-147-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"833-291-9645\", \"availability\": \"Available\", \"related_info\": \"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "72266-147-10 \u00b7 Etomidate Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 25021-311-02\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"25021-311-02\", \"generic_name\": \"Furosemide Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Furosemide%20Injection&st=d\", \"contact_info\": \"866-625-1618\", \"availability\": \"Unavailable\", \"related_info\": \"Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "gland-pharma-limited-furosemide-injection-25021-311-02.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-furosemide-injection-25021-311-02", "initial_posting_date": "04/07/2020", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "25021-311-02", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"25021-311-02\", \"generic_name\": \"Furosemide Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Furosemide%20Injection&st=d\", \"contact_info\": \"866-625-1618\", \"availability\": \"Unavailable\", \"related_info\": \"Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "25021-311-02 \u00b7 Furosemide Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 25021-311-04\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"25021-311-04\", \"generic_name\": \"Furosemide Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Furosemide%20Injection&st=d\", \"contact_info\": \"866-625-1618\", \"availability\": \"Unavailable\", \"related_info\": \"Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "gland-pharma-limited-furosemide-injection-25021-311-04.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-furosemide-injection-25021-311-04", "initial_posting_date": "04/07/2020", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "25021-311-04", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"25021-311-04\", \"generic_name\": \"Furosemide Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Furosemide%20Injection&st=d\", \"contact_info\": \"866-625-1618\", \"availability\": \"Unavailable\", \"related_info\": \"Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "25021-311-04 \u00b7 Furosemide Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 25021-311-10\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"25021-311-10\", \"generic_name\": \"Furosemide Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Furosemide%20Injection&st=d\", \"contact_info\": \"866-625-1918\", \"availability\": \"Unavailable\", \"related_info\": \"Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "gland-pharma-limited-furosemide-injection-25021-311-10.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-furosemide-injection-25021-311-10", "initial_posting_date": "04/07/2020", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "25021-311-10", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"25021-311-10\", \"generic_name\": \"Furosemide Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Furosemide%20Injection&st=d\", \"contact_info\": \"866-625-1918\", \"availability\": \"Unavailable\", \"related_info\": \"Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "25021-311-10 \u00b7 Furosemide Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 25021-700-01\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"25021-700-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"833-291-9645\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "gland-pharma-limited-ketorolac-tromethamine-injection-25021-700-01.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-ketorolac-tromethamine-injection-25021-700-01", "initial_posting_date": "03/23/2018", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "25021-700-01", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Gland Pharma Limited\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"25021-700-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"833-291-9645\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "25021-700-01 \u00b7 Ketorolac Tromethamine Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 25021-701-01\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"25021-701-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"833-291-9645\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "gland-pharma-limited-ketorolac-tromethamine-injection-25021-701-01.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-ketorolac-tromethamine-injection-25021-701-01", "initial_posting_date": "03/23/2018", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "25021-701-01", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"25021-701-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"833-291-9645\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "25021-701-01 \u00b7 Ketorolac Tromethamine Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 25021-701-02\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"25021-701-02\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"833-291-9645\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "gland-pharma-limited-ketorolac-tromethamine-injection-25021-701-02.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-ketorolac-tromethamine-injection-25021-701-02", "initial_posting_date": "03/23/2018", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "25021-701-02", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"25021-701-02\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"833-291-9645\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "25021-701-02 \u00b7 Ketorolac Tromethamine Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72266-118-25\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.\n\n**Initial posting date:** 06/06/2018\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3009\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"72266-118-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"833-291-9645\", \"availability\": \"Available\", \"related_info\": \"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3009", "dosage_form": "Injection", "file": "gland-pharma-limited-ketorolac-tromethamine-injection-72266-118-25.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-ketorolac-tromethamine-injection-72266-118-25", "initial_posting_date": "06/06/2018", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "72266-118-25", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"72266-118-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"833-291-9645\", \"availability\": \"Available\", \"related_info\": \"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "72266-118-25 \u00b7 Ketorolac Tromethamine Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72266-119-25\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.\n\n**Initial posting date:** 06/06/2018\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3009\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"72266-119-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"833-291-9645\", \"availability\": \"Available\", \"related_info\": \"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3009", "dosage_form": "Injection", "file": "gland-pharma-limited-ketorolac-tromethamine-injection-72266-119-25.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-ketorolac-tromethamine-injection-72266-119-25", "initial_posting_date": "06/06/2018", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "72266-119-25", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"72266-119-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"833-291-9645\", \"availability\": \"Available\", \"related_info\": \"Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "72266-119-25 \u00b7 Ketorolac Tromethamine Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 47335-993-01\n\n**Generic name:** Metronidazole Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/13/2022\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1692\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/13/2022\", \"package_ndc\": \"47335-993-01\", \"generic_name\": \"Metronidazole Injection\", \"contact_info\": \"Distributed by Sun Pharma\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Metronidazole%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1692", "dosage_form": "Injection", "file": "gland-pharma-limited-metronidazole-injection-47335-993-01.md", "generated": true, "generic_name": "Metronidazole Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-metronidazole-injection-47335-993-01", "initial_posting_date": "01/13/2022", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "47335-993-01", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/13/2022\", \"package_ndc\": \"47335-993-01\", \"generic_name\": \"Metronidazole Injection\", \"contact_info\": \"Distributed by Sun Pharma\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Metronidazole%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "47335-993-01 \u00b7 Metronidazole Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 25021-655-02\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"25021-655-02\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"Avet Pharmaceuticals, Inc.: 855-228-9470; Sagent Pharmaceuticals: 866-625-1618\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "gland-pharma-limited-midazolam-hydrochloride-injection-25021-655-02.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-midazolam-hydrochloride-injection-25021-655-02", "initial_posting_date": "04/02/2020", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "25021-655-02", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"25021-655-02\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"Avet Pharmaceuticals, Inc.: 855-228-9470; Sagent Pharmaceuticals: 866-625-1618\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "25021-655-02 \u00b7 Midazolam Hydrochloride Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 25021-661-10\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Gland Pharma Limited\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 07/22/2026\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"25021-661-10\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"Avet Pharmaceuticals, Inc.: 855-228-9470; Sagent Pharmaceuticals: 866-625-1618\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "gland-pharma-limited-midazolam-hydrochloride-injection-25021-661-10.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "gland-pharma-limited-midazolam-hydrochloride-injection-25021-661-10", "initial_posting_date": "04/02/2020", "manufacturer_name": "Gland Pharma Limited", "package_ndc": "25021-661-10", "quote_dosage_form": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/22/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10)\", \"company_name\": \"Gland Pharma Limited\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"25021-661-10\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"Avet Pharmaceuticals, Inc.: 855-228-9470; Sagent Pharmaceuticals: 866-625-1618\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Gland%20Pharma%20Limited%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "25021-661-10 \u00b7 Midazolam Hydrochloride Injection \u00b7 Gland Pharma Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 70010-111-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Granules Pharmaceuticals Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"70010-111-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"877-770-3183\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Granules%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "granules-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-70010-111-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "granules-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-70010-111-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Granules Pharmaceuticals Inc.", "package_ndc": "70010-111-01", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"70010-111-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"877-770-3183\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Granules%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "70010-111-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Granules Pharmaceuticals Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 70010-112-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Granules Pharmaceuticals Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"70010-112-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"877-770-3183\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Granules%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "granules-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-70010-112-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "granules-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-70010-112-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Granules Pharmaceuticals Inc.", "package_ndc": "70010-112-01", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"70010-112-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"877-770-3183\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Granules%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "70010-112-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Granules Pharmaceuticals Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 70010-113-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Granules Pharmaceuticals Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"70010-113-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"877-770-3183\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Granules%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "granules-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-70010-113-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "granules-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-70010-113-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Granules Pharmaceuticals Inc.", "package_ndc": "70010-113-01", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"70010-113-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"877-770-3183\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Granules%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "70010-113-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Granules Pharmaceuticals Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 70010-114-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Granules Pharmaceuticals Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"70010-114-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"877-770-3183\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Granules%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "granules-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-70010-114-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "granules-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-70010-114-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Granules Pharmaceuticals Inc.", "package_ndc": "70010-114-01", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"70010-114-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"877-770-3183\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Granules%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "70010-114-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Granules Pharmaceuticals Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 70010-115-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Granules Pharmaceuticals Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"70010-115-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"877-770-3183\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Granules%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "granules-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-70010-115-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "granules-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-70010-115-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Granules Pharmaceuticals Inc.", "package_ndc": "70010-115-01", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"70010-115-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"877-770-3183\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Granules%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "70010-115-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Granules Pharmaceuticals Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 70010-116-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Granules Pharmaceuticals Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"70010-116-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"877-770-3183\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Granules%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "granules-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-70010-116-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "granules-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-70010-116-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Granules Pharmaceuticals Inc.", "package_ndc": "70010-116-01", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"70010-116-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"877-770-3183\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Granules%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "70010-116-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Granules Pharmaceuticals Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 70010-117-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Granules Pharmaceuticals Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"70010-117-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"877-770-3183\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Granules%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "granules-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-70010-117-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "granules-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-70010-117-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Granules Pharmaceuticals Inc.", "package_ndc": "70010-117-01", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)\", \"company_name\": \"Granules Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"70010-117-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"877-770-3183\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Granules%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "70010-117-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Granules Pharmaceuticals Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70436-203-80\n\n**Generic name:** Dobutamine Hydrochloride Injection\n\n**Manufacturer:** Hainan Poly Pharm. Co., Ltd.\n\n> \"update_date\": \"05/08/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)\", \"company_name\": \"Hainan Poly Pharm. Co., Ltd.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"05/08/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)\", \"company_name\": \"Hainan Poly Pharm. Co., Ltd.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 05/08/2026\n\n> \"update_date\": \"05/08/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)\", \"company_name\": \"Hainan Poly Pharm. Co., Ltd.\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Dosage form:** Injection\n\n> \"update_date\": \"05/08/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)\", \"company_name\": \"Hainan Poly Pharm. Co., Ltd.\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"05/08/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)\", \"company_name\": \"Hainan Poly Pharm. Co., Ltd.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"70436-203-80\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"Slate Run Pharmaceuticals, LLC: 844-529-8988\", \"availability\": \"Available\", \"related_info\": \"Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hainan%20Poly%20Pharm.%20Co.,%20Ltd.%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "hainan-poly-pharm-co-ltd-dobutamine-hydrochloride-injection-70436-203-80.md", "generated": true, "generic_name": "Dobutamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hainan-poly-pharm-co-ltd-dobutamine-hydrochloride-injection-70436-203-80", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hainan Poly Pharm. Co., Ltd.", "package_ndc": "70436-203-80", "quote_dosage_form": "\"update_date\": \"05/08/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)\", \"company_name\": \"Hainan Poly Pharm. Co., Ltd.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"05/08/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)\", \"company_name\": \"Hainan Poly Pharm. Co., Ltd.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"05/08/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)\", \"company_name\": \"Hainan Poly Pharm. Co., Ltd.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"05/08/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)\", \"company_name\": \"Hainan Poly Pharm. Co., Ltd.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"05/08/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)\", \"company_name\": \"Hainan Poly Pharm. Co., Ltd.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"70436-203-80\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"Slate Run Pharmaceuticals, LLC: 844-529-8988\", \"availability\": \"Available\", \"related_info\": \"Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hainan%20Poly%20Pharm.%20Co.,%20Ltd.%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "70436-203-80 \u00b7 Dobutamine Hydrochloride Injection \u00b7 Hainan Poly Pharm. Co., Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "05/08/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6251-10\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/20/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 986\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6251-10\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "986", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-atropine-sulfate-injection-0641-6251-10.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-atropine-sulfate-injection-0641-6251-10", "initial_posting_date": "12/20/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6251-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6251-10\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0641-6251-10 \u00b7 Atropine Sulfate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0143-9606-01\n\n**Generic name:** Azacitidine Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\n\n**Initial posting date:** 12/18/2020\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2083\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/18/2020\", \"package_ndc\": \"0143-9606-01\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"1-800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2083", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-azacitidine-injection-0143-9606-01.md", "generated": true, "generic_name": "Azacitidine Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-azacitidine-injection-0143-9606-01", "initial_posting_date": "12/18/2020", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9606-01", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"12/18/2020\", \"package_ndc\": \"0143-9606-01\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"1-800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Oncology", "title": "0143-9606-01 \u00b7 Azacitidine Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6007-10\n\n**Generic name:** Bumetanide Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\n\n**Initial posting date:** 01/31/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3135\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/31/2018\", \"package_ndc\": \"0641-6007-10\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3135", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-bumetanide-injection-0641-6007-10.md", "generated": true, "generic_name": "Bumetanide Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-bumetanide-injection-0641-6007-10", "initial_posting_date": "01/31/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6007-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"01/31/2018\", \"package_ndc\": \"0641-6007-10\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0641-6007-10 \u00b7 Bumetanide Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6008-10\n\n**Generic name:** Bumetanide Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\n\n**Initial posting date:** 01/31/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3135\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/31/2018\", \"package_ndc\": \"0641-6008-10\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3135", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-bumetanide-injection-0641-6008-10.md", "generated": true, "generic_name": "Bumetanide Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-bumetanide-injection-0641-6008-10", "initial_posting_date": "01/31/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6008-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"01/31/2018\", \"package_ndc\": \"0641-6008-10\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0641-6008-10 \u00b7 Bumetanide Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0143-9930-10\n\n**Generic name:** Cefotaxime Sodium Powder, for Solution\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 02/17/2015\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 4214\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Powder, For Solution\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/17/2015\", \"package_ndc\": \"0143-9930-10\", \"generic_name\": \"Cefotaxime Sodium Powder, for Solution\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Cefotaxime%20Sodium%20Powder,%20for%20Solution%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "4214", "dosage_form": "Powder, For Solution", "file": "hikma-pharmaceuticals-usa-inc-cefotaxime-sodium-powder-for-solution-0143-9930-10.md", "generated": true, "generic_name": "Cefotaxime Sodium Powder, for Solution", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-cefotaxime-sodium-powder-for-solution-0143-9930-10", "initial_posting_date": "02/17/2015", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9930-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/17/2015\", \"package_ndc\": \"0143-9930-10\", \"generic_name\": \"Cefotaxime Sodium Powder, for Solution\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Cefotaxime%20Sodium%20Powder,%20for%20Solution%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0143-9930-10 \u00b7 Cefotaxime Sodium Powder, for Solution \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0143-9931-25\n\n**Generic name:** Cefotaxime Sodium Powder, for Solution\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 02/17/2015\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 4214\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Powder, For Solution\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/17/2015\", \"package_ndc\": \"0143-9931-25\", \"generic_name\": \"Cefotaxime Sodium Powder, for Solution\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Cefotaxime%20Sodium%20Powder,%20for%20Solution%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "4214", "dosage_form": "Powder, For Solution", "file": "hikma-pharmaceuticals-usa-inc-cefotaxime-sodium-powder-for-solution-0143-9931-25.md", "generated": true, "generic_name": "Cefotaxime Sodium Powder, for Solution", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-cefotaxime-sodium-powder-for-solution-0143-9931-25", "initial_posting_date": "02/17/2015", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9931-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/17/2015\", \"package_ndc\": \"0143-9931-25\", \"generic_name\": \"Cefotaxime Sodium Powder, for Solution\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Cefotaxime%20Sodium%20Powder,%20for%20Solution%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0143-9931-25 \u00b7 Cefotaxime Sodium Powder, for Solution \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0143-9933-25\n\n**Generic name:** Cefotaxime Sodium Powder, for Solution\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 02/17/2015\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 4214\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Powder, For Solution\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/17/2015\", \"package_ndc\": \"0143-9933-25\", \"generic_name\": \"Cefotaxime Sodium Powder, for Solution\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Cefotaxime%20Sodium%20Powder,%20for%20Solution%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "4214", "dosage_form": "Powder, For Solution", "file": "hikma-pharmaceuticals-usa-inc-cefotaxime-sodium-powder-for-solution-0143-9933-25.md", "generated": true, "generic_name": "Cefotaxime Sodium Powder, for Solution", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-cefotaxime-sodium-powder-for-solution-0143-9933-25", "initial_posting_date": "02/17/2015", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9933-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/17/2015\", \"package_ndc\": \"0143-9933-25\", \"generic_name\": \"Cefotaxime Sodium Powder, for Solution\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Cefotaxime%20Sodium%20Powder,%20for%20Solution%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0143-9933-25 \u00b7 Cefotaxime Sodium Powder, for Solution \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0143-9935-01\n\n**Generic name:** Cefotaxime Sodium Powder, for Solution\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 02/17/2015\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 4214\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Powder, For Solution\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/17/2015\", \"package_ndc\": \"0143-9935-01\", \"generic_name\": \"Cefotaxime Sodium Powder, for Solution\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Cefotaxime%20Sodium%20Powder,%20for%20Solution%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "4214", "dosage_form": "Powder, For Solution", "file": "hikma-pharmaceuticals-usa-inc-cefotaxime-sodium-powder-for-solution-0143-9935-01.md", "generated": true, "generic_name": "Cefotaxime Sodium Powder, for Solution", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-cefotaxime-sodium-powder-for-solution-0143-9935-01", "initial_posting_date": "02/17/2015", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9935-01", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/17/2015\", \"package_ndc\": \"0143-9935-01\", \"generic_name\": \"Cefotaxime Sodium Powder, for Solution\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Cefotaxime%20Sodium%20Powder,%20for%20Solution%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0143-9935-01 \u00b7 Cefotaxime Sodium Powder, for Solution \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-0367-25\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Product will be made available as it is released.\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"0641-0367-25\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-dexamethasone-sodium-phosphate-injection-0641-0367-25.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-dexamethasone-sodium-phosphate-injection-0641-0367-25", "initial_posting_date": "02/08/2019", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-0367-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"0641-0367-25\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Dermatology", "title": "0641-0367-25 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6145-25\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional product will be made available as it is released.\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"0641-6145-25\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-dexamethasone-sodium-phosphate-injection-0641-6145-25.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-dexamethasone-sodium-phosphate-injection-0641-6145-25", "initial_posting_date": "02/08/2019", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6145-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"0641-6145-25\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Dermatology", "title": "0641-6145-25 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6146-25\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional product will be made available as it is released.\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"0641-6146-25\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-dexamethasone-sodium-phosphate-injection-0641-6146-25.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-dexamethasone-sodium-phosphate-injection-0641-6146-25", "initial_posting_date": "02/08/2019", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6146-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"0641-6146-25\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Dermatology", "title": "0641-6146-25 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0143-9532-25\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Product temporarily on backorder. Additional lots will be available in the September 2026 timeframe.\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0143-9532-25\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Product temporarily on backorder. Additional lots will be available in the September 2026 timeframe.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-dexmedetomidine-hydrochloride-injection-0143-9532-25.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-dexmedetomidine-hydrochloride-injection-0143-9532-25", "initial_posting_date": "04/10/2020", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9532-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Product temporarily on backorder. Additional lots will be available in the September 2026 timeframe.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0143-9532-25\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Product temporarily on backorder. Additional lots will be available in the September 2026 timeframe.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0143-9532-25 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0143-9252-25\n\n**Generic name:** Dopamine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Product temporarily on backorder. Additional lots will be available in the February 2027 timeframe.\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0143-9252-25\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Product temporarily on backorder. Additional lots will be available in the February 2027 timeframe.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-dopamine-hydrochloride-injection-0143-9252-25.md", "generated": true, "generic_name": "Dopamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-dopamine-hydrochloride-injection-0143-9252-25", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9252-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Product temporarily on backorder. Additional lots will be available in the February 2027 timeframe.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0143-9252-25\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Product temporarily on backorder. Additional lots will be available in the February 2027 timeframe.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0143-9252-25 \u00b7 Dopamine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0143-9254-25\n\n**Generic name:** Dopamine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0143-9254-25\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-dopamine-hydrochloride-injection-0143-9254-25-2.md", "generated": true, "generic_name": "Dopamine Hydrochloride Injection", "harvested": "2026-09-07", "id": "hikma-pharmaceuticals-usa-inc-dopamine-hydrochloride-injection-0143-9254-25-2", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9254-25", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0143-9254-25\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0143-9254-25 \u00b7 Dopamine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0143-9254-25\n\n**Generic name:** Dopamine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0143-9254-25\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-dopamine-hydrochloride-injection-0143-9254-25.md", "generated": true, "generic_name": "Dopamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-dopamine-hydrochloride-injection-0143-9254-25", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9254-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0143-9254-25\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0143-9254-25 \u00b7 Dopamine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0143-9310-10\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Novaplus label\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"0143-9310-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Novaplus label\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-etomidate-injection-0143-9310-10.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-etomidate-injection-0143-9310-10", "initial_posting_date": "10/05/2022", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9310-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Novaplus label", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"0143-9310-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Novaplus label\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0143-9310-10 \u00b7 Etomidate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0143-9311-10\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Novaplus label\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"0143-9311-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Novaplus label\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-etomidate-injection-0143-9311-10.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-etomidate-injection-0143-9311-10", "initial_posting_date": "10/05/2022", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9311-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Novaplus label", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"0143-9311-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Novaplus label\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0143-9311-10 \u00b7 Etomidate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0143-9506-10\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional product will be made available as it is released.\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"0143-9506-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-etomidate-injection-0143-9506-10.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-etomidate-injection-0143-9506-10", "initial_posting_date": "10/05/2022", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9506-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Additional product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"0143-9506-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0143-9506-10 \u00b7 Etomidate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0143-9507-10\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional product will be made available as it is released.\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"0143-9507-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-etomidate-injection-0143-9507-10.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-etomidate-injection-0143-9507-10", "initial_posting_date": "10/05/2022", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9507-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Additional product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"0143-9507-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0143-9507-10 \u00b7 Etomidate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72572-160-10\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Civica\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"72572-160-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Distributed by Civica\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-etomidate-injection-72572-160-10.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-etomidate-injection-72572-160-10", "initial_posting_date": "10/05/2022", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "72572-160-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Distributed by Civica", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"72572-160-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Distributed by Civica\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "72572-160-10 \u00b7 Etomidate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72572-161-10\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Civica\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"72572-161-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Distributed by Civica\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-etomidate-injection-72572-161-10.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-etomidate-injection-72572-161-10", "initial_posting_date": "10/05/2022", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "72572-161-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Distributed by Civica", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"72572-161-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Distributed by Civica\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "72572-161-10 \u00b7 Etomidate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6024-10\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Inventory available in vial presentations.\n\n**Initial posting date:** 12/20/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 986\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6024-10\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Inventory available in vial presentations.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "986", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6024-10.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6024-10", "initial_posting_date": "12/20/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6024-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Inventory available in vial presentations.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6024-10\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Inventory available in vial presentations.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6024-10 \u00b7 Fentanyl Citrate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6025-10\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Inventory available in vial presentations.\n\n**Initial posting date:** 12/20/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 986\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6025-10\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Inventory available in vial presentations.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "986", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6025-10.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6025-10", "initial_posting_date": "12/20/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6025-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Inventory available in vial presentations.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6025-10\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Inventory available in vial presentations.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6025-10 \u00b7 Fentanyl Citrate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6026-05\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Inventory available in vial presentations.\n\n**Initial posting date:** 12/20/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 986\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6026-05\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Inventory available in vial presentations.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "986", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6026-05.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6026-05", "initial_posting_date": "12/20/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6026-05", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Inventory available in vial presentations.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6026-05\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Inventory available in vial presentations.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6026-05 \u00b7 Fentanyl Citrate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6027-25\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Additional lots will be available September 2026 timeframe. Product will be made available as it is released.\n\n**Initial posting date:** 12/20/2023\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 992\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6027-25\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available September 2026 timeframe. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "992", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6027-25-2.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-07", "id": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6027-25-2", "initial_posting_date": "12/20/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6027-25", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be available September 2026 timeframe. Product will be made available as it is released.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6027-25\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available September 2026 timeframe. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6027-25 \u00b7 Fentanyl Citrate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6027-25\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Additional lots will be available August 2026 timeframe. Product will be made available as it is released.\n\n**Initial posting date:** 12/20/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 986\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6027-25\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available August 2026 timeframe. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "986", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6027-25.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6027-25", "initial_posting_date": "12/20/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6027-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Additional lots will be available August 2026 timeframe. Product will be made available as it is released.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6027-25\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available August 2026 timeframe. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6027-25 \u00b7 Fentanyl Citrate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6028-25\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.\n\n**Initial posting date:** 12/20/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 986\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6028-25\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "986", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6028-25.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6028-25", "initial_posting_date": "12/20/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6028-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6028-25\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6028-25 \u00b7 Fentanyl Citrate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6029-25\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.\n\n**Initial posting date:** 12/20/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 986\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6029-25\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "986", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6029-25.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6029-25", "initial_posting_date": "12/20/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6029-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6029-25\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6029-25 \u00b7 Fentanyl Citrate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6030-01\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.\n\n**Initial posting date:** 12/20/2023\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 992\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6030-01\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "992", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6030-01-2.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-07", "id": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6030-01-2", "initial_posting_date": "12/20/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6030-01", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6030-01\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6030-01 \u00b7 Fentanyl Citrate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6030-01\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Additional lots will be available September 2026 timeframe. Product will be made available as it is released.\n\n**Initial posting date:** 12/20/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 986\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6030-01\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available September 2026 timeframe. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "986", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6030-01.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6030-01", "initial_posting_date": "12/20/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6030-01", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Additional lots will be available September 2026 timeframe. Product will be made available as it is released.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6030-01\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available September 2026 timeframe. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6030-01 \u00b7 Fentanyl Citrate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6247-25\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.\n\n**Initial posting date:** 12/20/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 986\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6247-25\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "986", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6247-25.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-fentanyl-citrate-injection-0641-6247-25", "initial_posting_date": "12/20/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6247-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"12/20/2023\", \"package_ndc\": \"0641-6247-25\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6247-25 \u00b7 Fentanyl Citrate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0054-3294-46\n\n**Generic name:** Furosemide Oral Solution\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Available on allocation\n\n**Initial posting date:** 03/31/2026\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Days in shortage:** 154\n\n**Reason for shortage:** Shortage of an inactive ingredient component\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Dosage form:** Oral Solution\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/31/2026\", \"package_ndc\": \"0054-3294-46\", \"generic_name\": \"Furosemide Oral Solution\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Oral%20Solution%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "154", "dosage_form": "Oral Solution", "file": "hikma-pharmaceuticals-usa-inc-furosemide-oral-solution-0054-3294-46.md", "generated": true, "generic_name": "Furosemide Oral Solution", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-furosemide-oral-solution-0054-3294-46", "initial_posting_date": "03/31/2026", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0054-3294-46", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Available on allocation", "shortage_reason": "Shortage of an inactive ingredient component", "source_quote": "\"initial_posting_date\": \"03/31/2026\", \"package_ndc\": \"0054-3294-46\", \"generic_name\": \"Furosemide Oral Solution\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Oral%20Solution%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0054-3294-46 \u00b7 Furosemide Oral Solution \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0054-3294-50\n\n**Generic name:** Furosemide Oral Solution\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Available on allocation\n\n**Initial posting date:** 03/31/2026\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Days in shortage:** 154\n\n**Reason for shortage:** Shortage of an inactive ingredient component\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Dosage form:** Oral Solution\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/31/2026\", \"package_ndc\": \"0054-3294-50\", \"generic_name\": \"Furosemide Oral Solution\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Oral%20Solution%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "154", "dosage_form": "Oral Solution", "file": "hikma-pharmaceuticals-usa-inc-furosemide-oral-solution-0054-3294-50.md", "generated": true, "generic_name": "Furosemide Oral Solution", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-furosemide-oral-solution-0054-3294-50", "initial_posting_date": "03/31/2026", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0054-3294-50", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Available on allocation", "shortage_reason": "Shortage of an inactive ingredient component", "source_quote": "\"initial_posting_date\": \"03/31/2026\", \"package_ndc\": \"0054-3294-50\", \"generic_name\": \"Furosemide Oral Solution\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Oral%20Solution%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0054-3294-50 \u00b7 Furosemide Oral Solution \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0054-3298-63\n\n**Generic name:** Furosemide Oral Solution\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Available on allocation\n\n**Initial posting date:** 03/31/2026\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Days in shortage:** 154\n\n**Reason for shortage:** Shortage of an inactive ingredient component\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Dosage form:** Oral Solution\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/31/2026\", \"package_ndc\": \"0054-3298-63\", \"generic_name\": \"Furosemide Oral Solution\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Oral%20Solution%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "154", "dosage_form": "Oral Solution", "file": "hikma-pharmaceuticals-usa-inc-furosemide-oral-solution-0054-3298-63.md", "generated": true, "generic_name": "Furosemide Oral Solution", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-furosemide-oral-solution-0054-3298-63", "initial_posting_date": "03/31/2026", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0054-3298-63", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Oral Solution\", \"presentation\": \"Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an inactive ingredient component\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Available on allocation", "shortage_reason": "Shortage of an inactive ingredient component", "source_quote": "\"initial_posting_date\": \"03/31/2026\", \"package_ndc\": \"0054-3298-63\", \"generic_name\": \"Furosemide Oral Solution\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Oral%20Solution%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0054-3298-63 \u00b7 Furosemide Oral Solution \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-0121-25\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\n\n**Initial posting date:** 11/03/2017\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3224\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/03/2017\", \"change_date\": \"01/03/2025\", \"package_ndc\": \"0641-0121-25\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3224", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-hydromorphone-hydrochloride-injection-0641-0121-25.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-hydromorphone-hydrochloride-injection-0641-0121-25", "initial_posting_date": "11/03/2017", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-0121-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"11/03/2017\", \"change_date\": \"01/03/2025\", \"package_ndc\": \"0641-0121-25\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-0121-25 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6254-01\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Product temporarily on backorder. Additional lots will be available in the September 2026 timeframe.\n\n**Initial posting date:** 11/01/2017\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3232\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0641-6254-01\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Product temporarily on backorder. Additional lots will be available in the September 2026 timeframe.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3232", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-hydromorphone-hydrochloride-injection-0641-6254-01-2.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-07", "id": "hikma-pharmaceuticals-usa-inc-hydromorphone-hydrochloride-injection-0641-6254-01-2", "initial_posting_date": "11/01/2017", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6254-01", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Product temporarily on backorder. Additional lots will be available in the September 2026 timeframe.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0641-6254-01\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Product temporarily on backorder. Additional lots will be available in the September 2026 timeframe.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6254-01 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6254-01\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Product temporarily on backorder. Additional lots will be available in the August 2026 timeframe.\n\n**Initial posting date:** 11/01/2017\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3226\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0641-6254-01\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Product temporarily on backorder. Additional lots will be available in the August 2026 timeframe.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3226", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-hydromorphone-hydrochloride-injection-0641-6254-01.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-hydromorphone-hydrochloride-injection-0641-6254-01", "initial_posting_date": "11/01/2017", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6254-01", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Product temporarily on backorder. Additional lots will be available in the August 2026 timeframe.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0641-6254-01\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Product temporarily on backorder. Additional lots will be available in the August 2026 timeframe.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6254-01 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0143-9530-01\n\n**Generic name:** Ifosfamide Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\n\n**Initial posting date:** 06/12/2026\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 81\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"0143-9530-01\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "81", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-ifosfamide-injection-0143-9530-01.md", "generated": true, "generic_name": "Ifosfamide Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-ifosfamide-injection-0143-9530-01", "initial_posting_date": "06/12/2026", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9530-01", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"0143-9530-01\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Oncology", "title": "0143-9530-01 \u00b7 Ifosfamide Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0143-9531-01\n\n**Generic name:** Ifosfamide Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\n\n**Initial posting date:** 06/12/2026\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 81\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"0143-9531-01\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "81", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-ifosfamide-injection-0143-9531-01.md", "generated": true, "generic_name": "Ifosfamide Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-ifosfamide-injection-0143-9531-01", "initial_posting_date": "06/12/2026", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9531-01", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"0143-9531-01\", \"generic_name\": \"Ifosfamide Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Oncology", "title": "0143-9531-01 \u00b7 Ifosfamide Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6041-25\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 06/06/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3009\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"0641-6041-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3009", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-ketorolac-tromethamine-injection-0641-6041-25.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-ketorolac-tromethamine-injection-0641-6041-25", "initial_posting_date": "06/06/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6041-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"0641-6041-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6041-25 \u00b7 Ketorolac Tromethamine Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6042-25\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 06/06/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3009\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"0641-6042-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3009", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-ketorolac-tromethamine-injection-0641-6042-25.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-ketorolac-tromethamine-injection-0641-6042-25", "initial_posting_date": "06/06/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6042-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"0641-6042-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6042-25 \u00b7 Ketorolac Tromethamine Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6043-25\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 06/06/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3009\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"0641-6043-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3009", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-ketorolac-tromethamine-injection-0641-6043-25.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-ketorolac-tromethamine-injection-0641-6043-25", "initial_posting_date": "06/06/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6043-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"06/06/2018\", \"package_ndc\": \"0641-6043-25\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6043-25 \u00b7 Ketorolac Tromethamine Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0143-9575-10\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\n\n**Initial posting date:** 06/13/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3002\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"0143-9575-10\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3002", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-lidocaine-hydrochloride-injection-0143-9575-10.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lidocaine-hydrochloride-injection-0143-9575-10", "initial_posting_date": "06/13/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9575-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"0143-9575-10\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0143-9575-10 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0143-9577-10\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\n\n**Initial posting date:** 06/13/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3002\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"0143-9577-10\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3002", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-lidocaine-hydrochloride-injection-0143-9577-10.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lidocaine-hydrochloride-injection-0143-9577-10", "initial_posting_date": "06/13/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9577-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"0143-9577-10\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0143-9577-10 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0143-9594-25\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 06/13/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3002\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"0143-9594-25\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3002", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-lidocaine-hydrochloride-injection-0143-9594-25.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lidocaine-hydrochloride-injection-0143-9594-25", "initial_posting_date": "06/13/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9594-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"0143-9594-25\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0143-9594-25 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0143-9595-25\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\n\n**Initial posting date:** 06/13/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3002\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"0143-9595-25\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3002", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-lidocaine-hydrochloride-injection-0143-9595-25.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lidocaine-hydrochloride-injection-0143-9595-25", "initial_posting_date": "06/13/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9595-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"06/13/2018\", \"package_ndc\": \"0143-9595-25\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0143-9595-25 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0143-9144-02\n\n**Generic name:** Liraglutide Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/18/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1141\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"0143-9144-02\", \"generic_name\": \"Liraglutide Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1141", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-liraglutide-injection-0143-9144-02.md", "generated": true, "generic_name": "Liraglutide Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-liraglutide-injection-0143-9144-02", "initial_posting_date": "07/18/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9144-02", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"0143-9144-02\", \"generic_name\": \"Liraglutide Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0143-9144-02 \u00b7 Liraglutide Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0143-9144-03\n\n**Generic name:** Liraglutide Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/18/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1141\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"0143-9144-03\", \"generic_name\": \"Liraglutide Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1141", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-liraglutide-injection-0143-9144-03.md", "generated": true, "generic_name": "Liraglutide Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-liraglutide-injection-0143-9144-03", "initial_posting_date": "07/18/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9144-03", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"0143-9144-03\", \"generic_name\": \"Liraglutide Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0143-9144-03 \u00b7 Liraglutide Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0054-0370-25\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Available on allocation\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0054-0370-25\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "hikma-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0054-0370-25.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0054-0370-25", "initial_posting_date": "07/14/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0054-0370-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Available on allocation", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0054-0370-25\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0054-0370-25 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0054-0371-25\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Available on allocation\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0054-0371-25\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "hikma-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0054-0371-25.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0054-0371-25", "initial_posting_date": "07/14/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0054-0371-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Available on allocation", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0054-0371-25\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0054-0371-25 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0054-0372-25\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Available on allocation\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0054-0372-25\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "hikma-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0054-0372-25.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0054-0372-25", "initial_posting_date": "07/14/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0054-0372-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Available on allocation", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0054-0372-25\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0054-0372-25 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0054-0373-25\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Available on allocation\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0054-0373-25\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "hikma-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0054-0373-25.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0054-0373-25", "initial_posting_date": "07/14/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0054-0373-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Available on allocation", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0054-0373-25\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0054-0373-25 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0054-0374-25\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Available on allocation\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0054-0374-25\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "hikma-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0054-0374-25.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0054-0374-25", "initial_posting_date": "07/14/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0054-0374-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Available on allocation", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0054-0374-25\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0054-0374-25 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0054-0375-25\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Available on allocation\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0054-0375-25\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "hikma-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0054-0375-25.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0054-0375-25", "initial_posting_date": "07/14/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0054-0375-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Available on allocation", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0054-0375-25\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0054-0375-25 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0054-0660-25\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"05/12/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"05/12/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Available on allocation\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 05/12/2026\n\n> \"update_date\": \"05/12/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"05/12/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"05/12/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"05/12/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0054-0660-25\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "hikma-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0054-0660-25.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0054-0660-25", "initial_posting_date": "07/14/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0054-0660-25", "quote_dosage_form": "\"update_date\": \"05/12/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"05/12/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"05/12/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"05/12/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"05/12/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"05/12/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Available on allocation", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0054-0660-25\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Available on allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0054-0660-25 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "05/12/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6000-10\n\n**Generic name:** Lorazepam Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 09/05/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2918\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6000-10\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2918", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6000-10.md", "generated": true, "generic_name": "Lorazepam Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6000-10", "initial_posting_date": "09/05/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6000-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6000-10\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Neurology", "title": "0641-6000-10 \u00b7 Lorazepam Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0641-6001-25\n\n**Generic name:** Lorazepam Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 09/05/2018\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2927\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6001-25\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2927", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6001-25-2.md", "generated": true, "generic_name": "Lorazepam Injection", "harvested": "2026-09-10", "id": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6001-25-2", "initial_posting_date": "09/05/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6001-25", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6001-25\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Neurology", "title": "0641-6001-25 \u00b7 Lorazepam Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0641-6001-25\n\n**Generic name:** Lorazepam Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Lots are being manufactured to meet demand\n\n**Initial posting date:** 09/05/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2918\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6001-25\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Lots are being manufactured to meet demand\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2918", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6001-25.md", "generated": true, "generic_name": "Lorazepam Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6001-25", "initial_posting_date": "09/05/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6001-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Lots are being manufactured to meet demand", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6001-25\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Lots are being manufactured to meet demand\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "0641-6001-25 \u00b7 Lorazepam Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6002-10\n\n**Generic name:** Lorazepam Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 09/05/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2918\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6002-10\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2918", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6002-10.md", "generated": true, "generic_name": "Lorazepam Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6002-10", "initial_posting_date": "09/05/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6002-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6002-10\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Neurology", "title": "0641-6002-10 \u00b7 Lorazepam Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6003-25\n\n**Generic name:** Lorazepam Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 09/05/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2918\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6003-25\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2918", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6003-25.md", "generated": true, "generic_name": "Lorazepam Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6003-25", "initial_posting_date": "09/05/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6003-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6003-25\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Neurology", "title": "0641-6003-25 \u00b7 Lorazepam Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0641-6044-25\n\n**Generic name:** Lorazepam Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 09/05/2018\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2927\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6044-25\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2927", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6044-25-2.md", "generated": true, "generic_name": "Lorazepam Injection", "harvested": "2026-09-10", "id": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6044-25-2", "initial_posting_date": "09/05/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6044-25", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6044-25\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Neurology", "title": "0641-6044-25 \u00b7 Lorazepam Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0641-6044-25\n\n**Generic name:** Lorazepam Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Lots are being manufactured to meet demand\n\n**Initial posting date:** 09/05/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2918\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6044-25\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Lots are being manufactured to meet demand\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2918", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6044-25.md", "generated": true, "generic_name": "Lorazepam Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6044-25", "initial_posting_date": "09/05/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6044-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Lots are being manufactured to meet demand", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6044-25\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Limited Availability\", \"related_info\": \"Lots are being manufactured to meet demand\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "0641-6044-25 \u00b7 Lorazepam Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6045-25\n\n**Generic name:** Lorazepam Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 09/05/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2918\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6045-25\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2918", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6045-25.md", "generated": true, "generic_name": "Lorazepam Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6045-25", "initial_posting_date": "09/05/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6045-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6045-25\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Neurology", "title": "0641-6045-25 \u00b7 Lorazepam Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6046-10\n\n**Generic name:** Lorazepam Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 09/05/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2918\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6046-10\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2918", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6046-10.md", "generated": true, "generic_name": "Lorazepam Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6046-10", "initial_posting_date": "09/05/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6046-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"09/05/2018\", \"package_ndc\": \"0641-6046-10\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Neurology", "title": "0641-6046-10 \u00b7 Lorazepam Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6047-10\n\n**Generic name:** Lorazepam Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 05/03/2018\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3043\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/03/2018\", \"package_ndc\": \"0641-6047-10\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3043", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6047-10.md", "generated": true, "generic_name": "Lorazepam Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-lorazepam-injection-0641-6047-10", "initial_posting_date": "05/03/2018", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6047-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"05/03/2018\", \"package_ndc\": \"0641-6047-10\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Neurology", "title": "0641-6047-10 \u00b7 Lorazepam Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6052-25\n\n**Generic name:** Meperidine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 05/30/2025\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 459\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0641-6052-25\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "459", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-meperidine-hydrochloride-injection-0641-6052-25.md", "generated": true, "generic_name": "Meperidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-meperidine-hydrochloride-injection-0641-6052-25", "initial_posting_date": "05/30/2025", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6052-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0641-6052-25\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6052-25 \u00b7 Meperidine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6053-25\n\n**Generic name:** Meperidine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 05/30/2025\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 459\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0641-6053-25\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "459", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-meperidine-hydrochloride-injection-0641-6053-25.md", "generated": true, "generic_name": "Meperidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-meperidine-hydrochloride-injection-0641-6053-25", "initial_posting_date": "05/30/2025", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6053-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0641-6053-25\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6053-25 \u00b7 Meperidine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6054-25\n\n**Generic name:** Meperidine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 05/30/2025\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 459\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0641-6054-25\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "459", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-meperidine-hydrochloride-injection-0641-6054-25.md", "generated": true, "generic_name": "Meperidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-meperidine-hydrochloride-injection-0641-6054-25", "initial_posting_date": "05/30/2025", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6054-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0641-6054-25\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6054-25 \u00b7 Meperidine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0143-9519-10\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1274\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0143-9519-10\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1274", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0143-9519-10-2.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-07", "id": "hikma-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0143-9519-10-2", "initial_posting_date": "03/13/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9519-10", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0143-9519-10\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0143-9519-10 \u00b7 Methotrexate Sodium Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0143-9519-10\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1268\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0143-9519-10\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1268", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0143-9519-10.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0143-9519-10", "initial_posting_date": "03/13/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9519-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0143-9519-10\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0143-9519-10 \u00b7 Methotrexate Sodium Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0143-9830-01\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1268\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0143-9830-01\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1268", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0143-9830-01.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0143-9830-01", "initial_posting_date": "03/13/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9830-01", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0143-9830-01\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0143-9830-01 \u00b7 Methotrexate Sodium Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6056-10\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0641-6056-10\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-midazolam-hydrochloride-injection-0641-6056-10.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-midazolam-hydrochloride-injection-0641-6056-10", "initial_posting_date": "04/02/2020", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6056-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0641-6056-10\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0641-6056-10 \u00b7 Midazolam Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6057-25\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0641-6057-25\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-midazolam-hydrochloride-injection-0641-6057-25.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-midazolam-hydrochloride-injection-0641-6057-25", "initial_posting_date": "04/02/2020", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6057-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0641-6057-25\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0641-6057-25 \u00b7 Midazolam Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6059-01\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2352\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0641-6059-01\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2352", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-midazolam-hydrochloride-injection-0641-6059-01-2.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-10", "id": "hikma-pharmaceuticals-usa-inc-midazolam-hydrochloride-injection-0641-6059-01-2", "initial_posting_date": "04/02/2020", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6059-01", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0641-6059-01\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0641-6059-01 \u00b7 Midazolam Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6059-01\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0641-6059-01\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-midazolam-hydrochloride-injection-0641-6059-01.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-midazolam-hydrochloride-injection-0641-6059-01", "initial_posting_date": "04/02/2020", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6059-01", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0641-6059-01\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0641-6059-01 \u00b7 Midazolam Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6060-10\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0641-6060-10\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-midazolam-hydrochloride-injection-0641-6060-10.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-midazolam-hydrochloride-injection-0641-6060-10", "initial_posting_date": "04/02/2020", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6060-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0641-6060-10\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0641-6060-10 \u00b7 Midazolam Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6061-25\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0641-6061-25\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-midazolam-hydrochloride-injection-0641-6061-25.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-midazolam-hydrochloride-injection-0641-6061-25", "initial_posting_date": "04/02/2020", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6061-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0641-6061-25\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0641-6061-25 \u00b7 Midazolam Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6019-10\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 11/03/2017\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3224\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/03/2017\", \"package_ndc\": \"0641-6019-10\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3224", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-morphine-sulfate-injection-0641-6019-10.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-morphine-sulfate-injection-0641-6019-10", "initial_posting_date": "11/03/2017", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6019-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"11/03/2017\", \"package_ndc\": \"0641-6019-10\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6019-10 \u00b7 Morphine Sulfate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6020-10\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 11/03/2017\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3224\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/03/2017\", \"package_ndc\": \"0641-6020-10\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3224", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-morphine-sulfate-injection-0641-6020-10.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-morphine-sulfate-injection-0641-6020-10", "initial_posting_date": "11/03/2017", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6020-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"11/03/2017\", \"package_ndc\": \"0641-6020-10\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6020-10 \u00b7 Morphine Sulfate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6039-01\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 11/03/2017\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3224\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/03/2017\", \"package_ndc\": \"0641-6039-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3224", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-morphine-sulfate-injection-0641-6039-01.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-morphine-sulfate-injection-0641-6039-01", "initial_posting_date": "11/03/2017", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6039-01", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"11/03/2017\", \"package_ndc\": \"0641-6039-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6039-01 \u00b7 Morphine Sulfate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6040-01\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 11/03/2017\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3224\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/03/2017\", \"package_ndc\": \"0641-6040-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3224", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-morphine-sulfate-injection-0641-6040-01.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-morphine-sulfate-injection-0641-6040-01", "initial_posting_date": "11/03/2017", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6040-01", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"11/03/2017\", \"package_ndc\": \"0641-6040-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6040-01 \u00b7 Morphine Sulfate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6125-25\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 11/03/2017\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3224\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/03/2017\", \"package_ndc\": \"0641-6125-25\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3224", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-morphine-sulfate-injection-0641-6125-25.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-morphine-sulfate-injection-0641-6125-25", "initial_posting_date": "11/03/2017", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6125-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"11/03/2017\", \"package_ndc\": \"0641-6125-25\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6125-25 \u00b7 Morphine Sulfate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6126-25\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 11/03/2017\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3224\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/03/2017\", \"package_ndc\": \"0641-6126-25\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3224", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-morphine-sulfate-injection-0641-6126-25.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-morphine-sulfate-injection-0641-6126-25", "initial_posting_date": "11/03/2017", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6126-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"11/03/2017\", \"package_ndc\": \"0641-6126-25\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6126-25 \u00b7 Morphine Sulfate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6127-25\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.\n\n**Initial posting date:** 11/03/2017\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3230\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/03/2017\", \"package_ndc\": \"0641-6127-25\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3230", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-morphine-sulfate-injection-0641-6127-25-2.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-07", "id": "hikma-pharmaceuticals-usa-inc-morphine-sulfate-injection-0641-6127-25-2", "initial_posting_date": "11/03/2017", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6127-25", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"11/03/2017\", \"package_ndc\": \"0641-6127-25\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6127-25 \u00b7 Morphine Sulfate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6127-25\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 11/03/2017\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3224\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/03/2017\", \"package_ndc\": \"0641-6127-25\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3224", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-morphine-sulfate-injection-0641-6127-25.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-morphine-sulfate-injection-0641-6127-25", "initial_posting_date": "11/03/2017", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6127-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"11/03/2017\", \"package_ndc\": \"0641-6127-25\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6127-25 \u00b7 Morphine Sulfate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-0928-25\n\n**Generic name:** Promethazine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 11/21/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1015\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-0928-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1015", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-0928-25.md", "generated": true, "generic_name": "Promethazine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-0928-25", "initial_posting_date": "11/21/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-0928-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-0928-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-0928-25 \u00b7 Promethazine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-0929-25\n\n**Generic name:** Promethazine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 11/21/2023\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1024\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-0929-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1024", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-0929-25-2.md", "generated": true, "generic_name": "Promethazine Hydrochloride Injection", "harvested": "2026-09-10", "id": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-0929-25-2", "initial_posting_date": "11/21/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-0929-25", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-0929-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-0929-25 \u00b7 Promethazine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-0929-25\n\n**Generic name:** Promethazine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 11/21/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1015\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-0929-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1015", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-0929-25.md", "generated": true, "generic_name": "Promethazine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-0929-25", "initial_posting_date": "11/21/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-0929-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-0929-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-0929-25 \u00b7 Promethazine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-1495-35\n\n**Generic name:** Promethazine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.\n\n**Initial posting date:** 11/21/2023\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1024\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-1495-35\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1024", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-1495-35-2.md", "generated": true, "generic_name": "Promethazine Hydrochloride Injection", "harvested": "2026-09-10", "id": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-1495-35-2", "initial_posting_date": "11/21/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-1495-35", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-1495-35\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-1495-35 \u00b7 Promethazine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-1495-35\n\n**Generic name:** Promethazine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 11/21/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1015\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-1495-35\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1015", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-1495-35.md", "generated": true, "generic_name": "Promethazine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-1495-35", "initial_posting_date": "11/21/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-1495-35", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-1495-35\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-1495-35 \u00b7 Promethazine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-1496-35\n\n**Generic name:** Promethazine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.\n\n**Initial posting date:** 11/21/2023\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1024\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-1496-35\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1024", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-1496-35-2.md", "generated": true, "generic_name": "Promethazine Hydrochloride Injection", "harvested": "2026-09-10", "id": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-1496-35-2", "initial_posting_date": "11/21/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-1496-35", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-1496-35\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-1496-35 \u00b7 Promethazine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-1496-35\n\n**Generic name:** Promethazine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 11/21/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1015\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-1496-35\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1015", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-1496-35.md", "generated": true, "generic_name": "Promethazine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-1496-35", "initial_posting_date": "11/21/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-1496-35", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-1496-35\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-1496-35 \u00b7 Promethazine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6082-25\n\n**Generic name:** Promethazine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 11/21/2023\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1024\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-6082-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1024", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-6082-25-2.md", "generated": true, "generic_name": "Promethazine Hydrochloride Injection", "harvested": "2026-09-10", "id": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-6082-25-2", "initial_posting_date": "11/21/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6082-25", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-6082-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6082-25 \u00b7 Promethazine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6082-25\n\n**Generic name:** Promethazine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 11/21/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1015\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-6082-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1015", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-6082-25.md", "generated": true, "generic_name": "Promethazine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-6082-25", "initial_posting_date": "11/21/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6082-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-6082-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6082-25 \u00b7 Promethazine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6083-25\n\n**Generic name:** Promethazine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** This presentation is temporarily on backorder. Expected in October 2026 timeframe\n\n**Initial posting date:** 11/21/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1015\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-6083-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"This presentation is temporarily on backorder. Expected in October 2026 timeframe\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1015", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-6083-25.md", "generated": true, "generic_name": "Promethazine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-6083-25", "initial_posting_date": "11/21/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6083-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "This presentation is temporarily on backorder. Expected in October 2026 timeframe", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-6083-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"This presentation is temporarily on backorder. Expected in October 2026 timeframe\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6083-25 \u00b7 Promethazine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6084-25\n\n**Generic name:** Promethazine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 11/21/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1015\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-6084-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1015", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-6084-25.md", "generated": true, "generic_name": "Promethazine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-6084-25", "initial_posting_date": "11/21/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6084-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-6084-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6084-25 \u00b7 Promethazine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0641-6085-25\n\n**Generic name:** Promethazine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 11/21/2023\n\n**Last update date:** 09/03/2026\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1024\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-6085-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1024", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-6085-25-2.md", "generated": true, "generic_name": "Promethazine Hydrochloride Injection", "harvested": "2026-09-10", "id": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-6085-25-2", "initial_posting_date": "11/21/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6085-25", "quote_dosage_form": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/03/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-6085-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6085-25 \u00b7 Promethazine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/03/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6085-25\n\n**Generic name:** Promethazine Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots are scheduled to be manufactured. Product will be made available as it is released.\n\n**Initial posting date:** 11/21/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1015\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-6085-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1015", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-6085-25.md", "generated": true, "generic_name": "Promethazine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-promethazine-hydrochloride-injection-0641-6085-25", "initial_posting_date": "11/21/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6085-25", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Pediatric\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"0641-6085-25\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots are scheduled to be manufactured. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0641-6085-25 \u00b7 Promethazine Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0143-9872-10\n\n**Generic name:** Propranolol Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 10/31/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1036\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2023\", \"package_ndc\": \"0143-9872-10\", \"generic_name\": \"Propranolol Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Propranolol%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1036", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-propranolol-hydrochloride-injection-0143-9872-10.md", "generated": true, "generic_name": "Propranolol Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-propranolol-hydrochloride-injection-0143-9872-10", "initial_posting_date": "10/31/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9872-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/31/2023\", \"package_ndc\": \"0143-9872-10\", \"generic_name\": \"Propranolol Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Propranolol%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0143-9872-10 \u00b7 Propranolol Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0143-9391-10\n\n**Generic name:** Remifentanil Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 06/28/2022\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1526\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"0143-9391-10\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1526", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-remifentanil-hydrochloride-injection-0143-9391-10.md", "generated": true, "generic_name": "Remifentanil Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-remifentanil-hydrochloride-injection-0143-9391-10", "initial_posting_date": "06/28/2022", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9391-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"0143-9391-10\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0143-9391-10 \u00b7 Remifentanil Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0143-9392-10\n\n**Generic name:** Remifentanil Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 06/28/2022\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1526\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"0143-9392-10\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1526", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-remifentanil-hydrochloride-injection-0143-9392-10.md", "generated": true, "generic_name": "Remifentanil Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-remifentanil-hydrochloride-injection-0143-9392-10", "initial_posting_date": "06/28/2022", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9392-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"0143-9392-10\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0143-9392-10 \u00b7 Remifentanil Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0143-9393-10\n\n**Generic name:** Remifentanil Hydrochloride Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots will be available. Product will be made available as it is released.\n\n**Initial posting date:** 06/28/2022\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1526\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"0143-9393-10\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be available. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1526", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-remifentanil-hydrochloride-injection-0143-9393-10.md", "generated": true, "generic_name": "Remifentanil Hydrochloride Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-remifentanil-hydrochloride-injection-0143-9393-10", "initial_posting_date": "06/28/2022", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9393-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be available. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"0143-9393-10\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be available. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0143-9393-10 \u00b7 Remifentanil Hydrochloride Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0143-9250-10\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots will be available. Product will be made available as it is released.\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"0143-9250-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be available. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-rocuronium-bromide-injection-0143-9250-10.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-rocuronium-bromide-injection-0143-9250-10", "initial_posting_date": "02/15/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9250-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be available. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"0143-9250-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be available. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0143-9250-10 \u00b7 Rocuronium Bromide Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0143-9251-10\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots will be available. Product will be made available as it is released.\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"0143-9251-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be available. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-rocuronium-bromide-injection-0143-9251-10.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-rocuronium-bromide-injection-0143-9251-10", "initial_posting_date": "02/15/2023", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9251-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be available. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"0143-9251-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be available. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0143-9251-10 \u00b7 Rocuronium Bromide Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6261-01\n\n**Generic name:** Sodium Acetate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots will be available. Product will be made available as it is released.\n\n**Initial posting date:** 02/03/2016\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3863\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"0641-6261-01\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be available. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3863", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-sodium-acetate-injection-0641-6261-01.md", "generated": true, "generic_name": "Sodium Acetate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-sodium-acetate-injection-0641-6261-01", "initial_posting_date": "02/03/2016", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6261-01", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be available. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"0641-6261-01\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be available. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0641-6261-01 \u00b7 Sodium Acetate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6262-01\n\n**Generic name:** Sodium Acetate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots will be available. Product will be made available as it is released.\n\n**Initial posting date:** 02/03/2016\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3863\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"0641-6262-01\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be available. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3863", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-sodium-acetate-injection-0641-6262-01.md", "generated": true, "generic_name": "Sodium Acetate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-sodium-acetate-injection-0641-6262-01", "initial_posting_date": "02/03/2016", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6262-01", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Additional lots will be available. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"0641-6262-01\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be available. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0641-6262-01 \u00b7 Sodium Acetate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0641-6147-10\n\n**Generic name:** Sterile Water Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots will be scheduled for manufacturing. Product will be made available as it is released.\n\n**Initial posting date:** 11/23/2021\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1743\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"0641-6147-10\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be scheduled for manufacturing. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1743", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-sterile-water-injection-0641-6147-10.md", "generated": true, "generic_name": "Sterile Water Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-sterile-water-injection-0641-6147-10", "initial_posting_date": "11/23/2021", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0641-6147-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Additional lots will be scheduled for manufacturing. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"0641-6147-10\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be scheduled for manufacturing. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Other", "title": "0641-6147-10 \u00b7 Sterile Water Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 17478-050-01\n\n**Generic name:** Sufentanil Citrate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Not currently manufactured\n\n**Initial posting date:** 05/03/2022\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1582\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/03/2022\", \"package_ndc\": \"17478-050-01\", \"generic_name\": \"Sufentanil Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Not currently manufactured\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Sufentanil%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1582", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-sufentanil-citrate-injection-17478-050-01.md", "generated": true, "generic_name": "Sufentanil Citrate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-sufentanil-citrate-injection-17478-050-01", "initial_posting_date": "05/03/2022", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "17478-050-01", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Not currently manufactured", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"05/03/2022\", \"package_ndc\": \"17478-050-01\", \"generic_name\": \"Sufentanil Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Not currently manufactured\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Sufentanil%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "17478-050-01 \u00b7 Sufentanil Citrate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 17478-050-02\n\n**Generic name:** Sufentanil Citrate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Not currently manufactured\n\n**Initial posting date:** 05/03/2022\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1582\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/03/2022\", \"package_ndc\": \"17478-050-02\", \"generic_name\": \"Sufentanil Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Not currently manufactured\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Sufentanil%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1582", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-sufentanil-citrate-injection-17478-050-02.md", "generated": true, "generic_name": "Sufentanil Citrate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-sufentanil-citrate-injection-17478-050-02", "initial_posting_date": "05/03/2022", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "17478-050-02", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Not currently manufactured", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"05/03/2022\", \"package_ndc\": \"17478-050-02\", \"generic_name\": \"Sufentanil Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Not currently manufactured\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Sufentanil%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "17478-050-02 \u00b7 Sufentanil Citrate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 17478-050-05\n\n**Generic name:** Sufentanil Citrate Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Not currently manufactured\n\n**Initial posting date:** 05/03/2022\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1582\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/03/2022\", \"package_ndc\": \"17478-050-05\", \"generic_name\": \"Sufentanil Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Not currently manufactured\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Sufentanil%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1582", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-sufentanil-citrate-injection-17478-050-05.md", "generated": true, "generic_name": "Sufentanil Citrate Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-sufentanil-citrate-injection-17478-050-05", "initial_posting_date": "05/03/2022", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "17478-050-05", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Not currently manufactured", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"05/03/2022\", \"package_ndc\": \"17478-050-05\", \"generic_name\": \"Sufentanil Citrate Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Unavailable\", \"related_info\": \"Not currently manufactured\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Sufentanil%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "17478-050-05 \u00b7 Sufentanil Citrate Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0143-9785-10\n\n**Generic name:** Valproate Sodium Injection\n\n**Manufacturer:** Hikma Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Additional lots will be available. Product will be made available as it is released.\n\n**Initial posting date:** 12/30/2020\n\n**Last update date:** 08/13/2026\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2071\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/30/2020\", \"package_ndc\": \"0143-9785-10\", \"generic_name\": \"Valproate Sodium Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be available. Product will be made available as it is released.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Valproate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2071", "dosage_form": "Injection", "file": "hikma-pharmaceuticals-usa-inc-valproate-sodium-injection-0143-9785-10.md", "generated": true, "generic_name": "Valproate Sodium Injection", "harvested": "2026-09-01", "id": "hikma-pharmaceuticals-usa-inc-valproate-sodium-injection-0143-9785-10", "initial_posting_date": "12/30/2020", "manufacturer_name": "Hikma Pharmaceuticals USA, Inc.", "package_ndc": "0143-9785-10", "quote_dosage_form": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/13/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)\", \"company_name\": \"Hikma Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Additional lots will be available. Product will be made available as it is released.", "source_quote": "\"initial_posting_date\": \"12/30/2020\", \"package_ndc\": \"0143-9785-10\", \"generic_name\": \"Valproate Sodium Injection\", \"contact_info\": \"800-631-2174\", \"availability\": \"Available\", \"related_info\": \"Additional lots will be available. Product will be made available as it is released.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hikma%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Valproate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Neurology", "title": "0143-9785-10 \u00b7 Valproate Sodium Injection \u00b7 Hikma Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/13/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1630-10\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-1630-10\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-atropine-sulfate-injection-0409-1630-10.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-atropine-sulfate-injection-0409-1630-10", "initial_posting_date": "01/01/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1630-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-1630-10\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1630-10 \u00b7 Atropine Sulfate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-4910-34\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-4910-34\", \"generic_name\": \"Atropine Sulfate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Atropine+Sulfate+Injection&st=d&tab=tabs-2\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-atropine-sulfate-injection-0409-4910-34.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-atropine-sulfate-injection-0409-4910-34", "initial_posting_date": "01/01/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4910-34", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-4910-34\", \"generic_name\": \"Atropine Sulfate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Atropine+Sulfate+Injection&st=d&tab=tabs-2\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4910-34 \u00b7 Atropine Sulfate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-4911-34\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-4911-34\", \"generic_name\": \"Atropine Sulfate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Atropine+Sulfate+Injection&st=d&tab=tabs-2\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-atropine-sulfate-injection-0409-4911-34.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-atropine-sulfate-injection-0409-4911-34", "initial_posting_date": "01/01/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4911-34", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield\u00ae ABBOJECT\u00ae Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\\\"\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-4911-34\", \"generic_name\": \"Atropine Sulfate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Atropine+Sulfate+Injection&st=d&tab=tabs-2\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4911-34 \u00b7 Atropine Sulfate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-9630-05\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-9630-05\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-atropine-sulfate-injection-0409-9630-05.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-atropine-sulfate-injection-0409-9630-05", "initial_posting_date": "01/01/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-9630-05", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-9630-05\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-9630-05 \u00b7 Atropine Sulfate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1746-10\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1746-10\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-1746-10.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-1746-10", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1746-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1746-10\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1746-10 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1746-30\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1746-30\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-1746-30.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-1746-30", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1746-30", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1746-30\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1746-30 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1749-10\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1749-10\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-1749-10.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-1749-10", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1749-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1749-10\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1749-10 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1749-29\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1749-29\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-1749-29.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-1749-29", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1749-29", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1749-29\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1749-29 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1752-50\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1752-50\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-1752-50.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-1752-50", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1752-50", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1752-50\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1752-50 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1755-50\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1755-50\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-1755-50.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-1755-50", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1755-50", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1755-50\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1755-50 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-9042-01\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-9042-01\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-9042-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-9042-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-9042-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-9042-01\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-9042-01 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-9042-17\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-9042-17\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-9042-17.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-9042-17", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-9042-17", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-9042-17\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-9042-17 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-9043-01\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-9043-01\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-9043-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-9043-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-9043-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-9043-01\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-9043-01 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-9045-01\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-9045-01\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-9045-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-9045-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-9045-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-9045-01\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-9045-01 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-9045-17\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-9045-17\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-9045-17.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-9045-17", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-9045-17", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-9045-17\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-9045-17 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-9046-01\n\n**Generic name:** Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-9046-01\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-9046-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-epinephrine-bitartrate-injection-0409-9046-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-9046-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-9046-01\", \"generic_name\": \"Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride,%20Epinephrine%20Bitartrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-9046-01 \u00b7 Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-0525-25\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 250 mg/50 mL (NDC 0409-0525-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 250 mg/50 mL (NDC 0409-0525-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Historical NDC: 0409-1610-50\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/31/2026\n\n> \"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 250 mg/50 mL (NDC 0409-0525-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3117\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 250 mg/50 mL (NDC 0409-0525-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 250 mg/50 mL (NDC 0409-0525-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-0525-25\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"related_info\": \"Historical NDC: 0409-1610-50\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3117", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-0525-25.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-03", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-0525-25", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-0525-25", "quote_dosage_form": "\"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 250 mg/50 mL (NDC 0409-0525-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 250 mg/50 mL (NDC 0409-0525-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 250 mg/50 mL (NDC 0409-0525-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 250 mg/50 mL (NDC 0409-0525-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 250 mg/50 mL (NDC 0409-0525-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Historical NDC: 0409-1610-50", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-0525-25\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"related_info\": \"Historical NDC: 0409-1610-50\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-0525-25 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/31/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1159-01\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1159-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1159-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1159-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1159-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1159-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1159-01 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1159-02\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1159-02\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1159-02.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1159-02", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1159-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1159-02\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1159-02 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1159-10\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1159-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1159-10.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1159-10", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1159-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1159-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1159-10 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1160-01\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1160-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1160-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1160-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1160-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1160-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1160-01 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1162-01\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1162-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1162-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1162-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1162-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1162-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1162-01 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1162-02\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1162-02\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1162-02.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1162-02", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1162-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1162-02\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1162-02 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1163-01\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1163-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1163-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1163-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1163-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1163-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1163-01 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1165-01\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1165-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1165-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1165-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1165-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1165-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1165-01 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1165-02\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1165-02\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1165-02.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1165-02", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1165-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1165-02\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1165-02 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1530-01\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1530-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1530-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 09/11/2026\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1530-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3129\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1530-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1530-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1530-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3129", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1530-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1530-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1530-01", "quote_dosage_form": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1530-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1530-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1530-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1530-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1530-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1530-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1530-01 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/11/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1559-10\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Status:** Current\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Therapeutic category:** Anesthesia\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1559-10.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1559-10", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1559-10", "quote_dosage_form": "\"presentation\": \"Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_manufacturer_name": "\"presentation\": \"Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_status": "\"presentation\": \"Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_therapeutic_category": "\"presentation\": \"Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_update_date": "\"presentation\": \"Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1559-10 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1559-30\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Status:** Current\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Therapeutic category:** Anesthesia\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1559-30.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1559-30", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1559-30", "quote_dosage_form": "\"presentation\": \"Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_manufacturer_name": "\"presentation\": \"Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_status": "\"presentation\": \"Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_therapeutic_category": "\"presentation\": \"Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_update_date": "\"presentation\": \"Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1559-30\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1559-30 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1560-10\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Status:** Current\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Therapeutic category:** Anesthesia\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1560-10.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1560-10", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1560-10", "quote_dosage_form": "\"presentation\": \"Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_manufacturer_name": "\"presentation\": \"Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_status": "\"presentation\": \"Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_therapeutic_category": "\"presentation\": \"Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_update_date": "\"presentation\": \"Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1560-10 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1560-29\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-29\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Status:** Current\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-29\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-29\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-29\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Therapeutic category:** Anesthesia\n\n> \"presentation\": \"Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-29\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-29\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1560-29.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1560-29", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1560-29", "quote_dosage_form": "\"presentation\": \"Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-29\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_manufacturer_name": "\"presentation\": \"Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-29\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_status": "\"presentation\": \"Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-29\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_therapeutic_category": "\"presentation\": \"Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-29\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_update_date": "\"presentation\": \"Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-29\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1560-29\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1560-29 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1761-10\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3125\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1761-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3125", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1761-10-2.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-11", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1761-10-2", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1761-10", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1761-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1761-10 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1761-10\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: October 2026; Estimated Recovery: December 2026\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1761-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: October 2026; Estimated Recovery: December 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1761-10.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1761-10", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1761-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Next Delivery: October 2026; Estimated Recovery: December 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1761-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: October 2026; Estimated Recovery: December 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1761-10 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1761-62\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1761-62\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1761-62.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-1761-62", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1761-62", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-1761-62\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1761-62 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-2253-01\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-2253-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-2253-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Historical NDC: 0409-1582-29\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-2253-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-2253-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-2253-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-2253-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"related_info\": \"Historical NDC: 0409-1582-29\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-2253-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-2253-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2253-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-2253-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-2253-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-2253-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-2253-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-2253-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Historical NDC: 0409-1582-29", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-2253-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"related_info\": \"Historical NDC: 0409-1582-29\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-2253-01 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-2253-25\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 225 mg/30 mL (NDC 0409-2253-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 225 mg/30 mL (NDC 0409-2253-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Historical NDC: 0409-1582-29\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/31/2026\n\n> \"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 225 mg/30 mL (NDC 0409-2253-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3117\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 225 mg/30 mL (NDC 0409-2253-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 225 mg/30 mL (NDC 0409-2253-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-2253-25\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"related_info\": \"Historical NDC: 0409-1582-29\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3117", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-2253-25.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-03", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-2253-25", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2253-25", "quote_dosage_form": "\"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 225 mg/30 mL (NDC 0409-2253-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 225 mg/30 mL (NDC 0409-2253-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 225 mg/30 mL (NDC 0409-2253-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 225 mg/30 mL (NDC 0409-2253-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 225 mg/30 mL (NDC 0409-2253-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Historical NDC: 0409-1582-29", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-2253-25\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"related_info\": \"Historical NDC: 0409-1582-29\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-2253-25 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/31/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-2510-01\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-2510-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-2510-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 09/11/2026\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-2510-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3129\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-2510-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-2510-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-2510-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3129", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-2510-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-2510-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2510-01", "quote_dosage_form": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-2510-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-2510-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-2510-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-2510-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-2510-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-2510-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-2510-01 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/11/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-3613-01\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3125\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-3613-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3125", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-3613-01-2.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-11", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-3613-01-2", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3613-01", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-3613-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-3613-01 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-3613-01\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-3613-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-3613-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-3613-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3613-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-3613-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-3613-01 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-5010-01\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-5010-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-5010-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 09/11/2026\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-5010-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3129\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-5010-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-5010-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-5010-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3129", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-5010-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-5010-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-5010-01", "quote_dosage_form": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-5010-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-5010-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-5010-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-5010-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-5010-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-5010-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-5010-01 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/11/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-7535-01\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-7535-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-7535-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 09/11/2026\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-7535-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3129\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-7535-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-7535-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-7535-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3129", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-7535-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-bupivacaine-hydrochloride-injection-0409-7535-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-7535-01", "quote_dosage_form": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-7535-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-7535-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-7535-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-7535-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Marcaine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-7535-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"0409-7535-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-7535-01 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/11/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 61703-150-05\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-150-05\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-150-05.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-150-05", "initial_posting_date": "04/28/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "61703-150-05", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-150-05\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Oncology", "title": "61703-150-05 \u00b7 Carboplatin Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 61703-262-05\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-262-05\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-262-05.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-262-05", "initial_posting_date": "04/28/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "61703-262-05", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-262-05\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Oncology", "title": "61703-262-05 \u00b7 Carboplatin Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 61703-339-18\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: February 2027; Estimated Recovery: March 2027\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-339-18\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: February 2027; Estimated Recovery: March 2027\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-339-18.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-339-18", "initial_posting_date": "04/28/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "61703-339-18", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Limited Supply Available. Next Delivery: February 2027; Estimated Recovery: March 2027", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-339-18\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: February 2027; Estimated Recovery: March 2027\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Oncology", "title": "61703-339-18 \u00b7 Carboplatin Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 61703-339-22\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1236\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-339-22\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1236", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-339-22-2.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-339-22-2", "initial_posting_date": "04/28/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "61703-339-22", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-339-22\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Oncology", "title": "61703-339-22 \u00b7 Carboplatin Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 61703-339-22\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-339-22\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-339-22.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-339-22", "initial_posting_date": "04/28/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "61703-339-22", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-339-22\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "61703-339-22 \u00b7 Carboplatin Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 61703-339-50\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-339-50\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-339-50.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-339-50", "initial_posting_date": "04/28/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "61703-339-50", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-339-50\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Oncology", "title": "61703-339-50 \u00b7 Carboplatin Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 61703-339-56\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-339-56\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-339-56.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-339-56", "initial_posting_date": "04/28/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "61703-339-56", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-339-56\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Oncology", "title": "61703-339-56 \u00b7 Carboplatin Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 61703-360-18\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-360-18\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-360-18.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-360-18", "initial_posting_date": "04/28/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "61703-360-18", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-360-18\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Oncology", "title": "61703-360-18 \u00b7 Carboplatin Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 61703-600-05\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-600-05\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-600-05.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-carboplatin-injection-61703-600-05", "initial_posting_date": "04/28/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "61703-600-05", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"61703-600-05\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Oncology", "title": "61703-600-05 \u00b7 Carboplatin Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-4902-34\n\n**Generic name:** Dextrose Monohydrate 50% Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/13/2022\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1692\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/13/2022\", \"package_ndc\": \"0409-4902-34\", \"generic_name\": \"Dextrose Monohydrate 50% Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dextrose%20Monohydrate%2050per%20Injection&st=d\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2050%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1692", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dextrose-monohydrate-50-injection-0409-4902-34.md", "generated": true, "generic_name": "Dextrose Monohydrate 50% Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-dextrose-monohydrate-50-injection-0409-4902-34", "initial_posting_date": "01/13/2022", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4902-34", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/13/2022\", \"package_ndc\": \"0409-4902-34\", \"generic_name\": \"Dextrose Monohydrate 50% Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dextrose%20Monohydrate%2050per%20Injection&st=d\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2050%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-4902-34 \u00b7 Dextrose Monohydrate 50% Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-6648-02\n\n**Generic name:** Dextrose Monohydrate 50% Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Next Delivery: November 2026; Estimated Recovery: December 2026. Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 01/13/2022\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1692\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/13/2022\", \"package_ndc\": \"0409-6648-02\", \"generic_name\": \"Dextrose Monohydrate 50% Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Next Delivery: November 2026; Estimated Recovery: December 2026. Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2050%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1692", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dextrose-monohydrate-50-injection-0409-6648-02.md", "generated": true, "generic_name": "Dextrose Monohydrate 50% Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-dextrose-monohydrate-50-injection-0409-6648-02", "initial_posting_date": "01/13/2022", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-6648-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Next Delivery: November 2026; Estimated Recovery: December 2026. Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"01/13/2022\", \"package_ndc\": \"0409-6648-02\", \"generic_name\": \"Dextrose Monohydrate 50% Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Next Delivery: November 2026; Estimated Recovery: December 2026. Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2050%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-6648-02 \u00b7 Dextrose Monohydrate 50% Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-7517-16\n\n**Generic name:** Dextrose Monohydrate 50% Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/13/2022\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1692\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/13/2022\", \"package_ndc\": \"0409-7517-16\", \"generic_name\": \"Dextrose Monohydrate 50% Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2050%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1692", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dextrose-monohydrate-50-injection-0409-7517-16.md", "generated": true, "generic_name": "Dextrose Monohydrate 50% Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-dextrose-monohydrate-50-injection-0409-7517-16", "initial_posting_date": "01/13/2022", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-7517-16", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"01/13/2022\", \"package_ndc\": \"0409-7517-16\", \"generic_name\": \"Dextrose Monohydrate 50% Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2050%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-7517-16 \u00b7 Dextrose Monohydrate 50% Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-0025-10\n\n**Generic name:** Dobutamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-0025-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-0025-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 09/11/2026\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-0025-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3235\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-0025-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-0025-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-0025-10\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3235", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-0025-10.md", "generated": true, "generic_name": "Dobutamine Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-0025-10", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-0025-10", "quote_dosage_form": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-0025-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-0025-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-0025-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-0025-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-0025-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-0025-10\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-0025-10 \u00b7 Dobutamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/11/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-0151-10\n\n**Generic name:** Dobutamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-0151-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-0151-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 09/11/2026\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-0151-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3235\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-0151-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-0151-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-0151-10\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3235", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-0151-10.md", "generated": true, "generic_name": "Dobutamine Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-0151-10", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-0151-10", "quote_dosage_form": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-0151-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-0151-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-0151-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-0151-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-0151-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-0151-10\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-0151-10 \u00b7 Dobutamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/11/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1100-10\n\n**Generic name:** Dobutamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-1100-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-1100-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 09/11/2026\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-1100-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3235\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-1100-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-1100-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-1100-10\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3235", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-1100-10.md", "generated": true, "generic_name": "Dobutamine Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-1100-10", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1100-10", "quote_dosage_form": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-1100-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-1100-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-1100-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-1100-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-1100-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-1100-10\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-1100-10 \u00b7 Dobutamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/11/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-2344-01\n\n**Generic name:** Dobutamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2344-01\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-2344-01.md", "generated": true, "generic_name": "Dobutamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-2344-01", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2344-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2344-01\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-2344-01 \u00b7 Dobutamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-2344-02\n\n**Generic name:** Dobutamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2344-02\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-2344-02.md", "generated": true, "generic_name": "Dobutamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-2344-02", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2344-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2344-02\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-2344-02 \u00b7 Dobutamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-2344-88\n\n**Generic name:** Dobutamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2344-88\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-2344-88.md", "generated": true, "generic_name": "Dobutamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-2344-88", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2344-88", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2344-88\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-2344-88 \u00b7 Dobutamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-2346-32\n\n**Generic name:** Dobutamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2346-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Status:** Current\n\n> \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2346-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/24/2026\n\n> \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2346-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Days in shortage:** 3221\n\n**Dosage form:** Injection\n\n> \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2346-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2346-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2346-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-2346-32.md", "generated": true, "generic_name": "Dobutamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-2346-32", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2346-32", "quote_dosage_form": "\"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2346-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_manufacturer_name": "\"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2346-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_status": "\"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2346-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_therapeutic_category": "\"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2346-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_update_date": "\"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2346-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2346-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-2346-32 \u00b7 Dobutamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-2347-32\n\n**Generic name:** Dobutamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2347-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Status:** Current\n\n> \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2347-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/24/2026\n\n> \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2347-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Days in shortage:** 3221\n\n**Dosage form:** Injection\n\n> \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2347-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2347-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2347-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-2347-32.md", "generated": true, "generic_name": "Dobutamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-2347-32", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2347-32", "quote_dosage_form": "\"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2347-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_manufacturer_name": "\"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2347-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_status": "\"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2347-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_therapeutic_category": "\"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2347-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_update_date": "\"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2347-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-2347-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-2347-32 \u00b7 Dobutamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-3724-32\n\n**Generic name:** Dobutamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-3724-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Status:** Current\n\n> \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-3724-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/24/2026\n\n> \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-3724-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Days in shortage:** 3221\n\n**Dosage form:** Injection\n\n> \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-3724-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-3724-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-3724-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-3724-32.md", "generated": true, "generic_name": "Dobutamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-dobutamine-hydrochloride-injection-0409-3724-32", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3724-32", "quote_dosage_form": "\"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-3724-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_manufacturer_name": "\"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-3724-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_status": "\"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-3724-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_therapeutic_category": "\"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-3724-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_update_date": "\"presentation\": \"Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-3724-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\", \"Pediatric\", \"Renal\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-3724-32\", \"generic_name\": \"Dobutamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dobutamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-3724-32 \u00b7 Dobutamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-0042-12\n\n**Generic name:** Dopamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-0042-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-0042-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 09/11/2026\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-0042-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3235\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-0042-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-0042-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-0042-12\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3235", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dopamine-hydrochloride-injection-0409-0042-12.md", "generated": true, "generic_name": "Dopamine Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-dopamine-hydrochloride-injection-0409-0042-12", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-0042-12", "quote_dosage_form": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-0042-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-0042-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-0042-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-0042-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-0042-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-0042-12\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-0042-12 \u00b7 Dopamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/11/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1858-12\n\n**Generic name:** Dopamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-1858-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-1858-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 09/11/2026\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-1858-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3235\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-1858-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-1858-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-1858-12\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3235", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dopamine-hydrochloride-injection-0409-1858-12.md", "generated": true, "generic_name": "Dopamine Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-dopamine-hydrochloride-injection-0409-1858-12", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1858-12", "quote_dosage_form": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-1858-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-1858-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-1858-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-1858-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-1858-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-1858-12\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-1858-12 \u00b7 Dopamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/11/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-5820-01\n\n**Generic name:** Dopamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 09/11/2026\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3235\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-5820-01\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3235", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dopamine-hydrochloride-injection-0409-5820-01-2.md", "generated": true, "generic_name": "Dopamine Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-dopamine-hydrochloride-injection-0409-5820-01-2", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-5820-01", "quote_dosage_form": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-5820-01\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-5820-01 \u00b7 Dopamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/11/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-5820-01\n\n**Generic name:** Dopamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-5820-01\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dopamine-hydrochloride-injection-0409-5820-01.md", "generated": true, "generic_name": "Dopamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-dopamine-hydrochloride-injection-0409-5820-01", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-5820-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-5820-01\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-5820-01 \u00b7 Dopamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-7809-22\n\n**Generic name:** Dopamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-7809-22\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dopamine-hydrochloride-injection-0409-7809-22.md", "generated": true, "generic_name": "Dopamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-dopamine-hydrochloride-injection-0409-7809-22", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-7809-22", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-7809-22\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-7809-22 \u00b7 Dopamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-7809-24\n\n**Generic name:** Dopamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-7809-24\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dopamine-hydrochloride-injection-0409-7809-24.md", "generated": true, "generic_name": "Dopamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-dopamine-hydrochloride-injection-0409-7809-24", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-7809-24", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-7809-24\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-7809-24 \u00b7 Dopamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-7810-22\n\n**Generic name:** Dopamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-7810-22\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Status:** Current\n\n> \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-7810-22\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/24/2026\n\n> \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-7810-22\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Days in shortage:** 3221\n\n**Dosage form:** Injection\n\n> \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-7810-22\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-7810-22\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-7810-22\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dopamine-hydrochloride-injection-0409-7810-22.md", "generated": true, "generic_name": "Dopamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-dopamine-hydrochloride-injection-0409-7810-22", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-7810-22", "quote_dosage_form": "\"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-7810-22\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_manufacturer_name": "\"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-7810-22\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_status": "\"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-7810-22\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_therapeutic_category": "\"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-7810-22\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_update_date": "\"presentation\": \"Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-7810-22\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-7810-22\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-7810-22 \u00b7 Dopamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-9104-20\n\n**Generic name:** Dopamine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/06/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3221\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-9104-20\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3221", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-dopamine-hydrochloride-injection-0409-9104-20.md", "generated": true, "generic_name": "Dopamine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-dopamine-hydrochloride-injection-0409-9104-20", "initial_posting_date": "11/06/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-9104-20", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"11/06/2017\", \"package_ndc\": \"0409-9104-20\", \"generic_name\": \"Dopamine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Dopamine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-9104-20 \u00b7 Dopamine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1209-01\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-1209-01\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-1209-01.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-1209-01", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1209-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-1209-01\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1209-01 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-3177-01\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3177-01\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3177-01.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3177-01", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3177-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3177-01\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-3177-01 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-3178-01\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3178-01\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3178-01.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3178-01", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3178-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3178-01\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-3178-01 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-3178-02\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 5315\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3178-02\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5315", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3178-02-2.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-11", "id": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3178-02-2", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3178-02", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3178-02\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-3178-02 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-3178-02\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: November 2026; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3178-02\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: November 2026; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3178-02.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3178-02", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3178-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Next Delivery: November 2026; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3178-02\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: November 2026; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-3178-02 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-3178-03\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3178-03\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3178-03.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3178-03", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3178-03", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3178-03\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-3178-03 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-3181-01\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3181-01\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3181-01.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3181-01", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3181-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3181-01\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-3181-01 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-3182-01\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3182-01\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3182-01.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3182-01", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3182-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3182-01\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-3182-01 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-3182-02\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: May 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3182-02\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: May 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3182-02.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3182-02", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3182-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Limited Supply Available. Next Delivery: May 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3182-02\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: May 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-3182-02 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-3182-03\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: May 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 5315\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3182-03\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: May 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5315", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3182-03-2.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-11", "id": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3182-03-2", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3182-03", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Limited Supply Available. Next Delivery: May 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3182-03\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: May 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-3182-03 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-3182-03\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: April 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3182-03\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: April 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3182-03.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3182-03", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3182-03", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Limited Supply Available. Next Delivery: April 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3182-03\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: April 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-3182-03 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-3183-01\n\n**Generic name:** Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3183-01\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3183-01.md", "generated": true, "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-epinephrine-bitartrate-lidocaine-hydrochloride-injection-0409-3183-01", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3183-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-3183-01\", \"generic_name\": \"Epinephrine Bitartrate, Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Epinephrine%20Bitartrate,%20Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-3183-01 \u00b7 Epinephrine Bitartrate, Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-6695-01\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"0409-6695-01\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-etomidate-injection-0409-6695-01.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-etomidate-injection-0409-6695-01", "initial_posting_date": "10/05/2022", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-6695-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"0409-6695-01\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-6695-01 \u00b7 Etomidate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-6695-02\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: November 2026; Estimated Recovery: December 2026. Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"0409-6695-02\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: November 2026; Estimated Recovery: December 2026. Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-etomidate-injection-0409-6695-02.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-etomidate-injection-0409-6695-02", "initial_posting_date": "10/05/2022", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-6695-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Next Delivery: November 2026; Estimated Recovery: December 2026. Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"0409-6695-02\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: November 2026; Estimated Recovery: December 2026. Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-6695-02 \u00b7 Etomidate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-9094-22\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-9094-22\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-fentanyl-citrate-injection-0409-9094-22.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-fentanyl-citrate-injection-0409-9094-22", "initial_posting_date": "01/01/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-9094-22", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-9094-22\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-9094-22 \u00b7 Fentanyl Citrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-9094-25\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-9094-25\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-fentanyl-citrate-injection-0409-9094-25.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-fentanyl-citrate-injection-0409-9094-25", "initial_posting_date": "01/01/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-9094-25", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-9094-25\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-9094-25 \u00b7 Fentanyl Citrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-9094-28\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-9094-28\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-fentanyl-citrate-injection-0409-9094-28.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-fentanyl-citrate-injection-0409-9094-28", "initial_posting_date": "01/01/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-9094-28", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-9094-28\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-9094-28 \u00b7 Fentanyl Citrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-9094-31\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 5371\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-9094-31\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5371", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-fentanyl-citrate-injection-0409-9094-31-2.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-fentanyl-citrate-injection-0409-9094-31-2", "initial_posting_date": "01/01/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-9094-31", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-9094-31\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-9094-31 \u00b7 Fentanyl Citrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-9094-31\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-9094-31\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-fentanyl-citrate-injection-0409-9094-31.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-fentanyl-citrate-injection-0409-9094-31", "initial_posting_date": "01/01/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-9094-31", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-9094-31\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-9094-31 \u00b7 Fentanyl Citrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-9094-61\n\n**Generic name:** Fentanyl Citrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-9094-61\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-fentanyl-citrate-injection-0409-9094-61.md", "generated": true, "generic_name": "Fentanyl Citrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-fentanyl-citrate-injection-0409-9094-61", "initial_posting_date": "01/01/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-9094-61", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"0409-9094-61\", \"generic_name\": \"Fentanyl Citrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Fentanyl%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-9094-61 \u00b7 Fentanyl Citrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-6102-02\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"0409-6102-02\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-furosemide-injection-0409-6102-02.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-furosemide-injection-0409-6102-02", "initial_posting_date": "04/07/2020", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-6102-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"0409-6102-02\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-6102-02 \u00b7 Furosemide Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-6102-04\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"0409-6102-04\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-furosemide-injection-0409-6102-04.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-furosemide-injection-0409-6102-04", "initial_posting_date": "04/07/2020", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-6102-04", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"0409-6102-04\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-6102-04 \u00b7 Furosemide Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-6102-10\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"0409-6102-10\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-furosemide-injection-0409-6102-10.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-furosemide-injection-0409-6102-10", "initial_posting_date": "04/07/2020", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-6102-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"0409-6102-10\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-6102-10 \u00b7 Furosemide Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-6102-25\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"0409-6102-25\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-furosemide-injection-0409-6102-25.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-furosemide-injection-0409-6102-25", "initial_posting_date": "04/07/2020", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-6102-25", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"0409-6102-25\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-6102-25 \u00b7 Furosemide Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-6102-26\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"0409-6102-26\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-furosemide-injection-0409-6102-26.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-furosemide-injection-0409-6102-26", "initial_posting_date": "04/07/2020", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-6102-26", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"0409-6102-26\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-6102-26 \u00b7 Furosemide Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-6102-27\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"0409-6102-27\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-furosemide-injection-0409-6102-27.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-furosemide-injection-0409-6102-27", "initial_posting_date": "04/07/2020", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-6102-27", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"0409-6102-27\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0409-6102-27 \u00b7 Furosemide Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1005-20\n\n**Generic name:** Heparin Sodium Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-1005-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-1005-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/14/2017\n\n**Last update date:** 09/11/2026\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-1005-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-1005-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Hematology\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-1005-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-1005-20\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-heparin-sodium-injection-0409-1005-20.md", "generated": true, "generic_name": "Heparin Sodium Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-heparin-sodium-injection-0409-1005-20", "initial_posting_date": "11/14/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1005-20", "quote_dosage_form": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-1005-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-1005-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-1005-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-1005-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-1005-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-1005-20\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Hematology", "title": "0409-1005-20 \u00b7 Heparin Sodium Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/11/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-2222-12\n\n**Generic name:** Heparin Sodium Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-2222-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-2222-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/14/2017\n\n**Last update date:** 09/11/2026\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-2222-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-2222-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Hematology\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-2222-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-2222-12\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-heparin-sodium-injection-0409-2222-12.md", "generated": true, "generic_name": "Heparin Sodium Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-heparin-sodium-injection-0409-2222-12", "initial_posting_date": "11/14/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2222-12", "quote_dosage_form": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-2222-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-2222-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-2222-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-2222-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-2222-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-2222-12\", \"generic_name\": \"Heparin Sodium Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Hematology", "title": "0409-2222-12 \u00b7 Heparin Sodium Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/11/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-7620-03\n\n**Generic name:** Heparin Sodium Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-03\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Status:** Current\n\n> \"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-03\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/14/2017\n\n**Last update date:** 08/24/2026\n\n> \"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-03\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Days in shortage:** 3213\n\n**Dosage form:** Injection\n\n> \"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-03\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Therapeutic category:** Hematology\n\n> \"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-03\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n> \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-03\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3213", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-heparin-sodium-injection-0409-7620-03.md", "generated": true, "generic_name": "Heparin Sodium Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-heparin-sodium-injection-0409-7620-03", "initial_posting_date": "11/14/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-7620-03", "quote_dosage_form": "\"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-03\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_manufacturer_name": "\"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-03\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_status": "\"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-03\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_therapeutic_category": "\"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-03\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_update_date": "\"presentation\": \"Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-03\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-03\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Hematology", "title": "0409-7620-03 \u00b7 Heparin Sodium Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-7620-59\n\n**Generic name:** Heparin Sodium Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-59\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Status:** Current\n\n> \"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-59\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/14/2017\n\n**Last update date:** 08/24/2026\n\n> \"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-59\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Days in shortage:** 3213\n\n**Dosage form:** Injection\n\n> \"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-59\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n**Therapeutic category:** Hematology\n\n> \"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-59\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"\n\n> \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-59\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3213", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-heparin-sodium-injection-0409-7620-59.md", "generated": true, "generic_name": "Heparin Sodium Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-heparin-sodium-injection-0409-7620-59", "initial_posting_date": "11/14/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-7620-59", "quote_dosage_form": "\"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-59\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_manufacturer_name": "\"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-59\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_status": "\"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-59\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_therapeutic_category": "\"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-59\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "quote_update_date": "\"presentation\": \"Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)\", \"update_type\": \"Reverified\", \"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-59\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\", \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Hematology\" ], \"status\": \"Current\", \"dosage_form\": \"Injection\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"11/14/2017\", \"package_ndc\": \"0409-7620-59\", \"generic_name\": \"Heparin Sodium Injection\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Heparin%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Hematology", "title": "0409-7620-59 \u00b7 Heparin Sodium Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1283-31\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1283-31\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-1283-31.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-1283-31", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1283-31", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1283-31\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1283-31 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1283-37\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3241\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1283-37\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3241", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-1283-37-2.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-1283-37-2", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1283-37", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1283-37\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1283-37 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1283-37\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1283-37\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-1283-37.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-1283-37", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1283-37", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1283-37\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1283-37 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1304-31\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1304-31\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-1304-31.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-1304-31", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1304-31", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1304-31\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1304-31 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1312-30\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1312-30\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-1312-30.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-1312-30", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1312-30", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1312-30\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1312-30 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-1312-36\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1312-36\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-1312-36.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-1312-36", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1312-36", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1312-36\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1312-36 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1805-01\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 11/01/2017\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3240\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0409-1805-01\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3240", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-1805-01-2.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-1805-01-2", "initial_posting_date": "11/01/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1805-01", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0409-1805-01\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1805-01 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1805-01\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 11/01/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3226\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0409-1805-01\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3226", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-1805-01.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-1805-01", "initial_posting_date": "11/01/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1805-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0409-1805-01\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1805-01 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-2634-01\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-2634-01\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-2634-01.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-2634-01", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2634-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-2634-01\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-2634-01 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-2634-05\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-2634-05\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-2634-05.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-2634-05", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2634-05", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-2634-05\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-2634-05 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-2634-50\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-2634-50\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-2634-50.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-2634-50", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2634-50", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-2634-50\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-2634-50 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-3365-10\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-3365-10\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-3365-10.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-3365-10", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3365-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-3365-10\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-3365-10 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: December 2026", "body": "**Package NDC:** 0409-4264-01\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: December 2026\n\n**FDA note:** Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 11/01/2017\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3240\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0409-4264-01\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: December 2026\", \"related_info\": \"Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3240", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-4264-01-2.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-4264-01-2", "initial_posting_date": "11/01/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4264-01", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0409-4264-01\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: December 2026\", \"related_info\": \"Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-4264-01 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-4264-01\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 11/01/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3226\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0409-4264-01\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3226", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-4264-01.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-hydromorphone-hydrochloride-injection-0409-4264-01", "initial_posting_date": "11/01/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4264-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect\u2122 Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0409-4264-01\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-4264-01 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-3793-01\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 03/26/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3081\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/26/2018\", \"package_ndc\": \"0409-3793-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3081", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-ketorolac-tromethamine-injection-0409-3793-01.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-ketorolac-tromethamine-injection-0409-3793-01", "initial_posting_date": "03/26/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3793-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/26/2018\", \"package_ndc\": \"0409-3793-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-3793-01 \u00b7 Ketorolac Tromethamine Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-3795-01\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 03/26/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3081\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/26/2018\", \"package_ndc\": \"0409-3795-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3081", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-ketorolac-tromethamine-injection-0409-3795-01.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-ketorolac-tromethamine-injection-0409-3795-01", "initial_posting_date": "03/26/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3795-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/26/2018\", \"package_ndc\": \"0409-3795-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-3795-01 \u00b7 Ketorolac Tromethamine Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-3796-01\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Estimated Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 03/26/2018\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3095\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/26/2018\", \"package_ndc\": \"0409-3796-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Estimated Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3095", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-ketorolac-tromethamine-injection-0409-3796-01-2.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-ketorolac-tromethamine-injection-0409-3796-01-2", "initial_posting_date": "03/26/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3796-01", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next Estimated Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/26/2018\", \"package_ndc\": \"0409-3796-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Estimated Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-3796-01 \u00b7 Ketorolac Tromethamine Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-3796-01\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 03/26/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3081\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/26/2018\", \"package_ndc\": \"0409-3796-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3081", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-ketorolac-tromethamine-injection-0409-3796-01.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-ketorolac-tromethamine-injection-0409-3796-01", "initial_posting_date": "03/26/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3796-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/26/2018\", \"package_ndc\": \"0409-3796-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-3796-01 \u00b7 Ketorolac Tromethamine Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1323-05\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-1323-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-1323-05.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-1323-05", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1323-05", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-1323-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1323-05 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-2066-05\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-2066-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-2066-05.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-2066-05", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2066-05", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-2066-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-2066-05 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-4275-01\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4275-01\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4275-01.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4275-01", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4275-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4275-01\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4275-01 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4276-01\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4276-01\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4276-01.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4276-01", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4276-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4276-01\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4276-01 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4276-02\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4276-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4276-02.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4276-02", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4276-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4276-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4276-02 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4277-01\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4277-01\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4277-01.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4277-01", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4277-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4277-01\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4277-01 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4277-02\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4277-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4277-02.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4277-02", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4277-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4277-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4277-02 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4278-01\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4278-01\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4278-01.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4278-01", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4278-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4278-01\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4278-01 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4279-02\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4279-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4279-02.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4279-02", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4279-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4279-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4279-02 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4282-01\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4282-01\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4282-01.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4282-01", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4282-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4282-01\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4282-01 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4282-02\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4282-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4282-02.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4282-02", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4282-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4282-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4282-02 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4283-01\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4283-01\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4283-01.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4283-01", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4283-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4283-01\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4283-01 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4713-02\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4713-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4713-02.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4713-02", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4713-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4713-02\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4713-02 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4713-32\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4713-32\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4713-32.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4713-32", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4713-32", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4713-32\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4713-32 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4776-01\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4776-01\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4776-01.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4776-01", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4776-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4776-01\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4776-01 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-4903-34\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4903-34\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lidocaine%20Hydrochloride%20Injection&st=d\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4903-34.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4903-34", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4903-34", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4903-34\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lidocaine%20Hydrochloride%20Injection&st=d\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4903-34 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-4904-34\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4904-34\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lidocaine%20Hydrochloride%20Injection&st=d\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4904-34.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-4904-34", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4904-34", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-4904-34\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lidocaine%20Hydrochloride%20Injection&st=d\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4904-34 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-9137-05\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/22/2012\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 5305\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-9137-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5305", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-9137-05.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lidocaine-hydrochloride-injection-0409-9137-05", "initial_posting_date": "02/22/2012", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-9137-05", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-11", "source_quote": "\"initial_posting_date\": \"02/22/2012\", \"package_ndc\": \"0409-9137-05\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-9137-05 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-1985-30\n\n**Generic name:** Lorazepam Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery and Estimated Recovery: September 2026\n\n**Initial posting date:** 05/03/2018\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3057\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/03/2018\", \"package_ndc\": \"0409-1985-30\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3057", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lorazepam-injection-0409-1985-30-2.md", "generated": true, "generic_name": "Lorazepam Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-lorazepam-injection-0409-1985-30-2", "initial_posting_date": "05/03/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1985-30", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: September 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"05/03/2018\", \"package_ndc\": \"0409-1985-30\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Neurology", "title": "0409-1985-30 \u00b7 Lorazepam Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-1985-30\n\n**Generic name:** Lorazepam Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 05/03/2018\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3043\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/03/2018\", \"package_ndc\": \"0409-1985-30\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3043", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-lorazepam-injection-0409-1985-30.md", "generated": true, "generic_name": "Lorazepam Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-lorazepam-injection-0409-1985-30", "initial_posting_date": "05/03/2018", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1985-30", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"05/03/2018\", \"package_ndc\": \"0409-1985-30\", \"generic_name\": \"Lorazepam Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Lorazepam%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "0409-1985-30 \u00b7 Lorazepam Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1176-30\n\n**Generic name:** Meperidine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 05/30/2025\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 473\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0409-1176-30\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "473", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-meperidine-hydrochloride-injection-0409-1176-30-2.md", "generated": true, "generic_name": "Meperidine Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-meperidine-hydrochloride-injection-0409-1176-30-2", "initial_posting_date": "05/30/2025", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1176-30", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0409-1176-30\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1176-30 \u00b7 Meperidine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-1176-30\n\n**Generic name:** Meperidine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 05/30/2025\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 459\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0409-1176-30\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "459", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-meperidine-hydrochloride-injection-0409-1176-30.md", "generated": true, "generic_name": "Meperidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-meperidine-hydrochloride-injection-0409-1176-30", "initial_posting_date": "05/30/2025", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1176-30", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0409-1176-30\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1176-30 \u00b7 Meperidine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1178-30\n\n**Generic name:** Meperidine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 05/30/2025\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 459\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0409-1178-30\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "459", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-meperidine-hydrochloride-injection-0409-1178-30.md", "generated": true, "generic_name": "Meperidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-meperidine-hydrochloride-injection-0409-1178-30", "initial_posting_date": "05/30/2025", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1178-30", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0409-1178-30\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1178-30 \u00b7 Meperidine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1179-30\n\n**Generic name:** Meperidine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 05/30/2025\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 459\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0409-1179-30\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "459", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-meperidine-hydrochloride-injection-0409-1179-30.md", "generated": true, "generic_name": "Meperidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-meperidine-hydrochloride-injection-0409-1179-30", "initial_posting_date": "05/30/2025", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1179-30", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0409-1179-30\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1179-30 \u00b7 Meperidine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1180-69\n\n**Generic name:** Meperidine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 05/30/2025\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 459\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0409-1180-69\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "459", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-meperidine-hydrochloride-injection-0409-1180-69.md", "generated": true, "generic_name": "Meperidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-meperidine-hydrochloride-injection-0409-1180-69", "initial_posting_date": "05/30/2025", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1180-69", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0409-1180-69\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1180-69 \u00b7 Meperidine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1181-30\n\n**Generic name:** Meperidine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 05/30/2025\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 459\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0409-1181-30\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "459", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-meperidine-hydrochloride-injection-0409-1181-30.md", "generated": true, "generic_name": "Meperidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-meperidine-hydrochloride-injection-0409-1181-30", "initial_posting_date": "05/30/2025", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1181-30", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0409-1181-30\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1181-30 \u00b7 Meperidine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1362-01\n\n**Generic name:** Meperidine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 05/30/2025\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 459\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0409-1362-01\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "459", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-meperidine-hydrochloride-injection-0409-1362-01.md", "generated": true, "generic_name": "Meperidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-meperidine-hydrochloride-injection-0409-1362-01", "initial_posting_date": "05/30/2025", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1362-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0409-1362-01\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1362-01 \u00b7 Meperidine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1418-01\n\n**Generic name:** Meperidine Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 05/30/2025\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 459\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0409-1418-01\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "459", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-meperidine-hydrochloride-injection-0409-1418-01.md", "generated": true, "generic_name": "Meperidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-meperidine-hydrochloride-injection-0409-1418-01", "initial_posting_date": "05/30/2025", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1418-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"05/30/2025\", \"package_ndc\": \"0409-1418-01\", \"generic_name\": \"Meperidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Meperidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1418-01 \u00b7 Meperidine Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 61703-124-40\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1268\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"61703-124-40\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1268", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-methotrexate-sodium-injection-61703-124-40.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-methotrexate-sodium-injection-61703-124-40", "initial_posting_date": "03/13/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "61703-124-40", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"61703-124-40\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "61703-124-40 \u00b7 Methotrexate Sodium Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 61703-350-10\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1268\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"61703-350-10\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1268", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-methotrexate-sodium-injection-61703-350-10.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-methotrexate-sodium-injection-61703-350-10", "initial_posting_date": "03/13/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "61703-350-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"61703-350-10\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "61703-350-10 \u00b7 Methotrexate Sodium Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 61703-350-38\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1268\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"61703-350-38\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1268", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-methotrexate-sodium-injection-61703-350-38.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-methotrexate-sodium-injection-61703-350-38", "initial_posting_date": "03/13/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "61703-350-38", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"61703-350-38\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "61703-350-38 \u00b7 Methotrexate Sodium Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 61703-408-25\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1268\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"61703-408-25\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1268", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-methotrexate-sodium-injection-61703-408-25.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-methotrexate-sodium-injection-61703-408-25", "initial_posting_date": "03/13/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "61703-408-25", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"61703-408-25\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "61703-408-25 \u00b7 Methotrexate Sodium Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 61703-408-41\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1268\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"61703-408-41\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1268", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-methotrexate-sodium-injection-61703-408-41.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-methotrexate-sodium-injection-61703-408-41", "initial_posting_date": "03/13/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "61703-408-41", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"61703-408-41\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "61703-408-41 \u00b7 Methotrexate Sodium Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-0001-25\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2026\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 09/11/2026\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2357\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-0001-25\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2357", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-0001-25.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-0001-25", "initial_posting_date": "04/02/2020", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-0001-25", "quote_dosage_form": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-0001-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next Delivery and Estimated Recovery: December 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-0001-25\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-0001-25 \u00b7 Midazolam Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/11/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-2305-05\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: October 2026; Estimated Recovery: December 2026\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2305-05\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: October 2026; Estimated Recovery: December 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2305-05.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2305-05", "initial_posting_date": "04/02/2020", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2305-05", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery: October 2026; Estimated Recovery: December 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2305-05\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: October 2026; Estimated Recovery: December 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-2305-05 \u00b7 Midazolam Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-2305-17\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Next Estimated Delivery and Estimated Recovery: December 2026\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2357\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2305-17\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Next Estimated Delivery and Estimated Recovery: December 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2357", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2305-17-2.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2305-17-2", "initial_posting_date": "04/02/2020", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2305-17", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next Estimated Delivery and Estimated Recovery: December 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2305-17\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Next Estimated Delivery and Estimated Recovery: December 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-2305-17 \u00b7 Midazolam Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-2305-17\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2026\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2305-17\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2305-17.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2305-17", "initial_posting_date": "04/02/2020", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2305-17", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Next Delivery and Estimated Recovery: December 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2305-17\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-2305-17 \u00b7 Midazolam Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-2308-01\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2026\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2308-01\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2308-01.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2308-01", "initial_posting_date": "04/02/2020", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2308-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery and Estimated Recovery: December 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2308-01\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-2308-01 \u00b7 Midazolam Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-2308-02\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: September 2026\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2308-02\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2308-02.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2308-02", "initial_posting_date": "04/02/2020", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2308-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery and Estimated Recovery: September 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2308-02\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-2308-02 \u00b7 Midazolam Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-2587-05\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2026\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2587-05\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2587-05.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2587-05", "initial_posting_date": "04/02/2020", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2587-05", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery and Estimated Recovery: December 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2587-05\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-2587-05 \u00b7 Midazolam Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-2596-03\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: September 2026\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2357\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2596-03\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2357", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2596-03-2.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2596-03-2", "initial_posting_date": "04/02/2020", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2596-03", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next Delivery and Estimated Recovery: September 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2596-03\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-2596-03 \u00b7 Midazolam Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-2596-03\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2596-03\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2596-03.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2596-03", "initial_posting_date": "04/02/2020", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2596-03", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2596-03\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-2596-03 \u00b7 Midazolam Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-2596-05\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2596-05\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2596-05.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-midazolam-hydrochloride-injection-0409-2596-05", "initial_posting_date": "04/02/2020", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2596-05", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"0409-2596-05\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-2596-05 \u00b7 Midazolam Hydrochloride Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1134-05\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1134-05\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1134-05.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1134-05", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1134-05", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1134-05\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1134-05 \u00b7 Morphine Sulfate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1890-01\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1890-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1890-01.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1890-01", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1890-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1890-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1890-01 \u00b7 Morphine Sulfate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-1890-23\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3241\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1890-23\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3241", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1890-23-2.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1890-23-2", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1890-23", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1890-23\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1890-23 \u00b7 Morphine Sulfate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-1890-23\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Next Delivery November 2026; Estimated Recovery in December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/31/2026\n\n> \"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3229\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1890-23\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Next Delivery November 2026; Estimated Recovery in December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3229", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1890-23.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-03", "id": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1890-23", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1890-23", "quote_dosage_form": "\"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/31/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Next Delivery November 2026; Estimated Recovery in December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1890-23\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Next Delivery November 2026; Estimated Recovery in December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1890-23 \u00b7 Morphine Sulfate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/31/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1891-01\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1891-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1891-01.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1891-01", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1891-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1891-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1891-01 \u00b7 Morphine Sulfate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1892-01\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1892-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1892-01.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1892-01", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1892-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1892-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1892-01 \u00b7 Morphine Sulfate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1893-01\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1893-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1893-01.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1893-01", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1893-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1893-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1893-01 \u00b7 Morphine Sulfate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1896-20\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3241\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1896-20\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3241", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1896-20-2.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1896-20-2", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1896-20", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1896-20\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1896-20 \u00b7 Morphine Sulfate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-1896-20\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1896-20\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1896-20.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-1896-20", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1896-20", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-1896-20\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-1896-20 \u00b7 Morphine Sulfate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-2022-01\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 09/11/2026\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3241\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-2022-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3241", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-2022-01.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-2022-01", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-2022-01", "quote_dosage_form": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/11/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-2022-01\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-2022-01 \u00b7 Morphine Sulfate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/11/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-3814-12\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-3814-12\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-3814-12.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-3814-12", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3814-12", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-3814-12\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-3814-12 \u00b7 Morphine Sulfate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-3815-12\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-3815-12\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-3815-12.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-morphine-sulfate-injection-0409-3815-12", "initial_posting_date": "10/31/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3815-12", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"0409-3815-12\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-3815-12 \u00b7 Morphine Sulfate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-0801-01\n\n**Generic name:** Pentostatin Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next delivery: Q2 2027; Estimated recovery: Q3 2027; Shortage per manufacturer: manufacturing delays\n\n**Initial posting date:** 08/27/2026\n\n**Last update date:** 08/27/2026\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 5\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"08/27/2026\", \"package_ndc\": \"0409-0801-01\", \"generic_name\": \"Pentostatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next delivery: Q2 2027; Estimated recovery: Q3 2027; Shortage per manufacturer: manufacturing delays\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Pentostatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-pentostatin-injection-0409-0801-01.md", "generated": true, "generic_name": "Pentostatin Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-pentostatin-injection-0409-0801-01", "initial_posting_date": "08/27/2026", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-0801-01", "quote_dosage_form": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next delivery: Q2 2027; Estimated recovery: Q3 2027; Shortage per manufacturer: manufacturing delays", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"08/27/2026\", \"package_ndc\": \"0409-0801-01\", \"generic_name\": \"Pentostatin Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next delivery: Q2 2027; Estimated recovery: Q3 2027; Shortage per manufacturer: manufacturing delays\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Pentostatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "0409-0801-01 \u00b7 Pentostatin Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/27/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1403-10\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"0409-1403-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-rocuronium-bromide-injection-0409-1403-10.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-rocuronium-bromide-injection-0409-1403-10", "initial_posting_date": "02/15/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-1403-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"0409-1403-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1403-10 \u00b7 Rocuronium Bromide Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-3189-10\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"0409-3189-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-rocuronium-bromide-injection-0409-3189-10.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-rocuronium-bromide-injection-0409-3189-10", "initial_posting_date": "02/15/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3189-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"0409-3189-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-3189-10 \u00b7 Rocuronium Bromide Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-5160-10\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"0409-5160-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-rocuronium-bromide-injection-0409-5160-10.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-rocuronium-bromide-injection-0409-5160-10", "initial_posting_date": "02/15/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-5160-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"0409-5160-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-5160-10 \u00b7 Rocuronium Bromide Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-7037-10\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"0409-7037-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-rocuronium-bromide-injection-0409-7037-10.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-rocuronium-bromide-injection-0409-7037-10", "initial_posting_date": "02/15/2023", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-7037-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"0409-7037-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-7037-10 \u00b7 Rocuronium Bromide Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-3299-05\n\n**Generic name:** Sodium Acetate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/03/2016\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3863\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"0409-3299-05\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3863", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sodium-acetate-injection-0409-3299-05.md", "generated": true, "generic_name": "Sodium Acetate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sodium-acetate-injection-0409-3299-05", "initial_posting_date": "02/03/2016", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3299-05", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"0409-3299-05\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-3299-05 \u00b7 Sodium Acetate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-3299-06\n\n**Generic name:** Sodium Acetate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Next Delivery and Estimated Recovery: September 2026. Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 02/03/2016\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3863\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"0409-3299-06\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Next Delivery and Estimated Recovery: September 2026. Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3863", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sodium-acetate-injection-0409-3299-06.md", "generated": true, "generic_name": "Sodium Acetate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sodium-acetate-injection-0409-3299-06", "initial_posting_date": "02/03/2016", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3299-06", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Next Delivery and Estimated Recovery: September 2026. Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"0409-3299-06\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Next Delivery and Estimated Recovery: September 2026. Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-3299-06 \u00b7 Sodium Acetate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-3299-25\n\n**Generic name:** Sodium Acetate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/03/2016\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3863\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"0409-3299-25\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3863", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sodium-acetate-injection-0409-3299-25.md", "generated": true, "generic_name": "Sodium Acetate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sodium-acetate-injection-0409-3299-25", "initial_posting_date": "02/03/2016", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3299-25", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"0409-3299-25\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-3299-25 \u00b7 Sodium Acetate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-3299-26\n\n**Generic name:** Sodium Acetate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/03/2016\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3863\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"0409-3299-26\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3863", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sodium-acetate-injection-0409-3299-26.md", "generated": true, "generic_name": "Sodium Acetate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sodium-acetate-injection-0409-3299-26", "initial_posting_date": "02/03/2016", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3299-26", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"0409-3299-26\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-3299-26 \u00b7 Sodium Acetate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-7299-25\n\n**Generic name:** Sodium Acetate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/03/2016\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3863\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"0409-7299-25\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3863", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sodium-acetate-injection-0409-7299-25.md", "generated": true, "generic_name": "Sodium Acetate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sodium-acetate-injection-0409-7299-25", "initial_posting_date": "02/03/2016", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-7299-25", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"0409-7299-25\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-7299-25 \u00b7 Sodium Acetate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-7299-73\n\n**Generic name:** Sodium Acetate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/03/2016\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3863\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"0409-7299-73\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3863", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sodium-acetate-injection-0409-7299-73.md", "generated": true, "generic_name": "Sodium Acetate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sodium-acetate-injection-0409-7299-73", "initial_posting_date": "02/03/2016", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-7299-73", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"0409-7299-73\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-7299-73 \u00b7 Sodium Acetate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-4900-14\n\n**Generic name:** Sodium Bicarbonate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 03/01/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3471\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"0409-4900-14\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3471", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sodium-bicarbonate-injection-0409-4900-14.md", "generated": true, "generic_name": "Sodium Bicarbonate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sodium-bicarbonate-injection-0409-4900-14", "initial_posting_date": "03/01/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4900-14", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"0409-4900-14\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-4900-14 \u00b7 Sodium Bicarbonate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-4916-14\n\n**Generic name:** Sodium Bicarbonate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 03/01/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3471\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"0409-4916-14\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3471", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sodium-bicarbonate-injection-0409-4916-14.md", "generated": true, "generic_name": "Sodium Bicarbonate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sodium-bicarbonate-injection-0409-4916-14", "initial_posting_date": "03/01/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4916-14", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"0409-4916-14\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-4916-14 \u00b7 Sodium Bicarbonate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-5534-14\n\n**Generic name:** Sodium Bicarbonate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 03/01/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3471\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"0409-5534-14\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3471", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sodium-bicarbonate-injection-0409-5534-14.md", "generated": true, "generic_name": "Sodium Bicarbonate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sodium-bicarbonate-injection-0409-5534-14", "initial_posting_date": "03/01/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-5534-14", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"0409-5534-14\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-5534-14 \u00b7 Sodium Bicarbonate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-5555-01\n\n**Generic name:** Sodium Bicarbonate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: April 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 03/01/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3471\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"0409-5555-01\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: April 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3471", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sodium-bicarbonate-injection-0409-5555-01.md", "generated": true, "generic_name": "Sodium Bicarbonate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sodium-bicarbonate-injection-0409-5555-01", "initial_posting_date": "03/01/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-5555-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery: April 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"0409-5555-01\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: April 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-5555-01 \u00b7 Sodium Bicarbonate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-5555-02\n\n**Generic name:** Sodium Bicarbonate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 03/01/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3471\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"0409-5555-02\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3471", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sodium-bicarbonate-injection-0409-5555-02.md", "generated": true, "generic_name": "Sodium Bicarbonate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sodium-bicarbonate-injection-0409-5555-02", "initial_posting_date": "03/01/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-5555-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"0409-5555-02\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-5555-02 \u00b7 Sodium Bicarbonate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-6625-14\n\n**Generic name:** Sodium Bicarbonate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/01/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 3471\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"0409-6625-14\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3471", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sodium-bicarbonate-injection-0409-6625-14.md", "generated": true, "generic_name": "Sodium Bicarbonate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sodium-bicarbonate-injection-0409-6625-14", "initial_posting_date": "03/01/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-6625-14", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"0409-6625-14\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-6625-14 \u00b7 Sodium Bicarbonate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-6625-35\n\n**Generic name:** Sodium Bicarbonate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 03/01/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3471\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"0409-6625-35\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3471", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sodium-bicarbonate-injection-0409-6625-35.md", "generated": true, "generic_name": "Sodium Bicarbonate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sodium-bicarbonate-injection-0409-6625-35", "initial_posting_date": "03/01/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-6625-35", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-15", "related_info": "Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"0409-6625-35\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-6625-35 \u00b7 Sodium Bicarbonate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-6637-14\n\n**Generic name:** Sodium Bicarbonate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 03/01/2017\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3471\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"0409-6637-14\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3471", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sodium-bicarbonate-injection-0409-6637-14.md", "generated": true, "generic_name": "Sodium Bicarbonate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sodium-bicarbonate-injection-0409-6637-14", "initial_posting_date": "03/01/2017", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-6637-14", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"0409-6637-14\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0409-6637-14 \u00b7 Sodium Bicarbonate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-3977-03\n\n**Generic name:** Sterile Water Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/03/2021\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1747\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Other\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/03/2021\", \"package_ndc\": \"0409-3977-03\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1747", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sterile-water-injection-0409-3977-03-2.md", "generated": true, "generic_name": "Sterile Water Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-sterile-water-injection-0409-3977-03-2", "initial_posting_date": "12/03/2021", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3977-03", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"12/03/2021\", \"package_ndc\": \"0409-3977-03\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Other", "title": "0409-3977-03 \u00b7 Sterile Water Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-3977-03\n\n**Generic name:** Sterile Water Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 12/03/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1733\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/03/2021\", \"package_ndc\": \"0409-3977-03\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1733", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sterile-water-injection-0409-3977-03.md", "generated": true, "generic_name": "Sterile Water Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sterile-water-injection-0409-3977-03", "initial_posting_date": "12/03/2021", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3977-03", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"12/03/2021\", \"package_ndc\": \"0409-3977-03\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Other", "title": "0409-3977-03 \u00b7 Sterile Water Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4887-10\n\n**Generic name:** Sterile Water Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/23/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1743\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"0409-4887-10\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1743", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sterile-water-injection-0409-4887-10.md", "generated": true, "generic_name": "Sterile Water Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sterile-water-injection-0409-4887-10", "initial_posting_date": "11/23/2021", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4887-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"0409-4887-10\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Other", "title": "0409-4887-10 \u00b7 Sterile Water Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4887-20\n\n**Generic name:** Sterile Water Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/23/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1743\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"0409-4887-20\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1743", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sterile-water-injection-0409-4887-20.md", "generated": true, "generic_name": "Sterile Water Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sterile-water-injection-0409-4887-20", "initial_posting_date": "11/23/2021", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4887-20", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"0409-4887-20\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Other", "title": "0409-4887-20 \u00b7 Sterile Water Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4887-50\n\n**Generic name:** Sterile Water Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/23/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1743\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"0409-4887-50\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1743", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sterile-water-injection-0409-4887-50.md", "generated": true, "generic_name": "Sterile Water Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sterile-water-injection-0409-4887-50", "initial_posting_date": "11/23/2021", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4887-50", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"0409-4887-50\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Other", "title": "0409-4887-50 \u00b7 Sterile Water Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4887-99\n\n**Generic name:** Sterile Water Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/23/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1743\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"0409-4887-99\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1743", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sterile-water-injection-0409-4887-99.md", "generated": true, "generic_name": "Sterile Water Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sterile-water-injection-0409-4887-99", "initial_posting_date": "11/23/2021", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-4887-99", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"0409-4887-99\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Other", "title": "0409-4887-99 \u00b7 Sterile Water Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-3382-21\n\n**Generic name:** Sufentanil Citrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 05/03/2022\n\n**Last update date:** 09/09/2026\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1596\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/03/2022\", \"package_ndc\": \"0409-3382-21\", \"generic_name\": \"Sufentanil Citrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sufentanil%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1596", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sufentanil-citrate-injection-0409-3382-21-2.md", "generated": true, "generic_name": "Sufentanil Citrate Injection", "harvested": "2026-09-15", "id": "hospira-inc-a-pfizer-company-sufentanil-citrate-injection-0409-3382-21-2", "initial_posting_date": "05/03/2022", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3382-21", "quote_dosage_form": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/09/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"05/03/2022\", \"package_ndc\": \"0409-3382-21\", \"generic_name\": \"Sufentanil Citrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sufentanil%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-3382-21 \u00b7 Sufentanil Citrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/09/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0409-3382-21\n\n**Generic name:** Sufentanil Citrate Injection\n\n**Manufacturer:** Hospira, Inc., a Pfizer Company\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 05/03/2022\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1582\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/03/2022\", \"package_ndc\": \"0409-3382-21\", \"generic_name\": \"Sufentanil Citrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sufentanil%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1582", "dosage_form": "Injection", "file": "hospira-inc-a-pfizer-company-sufentanil-citrate-injection-0409-3382-21.md", "generated": true, "generic_name": "Sufentanil Citrate Injection", "harvested": "2026-09-01", "id": "hospira-inc-a-pfizer-company-sufentanil-citrate-injection-0409-3382-21", "initial_posting_date": "05/03/2022", "manufacturer_name": "Hospira, Inc., a Pfizer Company", "package_ndc": "0409-3382-21", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)\", \"company_name\": \"Hospira, Inc., a Pfizer Company\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"05/03/2022\", \"package_ndc\": \"0409-3382-21\", \"generic_name\": \"Sufentanil Citrate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Hospira,%20Inc.,%20a%20Pfizer%20Company%22+AND+generic_name%3A%22Sufentanil%20Citrate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0409-3382-21 \u00b7 Sufentanil Citrate Injection \u00b7 Hospira, Inc., a Pfizer Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 44567-600-04\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** HQ Specialty Pharma\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by WG Critical Care\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"44567-600-04\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"WG Critical Care 888-493-0861\", \"availability\": \"Available\", \"related_info\": \"Marketed by WG Critical Care\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22HQ%20Specialty%20Pharma%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "hq-specialty-pharma-dexmedetomidine-hydrochloride-injection-44567-600-04.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hq-specialty-pharma-dexmedetomidine-hydrochloride-injection-44567-600-04", "initial_posting_date": "04/10/2020", "manufacturer_name": "HQ Specialty Pharma", "package_ndc": "44567-600-04", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "related_info": "Marketed by WG Critical Care", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"44567-600-04\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"WG Critical Care 888-493-0861\", \"availability\": \"Available\", \"related_info\": \"Marketed by WG Critical Care\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22HQ%20Specialty%20Pharma%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "44567-600-04 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 HQ Specialty Pharma \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 44567-601-04\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** HQ Specialty Pharma\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by WG Critical Care\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"44567-601-04\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"WG Critical Care 888-493-0861\", \"availability\": \"Available\", \"related_info\": \"Marketed by WG Critical Care\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22HQ%20Specialty%20Pharma%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "hq-specialty-pharma-dexmedetomidine-hydrochloride-injection-44567-601-04.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hq-specialty-pharma-dexmedetomidine-hydrochloride-injection-44567-601-04", "initial_posting_date": "04/10/2020", "manufacturer_name": "HQ Specialty Pharma", "package_ndc": "44567-601-04", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "related_info": "Marketed by WG Critical Care", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"44567-601-04\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"WG Critical Care 888-493-0861\", \"availability\": \"Available\", \"related_info\": \"Marketed by WG Critical Care\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22HQ%20Specialty%20Pharma%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "44567-601-04 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 HQ Specialty Pharma \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 44567-602-24\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** HQ Specialty Pharma\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by WG Critical Care\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"44567-602-24\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"WG Critical Care 888-493-0861\", \"availability\": \"Available\", \"related_info\": \"Marketed by WG Critical Care\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22HQ%20Specialty%20Pharma%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "hq-specialty-pharma-dexmedetomidine-hydrochloride-injection-44567-602-24.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hq-specialty-pharma-dexmedetomidine-hydrochloride-injection-44567-602-24", "initial_posting_date": "04/10/2020", "manufacturer_name": "HQ Specialty Pharma", "package_ndc": "44567-602-24", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "related_info": "Marketed by WG Critical Care", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"44567-602-24\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"WG Critical Care 888-493-0861\", \"availability\": \"Available\", \"related_info\": \"Marketed by WG Critical Care\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22HQ%20Specialty%20Pharma%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "44567-602-24 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 HQ Specialty Pharma \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 44567-603-24\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** HQ Specialty Pharma\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by WG Critical Care\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"44567-603-24\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"WG Critical Care 888-493-0861\", \"availability\": \"Available\", \"related_info\": \"Marketed by WG Critical Care\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22HQ%20Specialty%20Pharma%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "hq-specialty-pharma-dexmedetomidine-hydrochloride-injection-44567-603-24.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "hq-specialty-pharma-dexmedetomidine-hydrochloride-injection-44567-603-24", "initial_posting_date": "04/10/2020", "manufacturer_name": "HQ Specialty Pharma", "package_ndc": "44567-603-24", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)\", \"company_name\": \"HQ Specialty Pharma\", \"status\": \"Current\"", "related_info": "Marketed by WG Critical Care", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"44567-603-24\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"WG Critical Care 888-493-0861\", \"availability\": \"Available\", \"related_info\": \"Marketed by WG Critical Care\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22HQ%20Specialty%20Pharma%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "44567-603-24 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 HQ Specialty Pharma \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 73293-0002-2\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Huons Co., Ltd\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)\", \"company_name\": \"Huons Co., Ltd\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)\", \"company_name\": \"Huons Co., Ltd\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 07/30/2026\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)\", \"company_name\": \"Huons Co., Ltd\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)\", \"company_name\": \"Huons Co., Ltd\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)\", \"company_name\": \"Huons Co., Ltd\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)\", \"company_name\": \"Huons Co., Ltd\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"73293-0002-2\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"+82-2-854-4700 or via email intbiz@huons.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Huons%20Co.,%20Ltd%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "huons-co-ltd-bupivacaine-hydrochloride-injection-73293-0002-2.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "huons-co-ltd-bupivacaine-hydrochloride-injection-73293-0002-2", "initial_posting_date": "02/20/2018", "manufacturer_name": "Huons Co., Ltd", "package_ndc": "73293-0002-2", "quote_dosage_form": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)\", \"company_name\": \"Huons Co., Ltd\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)\", \"company_name\": \"Huons Co., Ltd\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)\", \"company_name\": \"Huons Co., Ltd\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)\", \"company_name\": \"Huons Co., Ltd\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)\", \"company_name\": \"Huons Co., Ltd\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)\", \"company_name\": \"Huons Co., Ltd\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"73293-0002-2\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"+82-2-854-4700 or via email intbiz@huons.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Huons%20Co.,%20Ltd%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "73293-0002-2 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Huons Co., Ltd \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/30/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 73293-0001-2\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Huons Co., Ltd. (South Korea)\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)\", \"company_name\": \"Huons Co., Ltd. (South Korea)\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)\", \"company_name\": \"Huons Co., Ltd. (South Korea)\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2018\n\n**Last update date:** 07/30/2026\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)\", \"company_name\": \"Huons Co., Ltd. (South Korea)\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2971\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)\", \"company_name\": \"Huons Co., Ltd. (South Korea)\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)\", \"company_name\": \"Huons Co., Ltd. (South Korea)\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)\", \"company_name\": \"Huons Co., Ltd. (South Korea)\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2018\", \"package_ndc\": \"73293-0001-2\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"intbiz@huons.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Huons%20Co.,%20Ltd.%20(South%20Korea)%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2971", "dosage_form": "Injection", "file": "huons-co-ltd-south-korea-lidocaine-hydrochloride-injection-73293-0001-2.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "huons-co-ltd-south-korea-lidocaine-hydrochloride-injection-73293-0001-2", "initial_posting_date": "07/14/2018", "manufacturer_name": "Huons Co., Ltd. (South Korea)", "package_ndc": "73293-0001-2", "quote_dosage_form": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)\", \"company_name\": \"Huons Co., Ltd. (South Korea)\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)\", \"company_name\": \"Huons Co., Ltd. (South Korea)\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)\", \"company_name\": \"Huons Co., Ltd. (South Korea)\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)\", \"company_name\": \"Huons Co., Ltd. (South Korea)\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)\", \"company_name\": \"Huons Co., Ltd. (South Korea)\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)\", \"company_name\": \"Huons Co., Ltd. (South Korea)\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"07/14/2018\", \"package_ndc\": \"73293-0001-2\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"intbiz@huons.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Huons%20Co.,%20Ltd.%20(South%20Korea)%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "73293-0001-2 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Huons Co., Ltd. (South Korea) \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/30/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0409-0152-24\n\n**Generic name:** Metronidazole Injection\n\n**Manufacturer:** InfoRLife SA\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Labeler: Hospira Inc.\n\n**Initial posting date:** 01/13/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1692\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/13/2022\", \"package_ndc\": \"0409-0152-24\", \"generic_name\": \"Metronidazole Injection\", \"contact_info\": \"Sagent: 866-625-1618\", \"availability\": \"Limited Availability\", \"related_info\": \"Labeler: Hospira Inc.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Metronidazole%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1692", "dosage_form": "Injection", "file": "inforlife-sa-metronidazole-injection-0409-0152-24.md", "generated": true, "generic_name": "Metronidazole Injection", "harvested": "2026-09-01", "id": "inforlife-sa-metronidazole-injection-0409-0152-24", "initial_posting_date": "01/13/2022", "manufacturer_name": "InfoRLife SA", "package_ndc": "0409-0152-24", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Labeler: Hospira Inc.", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"01/13/2022\", \"package_ndc\": \"0409-0152-24\", \"generic_name\": \"Metronidazole Injection\", \"contact_info\": \"Sagent: 866-625-1618\", \"availability\": \"Limited Availability\", \"related_info\": \"Labeler: Hospira Inc.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Metronidazole%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0409-0152-24 \u00b7 Metronidazole Injection \u00b7 InfoRLife SA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 25021-131-82\n\n**Generic name:** Metronidazole Injection\n\n**Manufacturer:** InfoRLife SA\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: August 2026; Marketed by Sagent Pharmaceuticals\n\n**Initial posting date:** 01/13/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1692\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/13/2022\", \"package_ndc\": \"25021-131-82\", \"generic_name\": \"Metronidazole Injection\", \"contact_info\": \"Sagent: 866-625-1618\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: August 2026; Marketed by Sagent Pharmaceuticals\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Metronidazole%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1692", "dosage_form": "Injection", "file": "inforlife-sa-metronidazole-injection-25021-131-82.md", "generated": true, "generic_name": "Metronidazole Injection", "harvested": "2026-09-01", "id": "inforlife-sa-metronidazole-injection-25021-131-82", "initial_posting_date": "01/13/2022", "manufacturer_name": "InfoRLife SA", "package_ndc": "25021-131-82", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: August 2026; Marketed by Sagent Pharmaceuticals", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"01/13/2022\", \"package_ndc\": \"25021-131-82\", \"generic_name\": \"Metronidazole Injection\", \"contact_info\": \"Sagent: 866-625-1618\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: August 2026; Marketed by Sagent Pharmaceuticals\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Metronidazole%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "25021-131-82 \u00b7 Metronidazole Injection \u00b7 InfoRLife SA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 25021-652-82\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** InfoRLife SA\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Sagent Pharmaceuticals\n\n**Initial posting date:** 03/27/2018\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n**Days in shortage:** 3080\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/27/2018\", \"package_ndc\": \"25021-652-82\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"Sagent: 866-625-1618\", \"availability\": \"Available\", \"related_info\": \"Marketed by Sagent Pharmaceuticals\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3080", "dosage_form": "Injection", "file": "inforlife-sa-ropivacaine-hydrochloride-injection-25021-652-82.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "inforlife-sa-ropivacaine-hydrochloride-injection-25021-652-82", "initial_posting_date": "03/27/2018", "manufacturer_name": "InfoRLife SA", "package_ndc": "25021-652-82", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "related_info": "Marketed by Sagent Pharmaceuticals", "source_quote": "\"initial_posting_date\": \"03/27/2018\", \"package_ndc\": \"25021-652-82\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"Sagent: 866-625-1618\", \"availability\": \"Available\", \"related_info\": \"Marketed by Sagent Pharmaceuticals\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "25021-652-82 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 InfoRLife SA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 25021-652-87\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** InfoRLife SA\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Sagent Pharmaceuticals\n\n**Initial posting date:** 03/27/2018\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n**Days in shortage:** 3080\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/27/2018\", \"package_ndc\": \"25021-652-87\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"Sagent: 866-625-1618\", \"availability\": \"Available\", \"related_info\": \"Marketed by Sagent Pharmaceuticals\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3080", "dosage_form": "Injection", "file": "inforlife-sa-ropivacaine-hydrochloride-injection-25021-652-87.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "inforlife-sa-ropivacaine-hydrochloride-injection-25021-652-87", "initial_posting_date": "03/27/2018", "manufacturer_name": "InfoRLife SA", "package_ndc": "25021-652-87", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "related_info": "Marketed by Sagent Pharmaceuticals", "source_quote": "\"initial_posting_date\": \"03/27/2018\", \"package_ndc\": \"25021-652-87\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"Sagent: 866-625-1618\", \"availability\": \"Available\", \"related_info\": \"Marketed by Sagent Pharmaceuticals\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "25021-652-87 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 InfoRLife SA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 25021-671-66\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** InfoRLife SA\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD; Marketed by Sagent Pharmaceuticals\n\n**Initial posting date:** 03/27/2018\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3080\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/27/2018\", \"package_ndc\": \"25021-671-66\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"Sagent: 866-625-1618\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD; Marketed by Sagent Pharmaceuticals\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3080", "dosage_form": "Injection", "file": "inforlife-sa-ropivacaine-hydrochloride-injection-25021-671-66.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "inforlife-sa-ropivacaine-hydrochloride-injection-25021-671-66", "initial_posting_date": "03/27/2018", "manufacturer_name": "InfoRLife SA", "package_ndc": "25021-671-66", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD; Marketed by Sagent Pharmaceuticals", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/27/2018\", \"package_ndc\": \"25021-671-66\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"Sagent: 866-625-1618\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD; Marketed by Sagent Pharmaceuticals\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "25021-671-66 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 InfoRLife SA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 25021-671-67\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** InfoRLife SA\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD; Marketed by Sagent Pharmaceuticals\n\n**Initial posting date:** 03/27/2018\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3080\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/27/2018\", \"package_ndc\": \"25021-671-67\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"Sagent: 866-625-1618\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; Marketed by Sagent Pharmaceuticals\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3080", "dosage_form": "Injection", "file": "inforlife-sa-ropivacaine-hydrochloride-injection-25021-671-67.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "inforlife-sa-ropivacaine-hydrochloride-injection-25021-671-67", "initial_posting_date": "03/27/2018", "manufacturer_name": "InfoRLife SA", "package_ndc": "25021-671-67", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)\", \"company_name\": \"InfoRLife SA\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD; Marketed by Sagent Pharmaceuticals", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/27/2018\", \"package_ndc\": \"25021-671-67\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"Sagent: 866-625-1618\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; Marketed by Sagent Pharmaceuticals\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "25021-671-67 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 InfoRLife SA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 25021-671-82\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** InfoRLife SA\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Sagent Pharmaceuticals\n\n**Initial posting date:** 03/27/2018\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n**Days in shortage:** 3080\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/27/2018\", \"package_ndc\": \"25021-671-82\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"Sagent: 866-625-1618\", \"availability\": \"Available\", \"related_info\": \"Marketed by Sagent Pharmaceuticals\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3080", "dosage_form": "Injection", "file": "inforlife-sa-ropivacaine-hydrochloride-injection-25021-671-82.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "inforlife-sa-ropivacaine-hydrochloride-injection-25021-671-82", "initial_posting_date": "03/27/2018", "manufacturer_name": "InfoRLife SA", "package_ndc": "25021-671-82", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "related_info": "Marketed by Sagent Pharmaceuticals", "source_quote": "\"initial_posting_date\": \"03/27/2018\", \"package_ndc\": \"25021-671-82\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"Sagent: 866-625-1618\", \"availability\": \"Available\", \"related_info\": \"Marketed by Sagent Pharmaceuticals\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "25021-671-82 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 InfoRLife SA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 25021-671-87\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** InfoRLife SA\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Sagent Pharmaceuticals\n\n**Initial posting date:** 03/27/2018\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n**Days in shortage:** 3080\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/27/2018\", \"package_ndc\": \"25021-671-87\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"Sagent: 866-625-1618\", \"availability\": \"Available\", \"related_info\": \"Marketed by Sagent Pharmaceuticals\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3080", "dosage_form": "Injection", "file": "inforlife-sa-ropivacaine-hydrochloride-injection-25021-671-87.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "inforlife-sa-ropivacaine-hydrochloride-injection-25021-671-87", "initial_posting_date": "03/27/2018", "manufacturer_name": "InfoRLife SA", "package_ndc": "25021-671-87", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)\", \"company_name\": \"InfoRLife SA\", \"status\": \"Current\"", "related_info": "Marketed by Sagent Pharmaceuticals", "source_quote": "\"initial_posting_date\": \"03/27/2018\", \"package_ndc\": \"25021-671-87\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"Sagent: 866-625-1618\", \"availability\": \"Available\", \"related_info\": \"Marketed by Sagent Pharmaceuticals\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22InfoRLife%20SA%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "25021-671-87 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 InfoRLife SA \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 50458-585-01\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Janssen Pharmaceuticals\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/19/2026\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"50458-585-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Janssen%20Pharmaceuticals%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "janssen-pharmaceuticals-methylphenidate-hydrochloride-tablet-extended-release-50458-585-01.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "janssen-pharmaceuticals-methylphenidate-hydrochloride-tablet-extended-release-50458-585-01", "initial_posting_date": "07/26/2023", "manufacturer_name": "Janssen Pharmaceuticals", "package_ndc": "50458-585-01", "quote_dosage_form": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"50458-585-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Janssen%20Pharmaceuticals%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "50458-585-01 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Janssen Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/19/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 50458-586-01\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Janssen Pharmaceuticals\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/19/2026\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"50458-586-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Janssen%20Pharmaceuticals%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "janssen-pharmaceuticals-methylphenidate-hydrochloride-tablet-extended-release-50458-586-01.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "janssen-pharmaceuticals-methylphenidate-hydrochloride-tablet-extended-release-50458-586-01", "initial_posting_date": "07/26/2023", "manufacturer_name": "Janssen Pharmaceuticals", "package_ndc": "50458-586-01", "quote_dosage_form": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"50458-586-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Janssen%20Pharmaceuticals%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "50458-586-01 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Janssen Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/19/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 50458-587-01\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Janssen Pharmaceuticals\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/19/2026\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"50458-587-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Janssen%20Pharmaceuticals%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "janssen-pharmaceuticals-methylphenidate-hydrochloride-tablet-extended-release-50458-587-01.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "janssen-pharmaceuticals-methylphenidate-hydrochloride-tablet-extended-release-50458-587-01", "initial_posting_date": "07/26/2023", "manufacturer_name": "Janssen Pharmaceuticals", "package_ndc": "50458-587-01", "quote_dosage_form": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"50458-587-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Janssen%20Pharmaceuticals%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "50458-587-01 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Janssen Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/19/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 50458-588-01\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Janssen Pharmaceuticals\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/19/2026\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"50458-588-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Janssen%20Pharmaceuticals%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "janssen-pharmaceuticals-methylphenidate-hydrochloride-tablet-extended-release-50458-588-01.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "janssen-pharmaceuticals-methylphenidate-hydrochloride-tablet-extended-release-50458-588-01", "initial_posting_date": "07/26/2023", "manufacturer_name": "Janssen Pharmaceuticals", "package_ndc": "50458-588-01", "quote_dosage_form": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/19/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)\", \"company_name\": \"Janssen Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"50458-588-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Janssen%20Pharmaceuticals%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "50458-588-01 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Janssen Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/19/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0781-3493-95\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Jiangsu Hengrui Pharmaceuticals Co., Ltd.\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL (NDC 0781-3493-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL (NDC 0781-3493-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Sandoz Inc.; Customer service: 800-525-8747\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 07/30/2026\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL (NDC 0781-3493-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL (NDC 0781-3493-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL (NDC 0781-3493-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0781-3493-95\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"See Related Information section below for customer service information\", \"availability\": \"Available\", \"related_info\": \"Marketed by Sandoz Inc.; Customer service: 800-525-8747\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Jiangsu%20Hengrui%20Pharmaceuticals%20Co.,%20Ltd.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "jiangsu-hengrui-pharmaceuticals-co-ltd-dexmedetomidine-hydrochloride-injection-0781-3493-95.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "jiangsu-hengrui-pharmaceuticals-co-ltd-dexmedetomidine-hydrochloride-injection-0781-3493-95", "initial_posting_date": "04/10/2020", "manufacturer_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "package_ndc": "0781-3493-95", "quote_dosage_form": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL (NDC 0781-3493-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL (NDC 0781-3493-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL (NDC 0781-3493-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL (NDC 0781-3493-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL (NDC 0781-3493-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Marketed by Sandoz Inc.; Customer service: 800-525-8747", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0781-3493-95\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"See Related Information section below for customer service information\", \"availability\": \"Available\", \"related_info\": \"Marketed by Sandoz Inc.; Customer service: 800-525-8747\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Jiangsu%20Hengrui%20Pharmaceuticals%20Co.,%20Ltd.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0781-3493-95 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Jiangsu Hengrui Pharmaceuticals Co., Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/30/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0781-3494-95\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Jiangsu Hengrui Pharmaceuticals Co., Ltd.\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (NDC 0781-3494-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (NDC 0781-3494-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Sandoz Inc.; Customer service: 800-525-8747\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 07/30/2026\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (NDC 0781-3494-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (NDC 0781-3494-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (NDC 0781-3494-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0781-3494-95\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"See Related Information section below for customer service information\", \"availability\": \"Available\", \"related_info\": \"Marketed by Sandoz Inc.; Customer service: 800-525-8747\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Jiangsu%20Hengrui%20Pharmaceuticals%20Co.,%20Ltd.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "jiangsu-hengrui-pharmaceuticals-co-ltd-dexmedetomidine-hydrochloride-injection-0781-3494-95.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "jiangsu-hengrui-pharmaceuticals-co-ltd-dexmedetomidine-hydrochloride-injection-0781-3494-95", "initial_posting_date": "04/10/2020", "manufacturer_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "package_ndc": "0781-3494-95", "quote_dosage_form": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (NDC 0781-3494-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (NDC 0781-3494-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (NDC 0781-3494-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (NDC 0781-3494-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (NDC 0781-3494-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Marketed by Sandoz Inc.; Customer service: 800-525-8747", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0781-3494-95\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"See Related Information section below for customer service information\", \"availability\": \"Available\", \"related_info\": \"Marketed by Sandoz Inc.; Customer service: 800-525-8747\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Jiangsu%20Hengrui%20Pharmaceuticals%20Co.,%20Ltd.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0781-3494-95 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Jiangsu Hengrui Pharmaceuticals Co., Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/30/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0781-3495-95\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Jiangsu Hengrui Pharmaceuticals Co., Ltd.\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Sandoz Inc.; Customer service: 800-525-8747\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 07/30/2026\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0781-3495-95\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"See Related Information section below for customer service information\", \"availability\": \"Available\", \"related_info\": \"Marketed by Sandoz Inc.; Customer service: 800-525-8747\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Jiangsu%20Hengrui%20Pharmaceuticals%20Co.,%20Ltd.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "jiangsu-hengrui-pharmaceuticals-co-ltd-dexmedetomidine-hydrochloride-injection-0781-3495-95.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "jiangsu-hengrui-pharmaceuticals-co-ltd-dexmedetomidine-hydrochloride-injection-0781-3495-95", "initial_posting_date": "04/10/2020", "manufacturer_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "package_ndc": "0781-3495-95", "quote_dosage_form": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co., Ltd.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Marketed by Sandoz Inc.; Customer service: 800-525-8747", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0781-3495-95\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"See Related Information section below for customer service information\", \"availability\": \"Available\", \"related_info\": \"Marketed by Sandoz Inc.; Customer service: 800-525-8747\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Jiangsu%20Hengrui%20Pharmaceuticals%20Co.,%20Ltd.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0781-3495-95 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Jiangsu Hengrui Pharmaceuticals Co., Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/30/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 83634-600-02\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Avenacy; Contact information: 877-283-6229\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 07/30/2026\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"83634-600-02\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"See Related Information section below for customer service information\", \"availability\": \"Available\", \"related_info\": \"Distributed by Avenacy; Contact information: 877-283-6229\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Jiangsu%20Hengrui%20Pharmaceuticals%20Co.%20(US%20Agent%20eVenus%20Pharmaceutical%20Laboratories,%20Inc.)%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "jiangsu-hengrui-pharmaceuticals-co-us-agent-evenus-pharmaceutical-laboratories-i-dexmedetomidine-hydrochloride-injection-83634-600-02.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "jiangsu-hengrui-pharmaceuticals-co-us-agent-evenus-pharmaceutical-laboratories-i-dexmedetomidine-hydrochloride-injection-83634-600-02", "initial_posting_date": "04/10/2020", "manufacturer_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "package_ndc": "83634-600-02", "quote_dosage_form": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/30/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)\", \"company_name\": \"Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Distributed by Avenacy; Contact information: 877-283-6229", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"83634-600-02\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"See Related Information section below for customer service information\", \"availability\": \"Available\", \"related_info\": \"Distributed by Avenacy; Contact information: 877-283-6229\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Jiangsu%20Hengrui%20Pharmaceuticals%20Co.%20(US%20Agent%20eVenus%20Pharmaceutical%20Laboratories,%20Inc.)%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "83634-600-02 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/30/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 71288-722-32\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Kindos Pharmaceuticals Co. Ltd.\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Meitheal Pharmaceuticals is distributor/labeler\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 05/05/2026\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"71288-722-32\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d\", \"contact_info\": \"844-824-8426\", \"availability\": \"Limited Availability\", \"related_info\": \"Meitheal Pharmaceuticals is distributor/labeler\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Kindos%20Pharmaceuticals%20Co.%20Ltd.%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "kindos-pharmaceuticals-co-ltd-bupivacaine-hydrochloride-injection-71288-722-32.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "kindos-pharmaceuticals-co-ltd-bupivacaine-hydrochloride-injection-71288-722-32", "initial_posting_date": "02/20/2018", "manufacturer_name": "Kindos Pharmaceuticals Co. Ltd.", "package_ndc": "71288-722-32", "quote_dosage_form": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"71288-722-32\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d\", \"contact_info\": \"844-824-8426\", \"availability\": \"Limited Availability\", \"related_info\": \"Meitheal Pharmaceuticals is distributor/labeler\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Kindos%20Pharmaceuticals%20Co.%20Ltd.%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "71288-722-32 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Kindos Pharmaceuticals Co. Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "05/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 71288-723-52\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Kindos Pharmaceuticals Co. Ltd.\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Meitheal Pharmaceuticals is distributor/labeler\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 05/05/2026\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"71288-723-52\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d\", \"contact_info\": \"844-824-8426\", \"availability\": \"Limited Availability\", \"related_info\": \"Meitheal Pharmaceuticals is distributor/labeler\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Kindos%20Pharmaceuticals%20Co.%20Ltd.%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "kindos-pharmaceuticals-co-ltd-bupivacaine-hydrochloride-injection-71288-723-52.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "kindos-pharmaceuticals-co-ltd-bupivacaine-hydrochloride-injection-71288-723-52", "initial_posting_date": "02/20/2018", "manufacturer_name": "Kindos Pharmaceuticals Co. Ltd.", "package_ndc": "71288-723-52", "quote_dosage_form": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"71288-723-52\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d\", \"contact_info\": \"844-824-8426\", \"availability\": \"Limited Availability\", \"related_info\": \"Meitheal Pharmaceuticals is distributor/labeler\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Kindos%20Pharmaceuticals%20Co.%20Ltd.%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "71288-723-52 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Kindos Pharmaceuticals Co. Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "05/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 71288-725-32\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Kindos Pharmaceuticals Co. Ltd.\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Meitheal Pharmaceuticals is distributor/labeler\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 05/05/2026\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"71288-725-32\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d\", \"contact_info\": \"844-824-8426\", \"availability\": \"Limited Availability\", \"related_info\": \"Meitheal Pharmaceuticals is distributor/labeler\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Kindos%20Pharmaceuticals%20Co.%20Ltd.%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "kindos-pharmaceuticals-co-ltd-bupivacaine-hydrochloride-injection-71288-725-32.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "kindos-pharmaceuticals-co-ltd-bupivacaine-hydrochloride-injection-71288-725-32", "initial_posting_date": "02/20/2018", "manufacturer_name": "Kindos Pharmaceuticals Co. Ltd.", "package_ndc": "71288-725-32", "quote_dosage_form": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"71288-725-32\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d\", \"contact_info\": \"844-824-8426\", \"availability\": \"Limited Availability\", \"related_info\": \"Meitheal Pharmaceuticals is distributor/labeler\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Kindos%20Pharmaceuticals%20Co.%20Ltd.%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "71288-725-32 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Kindos Pharmaceuticals Co. Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "05/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 71288-726-52\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Kindos Pharmaceuticals Co. Ltd.\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Meitheal Pharmaceuticals is distributor/labeler\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 05/05/2026\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"71288-726-52\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d\", \"contact_info\": \"844-824-8426\", \"availability\": \"Limited Availability\", \"related_info\": \"Meitheal Pharmaceuticals is distributor/labeler\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Kindos%20Pharmaceuticals%20Co.%20Ltd.%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "kindos-pharmaceuticals-co-ltd-bupivacaine-hydrochloride-injection-71288-726-52.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "kindos-pharmaceuticals-co-ltd-bupivacaine-hydrochloride-injection-71288-726-52", "initial_posting_date": "02/20/2018", "manufacturer_name": "Kindos Pharmaceuticals Co. Ltd.", "package_ndc": "71288-726-52", "quote_dosage_form": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"71288-726-52\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d\", \"contact_info\": \"844-824-8426\", \"availability\": \"Limited Availability\", \"related_info\": \"Meitheal Pharmaceuticals is distributor/labeler\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Kindos%20Pharmaceuticals%20Co.%20Ltd.%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "71288-726-52 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Kindos Pharmaceuticals Co. Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "05/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 71288-728-32\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Kindos Pharmaceuticals Co. Ltd.\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Meitheal Pharmaceuticals is distributor/labeler\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 05/05/2026\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"71288-728-32\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d\", \"contact_info\": \"844-824-8426\", \"availability\": \"Limited Availability\", \"related_info\": \"Meitheal Pharmaceuticals is distributor/labeler\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Kindos%20Pharmaceuticals%20Co.%20Ltd.%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "kindos-pharmaceuticals-co-ltd-bupivacaine-hydrochloride-injection-71288-728-32.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "kindos-pharmaceuticals-co-ltd-bupivacaine-hydrochloride-injection-71288-728-32", "initial_posting_date": "02/20/2018", "manufacturer_name": "Kindos Pharmaceuticals Co. Ltd.", "package_ndc": "71288-728-32", "quote_dosage_form": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"05/05/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)\", \"company_name\": \"Kindos Pharmaceuticals Co. Ltd.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"71288-728-32\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d\", \"contact_info\": \"844-824-8426\", \"availability\": \"Limited Availability\", \"related_info\": \"Meitheal Pharmaceuticals is distributor/labeler\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Kindos%20Pharmaceuticals%20Co.%20Ltd.%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "71288-728-32 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Kindos Pharmaceuticals Co. Ltd. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "05/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 84383-110-01\n\n**Generic name:** Penicillin G Benzathine Injection\n\n**Manufacturer:** Laboratorios Atral\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)\", \"company_name\": \"Laboratorios Atral\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)\", \"company_name\": \"Laboratorios Atral\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)\", \"company_name\": \"Laboratorios Atral\", \"status\": \"Current\"\n\n**Days in shortage:** 1224\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)\", \"company_name\": \"Laboratorios Atral\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)\", \"company_name\": \"Laboratorios Atral\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/26/2023\", \"package_ndc\": \"84383-110-01\", \"generic_name\": \"Penicillin G Benzathine Injection\", \"related_info_link\": \"https://www.fda.gov/media/193578/download\", \"contact_info\": \"Mark Cuban Cost Plus Drug Company: 682-428-8081\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Laboratorios%20Atral%22+AND+generic_name%3A%22Penicillin%20G%20Benzathine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1224", "dosage_form": "Injection", "file": "laboratorios-atral-penicillin-g-benzathine-injection-84383-110-01.md", "generated": true, "generic_name": "Penicillin G Benzathine Injection", "harvested": "2026-09-01", "id": "laboratorios-atral-penicillin-g-benzathine-injection-84383-110-01", "initial_posting_date": "04/26/2023", "manufacturer_name": "Laboratorios Atral", "package_ndc": "84383-110-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)\", \"company_name\": \"Laboratorios Atral\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)\", \"company_name\": \"Laboratorios Atral\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)\", \"company_name\": \"Laboratorios Atral\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)\", \"company_name\": \"Laboratorios Atral\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)\", \"company_name\": \"Laboratorios Atral\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"04/26/2023\", \"package_ndc\": \"84383-110-01\", \"generic_name\": \"Penicillin G Benzathine Injection\", \"related_info_link\": \"https://www.fda.gov/media/193578/download\", \"contact_info\": \"Mark Cuban Cost Plus Drug Company: 682-428-8081\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Laboratorios%20Atral%22+AND+generic_name%3A%22Penicillin%20G%20Benzathine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "84383-110-01 \u00b7 Penicillin G Benzathine Injection \u00b7 Laboratorios Atral \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0527-0760-37\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-0760-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "lannett-company-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0527-0760-37.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "lannett-company-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0527-0760-37", "initial_posting_date": "10/12/2022", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "0527-0760-37", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-0760-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0527-0760-37 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0527-0761-37\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-0761-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "lannett-company-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0527-0761-37.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "lannett-company-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0527-0761-37", "initial_posting_date": "10/12/2022", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "0527-0761-37", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-0761-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0527-0761-37 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0527-0763-37\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-0763-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "lannett-company-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0527-0763-37.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "lannett-company-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0527-0763-37", "initial_posting_date": "10/12/2022", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "0527-0763-37", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-0763-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0527-0763-37 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0527-0764-37\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-0764-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "lannett-company-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0527-0764-37.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "lannett-company-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0527-0764-37", "initial_posting_date": "10/12/2022", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "0527-0764-37", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-0764-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0527-0764-37 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0527-0766-37\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-0766-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "lannett-company-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0527-0766-37.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "lannett-company-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0527-0766-37", "initial_posting_date": "10/12/2022", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "0527-0766-37", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-0766-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0527-0766-37 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0527-1502-37\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1502-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"\n\n**Status:** Current\n\n> \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1502-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1502-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1502-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"\n\n**Therapeutic category:** Psychiatry\n\n> \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1502-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1502-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "lannett-company-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0527-1502-37.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "lannett-company-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0527-1502-37", "initial_posting_date": "10/12/2022", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "0527-1502-37", "quote_dosage_form": "\"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1502-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"", "quote_manufacturer_name": "\"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1502-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"", "quote_status": "\"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1502-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"", "quote_therapeutic_category": "\"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1502-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"", "quote_update_date": "\"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1502-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1502-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0527-1502-37 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0527-1505-37\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1505-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"\n\n**Status:** Current\n\n> \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1505-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1505-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1505-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"\n\n**Therapeutic category:** Psychiatry\n\n> \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1505-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1505-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "lannett-company-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0527-1505-37.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "lannett-company-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0527-1505-37", "initial_posting_date": "10/12/2022", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "0527-1505-37", "quote_dosage_form": "\"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1505-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"", "quote_manufacturer_name": "\"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1505-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"", "quote_status": "\"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1505-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"", "quote_therapeutic_category": "\"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1505-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"", "quote_update_date": "\"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)\", \"update_type\": \"Revised\", \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1505-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\", \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"status\": \"Current\", \"dosage_form\": \"Tablet\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0527-1505-37\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"company_name\": \"Lannett Company, Inc.\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0527-1505-37 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0527-4661-37\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0527-4661-37\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "lannett-company-inc-lisdexamfetamine-dimesylate-capsule-0527-4661-37.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "lannett-company-inc-lisdexamfetamine-dimesylate-capsule-0527-4661-37", "initial_posting_date": "07/14/2023", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "0527-4661-37", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0527-4661-37\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0527-4661-37 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0527-4662-37\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0527-4662-37\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "lannett-company-inc-lisdexamfetamine-dimesylate-capsule-0527-4662-37.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "lannett-company-inc-lisdexamfetamine-dimesylate-capsule-0527-4662-37", "initial_posting_date": "07/14/2023", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "0527-4662-37", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0527-4662-37\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0527-4662-37 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0527-4663-37\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0527-4663-37\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "lannett-company-inc-lisdexamfetamine-dimesylate-capsule-0527-4663-37.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "lannett-company-inc-lisdexamfetamine-dimesylate-capsule-0527-4663-37", "initial_posting_date": "07/14/2023", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "0527-4663-37", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0527-4663-37\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0527-4663-37 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0527-4664-37\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0527-4664-37\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "lannett-company-inc-lisdexamfetamine-dimesylate-capsule-0527-4664-37.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "lannett-company-inc-lisdexamfetamine-dimesylate-capsule-0527-4664-37", "initial_posting_date": "07/14/2023", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "0527-4664-37", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0527-4664-37\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0527-4664-37 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0527-4665-37\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0527-4665-37\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "lannett-company-inc-lisdexamfetamine-dimesylate-capsule-0527-4665-37.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "lannett-company-inc-lisdexamfetamine-dimesylate-capsule-0527-4665-37", "initial_posting_date": "07/14/2023", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "0527-4665-37", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0527-4665-37\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0527-4665-37 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0527-4666-37\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 09/20/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1077\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"09/20/2023\", \"package_ndc\": \"0527-4666-37\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1077", "dosage_form": "Capsule", "file": "lannett-company-inc-lisdexamfetamine-dimesylate-capsule-0527-4666-37.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "lannett-company-inc-lisdexamfetamine-dimesylate-capsule-0527-4666-37", "initial_posting_date": "09/20/2023", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "0527-4666-37", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"09/20/2023\", \"package_ndc\": \"0527-4666-37\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0527-4666-37 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0527-4667-37\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0527-4667-37\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "lannett-company-inc-lisdexamfetamine-dimesylate-capsule-0527-4667-37.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "lannett-company-inc-lisdexamfetamine-dimesylate-capsule-0527-4667-37", "initial_posting_date": "07/14/2023", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "0527-4667-37", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0527-4667-37\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0527-4667-37 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62175-310-37\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62175-310-37\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "lannett-company-inc-methylphenidate-hydrochloride-tablet-extended-release-62175-310-37.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "lannett-company-inc-methylphenidate-hydrochloride-tablet-extended-release-62175-310-37", "initial_posting_date": "07/26/2023", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "62175-310-37", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62175-310-37\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "62175-310-37 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62175-311-37\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62175-311-37\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "lannett-company-inc-methylphenidate-hydrochloride-tablet-extended-release-62175-311-37.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "lannett-company-inc-methylphenidate-hydrochloride-tablet-extended-release-62175-311-37", "initial_posting_date": "07/26/2023", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "62175-311-37", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62175-311-37\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "62175-311-37 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62175-312-37\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62175-312-37\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "lannett-company-inc-methylphenidate-hydrochloride-tablet-extended-release-62175-312-37.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "lannett-company-inc-methylphenidate-hydrochloride-tablet-extended-release-62175-312-37", "initial_posting_date": "07/26/2023", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "62175-312-37", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62175-312-37\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "62175-312-37 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62175-313-37\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Lannett Company, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62175-313-37\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "lannett-company-inc-methylphenidate-hydrochloride-tablet-extended-release-62175-313-37.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "lannett-company-inc-methylphenidate-hydrochloride-tablet-extended-release-62175-313-37", "initial_posting_date": "07/26/2023", "manufacturer_name": "Lannett Company, Inc.", "package_ndc": "62175-313-37", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)\", \"company_name\": \"Lannett Company, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62175-313-37\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"844-834-0530\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lannett%20Company,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "62175-313-37 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Lannett Company, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 72336-032-01\n\n**Generic name:** Isocarboxazid Tablet\n\n**Manufacturer:** Lifsa Drugs LLC\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01)\", \"company_name\": \"Lifsa Drugs LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01)\", \"company_name\": \"Lifsa Drugs LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 04/16/2026\n\n**Last update date:** 08/06/2026\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01)\", \"company_name\": \"Lifsa Drugs LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 138\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01)\", \"company_name\": \"Lifsa Drugs LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01)\", \"company_name\": \"Lifsa Drugs LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01)\", \"company_name\": \"Lifsa Drugs LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/16/2026\", \"package_ndc\": \"72336-032-01\", \"generic_name\": \"Isocarboxazid Tablet\", \"contact_info\": \"833.627.0070\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lifsa%20Drugs%20LLC%22+AND+generic_name%3A%22Isocarboxazid%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "138", "dosage_form": "Tablet", "file": "lifsa-drugs-llc-isocarboxazid-tablet-72336-032-01.md", "generated": true, "generic_name": "Isocarboxazid Tablet", "harvested": "2026-09-01", "id": "lifsa-drugs-llc-isocarboxazid-tablet-72336-032-01", "initial_posting_date": "04/16/2026", "manufacturer_name": "Lifsa Drugs LLC", "package_ndc": "72336-032-01", "quote_dosage_form": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01)\", \"company_name\": \"Lifsa Drugs LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01)\", \"company_name\": \"Lifsa Drugs LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01)\", \"company_name\": \"Lifsa Drugs LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01)\", \"company_name\": \"Lifsa Drugs LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01)\", \"company_name\": \"Lifsa Drugs LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/06/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01)\", \"company_name\": \"Lifsa Drugs LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/16/2026\", \"package_ndc\": \"72336-032-01\", \"generic_name\": \"Isocarboxazid Tablet\", \"contact_info\": \"833.627.0070\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lifsa%20Drugs%20LLC%22+AND+generic_name%3A%22Isocarboxazid%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "72336-032-01 \u00b7 Isocarboxazid Tablet \u00b7 Lifsa Drugs LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/06/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 81298-7620-3\n\n**Generic name:** Sodium Bicarbonate Injection\n\n**Manufacturer:** Long Grove Pharmaceuticals LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)\", \"company_name\": \"Long Grove Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)\", \"company_name\": \"Long Grove Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/01/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)\", \"company_name\": \"Long Grove Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3471\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)\", \"company_name\": \"Long Grove Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)\", \"company_name\": \"Long Grove Pharmaceuticals LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"81298-7620-3\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"833-268-5559\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Long%20Grove%20Pharmaceuticals%20LLC%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3471", "dosage_form": "Injection", "file": "long-grove-pharmaceuticals-llc-sodium-bicarbonate-injection-81298-7620-3.md", "generated": true, "generic_name": "Sodium Bicarbonate Injection", "harvested": "2026-09-01", "id": "long-grove-pharmaceuticals-llc-sodium-bicarbonate-injection-81298-7620-3", "initial_posting_date": "03/01/2017", "manufacturer_name": "Long Grove Pharmaceuticals LLC", "package_ndc": "81298-7620-3", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)\", \"company_name\": \"Long Grove Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)\", \"company_name\": \"Long Grove Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)\", \"company_name\": \"Long Grove Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)\", \"company_name\": \"Long Grove Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)\", \"company_name\": \"Long Grove Pharmaceuticals LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/01/2017\", \"package_ndc\": \"81298-7620-3\", \"generic_name\": \"Sodium Bicarbonate Injection\", \"contact_info\": \"833-268-5559\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Long%20Grove%20Pharmaceuticals%20LLC%22+AND+generic_name%3A%22Sodium%20Bicarbonate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "81298-7620-3 \u00b7 Sodium Bicarbonate Injection \u00b7 Long Grove Pharmaceuticals LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 68180-554-09\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Lupin Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"68180-554-09\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-587-4617\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lupin%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "lupin-pharmaceuticals-inc-quinapril-hydrochloride-tablet-68180-554-09.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "lupin-pharmaceuticals-inc-quinapril-hydrochloride-tablet-68180-554-09", "initial_posting_date": "01/19/2023", "manufacturer_name": "Lupin Pharmaceuticals, Inc.", "package_ndc": "68180-554-09", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"68180-554-09\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-587-4617\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lupin%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "68180-554-09 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Lupin Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 68180-556-09\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Lupin Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"68180-556-09\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-587-4617\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lupin%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "lupin-pharmaceuticals-inc-quinapril-hydrochloride-tablet-68180-556-09.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "lupin-pharmaceuticals-inc-quinapril-hydrochloride-tablet-68180-556-09", "initial_posting_date": "01/19/2023", "manufacturer_name": "Lupin Pharmaceuticals, Inc.", "package_ndc": "68180-556-09", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"68180-556-09\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-587-4617\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lupin%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "68180-556-09 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Lupin Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 68180-557-09\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Lupin Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"68180-557-09\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"Lupin Pharmaceuticals, Inc.\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lupin%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "lupin-pharmaceuticals-inc-quinapril-hydrochloride-tablet-68180-557-09.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "lupin-pharmaceuticals-inc-quinapril-hydrochloride-tablet-68180-557-09", "initial_posting_date": "01/19/2023", "manufacturer_name": "Lupin Pharmaceuticals, Inc.", "package_ndc": "68180-557-09", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"68180-557-09\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"Lupin Pharmaceuticals, Inc.\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lupin%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "68180-557-09 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Lupin Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 68180-558-09\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Lupin Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Requirements related to complying with good manufacturing practices\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"68180-558-09\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-587-4617\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lupin%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "lupin-pharmaceuticals-inc-quinapril-hydrochloride-tablet-68180-558-09.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "lupin-pharmaceuticals-inc-quinapril-hydrochloride-tablet-68180-558-09", "initial_posting_date": "01/19/2023", "manufacturer_name": "Lupin Pharmaceuticals, Inc.", "package_ndc": "68180-558-09", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"shortage_reason\": \"Requirements related to complying with good manufacturing practices\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Requirements related to complying with good manufacturing practices", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"68180-558-09\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-587-4617\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lupin%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "68180-558-09 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Lupin Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 68180-658-06\n\n**Generic name:** Rifampin Capsule\n\n**Manufacturer:** Lupin Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 68180-658-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 68180-658-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/22/2021\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 68180-658-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1714\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 68180-658-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 68180-658-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"68180-658-06\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"866-587-4617\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lupin%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1714", "dosage_form": "Capsule", "file": "lupin-pharmaceuticals-inc-rifampin-capsule-68180-658-06.md", "generated": true, "generic_name": "Rifampin Capsule", "harvested": "2026-09-01", "id": "lupin-pharmaceuticals-inc-rifampin-capsule-68180-658-06", "initial_posting_date": "12/22/2021", "manufacturer_name": "Lupin Pharmaceuticals, Inc.", "package_ndc": "68180-658-06", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 68180-658-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 68180-658-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 68180-658-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 68180-658-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 150 mg (NDC 68180-658-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"68180-658-06\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"866-587-4617\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lupin%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "68180-658-06 \u00b7 Rifampin Capsule \u00b7 Lupin Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 68180-659-06\n\n**Generic name:** Rifampin Capsule\n\n**Manufacturer:** Lupin Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/22/2021\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1714\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"68180-659-06\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"866-587-4617\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lupin%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1714", "dosage_form": "Capsule", "file": "lupin-pharmaceuticals-inc-rifampin-capsule-68180-659-06.md", "generated": true, "generic_name": "Rifampin Capsule", "harvested": "2026-09-01", "id": "lupin-pharmaceuticals-inc-rifampin-capsule-68180-659-06", "initial_posting_date": "12/22/2021", "manufacturer_name": "Lupin Pharmaceuticals, Inc.", "package_ndc": "68180-659-06", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-06)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"68180-659-06\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"866-587-4617\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lupin%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "68180-659-06 \u00b7 Rifampin Capsule \u00b7 Lupin Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 68180-659-07\n\n**Generic name:** Rifampin Capsule\n\n**Manufacturer:** Lupin Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-07)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-07)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/22/2021\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-07)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1714\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-07)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-07)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"68180-659-07\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"866-587-4617\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lupin%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1714", "dosage_form": "Capsule", "file": "lupin-pharmaceuticals-inc-rifampin-capsule-68180-659-07.md", "generated": true, "generic_name": "Rifampin Capsule", "harvested": "2026-09-01", "id": "lupin-pharmaceuticals-inc-rifampin-capsule-68180-659-07", "initial_posting_date": "12/22/2021", "manufacturer_name": "Lupin Pharmaceuticals, Inc.", "package_ndc": "68180-659-07", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-07)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-07)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-07)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-07)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Rifampin, Capsule, 300 mg (NDC 68180-659-07)\", \"company_name\": \"Lupin Pharmaceuticals, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"12/22/2021\", \"package_ndc\": \"68180-659-07\", \"generic_name\": \"Rifampin Capsule\", \"contact_info\": \"866-587-4617\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Lupin%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Rifampin%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "68180-659-07 \u00b7 Rifampin Capsule \u00b7 Lupin Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 64253-400-91\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Medefil, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"64253-400-91\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"630-682-4600\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Medefil,%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "medefil-inc-atropine-sulfate-injection-64253-400-91.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "medefil-inc-atropine-sulfate-injection-64253-400-91", "initial_posting_date": "01/01/2012", "manufacturer_name": "Medefil, Inc.", "package_ndc": "64253-400-91", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"64253-400-91\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"630-682-4600\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Medefil,%20Inc.%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "64253-400-91 \u00b7 Atropine Sulfate Injection \u00b7 Medefil, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 64253-020-30\n\n**Generic name:** Sterile Water Injection\n\n**Manufacturer:** Medefil, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/23/2021\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1743\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"64253-020-30\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"630-682-4600\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Medefil,%20Inc.%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1743", "dosage_form": "Injection", "file": "medefil-inc-sterile-water-injection-64253-020-30.md", "generated": true, "generic_name": "Sterile Water Injection", "harvested": "2026-09-01", "id": "medefil-inc-sterile-water-injection-64253-020-30", "initial_posting_date": "11/23/2021", "manufacturer_name": "Medefil, Inc.", "package_ndc": "64253-020-30", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)\", \"company_name\": \"Medefil, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"64253-020-30\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"630-682-4600\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Medefil,%20Inc.%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Other", "title": "64253-020-30 \u00b7 Sterile Water Injection \u00b7 Medefil, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59137-570-01\n\n**Generic name:** Triamcinolone Hexacetonide Injection\n\n**Manufacturer:** Medexus\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 05/04/2021\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"status\": \"Current\"\n\n**Days in shortage:** 1948\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/04/2021\", \"package_ndc\": \"59137-570-01\", \"generic_name\": \"Triamcinolone Hexacetonide Injection\", \"related_info_link\": \"https://www.fda.gov/media/192735/download?attachment\", \"contact_info\": \"1-855-336-3322 Option 9\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Medexus%22+AND+generic_name%3A%22Triamcinolone%20Hexacetonide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1948", "dosage_form": "Injection", "file": "medexus-triamcinolone-hexacetonide-injection-59137-570-01-2.md", "generated": true, "generic_name": "Triamcinolone Hexacetonide Injection", "harvested": "2026-09-03", "id": "medexus-triamcinolone-hexacetonide-injection-59137-570-01-2", "initial_posting_date": "05/04/2021", "manufacturer_name": "Medexus", "package_ndc": "59137-570-01", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"05/04/2021\", \"package_ndc\": \"59137-570-01\", \"generic_name\": \"Triamcinolone Hexacetonide Injection\", \"related_info_link\": \"https://www.fda.gov/media/192735/download?attachment\", \"contact_info\": \"1-855-336-3322 Option 9\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Medexus%22+AND+generic_name%3A%22Triamcinolone%20Hexacetonide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Rheumatology", "title": "59137-570-01 \u00b7 Triamcinolone Hexacetonide Injection \u00b7 Medexus \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 59137-570-01\n\n**Generic name:** Triamcinolone Hexacetonide Injection\n\n**Manufacturer:** Medexus\n\n> \"update_date\": \"05/27/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"05/27/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 05/04/2021\n\n**Last update date:** 05/27/2026\n\n> \"update_date\": \"05/27/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1946\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"05/27/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"05/27/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"05/27/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"05/04/2021\", \"package_ndc\": \"59137-570-01\", \"generic_name\": \"Triamcinolone Hexacetonide Injection\", \"related_info_link\": \"https://www.fda.gov/media/192735/download?attachment\", \"contact_info\": \"1-855-336-3322 Option 9\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Medexus%22+AND+generic_name%3A%22Triamcinolone%20Hexacetonide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1946", "dosage_form": "Injection", "file": "medexus-triamcinolone-hexacetonide-injection-59137-570-01.md", "generated": true, "generic_name": "Triamcinolone Hexacetonide Injection", "harvested": "2026-09-01", "id": "medexus-triamcinolone-hexacetonide-injection-59137-570-01", "initial_posting_date": "05/04/2021", "manufacturer_name": "Medexus", "package_ndc": "59137-570-01", "quote_dosage_form": "\"update_date\": \"05/27/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"05/27/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"05/27/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"05/27/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"05/27/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"05/27/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)\", \"company_name\": \"Medexus\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"05/04/2021\", \"package_ndc\": \"59137-570-01\", \"generic_name\": \"Triamcinolone Hexacetonide Injection\", \"related_info_link\": \"https://www.fda.gov/media/192735/download?attachment\", \"contact_info\": \"1-855-336-3322 Option 9\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Medexus%22+AND+generic_name%3A%22Triamcinolone%20Hexacetonide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "59137-570-01 \u00b7 Triamcinolone Hexacetonide Injection \u00b7 Medexus \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "05/27/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 71288-115-30\n\n**Generic name:** Azacitidine Injection\n\n**Manufacturer:** Meitheal Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/18/2020\n\n**Last update date:** 08/27/2026\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2083\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/18/2020\", \"package_ndc\": \"71288-115-30\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2083", "dosage_form": "Injection", "file": "meitheal-pharmaceuticals-inc-azacitidine-injection-71288-115-30.md", "generated": true, "generic_name": "Azacitidine Injection", "harvested": "2026-09-01", "id": "meitheal-pharmaceuticals-inc-azacitidine-injection-71288-115-30", "initial_posting_date": "12/18/2020", "manufacturer_name": "Meitheal Pharmaceuticals, Inc.", "package_ndc": "71288-115-30", "quote_dosage_form": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"12/18/2020\", \"package_ndc\": \"71288-115-30\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "71288-115-30 \u00b7 Azacitidine Injection \u00b7 Meitheal Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/27/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 71288-505-03\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Meitheal Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2021\n\n**Last update date:** 08/27/2026\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1970\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2021\", \"package_ndc\": \"71288-505-03\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1970", "dosage_form": "Injection", "file": "meitheal-pharmaceuticals-inc-dexmedetomidine-hydrochloride-injection-71288-505-03.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "meitheal-pharmaceuticals-inc-dexmedetomidine-hydrochloride-injection-71288-505-03", "initial_posting_date": "04/10/2021", "manufacturer_name": "Meitheal Pharmaceuticals, Inc.", "package_ndc": "71288-505-03", "quote_dosage_form": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"04/10/2021\", \"package_ndc\": \"71288-505-03\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "71288-505-03 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Meitheal Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/27/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 71288-203-05\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Meitheal Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/27/2026\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"71288-203-05\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "meitheal-pharmaceuticals-inc-furosemide-injection-71288-203-05.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "meitheal-pharmaceuticals-inc-furosemide-injection-71288-203-05", "initial_posting_date": "04/07/2020", "manufacturer_name": "Meitheal Pharmaceuticals, Inc.", "package_ndc": "71288-203-05", "quote_dosage_form": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"71288-203-05\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "71288-203-05 \u00b7 Furosemide Injection \u00b7 Meitheal Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/27/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 71288-203-11\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Meitheal Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/27/2026\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"71288-203-11\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "meitheal-pharmaceuticals-inc-furosemide-injection-71288-203-11.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "meitheal-pharmaceuticals-inc-furosemide-injection-71288-203-11", "initial_posting_date": "04/07/2020", "manufacturer_name": "Meitheal Pharmaceuticals, Inc.", "package_ndc": "71288-203-11", "quote_dosage_form": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"71288-203-11\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "71288-203-11 \u00b7 Furosemide Injection \u00b7 Meitheal Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/27/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 71288-205-03\n\n**Generic name:** Furosemide Injection\n\n**Manufacturer:** Meitheal Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Check wholesalers for inventory\n\n**Initial posting date:** 04/07/2020\n\n**Last update date:** 08/27/2026\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2338\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"71288-205-03\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2338", "dosage_form": "Injection", "file": "meitheal-pharmaceuticals-inc-furosemide-injection-71288-205-03.md", "generated": true, "generic_name": "Furosemide Injection", "harvested": "2026-09-01", "id": "meitheal-pharmaceuticals-inc-furosemide-injection-71288-205-03", "initial_posting_date": "04/07/2020", "manufacturer_name": "Meitheal Pharmaceuticals, Inc.", "package_ndc": "71288-205-03", "quote_dosage_form": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "related_info": "Check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"04/07/2020\", \"package_ndc\": \"71288-205-03\", \"generic_name\": \"Furosemide Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\", \"related_info\": \"Check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Furosemide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "71288-205-03 \u00b7 Furosemide Injection \u00b7 Meitheal Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/27/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 71288-563-84\n\n**Generic name:** Liraglutide Injection\n\n**Manufacturer:** Meitheal Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/18/2023\n\n**Last update date:** 08/27/2026\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1141\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"71288-563-84\", \"generic_name\": \"Liraglutide Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1141", "dosage_form": "Injection", "file": "meitheal-pharmaceuticals-inc-liraglutide-injection-71288-563-84.md", "generated": true, "generic_name": "Liraglutide Injection", "harvested": "2026-09-01", "id": "meitheal-pharmaceuticals-inc-liraglutide-injection-71288-563-84", "initial_posting_date": "07/18/2023", "manufacturer_name": "Meitheal Pharmaceuticals, Inc.", "package_ndc": "71288-563-84", "quote_dosage_form": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"71288-563-84\", \"generic_name\": \"Liraglutide Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "71288-563-84 \u00b7 Liraglutide Injection \u00b7 Meitheal Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/27/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 71288-563-85\n\n**Generic name:** Liraglutide Injection\n\n**Manufacturer:** Meitheal Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/18/2023\n\n**Last update date:** 08/27/2026\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1141\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"71288-563-85\", \"generic_name\": \"Liraglutide Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1141", "dosage_form": "Injection", "file": "meitheal-pharmaceuticals-inc-liraglutide-injection-71288-563-85.md", "generated": true, "generic_name": "Liraglutide Injection", "harvested": "2026-09-01", "id": "meitheal-pharmaceuticals-inc-liraglutide-injection-71288-563-85", "initial_posting_date": "07/18/2023", "manufacturer_name": "Meitheal Pharmaceuticals, Inc.", "package_ndc": "71288-563-85", "quote_dosage_form": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"71288-563-85\", \"generic_name\": \"Liraglutide Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "71288-563-85 \u00b7 Liraglutide Injection \u00b7 Meitheal Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/27/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 71288-700-06\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Meitheal Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/27/2026\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"71288-700-06\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "meitheal-pharmaceuticals-inc-rocuronium-bromide-injection-71288-700-06.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "meitheal-pharmaceuticals-inc-rocuronium-bromide-injection-71288-700-06", "initial_posting_date": "02/15/2023", "manufacturer_name": "Meitheal Pharmaceuticals, Inc.", "package_ndc": "71288-700-06", "quote_dosage_form": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"71288-700-06\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "71288-700-06 \u00b7 Rocuronium Bromide Injection \u00b7 Meitheal Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/27/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 71288-718-11\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Meitheal Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/27/2026\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"71288-718-11\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "meitheal-pharmaceuticals-inc-rocuronium-bromide-injection-71288-718-11.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "meitheal-pharmaceuticals-inc-rocuronium-bromide-injection-71288-718-11", "initial_posting_date": "02/15/2023", "manufacturer_name": "Meitheal Pharmaceuticals, Inc.", "package_ndc": "71288-718-11", "quote_dosage_form": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/27/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)\", \"company_name\": \"Meitheal Pharmaceuticals, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"71288-718-11\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"844-824-8426\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Meitheal%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "71288-718-11 \u00b7 Rocuronium Bromide Injection \u00b7 Meitheal Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/27/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 42571-132-52\n\n**Generic name:** Cromolyn Sodium Concentrate\n\n**Manufacturer:** Micro Labs LTD\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)\", \"company_name\": \"Micro Labs LTD\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)\", \"company_name\": \"Micro Labs LTD\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/03/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)\", \"company_name\": \"Micro Labs LTD\", \"status\": \"Current\"\n\n**Days in shortage:** 1033\n\n**Dosage form:** Concentrate\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)\", \"company_name\": \"Micro Labs LTD\", \"status\": \"Current\"\n\n**Therapeutic category:** Pulmonary/Allergy\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)\", \"company_name\": \"Micro Labs LTD\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/03/2023\", \"package_ndc\": \"42571-132-52\", \"generic_name\": \"Cromolyn Sodium Concentrate\", \"contact_info\": \"(908) 484-7410\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Micro%20Labs%20LTD%22+AND+generic_name%3A%22Cromolyn%20Sodium%20Concentrate%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1033", "dosage_form": "Concentrate", "file": "micro-labs-ltd-cromolyn-sodium-concentrate-42571-132-52.md", "generated": true, "generic_name": "Cromolyn Sodium Concentrate", "harvested": "2026-09-01", "id": "micro-labs-ltd-cromolyn-sodium-concentrate-42571-132-52", "initial_posting_date": "11/03/2023", "manufacturer_name": "Micro Labs LTD", "package_ndc": "42571-132-52", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)\", \"company_name\": \"Micro Labs LTD\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)\", \"company_name\": \"Micro Labs LTD\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)\", \"company_name\": \"Micro Labs LTD\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)\", \"company_name\": \"Micro Labs LTD\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)\", \"company_name\": \"Micro Labs LTD\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/03/2023\", \"package_ndc\": \"42571-132-52\", \"generic_name\": \"Cromolyn Sodium Concentrate\", \"contact_info\": \"(908) 484-7410\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Micro%20Labs%20LTD%22+AND+generic_name%3A%22Cromolyn%20Sodium%20Concentrate%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Pulmonary/Allergy", "title": "42571-132-52 \u00b7 Cromolyn Sodium Concentrate \u00b7 Micro Labs LTD \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 71357-002-10\n\n**Generic name:** Sodium Acetate Injection\n\n**Manufacturer:** Milla Pharmaceuticals\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/03/2016\n\n**Last update date:** 08/15/2026\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 3863\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"71357-002-10\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"833-251-8463\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Milla%20Pharmaceuticals%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3863", "dosage_form": "Injection", "file": "milla-pharmaceuticals-sodium-acetate-injection-71357-002-10.md", "generated": true, "generic_name": "Sodium Acetate Injection", "harvested": "2026-09-01", "id": "milla-pharmaceuticals-sodium-acetate-injection-71357-002-10", "initial_posting_date": "02/03/2016", "manufacturer_name": "Milla Pharmaceuticals", "package_ndc": "71357-002-10", "quote_dosage_form": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"71357-002-10\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"833-251-8463\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Milla%20Pharmaceuticals%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "71357-002-10 \u00b7 Sodium Acetate Injection \u00b7 Milla Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 71357-007-10\n\n**Generic name:** Sodium Acetate Injection\n\n**Manufacturer:** Milla Pharmaceuticals\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2016\n\n**Last update date:** 08/15/2026\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 3814\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Total Parenteral Nutrition\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2016\", \"package_ndc\": \"71357-007-10\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"833-251-8463\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Milla%20Pharmaceuticals%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3814", "dosage_form": "Injection", "file": "milla-pharmaceuticals-sodium-acetate-injection-71357-007-10.md", "generated": true, "generic_name": "Sodium Acetate Injection", "harvested": "2026-09-01", "id": "milla-pharmaceuticals-sodium-acetate-injection-71357-007-10", "initial_posting_date": "03/23/2016", "manufacturer_name": "Milla Pharmaceuticals", "package_ndc": "71357-007-10", "quote_dosage_form": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/23/2016\", \"package_ndc\": \"71357-007-10\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"833-251-8463\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Milla%20Pharmaceuticals%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Total Parenteral Nutrition", "title": "71357-007-10 \u00b7 Sodium Acetate Injection \u00b7 Milla Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 71357-008-10\n\n**Generic name:** Sodium Acetate Injection\n\n**Manufacturer:** Milla Pharmaceuticals\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2016\n\n**Last update date:** 08/15/2026\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 3814\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Total Parenteral Nutrition\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2016\", \"package_ndc\": \"71357-008-10\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"833-251-8463\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Milla%20Pharmaceuticals%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3814", "dosage_form": "Injection", "file": "milla-pharmaceuticals-sodium-acetate-injection-71357-008-10.md", "generated": true, "generic_name": "Sodium Acetate Injection", "harvested": "2026-09-01", "id": "milla-pharmaceuticals-sodium-acetate-injection-71357-008-10", "initial_posting_date": "03/23/2016", "manufacturer_name": "Milla Pharmaceuticals", "package_ndc": "71357-008-10", "quote_dosage_form": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/23/2016\", \"package_ndc\": \"71357-008-10\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"833-251-8463\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Milla%20Pharmaceuticals%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Total Parenteral Nutrition", "title": "71357-008-10 \u00b7 Sodium Acetate Injection \u00b7 Milla Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 71357-009-10\n\n**Generic name:** Sodium Acetate Injection\n\n**Manufacturer:** Milla Pharmaceuticals\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 02/03/2016\n\n**Last update date:** 08/15/2026\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3863\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"71357-009-10\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"833-251-8463\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Milla%20Pharmaceuticals%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3863", "dosage_form": "Injection", "file": "milla-pharmaceuticals-sodium-acetate-injection-71357-009-10.md", "generated": true, "generic_name": "Sodium Acetate Injection", "harvested": "2026-09-01", "id": "milla-pharmaceuticals-sodium-acetate-injection-71357-009-10", "initial_posting_date": "02/03/2016", "manufacturer_name": "Milla Pharmaceuticals", "package_ndc": "71357-009-10", "quote_dosage_form": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)\", \"company_name\": \"Milla Pharmaceuticals\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"71357-009-10\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"833-251-8463\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Milla%20Pharmaceuticals%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "71357-009-10 \u00b7 Sodium Acetate Injection \u00b7 Milla Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72205-101-01\n\n**Generic name:** Bumetanide Injection\n\n**Manufacturer:** MSN Laboratories Private Limited\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/13/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 3192\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"72205-101-01\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"855-668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3192", "dosage_form": "Injection", "file": "msn-laboratories-private-limited-bumetanide-injection-72205-101-01-2.md", "generated": true, "generic_name": "Bumetanide Injection", "harvested": "2026-09-09", "id": "msn-laboratories-private-limited-bumetanide-injection-72205-101-01-2", "initial_posting_date": "12/13/2017", "manufacturer_name": "MSN Laboratories Private Limited", "package_ndc": "72205-101-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"72205-101-01\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"855-668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-12", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "72205-101-01 \u00b7 Bumetanide Injection \u00b7 MSN Laboratories Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72205-101-01\n\n**Generic name:** Bumetanide Injection\n\n**Manufacturer:** MSN Laboratories Private Limited\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by: Novadoz Pharmaceuticals LLC\n\n**Initial posting date:** 12/13/2017\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 3184\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"72205-101-01\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"855-668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\", \"related_info\": \"Distributed by: Novadoz Pharmaceuticals LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3184", "dosage_form": "Injection", "file": "msn-laboratories-private-limited-bumetanide-injection-72205-101-01.md", "generated": true, "generic_name": "Bumetanide Injection", "harvested": "2026-09-01", "id": "msn-laboratories-private-limited-bumetanide-injection-72205-101-01", "initial_posting_date": "12/13/2017", "manufacturer_name": "MSN Laboratories Private Limited", "package_ndc": "72205-101-01", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "related_info": "Distributed by: Novadoz Pharmaceuticals LLC", "source_quote": "\"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"72205-101-01\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"855-668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\", \"related_info\": \"Distributed by: Novadoz Pharmaceuticals LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "72205-101-01 \u00b7 Bumetanide Injection \u00b7 MSN Laboratories Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72205-101-07\n\n**Generic name:** Bumetanide Injection\n\n**Manufacturer:** MSN Laboratories Private Limited\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/13/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 3192\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"72205-101-07\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"855-668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3192", "dosage_form": "Injection", "file": "msn-laboratories-private-limited-bumetanide-injection-72205-101-07-2.md", "generated": true, "generic_name": "Bumetanide Injection", "harvested": "2026-09-09", "id": "msn-laboratories-private-limited-bumetanide-injection-72205-101-07-2", "initial_posting_date": "12/13/2017", "manufacturer_name": "MSN Laboratories Private Limited", "package_ndc": "72205-101-07", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"72205-101-07\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"855-668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-12", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "72205-101-07 \u00b7 Bumetanide Injection \u00b7 MSN Laboratories Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72205-101-07\n\n**Generic name:** Bumetanide Injection\n\n**Manufacturer:** MSN Laboratories Private Limited\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by: Novadoz Pharmaceuticals LLC\n\n**Initial posting date:** 12/13/2017\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 3184\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"72205-101-07\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"855-668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\", \"related_info\": \"Distributed by: Novadoz Pharmaceuticals LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3184", "dosage_form": "Injection", "file": "msn-laboratories-private-limited-bumetanide-injection-72205-101-07.md", "generated": true, "generic_name": "Bumetanide Injection", "harvested": "2026-09-01", "id": "msn-laboratories-private-limited-bumetanide-injection-72205-101-07", "initial_posting_date": "12/13/2017", "manufacturer_name": "MSN Laboratories Private Limited", "package_ndc": "72205-101-07", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "related_info": "Distributed by: Novadoz Pharmaceuticals LLC", "source_quote": "\"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"72205-101-07\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"855-668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\", \"related_info\": \"Distributed by: Novadoz Pharmaceuticals LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "72205-101-07 \u00b7 Bumetanide Injection \u00b7 MSN Laboratories Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72205-102-01\n\n**Generic name:** Bumetanide Injection\n\n**Manufacturer:** MSN Laboratories Private Limited\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/13/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 3192\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"72205-102-01\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"855-668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3192", "dosage_form": "Injection", "file": "msn-laboratories-private-limited-bumetanide-injection-72205-102-01-2.md", "generated": true, "generic_name": "Bumetanide Injection", "harvested": "2026-09-09", "id": "msn-laboratories-private-limited-bumetanide-injection-72205-102-01-2", "initial_posting_date": "12/13/2017", "manufacturer_name": "MSN Laboratories Private Limited", "package_ndc": "72205-102-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"72205-102-01\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"855-668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-12", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "72205-102-01 \u00b7 Bumetanide Injection \u00b7 MSN Laboratories Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72205-102-01\n\n**Generic name:** Bumetanide Injection\n\n**Manufacturer:** MSN Laboratories Private Limited\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by: Novadoz Pharmaceuticals LLC\n\n**Initial posting date:** 12/13/2017\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 3184\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"72205-102-01\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"855-668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\", \"related_info\": \"Distributed by: Novadoz Pharmaceuticals LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3184", "dosage_form": "Injection", "file": "msn-laboratories-private-limited-bumetanide-injection-72205-102-01.md", "generated": true, "generic_name": "Bumetanide Injection", "harvested": "2026-09-01", "id": "msn-laboratories-private-limited-bumetanide-injection-72205-102-01", "initial_posting_date": "12/13/2017", "manufacturer_name": "MSN Laboratories Private Limited", "package_ndc": "72205-102-01", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "related_info": "Distributed by: Novadoz Pharmaceuticals LLC", "source_quote": "\"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"72205-102-01\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"855-668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\", \"related_info\": \"Distributed by: Novadoz Pharmaceuticals LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "72205-102-01 \u00b7 Bumetanide Injection \u00b7 MSN Laboratories Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72205-102-07\n\n**Generic name:** Bumetanide Injection\n\n**Manufacturer:** MSN Laboratories Private Limited\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/13/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 3192\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"72205-102-07\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"855-668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3192", "dosage_form": "Injection", "file": "msn-laboratories-private-limited-bumetanide-injection-72205-102-07-2.md", "generated": true, "generic_name": "Bumetanide Injection", "harvested": "2026-09-09", "id": "msn-laboratories-private-limited-bumetanide-injection-72205-102-07-2", "initial_posting_date": "12/13/2017", "manufacturer_name": "MSN Laboratories Private Limited", "package_ndc": "72205-102-07", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"72205-102-07\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"855-668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-12", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "72205-102-07 \u00b7 Bumetanide Injection \u00b7 MSN Laboratories Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72205-102-07\n\n**Generic name:** Bumetanide Injection\n\n**Manufacturer:** MSN Laboratories Private Limited\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by: Novadoz Pharmaceuticals LLC\n\n**Initial posting date:** 12/13/2017\n\n**Last update date:** 08/21/2026\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 3184\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"72205-102-07\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"855-668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\", \"related_info\": \"Distributed by: Novadoz Pharmaceuticals LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3184", "dosage_form": "Injection", "file": "msn-laboratories-private-limited-bumetanide-injection-72205-102-07.md", "generated": true, "generic_name": "Bumetanide Injection", "harvested": "2026-09-01", "id": "msn-laboratories-private-limited-bumetanide-injection-72205-102-07", "initial_posting_date": "12/13/2017", "manufacturer_name": "MSN Laboratories Private Limited", "package_ndc": "72205-102-07", "quote_dosage_form": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/21/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)\", \"company_name\": \"MSN Laboratories Private Limited\", \"status\": \"Current\"", "related_info": "Distributed by: Novadoz Pharmaceuticals LLC", "source_quote": "\"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"72205-102-07\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"855-668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\", \"related_info\": \"Distributed by: Novadoz Pharmaceuticals LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22MSN%20Laboratories%20Private%20Limited%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "72205-102-07 \u00b7 Bumetanide Injection \u00b7 MSN Laboratories Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/21/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 83301-0080-2\n\n**Generic name:** Bumetanide Injection\n\n**Manufacturer:** Mullan Pharmaceutical Inc.\n\n> \"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/13/2017\n\n**Last update date:** 08/11/2026\n\n> \"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3184\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"83301-0080-2\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"800-673-9839\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mullan%20Pharmaceutical%20Inc.%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3184", "dosage_form": "Injection", "file": "mullan-pharmaceutical-inc-bumetanide-injection-83301-0080-2.md", "generated": true, "generic_name": "Bumetanide Injection", "harvested": "2026-09-01", "id": "mullan-pharmaceutical-inc-bumetanide-injection-83301-0080-2", "initial_posting_date": "12/13/2017", "manufacturer_name": "Mullan Pharmaceutical Inc.", "package_ndc": "83301-0080-2", "quote_dosage_form": "\"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"83301-0080-2\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"800-673-9839\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mullan%20Pharmaceutical%20Inc.%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "83301-0080-2 \u00b7 Bumetanide Injection \u00b7 Mullan Pharmaceutical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/11/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 83301-0081-2\n\n**Generic name:** Bumetanide Injection\n\n**Manufacturer:** Mullan Pharmaceutical Inc.\n\n> \"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/13/2017\n\n**Last update date:** 08/11/2026\n\n> \"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3184\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"83301-0081-2\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"800-673-9839\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mullan%20Pharmaceutical%20Inc.%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3184", "dosage_form": "Injection", "file": "mullan-pharmaceutical-inc-bumetanide-injection-83301-0081-2.md", "generated": true, "generic_name": "Bumetanide Injection", "harvested": "2026-09-01", "id": "mullan-pharmaceutical-inc-bumetanide-injection-83301-0081-2", "initial_posting_date": "12/13/2017", "manufacturer_name": "Mullan Pharmaceutical Inc.", "package_ndc": "83301-0081-2", "quote_dosage_form": "\"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/11/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2)\", \"company_name\": \"Mullan Pharmaceutical Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"12/13/2017\", \"package_ndc\": \"83301-0081-2\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"800-673-9839\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mullan%20Pharmaceutical%20Inc.%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "83301-0081-2 \u00b7 Bumetanide Injection \u00b7 Mullan Pharmaceutical Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/11/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 67457-420-10\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Mylan Institutional, a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"67457-420-10\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "mylan-institutional-a-viatris-company-dexamethasone-sodium-phosphate-injection-67457-420-10.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "mylan-institutional-a-viatris-company-dexamethasone-sodium-phosphate-injection-67457-420-10", "initial_posting_date": "02/08/2019", "manufacturer_name": "Mylan Institutional, a Viatris Company", "package_ndc": "67457-420-10", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"67457-420-10\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Dermatology", "title": "67457-420-10 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Mylan Institutional, a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 67457-421-30\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Mylan Institutional, a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"67457-421-30\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "mylan-institutional-a-viatris-company-dexamethasone-sodium-phosphate-injection-67457-421-30.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "mylan-institutional-a-viatris-company-dexamethasone-sodium-phosphate-injection-67457-421-30", "initial_posting_date": "02/08/2019", "manufacturer_name": "Mylan Institutional, a Viatris Company", "package_ndc": "67457-421-30", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"67457-421-30\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Dermatology", "title": "67457-421-30 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Mylan Institutional, a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 67457-422-54\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Mylan Institutional, a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"67457-422-54\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "mylan-institutional-a-viatris-company-dexamethasone-sodium-phosphate-injection-67457-422-54.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "mylan-institutional-a-viatris-company-dexamethasone-sodium-phosphate-injection-67457-422-54", "initial_posting_date": "02/08/2019", "manufacturer_name": "Mylan Institutional, a Viatris Company", "package_ndc": "67457-422-54", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"67457-422-54\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Dermatology", "title": "67457-422-54 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Mylan Institutional, a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 67457-423-12\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Mylan Institutional, a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"67457-423-12\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "mylan-institutional-a-viatris-company-dexamethasone-sodium-phosphate-injection-67457-423-12.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "mylan-institutional-a-viatris-company-dexamethasone-sodium-phosphate-injection-67457-423-12", "initial_posting_date": "02/08/2019", "manufacturer_name": "Mylan Institutional, a Viatris Company", "package_ndc": "67457-423-12", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"67457-423-12\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Dermatology", "title": "67457-423-12 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Mylan Institutional, a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 67457-251-02\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Mylan Institutional, a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"67457-251-02\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "mylan-institutional-a-viatris-company-dexmedetomidine-hydrochloride-injection-67457-251-02.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "mylan-institutional-a-viatris-company-dexmedetomidine-hydrochloride-injection-67457-251-02", "initial_posting_date": "04/10/2020", "manufacturer_name": "Mylan Institutional, a Viatris Company", "package_ndc": "67457-251-02", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"67457-251-02\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "67457-251-02 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Mylan Institutional, a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 67457-924-50\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Mylan Institutional, a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"67457-924-50\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "mylan-institutional-a-viatris-company-dexmedetomidine-hydrochloride-injection-67457-924-50.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "mylan-institutional-a-viatris-company-dexmedetomidine-hydrochloride-injection-67457-924-50", "initial_posting_date": "04/10/2020", "manufacturer_name": "Mylan Institutional, a Viatris Company", "package_ndc": "67457-924-50", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"67457-924-50\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "67457-924-50 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Mylan Institutional, a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 67457-925-10\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Mylan Institutional, a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"67457-925-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "mylan-institutional-a-viatris-company-dexmedetomidine-hydrochloride-injection-67457-925-10.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "mylan-institutional-a-viatris-company-dexmedetomidine-hydrochloride-injection-67457-925-10", "initial_posting_date": "04/10/2020", "manufacturer_name": "Mylan Institutional, a Viatris Company", "package_ndc": "67457-925-10", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"67457-925-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "67457-925-10 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Mylan Institutional, a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 67457-902-10\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Mylan Institutional, a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"67457-902-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "mylan-institutional-a-viatris-company-etomidate-injection-67457-902-10.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "mylan-institutional-a-viatris-company-etomidate-injection-67457-902-10", "initial_posting_date": "10/05/2022", "manufacturer_name": "Mylan Institutional, a Viatris Company", "package_ndc": "67457-902-10", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"67457-902-10\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "67457-902-10 \u00b7 Etomidate Injection \u00b7 Mylan Institutional, a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 67457-903-20\n\n**Generic name:** Etomidate Injection\n\n**Manufacturer:** Mylan Institutional, a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/05/2022\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1427\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"67457-903-20\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1427", "dosage_form": "Injection", "file": "mylan-institutional-a-viatris-company-etomidate-injection-67457-903-20.md", "generated": true, "generic_name": "Etomidate Injection", "harvested": "2026-09-01", "id": "mylan-institutional-a-viatris-company-etomidate-injection-67457-903-20", "initial_posting_date": "10/05/2022", "manufacturer_name": "Mylan Institutional, a Viatris Company", "package_ndc": "67457-903-20", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"10/05/2022\", \"package_ndc\": \"67457-903-20\", \"generic_name\": \"Etomidate Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Etomidate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "67457-903-20 \u00b7 Etomidate Injection \u00b7 Mylan Institutional, a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72078-034-01\n\n**Generic name:** Remifentanil Hydrochloride Injection\n\n**Manufacturer:** Mylan Institutional, a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 06/28/2022\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1526\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"72078-034-01\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1526", "dosage_form": "Injection", "file": "mylan-institutional-a-viatris-company-remifentanil-hydrochloride-injection-72078-034-01.md", "generated": true, "generic_name": "Remifentanil Hydrochloride Injection", "harvested": "2026-09-01", "id": "mylan-institutional-a-viatris-company-remifentanil-hydrochloride-injection-72078-034-01", "initial_posting_date": "06/28/2022", "manufacturer_name": "Mylan Institutional, a Viatris Company", "package_ndc": "72078-034-01", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"72078-034-01\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "72078-034-01 \u00b7 Remifentanil Hydrochloride Injection \u00b7 Mylan Institutional, a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72078-035-02\n\n**Generic name:** Remifentanil Hydrochloride Injection\n\n**Manufacturer:** Mylan Institutional, a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 2 mg (NDC 72078-035-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 2 mg (NDC 72078-035-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 06/28/2022\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 2 mg (NDC 72078-035-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1526\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 2 mg (NDC 72078-035-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 2 mg (NDC 72078-035-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"72078-035-02\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1526", "dosage_form": "Injection", "file": "mylan-institutional-a-viatris-company-remifentanil-hydrochloride-injection-72078-035-02.md", "generated": true, "generic_name": "Remifentanil Hydrochloride Injection", "harvested": "2026-09-01", "id": "mylan-institutional-a-viatris-company-remifentanil-hydrochloride-injection-72078-035-02", "initial_posting_date": "06/28/2022", "manufacturer_name": "Mylan Institutional, a Viatris Company", "package_ndc": "72078-035-02", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 2 mg (NDC 72078-035-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 2 mg (NDC 72078-035-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 2 mg (NDC 72078-035-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 2 mg (NDC 72078-035-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 2 mg (NDC 72078-035-02)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"72078-035-02\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "72078-035-02 \u00b7 Remifentanil Hydrochloride Injection \u00b7 Mylan Institutional, a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72078-036-05\n\n**Generic name:** Remifentanil Hydrochloride Injection\n\n**Manufacturer:** Mylan Institutional, a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 5 mg (NDC 72078-036-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 5 mg (NDC 72078-036-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 06/28/2022\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 5 mg (NDC 72078-036-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1526\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 5 mg (NDC 72078-036-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 5 mg (NDC 72078-036-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"72078-036-05\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1526", "dosage_form": "Injection", "file": "mylan-institutional-a-viatris-company-remifentanil-hydrochloride-injection-72078-036-05.md", "generated": true, "generic_name": "Remifentanil Hydrochloride Injection", "harvested": "2026-09-01", "id": "mylan-institutional-a-viatris-company-remifentanil-hydrochloride-injection-72078-036-05", "initial_posting_date": "06/28/2022", "manufacturer_name": "Mylan Institutional, a Viatris Company", "package_ndc": "72078-036-05", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 5 mg (NDC 72078-036-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 5 mg (NDC 72078-036-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 5 mg (NDC 72078-036-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 5 mg (NDC 72078-036-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ultiva, Injection, 5 mg (NDC 72078-036-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"06/28/2022\", \"package_ndc\": \"72078-036-05\", \"generic_name\": \"Remifentanil Hydrochloride Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Remifentanil%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "72078-036-05 \u00b7 Remifentanil Hydrochloride Injection \u00b7 Mylan Institutional, a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 67457-445-60\n\n**Generic name:** Rifampin Injection\n\n**Manufacturer:** Mylan Institutional, a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 67457-445-60)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 67457-445-60)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: Q4 2026\n\n**Initial posting date:** 02/17/2021\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 67457-445-60)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2022\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 67457-445-60)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 67457-445-60)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 67457-445-60)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/17/2021\", \"package_ndc\": \"67457-445-60\", \"generic_name\": \"Rifampin Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: Q4 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Rifampin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2022", "dosage_form": "Injection", "file": "mylan-institutional-a-viatris-company-rifampin-injection-67457-445-60.md", "generated": true, "generic_name": "Rifampin Injection", "harvested": "2026-09-01", "id": "mylan-institutional-a-viatris-company-rifampin-injection-67457-445-60", "initial_posting_date": "02/17/2021", "manufacturer_name": "Mylan Institutional, a Viatris Company", "package_ndc": "67457-445-60", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 67457-445-60)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 67457-445-60)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 67457-445-60)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 67457-445-60)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 67457-445-60)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifampin, Injection, 600 mg (NDC 67457-445-60)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: Q4 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/17/2021\", \"package_ndc\": \"67457-445-60\", \"generic_name\": \"Rifampin Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: Q4 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Rifampin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "67457-445-60 \u00b7 Rifampin Injection \u00b7 Mylan Institutional, a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 67457-228-05\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Mylan Institutional, a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"67457-228-05\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "mylan-institutional-a-viatris-company-rocuronium-bromide-injection-67457-228-05.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "mylan-institutional-a-viatris-company-rocuronium-bromide-injection-67457-228-05", "initial_posting_date": "02/15/2023", "manufacturer_name": "Mylan Institutional, a Viatris Company", "package_ndc": "67457-228-05", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"67457-228-05\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "67457-228-05 \u00b7 Rocuronium Bromide Injection \u00b7 Mylan Institutional, a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 67457-228-10\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Mylan Institutional, a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"67457-228-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "mylan-institutional-a-viatris-company-rocuronium-bromide-injection-67457-228-10.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "mylan-institutional-a-viatris-company-rocuronium-bromide-injection-67457-228-10", "initial_posting_date": "02/15/2023", "manufacturer_name": "Mylan Institutional, a Viatris Company", "package_ndc": "67457-228-10", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)\", \"company_name\": \"Mylan Institutional, a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"67457-228-10\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Institutional,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "67457-228-10 \u00b7 Rocuronium Bromide Injection \u00b7 Mylan Institutional, a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0378-6854-77\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Mylan Pharmaceuticals Inc., a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0378-6854-77\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Pharmaceuticals%20Inc.,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "mylan-pharmaceuticals-inc-a-viatris-company-lisdexamfetamine-dimesylate-capsule-0378-6854-77.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "mylan-pharmaceuticals-inc-a-viatris-company-lisdexamfetamine-dimesylate-capsule-0378-6854-77", "initial_posting_date": "07/14/2023", "manufacturer_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "package_ndc": "0378-6854-77", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0378-6854-77\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Pharmaceuticals%20Inc.,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0378-6854-77 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Mylan Pharmaceuticals Inc., a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0378-6855-77\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Mylan Pharmaceuticals Inc., a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0378-6855-77\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Pharmaceuticals%20Inc.,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "mylan-pharmaceuticals-inc-a-viatris-company-lisdexamfetamine-dimesylate-capsule-0378-6855-77.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "mylan-pharmaceuticals-inc-a-viatris-company-lisdexamfetamine-dimesylate-capsule-0378-6855-77", "initial_posting_date": "07/14/2023", "manufacturer_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "package_ndc": "0378-6855-77", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0378-6855-77\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Pharmaceuticals%20Inc.,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0378-6855-77 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Mylan Pharmaceuticals Inc., a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0378-6856-77\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Mylan Pharmaceuticals Inc., a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0378-6856-77\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Pharmaceuticals%20Inc.,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "mylan-pharmaceuticals-inc-a-viatris-company-lisdexamfetamine-dimesylate-capsule-0378-6856-77.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "mylan-pharmaceuticals-inc-a-viatris-company-lisdexamfetamine-dimesylate-capsule-0378-6856-77", "initial_posting_date": "07/14/2023", "manufacturer_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "package_ndc": "0378-6856-77", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0378-6856-77\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Pharmaceuticals%20Inc.,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0378-6856-77 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Mylan Pharmaceuticals Inc., a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0378-6857-77\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Mylan Pharmaceuticals Inc., a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0378-6857-77\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Pharmaceuticals%20Inc.,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "mylan-pharmaceuticals-inc-a-viatris-company-lisdexamfetamine-dimesylate-capsule-0378-6857-77.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "mylan-pharmaceuticals-inc-a-viatris-company-lisdexamfetamine-dimesylate-capsule-0378-6857-77", "initial_posting_date": "07/14/2023", "manufacturer_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "package_ndc": "0378-6857-77", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0378-6857-77\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Pharmaceuticals%20Inc.,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0378-6857-77 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Mylan Pharmaceuticals Inc., a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0378-6858-77\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Mylan Pharmaceuticals Inc., a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0378-6858-77\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Pharmaceuticals%20Inc.,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "mylan-pharmaceuticals-inc-a-viatris-company-lisdexamfetamine-dimesylate-capsule-0378-6858-77.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "mylan-pharmaceuticals-inc-a-viatris-company-lisdexamfetamine-dimesylate-capsule-0378-6858-77", "initial_posting_date": "07/14/2023", "manufacturer_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "package_ndc": "0378-6858-77", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0378-6858-77\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Pharmaceuticals%20Inc.,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0378-6858-77 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Mylan Pharmaceuticals Inc., a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0378-6859-77\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Mylan Pharmaceuticals Inc., a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0378-6859-77\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Pharmaceuticals%20Inc.,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "mylan-pharmaceuticals-inc-a-viatris-company-lisdexamfetamine-dimesylate-capsule-0378-6859-77.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "mylan-pharmaceuticals-inc-a-viatris-company-lisdexamfetamine-dimesylate-capsule-0378-6859-77", "initial_posting_date": "07/14/2023", "manufacturer_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "package_ndc": "0378-6859-77", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0378-6859-77\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Pharmaceuticals%20Inc.,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0378-6859-77 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Mylan Pharmaceuticals Inc., a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0378-6860-77\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Mylan Pharmaceuticals Inc., a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0378-6860-77\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Pharmaceuticals%20Inc.,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "mylan-pharmaceuticals-inc-a-viatris-company-lisdexamfetamine-dimesylate-capsule-0378-6860-77.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "mylan-pharmaceuticals-inc-a-viatris-company-lisdexamfetamine-dimesylate-capsule-0378-6860-77", "initial_posting_date": "07/14/2023", "manufacturer_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "package_ndc": "0378-6860-77", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)\", \"company_name\": \"Mylan Pharmaceuticals Inc., a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0378-6860-77\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Pharmaceuticals%20Inc.,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0378-6860-77 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Mylan Pharmaceuticals Inc., a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0037-0678-96\n\n**Generic name:** Cromolyn Sodium Concentrate\n\n**Manufacturer:** Mylan Specialty, a Viatris Company\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)\", \"company_name\": \"Mylan Specialty, a Viatris Company\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)\", \"company_name\": \"Mylan Specialty, a Viatris Company\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/03/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)\", \"company_name\": \"Mylan Specialty, a Viatris Company\", \"status\": \"Current\"\n\n**Days in shortage:** 1033\n\n**Dosage form:** Concentrate\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)\", \"company_name\": \"Mylan Specialty, a Viatris Company\", \"status\": \"Current\"\n\n**Therapeutic category:** Pulmonary/Allergy\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)\", \"company_name\": \"Mylan Specialty, a Viatris Company\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/03/2023\", \"package_ndc\": \"0037-0678-96\", \"generic_name\": \"Cromolyn Sodium Concentrate\", \"contact_info\": \"(800) 796-9526\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Specialty,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Cromolyn%20Sodium%20Concentrate%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1033", "dosage_form": "Concentrate", "file": "mylan-specialty-a-viatris-company-cromolyn-sodium-concentrate-0037-0678-96.md", "generated": true, "generic_name": "Cromolyn Sodium Concentrate", "harvested": "2026-09-01", "id": "mylan-specialty-a-viatris-company-cromolyn-sodium-concentrate-0037-0678-96", "initial_posting_date": "11/03/2023", "manufacturer_name": "Mylan Specialty, a Viatris Company", "package_ndc": "0037-0678-96", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)\", \"company_name\": \"Mylan Specialty, a Viatris Company\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)\", \"company_name\": \"Mylan Specialty, a Viatris Company\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)\", \"company_name\": \"Mylan Specialty, a Viatris Company\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)\", \"company_name\": \"Mylan Specialty, a Viatris Company\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)\", \"company_name\": \"Mylan Specialty, a Viatris Company\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"11/03/2023\", \"package_ndc\": \"0037-0678-96\", \"generic_name\": \"Cromolyn Sodium Concentrate\", \"contact_info\": \"(800) 796-9526\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Mylan%20Specialty,%20a%20Viatris%20Company%22+AND+generic_name%3A%22Cromolyn%20Sodium%20Concentrate%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Pulmonary/Allergy", "title": "0037-0678-96 \u00b7 Cromolyn Sodium Concentrate \u00b7 Mylan Specialty, a Viatris Company \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0487-6105-01\n\n**Generic name:** Sterile Water Injection\n\n**Manufacturer:** Nephron Pharmaceuticals Corporation\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)\", \"company_name\": \"Nephron Pharmaceuticals Corporation\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)\", \"company_name\": \"Nephron Pharmaceuticals Corporation\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Small amount of inventory available with 12/31/2026 dating\n\n**Initial posting date:** 11/23/2021\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)\", \"company_name\": \"Nephron Pharmaceuticals Corporation\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1743\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)\", \"company_name\": \"Nephron Pharmaceuticals Corporation\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)\", \"company_name\": \"Nephron Pharmaceuticals Corporation\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Other\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)\", \"company_name\": \"Nephron Pharmaceuticals Corporation\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"0487-6105-01\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"800-443-4313\", \"availability\": \"Limited Availability\", \"related_info\": \"Small amount of inventory available with 12/31/2026 dating\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Nephron%20Pharmaceuticals%20Corporation%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1743", "dosage_form": "Injection", "file": "nephron-pharmaceuticals-corporation-sterile-water-injection-0487-6105-01.md", "generated": true, "generic_name": "Sterile Water Injection", "harvested": "2026-09-01", "id": "nephron-pharmaceuticals-corporation-sterile-water-injection-0487-6105-01", "initial_posting_date": "11/23/2021", "manufacturer_name": "Nephron Pharmaceuticals Corporation", "package_ndc": "0487-6105-01", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)\", \"company_name\": \"Nephron Pharmaceuticals Corporation\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)\", \"company_name\": \"Nephron Pharmaceuticals Corporation\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)\", \"company_name\": \"Nephron Pharmaceuticals Corporation\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)\", \"company_name\": \"Nephron Pharmaceuticals Corporation\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)\", \"company_name\": \"Nephron Pharmaceuticals Corporation\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)\", \"company_name\": \"Nephron Pharmaceuticals Corporation\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Small amount of inventory available with 12/31/2026 dating", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/23/2021\", \"package_ndc\": \"0487-6105-01\", \"generic_name\": \"Sterile Water Injection\", \"contact_info\": \"800-443-4313\", \"availability\": \"Limited Availability\", \"related_info\": \"Small amount of inventory available with 12/31/2026 dating\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Nephron%20Pharmaceuticals%20Corporation%22+AND+generic_name%3A%22Sterile%20Water%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Other", "title": "0487-6105-01 \u00b7 Sterile Water Injection \u00b7 Nephron Pharmaceuticals Corporation \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72205-132-91\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Novadoz Pharmaceuticals LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"72205-132-91\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"(855) 668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novadoz%20Pharmaceuticals%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "novadoz-pharmaceuticals-llc-lisdexamfetamine-dimesylate-tablet-chewable-72205-132-91.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "novadoz-pharmaceuticals-llc-lisdexamfetamine-dimesylate-tablet-chewable-72205-132-91", "initial_posting_date": "07/14/2023", "manufacturer_name": "Novadoz Pharmaceuticals LLC", "package_ndc": "72205-132-91", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"72205-132-91\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"(855) 668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novadoz%20Pharmaceuticals%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "72205-132-91 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Novadoz Pharmaceuticals LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72205-133-91\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Novadoz Pharmaceuticals LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"72205-133-91\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"(855) 668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novadoz%20Pharmaceuticals%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "novadoz-pharmaceuticals-llc-lisdexamfetamine-dimesylate-tablet-chewable-72205-133-91.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "novadoz-pharmaceuticals-llc-lisdexamfetamine-dimesylate-tablet-chewable-72205-133-91", "initial_posting_date": "07/14/2023", "manufacturer_name": "Novadoz Pharmaceuticals LLC", "package_ndc": "72205-133-91", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"72205-133-91\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"(855) 668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novadoz%20Pharmaceuticals%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "72205-133-91 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Novadoz Pharmaceuticals LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72205-134-91\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Novadoz Pharmaceuticals LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"72205-134-91\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"(855) 668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novadoz%20Pharmaceuticals%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "novadoz-pharmaceuticals-llc-lisdexamfetamine-dimesylate-tablet-chewable-72205-134-91.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "novadoz-pharmaceuticals-llc-lisdexamfetamine-dimesylate-tablet-chewable-72205-134-91", "initial_posting_date": "07/14/2023", "manufacturer_name": "Novadoz Pharmaceuticals LLC", "package_ndc": "72205-134-91", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"72205-134-91\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"(855) 668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novadoz%20Pharmaceuticals%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "72205-134-91 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Novadoz Pharmaceuticals LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72205-135-91\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Novadoz Pharmaceuticals LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"72205-135-91\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"(855) 668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novadoz%20Pharmaceuticals%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "novadoz-pharmaceuticals-llc-lisdexamfetamine-dimesylate-tablet-chewable-72205-135-91.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "novadoz-pharmaceuticals-llc-lisdexamfetamine-dimesylate-tablet-chewable-72205-135-91", "initial_posting_date": "07/14/2023", "manufacturer_name": "Novadoz Pharmaceuticals LLC", "package_ndc": "72205-135-91", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"72205-135-91\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"(855) 668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novadoz%20Pharmaceuticals%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "72205-135-91 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Novadoz Pharmaceuticals LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72205-136-91\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Novadoz Pharmaceuticals LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"72205-136-91\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"(855) 668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novadoz%20Pharmaceuticals%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "novadoz-pharmaceuticals-llc-lisdexamfetamine-dimesylate-tablet-chewable-72205-136-91.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "novadoz-pharmaceuticals-llc-lisdexamfetamine-dimesylate-tablet-chewable-72205-136-91", "initial_posting_date": "07/14/2023", "manufacturer_name": "Novadoz Pharmaceuticals LLC", "package_ndc": "72205-136-91", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"72205-136-91\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"(855) 668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novadoz%20Pharmaceuticals%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "72205-136-91 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Novadoz Pharmaceuticals LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72205-137-91\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Novadoz Pharmaceuticals LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"72205-137-91\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"(855) 668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novadoz%20Pharmaceuticals%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "novadoz-pharmaceuticals-llc-lisdexamfetamine-dimesylate-tablet-chewable-72205-137-91.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "novadoz-pharmaceuticals-llc-lisdexamfetamine-dimesylate-tablet-chewable-72205-137-91", "initial_posting_date": "07/14/2023", "manufacturer_name": "Novadoz Pharmaceuticals LLC", "package_ndc": "72205-137-91", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)\", \"company_name\": \"Novadoz Pharmaceuticals LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"72205-137-91\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"(855) 668-2369; customerservice@novadozpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novadoz%20Pharmaceuticals%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "72205-137-91 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Novadoz Pharmaceuticals LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0574-2410-65\n\n**Generic name:** Methylphenidate Film, Extended Release\n\n**Manufacturer:** Noven Pharmaceuticals, Inc.\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Padagis US LLC\n\n**Initial posting date:** 02/28/2025\n\n**Last update date:** 09/02/2026\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 552\n\n**Dosage form:** Film, Extended Release\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/28/2025\", \"package_ndc\": \"0574-2410-65\", \"generic_name\": \"Methylphenidate Film, Extended Release\", \"contact_info\": \"800-455-8070\", \"availability\": \"Available\", \"related_info\": \"Distributed by Padagis US LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "552", "dosage_form": "Film, Extended Release", "file": "noven-pharmaceuticals-inc-methylphenidate-film-extended-release-0574-2410-65-2.md", "generated": true, "generic_name": "Methylphenidate Film, Extended Release", "harvested": "2026-09-03", "id": "noven-pharmaceuticals-inc-methylphenidate-film-extended-release-0574-2410-65-2", "initial_posting_date": "02/28/2025", "manufacturer_name": "Noven Pharmaceuticals, Inc.", "package_ndc": "0574-2410-65", "quote_dosage_form": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "related_info": "Distributed by Padagis US LLC", "source_quote": "\"initial_posting_date\": \"02/28/2025\", \"package_ndc\": \"0574-2410-65\", \"generic_name\": \"Methylphenidate Film, Extended Release\", \"contact_info\": \"800-455-8070\", \"availability\": \"Available\", \"related_info\": \"Distributed by Padagis US LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0574-2410-65 \u00b7 Methylphenidate Film, Extended Release \u00b7 Noven Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/02/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0574-2410-65\n\n**Generic name:** Methylphenidate Film, Extended Release\n\n**Manufacturer:** Noven Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Available. Distributed by Padagis US LLC\n\n**Initial posting date:** 02/28/2025\n\n**Last update date:** 08/15/2026\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 550\n\n**Dosage form:** Film, Extended Release\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/28/2025\", \"package_ndc\": \"0574-2410-65\", \"generic_name\": \"Methylphenidate Film, Extended Release\", \"contact_info\": \"800-455-8070\", \"availability\": \"Available\", \"related_info\": \"Available. Distributed by Padagis US LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "550", "dosage_form": "Film, Extended Release", "file": "noven-pharmaceuticals-inc-methylphenidate-film-extended-release-0574-2410-65.md", "generated": true, "generic_name": "Methylphenidate Film, Extended Release", "harvested": "2026-09-01", "id": "noven-pharmaceuticals-inc-methylphenidate-film-extended-release-0574-2410-65", "initial_posting_date": "02/28/2025", "manufacturer_name": "Noven Pharmaceuticals, Inc.", "package_ndc": "0574-2410-65", "quote_dosage_form": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "related_info": "Available. Distributed by Padagis US LLC", "source_quote": "\"initial_posting_date\": \"02/28/2025\", \"package_ndc\": \"0574-2410-65\", \"generic_name\": \"Methylphenidate Film, Extended Release\", \"contact_info\": \"800-455-8070\", \"availability\": \"Available\", \"related_info\": \"Available. Distributed by Padagis US LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0574-2410-65 \u00b7 Methylphenidate Film, Extended Release \u00b7 Noven Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0574-2415-65\n\n**Generic name:** Methylphenidate Film, Extended Release\n\n**Manufacturer:** Noven Pharmaceuticals, Inc.\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Padagis US LLC\n\n**Initial posting date:** 02/28/2025\n\n**Last update date:** 09/02/2026\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 552\n\n**Dosage form:** Film, Extended Release\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/28/2025\", \"package_ndc\": \"0574-2415-65\", \"generic_name\": \"Methylphenidate Film, Extended Release\", \"contact_info\": \"800-455-8070\", \"availability\": \"Available\", \"related_info\": \"Distributed by Padagis US LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "552", "dosage_form": "Film, Extended Release", "file": "noven-pharmaceuticals-inc-methylphenidate-film-extended-release-0574-2415-65-2.md", "generated": true, "generic_name": "Methylphenidate Film, Extended Release", "harvested": "2026-09-03", "id": "noven-pharmaceuticals-inc-methylphenidate-film-extended-release-0574-2415-65-2", "initial_posting_date": "02/28/2025", "manufacturer_name": "Noven Pharmaceuticals, Inc.", "package_ndc": "0574-2415-65", "quote_dosage_form": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "related_info": "Distributed by Padagis US LLC", "source_quote": "\"initial_posting_date\": \"02/28/2025\", \"package_ndc\": \"0574-2415-65\", \"generic_name\": \"Methylphenidate Film, Extended Release\", \"contact_info\": \"800-455-8070\", \"availability\": \"Available\", \"related_info\": \"Distributed by Padagis US LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0574-2415-65 \u00b7 Methylphenidate Film, Extended Release \u00b7 Noven Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/02/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0574-2415-65\n\n**Generic name:** Methylphenidate Film, Extended Release\n\n**Manufacturer:** Noven Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Available. Distributed by Padagis US LLC\n\n**Initial posting date:** 02/28/2025\n\n**Last update date:** 08/15/2026\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 550\n\n**Dosage form:** Film, Extended Release\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/28/2025\", \"package_ndc\": \"0574-2415-65\", \"generic_name\": \"Methylphenidate Film, Extended Release\", \"contact_info\": \"800-455-8070\", \"availability\": \"Available\", \"related_info\": \"Available. Distributed by Padagis US LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "550", "dosage_form": "Film, Extended Release", "file": "noven-pharmaceuticals-inc-methylphenidate-film-extended-release-0574-2415-65.md", "generated": true, "generic_name": "Methylphenidate Film, Extended Release", "harvested": "2026-09-01", "id": "noven-pharmaceuticals-inc-methylphenidate-film-extended-release-0574-2415-65", "initial_posting_date": "02/28/2025", "manufacturer_name": "Noven Pharmaceuticals, Inc.", "package_ndc": "0574-2415-65", "quote_dosage_form": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "related_info": "Available. Distributed by Padagis US LLC", "source_quote": "\"initial_posting_date\": \"02/28/2025\", \"package_ndc\": \"0574-2415-65\", \"generic_name\": \"Methylphenidate Film, Extended Release\", \"contact_info\": \"800-455-8070\", \"availability\": \"Available\", \"related_info\": \"Available. Distributed by Padagis US LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0574-2415-65 \u00b7 Methylphenidate Film, Extended Release \u00b7 Noven Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0574-2420-65\n\n**Generic name:** Methylphenidate Film, Extended Release\n\n**Manufacturer:** Noven Pharmaceuticals, Inc.\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Padagis US LLC\n\n**Initial posting date:** 02/28/2025\n\n**Last update date:** 09/02/2026\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 552\n\n**Dosage form:** Film, Extended Release\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/28/2025\", \"package_ndc\": \"0574-2420-65\", \"generic_name\": \"Methylphenidate Film, Extended Release\", \"contact_info\": \"800-455-8070\", \"availability\": \"Available\", \"related_info\": \"Distributed by Padagis US LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "552", "dosage_form": "Film, Extended Release", "file": "noven-pharmaceuticals-inc-methylphenidate-film-extended-release-0574-2420-65-2.md", "generated": true, "generic_name": "Methylphenidate Film, Extended Release", "harvested": "2026-09-03", "id": "noven-pharmaceuticals-inc-methylphenidate-film-extended-release-0574-2420-65-2", "initial_posting_date": "02/28/2025", "manufacturer_name": "Noven Pharmaceuticals, Inc.", "package_ndc": "0574-2420-65", "quote_dosage_form": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "related_info": "Distributed by Padagis US LLC", "source_quote": "\"initial_posting_date\": \"02/28/2025\", \"package_ndc\": \"0574-2420-65\", \"generic_name\": \"Methylphenidate Film, Extended Release\", \"contact_info\": \"800-455-8070\", \"availability\": \"Available\", \"related_info\": \"Distributed by Padagis US LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0574-2420-65 \u00b7 Methylphenidate Film, Extended Release \u00b7 Noven Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/02/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0574-2420-65\n\n**Generic name:** Methylphenidate Film, Extended Release\n\n**Manufacturer:** Noven Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Available. Distributed by Padagis US LLC\n\n**Initial posting date:** 02/28/2025\n\n**Last update date:** 08/15/2026\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 550\n\n**Dosage form:** Film, Extended Release\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/28/2025\", \"package_ndc\": \"0574-2420-65\", \"generic_name\": \"Methylphenidate Film, Extended Release\", \"contact_info\": \"800-455-8070\", \"availability\": \"Available\", \"related_info\": \"Available. Distributed by Padagis US LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "550", "dosage_form": "Film, Extended Release", "file": "noven-pharmaceuticals-inc-methylphenidate-film-extended-release-0574-2420-65.md", "generated": true, "generic_name": "Methylphenidate Film, Extended Release", "harvested": "2026-09-01", "id": "noven-pharmaceuticals-inc-methylphenidate-film-extended-release-0574-2420-65", "initial_posting_date": "02/28/2025", "manufacturer_name": "Noven Pharmaceuticals, Inc.", "package_ndc": "0574-2420-65", "quote_dosage_form": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "related_info": "Available. Distributed by Padagis US LLC", "source_quote": "\"initial_posting_date\": \"02/28/2025\", \"package_ndc\": \"0574-2420-65\", \"generic_name\": \"Methylphenidate Film, Extended Release\", \"contact_info\": \"800-455-8070\", \"availability\": \"Available\", \"related_info\": \"Available. Distributed by Padagis US LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0574-2420-65 \u00b7 Methylphenidate Film, Extended Release \u00b7 Noven Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0574-2430-65\n\n**Generic name:** Methylphenidate Film, Extended Release\n\n**Manufacturer:** Noven Pharmaceuticals, Inc.\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Padagis US LLC\n\n**Initial posting date:** 02/28/2025\n\n**Last update date:** 09/02/2026\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 552\n\n**Dosage form:** Film, Extended Release\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/28/2025\", \"package_ndc\": \"0574-2430-65\", \"generic_name\": \"Methylphenidate Film, Extended Release\", \"contact_info\": \"800-455-8070\", \"availability\": \"Available\", \"related_info\": \"Distributed by Padagis US LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "552", "dosage_form": "Film, Extended Release", "file": "noven-pharmaceuticals-inc-methylphenidate-film-extended-release-0574-2430-65-2.md", "generated": true, "generic_name": "Methylphenidate Film, Extended Release", "harvested": "2026-09-03", "id": "noven-pharmaceuticals-inc-methylphenidate-film-extended-release-0574-2430-65-2", "initial_posting_date": "02/28/2025", "manufacturer_name": "Noven Pharmaceuticals, Inc.", "package_ndc": "0574-2430-65", "quote_dosage_form": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/02/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "related_info": "Distributed by Padagis US LLC", "source_quote": "\"initial_posting_date\": \"02/28/2025\", \"package_ndc\": \"0574-2430-65\", \"generic_name\": \"Methylphenidate Film, Extended Release\", \"contact_info\": \"800-455-8070\", \"availability\": \"Available\", \"related_info\": \"Distributed by Padagis US LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0574-2430-65 \u00b7 Methylphenidate Film, Extended Release \u00b7 Noven Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/02/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0574-2430-65\n\n**Generic name:** Methylphenidate Film, Extended Release\n\n**Manufacturer:** Noven Pharmaceuticals, Inc.\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Available. Distributed by Padagis US LLC\n\n**Initial posting date:** 02/28/2025\n\n**Last update date:** 08/15/2026\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 550\n\n**Dosage form:** Film, Extended Release\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/28/2025\", \"package_ndc\": \"0574-2430-65\", \"generic_name\": \"Methylphenidate Film, Extended Release\", \"contact_info\": \"800-455-8070\", \"availability\": \"Available\", \"related_info\": \"Available. Distributed by Padagis US LLC\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "550", "dosage_form": "Film, Extended Release", "file": "noven-pharmaceuticals-inc-methylphenidate-film-extended-release-0574-2430-65.md", "generated": true, "generic_name": "Methylphenidate Film, Extended Release", "harvested": "2026-09-01", "id": "noven-pharmaceuticals-inc-methylphenidate-film-extended-release-0574-2430-65", "initial_posting_date": "02/28/2025", "manufacturer_name": "Noven Pharmaceuticals, Inc.", "package_ndc": "0574-2430-65", "quote_dosage_form": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/15/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Film, Extended Release\", \"presentation\": \"Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)\", \"company_name\": \"Noven Pharmaceuticals, Inc.\", \"status\": \"Current\"", "related_info": "Available. Distributed by Padagis US LLC", "source_quote": "\"initial_posting_date\": \"02/28/2025\", \"package_ndc\": \"0574-2430-65\", \"generic_name\": \"Methylphenidate Film, Extended Release\", \"contact_info\": \"800-455-8070\", \"availability\": \"Available\", \"related_info\": \"Available. Distributed by Padagis US LLC\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Noven%20Pharmaceuticals,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Film,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0574-2430-65 \u00b7 Methylphenidate Film, Extended Release \u00b7 Noven Pharmaceuticals, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0169-2800-15\n\n**Generic name:** Liraglutide Injection\n\n**Manufacturer:** Novo Nordisk, Inc.\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Product will be available until discontinuation in January 2027\n\n**Initial posting date:** 07/18/2023\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1141\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"0169-2800-15\", \"generic_name\": \"Liraglutide Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Liraglutide+Injection&st=d\", \"contact_info\": \"833-493-4689\", \"availability\": \"Limited Availability\", \"related_info\": \"Product will be available until discontinuation in January 2027\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novo%20Nordisk,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1141", "dosage_form": "Injection", "file": "novo-nordisk-inc-liraglutide-injection-0169-2800-15.md", "generated": true, "generic_name": "Liraglutide Injection", "harvested": "2026-09-01", "id": "novo-nordisk-inc-liraglutide-injection-0169-2800-15", "initial_posting_date": "07/18/2023", "manufacturer_name": "Novo Nordisk, Inc.", "package_ndc": "0169-2800-15", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Product will be available until discontinuation in January 2027", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"0169-2800-15\", \"generic_name\": \"Liraglutide Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Liraglutide+Injection&st=d\", \"contact_info\": \"833-493-4689\", \"availability\": \"Limited Availability\", \"related_info\": \"Product will be available until discontinuation in January 2027\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novo%20Nordisk,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0169-2800-15 \u00b7 Liraglutide Injection \u00b7 Novo Nordisk, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0169-4060-12\n\n**Generic name:** Liraglutide Injection\n\n**Manufacturer:** Novo Nordisk, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated shortage duration: TBD\n\n**Initial posting date:** 07/18/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1141\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"0169-4060-12\", \"generic_name\": \"Liraglutide Injection\", \"contact_info\": \"833-493-4689\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated shortage duration: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novo%20Nordisk,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1141", "dosage_form": "Injection", "file": "novo-nordisk-inc-liraglutide-injection-0169-4060-12.md", "generated": true, "generic_name": "Liraglutide Injection", "harvested": "2026-09-01", "id": "novo-nordisk-inc-liraglutide-injection-0169-4060-12", "initial_posting_date": "07/18/2023", "manufacturer_name": "Novo Nordisk, Inc.", "package_ndc": "0169-4060-12", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated shortage duration: TBD", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"0169-4060-12\", \"generic_name\": \"Liraglutide Injection\", \"contact_info\": \"833-493-4689\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated shortage duration: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novo%20Nordisk,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0169-4060-12 \u00b7 Liraglutide Injection \u00b7 Novo Nordisk, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0169-4060-13\n\n**Generic name:** Liraglutide Injection\n\n**Manufacturer:** Novo Nordisk, Inc.\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated shortage duration: TBD\n\n**Initial posting date:** 07/18/2023\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1141\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"0169-4060-13\", \"generic_name\": \"Liraglutide Injection\", \"contact_info\": \"833-493-4689\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated shortage duration: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novo%20Nordisk,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1141", "dosage_form": "Injection", "file": "novo-nordisk-inc-liraglutide-injection-0169-4060-13.md", "generated": true, "generic_name": "Liraglutide Injection", "harvested": "2026-09-01", "id": "novo-nordisk-inc-liraglutide-injection-0169-4060-13", "initial_posting_date": "07/18/2023", "manufacturer_name": "Novo Nordisk, Inc.", "package_ndc": "0169-4060-13", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)\", \"company_name\": \"Novo Nordisk, Inc.\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated shortage duration: TBD", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"0169-4060-13\", \"generic_name\": \"Liraglutide Injection\", \"contact_info\": \"833-493-4689\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated shortage duration: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novo%20Nordisk,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0169-4060-13 \u00b7 Liraglutide Injection \u00b7 Novo Nordisk, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0480-3667-20\n\n**Generic name:** Liraglutide Injection\n\n**Manufacturer:** Novo Nordisk, Inc.\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Teva\n\n**Initial posting date:** 07/18/2023\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1141\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"0480-3667-20\", \"generic_name\": \"Liraglutide Injection\", \"contact_info\": \"833-493-4689\", \"availability\": \"Available\", \"related_info\": \"Distributed by Teva\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novo%20Nordisk,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1141", "dosage_form": "Injection", "file": "novo-nordisk-inc-liraglutide-injection-0480-3667-20.md", "generated": true, "generic_name": "Liraglutide Injection", "harvested": "2026-09-01", "id": "novo-nordisk-inc-liraglutide-injection-0480-3667-20", "initial_posting_date": "07/18/2023", "manufacturer_name": "Novo Nordisk, Inc.", "package_ndc": "0480-3667-20", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"", "related_info": "Distributed by Teva", "source_quote": "\"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"0480-3667-20\", \"generic_name\": \"Liraglutide Injection\", \"contact_info\": \"833-493-4689\", \"availability\": \"Available\", \"related_info\": \"Distributed by Teva\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novo%20Nordisk,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0480-3667-20 \u00b7 Liraglutide Injection \u00b7 Novo Nordisk, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0480-3667-22\n\n**Generic name:** Liraglutide Injection\n\n**Manufacturer:** Novo Nordisk, Inc.\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Teva\n\n**Initial posting date:** 07/18/2023\n\n**Last update date:** 08/25/2026\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1141\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"0480-3667-22\", \"generic_name\": \"Liraglutide Injection\", \"contact_info\": \"833-493-4689\", \"availability\": \"Available\", \"related_info\": \"Distributed by Teva\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novo%20Nordisk,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1141", "dosage_form": "Injection", "file": "novo-nordisk-inc-liraglutide-injection-0480-3667-22.md", "generated": true, "generic_name": "Liraglutide Injection", "harvested": "2026-09-01", "id": "novo-nordisk-inc-liraglutide-injection-0480-3667-22", "initial_posting_date": "07/18/2023", "manufacturer_name": "Novo Nordisk, Inc.", "package_ndc": "0480-3667-22", "quote_dosage_form": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/25/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)\", \"company_name\": \"Novo Nordisk, Inc.\", \"status\": \"Current\"", "related_info": "Distributed by Teva", "source_quote": "\"initial_posting_date\": \"07/18/2023\", \"package_ndc\": \"0480-3667-22\", \"generic_name\": \"Liraglutide Injection\", \"contact_info\": \"833-493-4689\", \"availability\": \"Available\", \"related_info\": \"Distributed by Teva\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Novo%20Nordisk,%20Inc.%22+AND+generic_name%3A%22Liraglutide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0480-3667-22 \u00b7 Liraglutide Injection \u00b7 Novo Nordisk, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/25/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72266-263-10\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** ONESOURCE SPECIALTY PTE LTD\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride PRESERVATIVE FREE, Injection, 2.5 mg/1 mL (NDC 72266-263-10)\", \"company_name\": \"ONESOURCE SPECIALTY PTE LTD\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride PRESERVATIVE FREE, Injection, 2.5 mg/1 mL (NDC 72266-263-10)\", \"company_name\": \"ONESOURCE SPECIALTY PTE LTD\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Distributed by Fosun Pharma USA Inc.\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride PRESERVATIVE FREE, Injection, 2.5 mg/1 mL (NDC 72266-263-10)\", \"company_name\": \"ONESOURCE SPECIALTY PTE LTD\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride PRESERVATIVE FREE, Injection, 2.5 mg/1 mL (NDC 72266-263-10)\", \"company_name\": \"ONESOURCE SPECIALTY PTE LTD\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride PRESERVATIVE FREE, Injection, 2.5 mg/1 mL (NDC 72266-263-10)\", \"company_name\": \"ONESOURCE SPECIALTY PTE LTD\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"72266-263-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-217-8103\", \"availability\": \"Available\", \"related_info\": \"Distributed by Fosun Pharma USA Inc.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22ONESOURCE%20SPECIALTY%20PTE%20LTD%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "onesource-specialty-pte-ltd-bupivacaine-hydrochloride-injection-72266-263-10.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "onesource-specialty-pte-ltd-bupivacaine-hydrochloride-injection-72266-263-10", "initial_posting_date": "02/20/2018", "manufacturer_name": "ONESOURCE SPECIALTY PTE LTD", "package_ndc": "72266-263-10", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride PRESERVATIVE FREE, Injection, 2.5 mg/1 mL (NDC 72266-263-10)\", \"company_name\": \"ONESOURCE SPECIALTY PTE LTD\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride PRESERVATIVE FREE, Injection, 2.5 mg/1 mL (NDC 72266-263-10)\", \"company_name\": \"ONESOURCE SPECIALTY PTE LTD\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride PRESERVATIVE FREE, Injection, 2.5 mg/1 mL (NDC 72266-263-10)\", \"company_name\": \"ONESOURCE SPECIALTY PTE LTD\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride PRESERVATIVE FREE, Injection, 2.5 mg/1 mL (NDC 72266-263-10)\", \"company_name\": \"ONESOURCE SPECIALTY PTE LTD\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride PRESERVATIVE FREE, Injection, 2.5 mg/1 mL (NDC 72266-263-10)\", \"company_name\": \"ONESOURCE SPECIALTY PTE LTD\", \"status\": \"Current\"", "rechecked": "2026-09-09", "related_info": "Distributed by Fosun Pharma USA Inc.", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"72266-263-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"888-217-8103\", \"availability\": \"Available\", \"related_info\": \"Distributed by Fosun Pharma USA Inc.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22ONESOURCE%20SPECIALTY%20PTE%20LTD%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-12", "status": "Current", "therapeutic_category": "Anesthesia", "title": "72266-263-10 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 ONESOURCE SPECIALTY PTE LTD \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 72516-011-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Oryza Pharmaceuticals Inc.\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated availability April 2027\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"72516-011-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"855-257-0292\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability April 2027\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Oryza%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "oryza-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-72516-011-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "oryza-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-72516-011-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Oryza Pharmaceuticals Inc.", "package_ndc": "72516-011-01", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated availability April 2027", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"72516-011-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"855-257-0292\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability April 2027\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Oryza%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "72516-011-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Oryza Pharmaceuticals Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 72516-012-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Oryza Pharmaceuticals Inc.\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated availability April 2027\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"72516-012-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"855-257-0292\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability April 2027\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Oryza%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "oryza-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-72516-012-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "oryza-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-72516-012-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Oryza Pharmaceuticals Inc.", "package_ndc": "72516-012-01", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated availability April 2027", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"72516-012-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"855-257-0292\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability April 2027\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Oryza%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "72516-012-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Oryza Pharmaceuticals Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 72516-013-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Oryza Pharmaceuticals Inc.\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated availability April 2027\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"72516-013-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"855-257-0292\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability April 2027\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Oryza%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "oryza-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-72516-013-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "oryza-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-72516-013-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Oryza Pharmaceuticals Inc.", "package_ndc": "72516-013-01", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated availability April 2027", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"72516-013-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"855-257-0292\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability April 2027\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Oryza%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "72516-013-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Oryza Pharmaceuticals Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 72516-014-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Oryza Pharmaceuticals Inc.\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated availability April 2027\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"72516-014-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"855-257-0292\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability April 2027\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Oryza%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "oryza-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-72516-014-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "oryza-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-72516-014-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Oryza Pharmaceuticals Inc.", "package_ndc": "72516-014-01", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated availability April 2027", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"72516-014-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"855-257-0292\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability April 2027\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Oryza%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "72516-014-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Oryza Pharmaceuticals Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 72516-016-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Oryza Pharmaceuticals Inc.\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated availability April 2027\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"72516-016-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"855-257-0292\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability April 2027\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Oryza%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "oryza-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-72516-016-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "oryza-pharmaceuticals-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-72516-016-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Oryza Pharmaceuticals Inc.", "package_ndc": "72516-016-01", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)\", \"company_name\": \"Oryza Pharmaceuticals Inc.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated availability April 2027", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"72516-016-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"855-257-0292\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated availability April 2027\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Oryza%20Pharmaceuticals%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "72516-016-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Oryza Pharmaceuticals Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0990-4178-03\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 2093\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0990-4178-03\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2093", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-amino-acid-injection-0990-4178-03.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-amino-acid-injection-0990-4178-03", "initial_posting_date": "12/08/2020", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-4178-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0990-4178-03\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0990-4178-03 \u00b7 Amino Acid Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0990-4179-05\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 2093\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0990-4179-05\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2093", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-amino-acid-injection-0990-4179-05.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-amino-acid-injection-0990-4179-05", "initial_posting_date": "12/08/2020", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-4179-05", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0990-4179-05\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0990-4179-05 \u00b7 Amino Acid Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7171-17\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2093\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0990-7171-17\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2093", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-amino-acid-injection-0990-7171-17.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-amino-acid-injection-0990-7171-17", "initial_posting_date": "12/08/2020", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7171-17", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0990-7171-17\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0990-7171-17 \u00b7 Amino Acid Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7172-17\n\n**Generic name:** Amino Acid Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 12/08/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2093\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0990-7172-17\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2093", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-amino-acid-injection-0990-7172-17.md", "generated": true, "generic_name": "Amino Acid Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-amino-acid-injection-0990-7172-17", "initial_posting_date": "12/08/2020", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7172-17", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"12/08/2020\", \"package_ndc\": \"0990-7172-17\", \"generic_name\": \"Amino Acid Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Amino%20Acid%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0990-7172-17 \u00b7 Amino Acid Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7930-02\n\n**Generic name:** Dextrose Monohydrate 10% Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 03/01/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1645\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0990-7930-02\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1645", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-dextrose-monohydrate-10-injection-0990-7930-02.md", "generated": true, "generic_name": "Dextrose Monohydrate 10% Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-dextrose-monohydrate-10-injection-0990-7930-02", "initial_posting_date": "03/01/2022", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7930-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0990-7930-02\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0990-7930-02 \u00b7 Dextrose Monohydrate 10% Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7930-03\n\n**Generic name:** Dextrose Monohydrate 10% Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 03/01/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1645\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0990-7930-03\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1645", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-dextrose-monohydrate-10-injection-0990-7930-03.md", "generated": true, "generic_name": "Dextrose Monohydrate 10% Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-dextrose-monohydrate-10-injection-0990-7930-03", "initial_posting_date": "03/01/2022", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7930-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0990-7930-03\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0990-7930-03 \u00b7 Dextrose Monohydrate 10% Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7930-09\n\n**Generic name:** Dextrose Monohydrate 10% Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 03/01/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1645\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0990-7930-09\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1645", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-dextrose-monohydrate-10-injection-0990-7930-09.md", "generated": true, "generic_name": "Dextrose Monohydrate 10% Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-dextrose-monohydrate-10-injection-0990-7930-09", "initial_posting_date": "03/01/2022", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7930-09", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0990-7930-09\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0990-7930-09 \u00b7 Dextrose Monohydrate 10% Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0990-7938-19\n\n**Generic name:** Dextrose Monohydrate 10% Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Product discontinued. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 03/01/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1645\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0990-7938-19\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Unavailable\", \"related_info\": \"Product discontinued. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1645", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-dextrose-monohydrate-10-injection-0990-7938-19.md", "generated": true, "generic_name": "Dextrose Monohydrate 10% Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-dextrose-monohydrate-10-injection-0990-7938-19", "initial_posting_date": "03/01/2022", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7938-19", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Product discontinued. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"03/01/2022\", \"package_ndc\": \"0990-7938-19\", \"generic_name\": \"Dextrose Monohydrate 10% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Unavailable\", \"related_info\": \"Product discontinued. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2010%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0990-7938-19 \u00b7 Dextrose Monohydrate 10% Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7922-02\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7922-02\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7922-02.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7922-02", "initial_posting_date": "02/14/2022", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7922-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7922-02\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0990-7922-02 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7922-03\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7922-03\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7922-03.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7922-03", "initial_posting_date": "02/14/2022", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7922-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7922-03\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0990-7922-03 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7922-09\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7922-09\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7922-09.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7922-09", "initial_posting_date": "02/14/2022", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7922-09", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7922-09\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0990-7922-09 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7922-55\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7922-55\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7922-55.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7922-55", "initial_posting_date": "02/14/2022", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7922-55", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7922-55\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0990-7922-55 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7922-61\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7922-61\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7922-61.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7922-61", "initial_posting_date": "02/14/2022", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7922-61", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7922-61\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0990-7922-61 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7923-13\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7923-13\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7923-13.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7923-13", "initial_posting_date": "02/14/2022", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7923-13", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7923-13\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0990-7923-13 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7923-20\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7923-20\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7923-20.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7923-20", "initial_posting_date": "02/14/2022", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7923-20", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7923-20\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0990-7923-20 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7923-23\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7923-23\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7923-23.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7923-23", "initial_posting_date": "02/14/2022", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7923-23", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7923-23\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0990-7923-23 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7923-36\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7923-36\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7923-36.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7923-36", "initial_posting_date": "02/14/2022", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7923-36", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7923-36\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0990-7923-36 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7923-37\n\n**Generic name:** Dextrose Monohydrate 5% Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 02/14/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1660\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7923-37\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1660", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7923-37.md", "generated": true, "generic_name": "Dextrose Monohydrate 5% Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-dextrose-monohydrate-5-injection-0990-7923-37", "initial_posting_date": "02/14/2022", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7923-37", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"02/14/2022\", \"package_ndc\": \"0990-7923-37\", \"generic_name\": \"Dextrose Monohydrate 5% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%205%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0990-7923-37 \u00b7 Dextrose Monohydrate 5% Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7120-07\n\n**Generic name:** Dextrose Monohydrate 70% Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 10/11/2024\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 690\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/11/2024\", \"package_ndc\": \"0990-7120-07\", \"generic_name\": \"Dextrose Monohydrate 70% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2070%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "690", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-dextrose-monohydrate-70-injection-0990-7120-07.md", "generated": true, "generic_name": "Dextrose Monohydrate 70% Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-dextrose-monohydrate-70-injection-0990-7120-07", "initial_posting_date": "10/11/2024", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7120-07", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"10/11/2024\", \"package_ndc\": \"0990-7120-07\", \"generic_name\": \"Dextrose Monohydrate 70% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2070%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0990-7120-07 \u00b7 Dextrose Monohydrate 70% Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0990-7918-19\n\n**Generic name:** Dextrose Monohydrate 70% Injection\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 10/11/2024\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 690\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/11/2024\", \"package_ndc\": \"0990-7918-19\", \"generic_name\": \"Dextrose Monohydrate 70% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2070%25%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "690", "dosage_form": "Injection", "file": "otsuka-icu-medical-llc-dextrose-monohydrate-70-injection-0990-7918-19.md", "generated": true, "generic_name": "Dextrose Monohydrate 70% Injection", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-dextrose-monohydrate-70-injection-0990-7918-19", "initial_posting_date": "10/11/2024", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7918-19", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"status\": \"Current\"", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "source_quote": "\"initial_posting_date\": \"10/11/2024\", \"package_ndc\": \"0990-7918-19\", \"generic_name\": \"Dextrose Monohydrate 70% Injection\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Available\", \"related_info\": \"This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Dextrose%20Monohydrate%2070%25%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "0990-7918-19 \u00b7 Dextrose Monohydrate 70% Injection \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0990-6139-03\n\n**Generic name:** Sterile Water Irrigant\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Irrigant\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0990-6139-03\", \"generic_name\": \"Sterile Water Irrigant\", \"related_info_link\": \"https://www.fda.gov/media/182619/download?attachment\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Unavailable\", \"related_info\": \"Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Irrigant", "file": "otsuka-icu-medical-llc-sterile-water-irrigant-0990-6139-03.md", "generated": true, "generic_name": "Sterile Water Irrigant", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-sterile-water-irrigant-0990-6139-03", "initial_posting_date": "04/28/2023", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-6139-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0990-6139-03\", \"generic_name\": \"Sterile Water Irrigant\", \"related_info_link\": \"https://www.fda.gov/media/182619/download?attachment\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Unavailable\", \"related_info\": \"Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0990-6139-03 \u00b7 Sterile Water Irrigant \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0990-6139-22\n\n**Generic name:** Sterile Water Irrigant\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Irrigant\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0990-6139-22\", \"generic_name\": \"Sterile Water Irrigant\", \"related_info_link\": \"https://www.fda.gov/media/182619/download?attachment\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Unavailable\", \"related_info\": \"Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Irrigant", "file": "otsuka-icu-medical-llc-sterile-water-irrigant-0990-6139-22.md", "generated": true, "generic_name": "Sterile Water Irrigant", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-sterile-water-irrigant-0990-6139-22", "initial_posting_date": "04/28/2023", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-6139-22", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0990-6139-22\", \"generic_name\": \"Sterile Water Irrigant\", \"related_info_link\": \"https://www.fda.gov/media/182619/download?attachment\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Unavailable\", \"related_info\": \"Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0990-6139-22 \u00b7 Sterile Water Irrigant \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0990-7139-09\n\n**Generic name:** Sterile Water Irrigant\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Irrigant\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0990-7139-09\", \"generic_name\": \"Sterile Water Irrigant\", \"related_info_link\": \"https://www.fda.gov/media/182619/download?attachment\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Unavailable\", \"related_info\": \"Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Irrigant", "file": "otsuka-icu-medical-llc-sterile-water-irrigant-0990-7139-09.md", "generated": true, "generic_name": "Sterile Water Irrigant", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-sterile-water-irrigant-0990-7139-09", "initial_posting_date": "04/28/2023", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7139-09", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0990-7139-09\", \"generic_name\": \"Sterile Water Irrigant\", \"related_info_link\": \"https://www.fda.gov/media/182619/download?attachment\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Unavailable\", \"related_info\": \"Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0990-7139-09 \u00b7 Sterile Water Irrigant \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0990-7139-36\n\n**Generic name:** Sterile Water Irrigant\n\n**Manufacturer:** Otsuka ICU Medical LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Irrigant\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Gastroenterology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0990-7139-36\", \"generic_name\": \"Sterile Water Irrigant\", \"related_info_link\": \"https://www.fda.gov/media/182619/download?attachment\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Unavailable\", \"related_info\": \"Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Irrigant", "file": "otsuka-icu-medical-llc-sterile-water-irrigant-0990-7139-36.md", "generated": true, "generic_name": "Sterile Water Irrigant", "harvested": "2026-09-01", "id": "otsuka-icu-medical-llc-sterile-water-irrigant-0990-7139-36", "initial_posting_date": "04/28/2023", "manufacturer_name": "Otsuka ICU Medical LLC", "package_ndc": "0990-7139-36", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Gastroenterology\", \"Other\", \"Pediatric\" ], \"dosage_form\": \"Irrigant\", \"presentation\": \"Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)\", \"company_name\": \"Otsuka ICU Medical LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0990-7139-36\", \"generic_name\": \"Sterile Water Irrigant\", \"related_info_link\": \"https://www.fda.gov/media/182619/download?attachment\", \"contact_info\": \"1-866-829-9025 or ProductAvailability@icumed.com\", \"availability\": \"Unavailable\", \"related_info\": \"Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Otsuka%20ICU%20Medical%20LLC%22+AND+generic_name%3A%22Sterile%20Water%20Irrigant%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Gastroenterology", "title": "0990-7139-36 \u00b7 Sterile Water Irrigant \u00b7 Otsuka ICU Medical LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0574-4022-35\n\n**Generic name:** Bacitracin Ophthalmic Ointment\n\n**Manufacturer:** Padagis US LLC\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Ointment\", \"presentation\": \"Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)\", \"company_name\": \"Padagis US LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Ointment\", \"presentation\": \"Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)\", \"company_name\": \"Padagis US LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Shortage is estimated for 24 months\n\n**Initial posting date:** 03/03/2025\n\n**Last update date:** 06/01/2026\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Ointment\", \"presentation\": \"Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)\", \"company_name\": \"Padagis US LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 547\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Ointment\", \"presentation\": \"Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)\", \"company_name\": \"Padagis US LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Ophthalmic Ointment\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Ointment\", \"presentation\": \"Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)\", \"company_name\": \"Padagis US LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Ointment\", \"presentation\": \"Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)\", \"company_name\": \"Padagis US LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/03/2025\", \"package_ndc\": \"0574-4022-35\", \"generic_name\": \"Bacitracin Ophthalmic Ointment\", \"contact_info\": \"866-634-9120\", \"availability\": \"Unavailable\", \"related_info\": \"Shortage is estimated for 24 months\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Padagis%20US%20LLC%22+AND+generic_name%3A%22Bacitracin%20Ophthalmic%20Ointment%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "547", "dosage_form": "Ophthalmic Ointment", "file": "padagis-us-llc-bacitracin-ophthalmic-ointment-0574-4022-35.md", "generated": true, "generic_name": "Bacitracin Ophthalmic Ointment", "harvested": "2026-09-01", "id": "padagis-us-llc-bacitracin-ophthalmic-ointment-0574-4022-35", "initial_posting_date": "03/03/2025", "manufacturer_name": "Padagis US LLC", "package_ndc": "0574-4022-35", "quote_dosage_form": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Ointment\", \"presentation\": \"Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)\", \"company_name\": \"Padagis US LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Ointment\", \"presentation\": \"Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)\", \"company_name\": \"Padagis US LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Ointment\", \"presentation\": \"Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)\", \"company_name\": \"Padagis US LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Ointment\", \"presentation\": \"Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)\", \"company_name\": \"Padagis US LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Ointment\", \"presentation\": \"Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)\", \"company_name\": \"Padagis US LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Ophthalmology\" ], \"dosage_form\": \"Ophthalmic Ointment\", \"presentation\": \"Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)\", \"company_name\": \"Padagis US LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Shortage is estimated for 24 months", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"03/03/2025\", \"package_ndc\": \"0574-4022-35\", \"generic_name\": \"Bacitracin Ophthalmic Ointment\", \"contact_info\": \"866-634-9120\", \"availability\": \"Unavailable\", \"related_info\": \"Shortage is estimated for 24 months\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Padagis%20US%20LLC%22+AND+generic_name%3A%22Bacitracin%20Ophthalmic%20Ointment%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0574-4022-35 \u00b7 Bacitracin Ophthalmic Ointment \u00b7 Padagis US LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 42023-146-25\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Par Health, USA LLC\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)\", \"company_name\": \"Par Health, USA LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)\", \"company_name\": \"Par Health, USA LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Please check wholesalers for inventory\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)\", \"company_name\": \"Par Health, USA LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)\", \"company_name\": \"Par Health, USA LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)\", \"company_name\": \"Par Health, USA LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"42023-146-25\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"800-828-9393\", \"availability\": \"Available\", \"related_info\": \"Please check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Par%20Health,%20USA%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "par-health-usa-llc-dexmedetomidine-hydrochloride-injection-42023-146-25.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "par-health-usa-llc-dexmedetomidine-hydrochloride-injection-42023-146-25", "initial_posting_date": "04/10/2020", "manufacturer_name": "Par Health, USA LLC", "package_ndc": "42023-146-25", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)\", \"company_name\": \"Par Health, USA LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)\", \"company_name\": \"Par Health, USA LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)\", \"company_name\": \"Par Health, USA LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)\", \"company_name\": \"Par Health, USA LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)\", \"company_name\": \"Par Health, USA LLC\", \"status\": \"Current\"", "related_info": "Please check wholesalers for inventory", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"42023-146-25\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"800-828-9393\", \"availability\": \"Available\", \"related_info\": \"Please check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Par%20Health,%20USA%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "42023-146-25 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Par Health, USA LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 42023-186-20\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Par Health, USA LLC\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD; Please check wholesalers for inventory\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"42023-186-20\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"800-828-9393\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; Please check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Par%20Health,%20USA%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "par-health-usa-llc-dexmedetomidine-hydrochloride-injection-42023-186-20.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "par-health-usa-llc-dexmedetomidine-hydrochloride-injection-42023-186-20", "initial_posting_date": "04/10/2020", "manufacturer_name": "Par Health, USA LLC", "package_ndc": "42023-186-20", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD; Please check wholesalers for inventory", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"42023-186-20\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"800-828-9393\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; Please check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Par%20Health,%20USA%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "42023-186-20 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Par Health, USA LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 42023-187-10\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Par Health, USA LLC\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD; Please check wholesalers for inventory\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"42023-187-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"800-828-9393\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; Please check wholesalers for inventory\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Par%20Health,%20USA%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "par-health-usa-llc-dexmedetomidine-hydrochloride-injection-42023-187-10.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "par-health-usa-llc-dexmedetomidine-hydrochloride-injection-42023-187-10", "initial_posting_date": "04/10/2020", "manufacturer_name": "Par Health, USA LLC", "package_ndc": "42023-187-10", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD; Please check wholesalers for inventory", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"42023-187-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"800-828-9393\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD; Please check wholesalers for inventory\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Par%20Health,%20USA%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "42023-187-10 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Par Health, USA LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 42023-240-01\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Par Health, USA LLC\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 06/16/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1538\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/16/2022\", \"package_ndc\": \"42023-240-01\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"800-828-9393\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Par%20Health,%20USA%20LLC%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1538", "dosage_form": "Injection", "file": "par-health-usa-llc-methylprednisolone-acetate-injection-42023-240-01.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "par-health-usa-llc-methylprednisolone-acetate-injection-42023-240-01", "initial_posting_date": "06/16/2022", "manufacturer_name": "Par Health, USA LLC", "package_ndc": "42023-240-01", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)\", \"company_name\": \"Par Health, USA LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"06/16/2022\", \"package_ndc\": \"42023-240-01\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"800-828-9393\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Par%20Health,%20USA%20LLC%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "42023-240-01 \u00b7 Methylprednisolone Acetate Injection \u00b7 Par Health, USA LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0009-0775-26\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0009-0775-26\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d\", \"contact_info\": \"800-533-4535\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "pfizer-inc-clindamycin-phosphate-injection-0009-0775-26.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-clindamycin-phosphate-injection-0009-0775-26", "initial_posting_date": "03/21/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-0775-26", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0009-0775-26\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d\", \"contact_info\": \"800-533-4535\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0009-0775-26 \u00b7 Clindamycin Phosphate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0009-0870-26\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2028\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0009-0870-26\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "pfizer-inc-clindamycin-phosphate-injection-0009-0870-26.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-clindamycin-phosphate-injection-0009-0870-26", "initial_posting_date": "03/21/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-0870-26", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Next Delivery and Estimated Recovery: December 2028", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0009-0870-26\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0009-0870-26 \u00b7 Clindamycin Phosphate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0009-0902-18\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 09/08/2026\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1269\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0009-0902-18\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1269", "dosage_form": "Injection", "file": "pfizer-inc-clindamycin-phosphate-injection-0009-0902-18-2.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-10", "id": "pfizer-inc-clindamycin-phosphate-injection-0009-0902-18-2", "initial_posting_date": "03/21/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-0902-18", "quote_dosage_form": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0009-0902-18\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0009-0902-18 \u00b7 Clindamycin Phosphate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/08/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0009-0902-18\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0009-0902-18\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d\", \"contact_info\": \"800-533-4535\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "pfizer-inc-clindamycin-phosphate-injection-0009-0902-18.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-clindamycin-phosphate-injection-0009-0902-18", "initial_posting_date": "03/21/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-0902-18", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0009-0902-18\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d\", \"contact_info\": \"800-533-4535\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0009-0902-18 \u00b7 Clindamycin Phosphate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0009-3051-02\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0009-3051-02\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "pfizer-inc-clindamycin-phosphate-injection-0009-3051-02.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-clindamycin-phosphate-injection-0009-3051-02", "initial_posting_date": "03/21/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-3051-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0009-3051-02\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0009-3051-02 \u00b7 Clindamycin Phosphate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0009-4073-04\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0009-4073-04\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "pfizer-inc-clindamycin-phosphate-injection-0009-4073-04.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-clindamycin-phosphate-injection-0009-4073-04", "initial_posting_date": "03/21/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-4073-04", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0009-4073-04\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0009-4073-04 \u00b7 Clindamycin Phosphate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0009-5095-06\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0009-5095-06\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "pfizer-inc-clindamycin-phosphate-injection-0009-5095-06.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-clindamycin-phosphate-injection-0009-5095-06", "initial_posting_date": "03/21/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-5095-06", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0009-5095-06\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0009-5095-06 \u00b7 Clindamycin Phosphate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-0155-02\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-0155-02\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-0155-02.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-0155-02", "initial_posting_date": "04/10/2020", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0409-0155-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-0155-02\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-0155-02 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1174-10\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-1174-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-1174-10.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-1174-10", "initial_posting_date": "04/10/2020", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0409-1174-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-1174-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1174-10 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1434-01\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-1434-01\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-1434-01.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-1434-01", "initial_posting_date": "04/10/2020", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0409-1434-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-1434-01\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1434-01 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1454-20\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-1454-20\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-1454-20.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-1454-20", "initial_posting_date": "04/10/2020", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0409-1454-20", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-1454-20\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1454-20 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1596-10\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-1596-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-1596-10.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-1596-10", "initial_posting_date": "04/10/2020", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0409-1596-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-1596-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1596-10 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1638-02\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-1638-02\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-1638-02.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-1638-02", "initial_posting_date": "04/10/2020", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0409-1638-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-1638-02\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1638-02 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1660-20\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-1660-20\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-1660-20.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-1660-20", "initial_posting_date": "04/10/2020", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0409-1660-20", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-1660-20\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1660-20 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-1660-50\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-1660-50\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-1660-50.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-1660-50", "initial_posting_date": "04/10/2020", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0409-1660-50", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-1660-50\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-1660-50 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-2815-01\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-2815-01\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-2815-01.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-2815-01", "initial_posting_date": "04/10/2020", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0409-2815-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-2815-01\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-2815-01 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-3301-10\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-3301-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-3301-10.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-3301-10", "initial_posting_date": "04/10/2020", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0409-3301-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-3301-10\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-3301-10 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-4596-20\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-4596-20\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-4596-20.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-4596-20", "initial_posting_date": "04/10/2020", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0409-4596-20", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-4596-20\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-4596-20 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-7838-24\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-7838-24\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-7838-24.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-7838-24", "initial_posting_date": "04/10/2020", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0409-7838-24", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-7838-24\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-7838-24 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-7853-24\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-7853-24\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-7853-24.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-7853-24", "initial_posting_date": "04/10/2020", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0409-7853-24", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-7853-24\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-7853-24 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0409-7875-12\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL (NDC 0409-7875-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL (NDC 0409-7875-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL (NDC 0409-7875-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL (NDC 0409-7875-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL (NDC 0409-7875-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-7875-12\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-7875-12.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "pfizer-inc-dexmedetomidine-hydrochloride-injection-0409-7875-12", "initial_posting_date": "04/10/2020", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0409-7875-12", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL (NDC 0409-7875-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL (NDC 0409-7875-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL (NDC 0409-7875-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL (NDC 0409-7875-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Precedex, Injection, 1000 mcg/250 mL (NDC 0409-7875-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"0409-7875-12\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0409-7875-12 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0009-0274-01\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-0274-01\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-0274-01.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-0274-01", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-0274-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-0274-01\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-0274-01 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0009-0280-02\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-0280-02\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-0280-02.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-0280-02", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-0280-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-0280-02\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-0280-02 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0009-0280-03\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 09/08/2026\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1730\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-0280-03\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1730", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-0280-03-2.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-10", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-0280-03-2", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-0280-03", "quote_dosage_form": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-0280-03\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-0280-03 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/08/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0009-0280-03\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-0280-03\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-0280-03.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-0280-03", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-0280-03", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-0280-03\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-0280-03 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0009-0280-51\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-0280-51\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-0280-51.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-0280-51", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-0280-51", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-0280-51\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-0280-51 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0009-0280-52\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-0280-52\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-0280-52.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-0280-52", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-0280-52", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-0280-52\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-0280-52 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0009-0306-02\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-0306-02\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-0306-02.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-0306-02", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-0306-02", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-0306-02\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-0306-02 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0009-0306-12\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-0306-12\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-0306-12.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-0306-12", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-0306-12", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-0306-12\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-0306-12 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0009-3073-01\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 09/08/2026\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1730\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3073-01\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1730", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-3073-01-2.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-10", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-3073-01-2", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-3073-01", "quote_dosage_form": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3073-01\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-3073-01 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/08/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0009-3073-01\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3073-01\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-3073-01.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-3073-01", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-3073-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3073-01\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-3073-01 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0009-3073-03\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3073-03\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-3073-03.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-3073-03", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-3073-03", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3073-03\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-3073-03 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0009-3073-22\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: October 2026; Estimated Recovery: December 2026\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 09/08/2026\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1730\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3073-22\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: October 2026; Estimated Recovery: December 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1730", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-3073-22-2.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-10", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-3073-22-2", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-3073-22", "quote_dosage_form": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next Delivery: October 2026; Estimated Recovery: December 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3073-22\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: October 2026; Estimated Recovery: December 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-3073-22 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/08/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0009-3073-22\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: September 2026; Estimated Recovery: December 2026\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3073-22\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: September 2026; Estimated Recovery: December 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-3073-22.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-3073-22", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-3073-22", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Next Delivery: September 2026; Estimated Recovery: December 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3073-22\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: September 2026; Estimated Recovery: December 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-3073-22 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0009-3073-23\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3073-23\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-3073-23.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-3073-23", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-3073-23", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-10", "related_info": "Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3073-23\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-3073-23 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0009-3475-01\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 09/08/2026\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1730\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3475-01\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1730", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-3475-01-2.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-10", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-3475-01-2", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-3475-01", "quote_dosage_form": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3475-01\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-3475-01 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/08/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0009-3475-01\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3475-01\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-3475-01.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-3475-01", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-3475-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3475-01\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-3475-01 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0009-3475-03\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3475-03\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "pfizer-inc-methylprednisolone-acetate-injection-0009-3475-03.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "pfizer-inc-methylprednisolone-acetate-injection-0009-3475-03", "initial_posting_date": "12/15/2021", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0009-3475-03", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)\", \"company_name\": \"Pfizer Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-10", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"0009-3475-03\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"844-646-4398\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0009-3475-03 \u00b7 Methylprednisolone Acetate Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 60793-700-10\n\n**Generic name:** Penicillin G Benzathine Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Next Delivery: October 2027; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 04/26/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1224\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/26/2023\", \"package_ndc\": \"60793-700-10\", \"generic_name\": \"Penicillin G Benzathine Injection\", \"related_info_link\": \"https://www.fda.gov/media/190713/download\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: October 2027; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Penicillin%20G%20Benzathine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1224", "dosage_form": "Injection", "file": "pfizer-inc-penicillin-g-benzathine-injection-60793-700-10.md", "generated": true, "generic_name": "Penicillin G Benzathine Injection", "harvested": "2026-09-01", "id": "pfizer-inc-penicillin-g-benzathine-injection-60793-700-10", "initial_posting_date": "04/26/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "60793-700-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Next Delivery: October 2027; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/26/2023\", \"package_ndc\": \"60793-700-10\", \"generic_name\": \"Penicillin G Benzathine Injection\", \"related_info_link\": \"https://www.fda.gov/media/190713/download\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Next Delivery: October 2027; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Penicillin%20G%20Benzathine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "60793-700-10 \u00b7 Penicillin G Benzathine Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 60793-701-10\n\n**Generic name:** Penicillin G Benzathine Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 04/26/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1224\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/26/2023\", \"package_ndc\": \"60793-701-10\", \"generic_name\": \"Penicillin G Benzathine Injection\", \"related_info_link\": \"https://www.fda.gov/media/190713/download\", \"contact_info\": \"800-533-4535\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Penicillin%20G%20Benzathine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1224", "dosage_form": "Injection", "file": "pfizer-inc-penicillin-g-benzathine-injection-60793-701-10.md", "generated": true, "generic_name": "Penicillin G Benzathine Injection", "harvested": "2026-09-01", "id": "pfizer-inc-penicillin-g-benzathine-injection-60793-701-10", "initial_posting_date": "04/26/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "60793-701-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/26/2023\", \"package_ndc\": \"60793-701-10\", \"generic_name\": \"Penicillin G Benzathine Injection\", \"related_info_link\": \"https://www.fda.gov/media/190713/download\", \"contact_info\": \"800-533-4535\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Penicillin%20G%20Benzathine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "60793-701-10 \u00b7 Penicillin G Benzathine Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 60793-702-10\n\n**Generic name:** Penicillin G Benzathine Injection\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\n\n**Initial posting date:** 04/26/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1224\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/26/2023\", \"package_ndc\": \"60793-702-10\", \"generic_name\": \"Penicillin G Benzathine Injection\", \"related_info_link\": \"https://www.fda.gov/media/190713/download\", \"contact_info\": \"800-533-4535\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Penicillin%20G%20Benzathine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1224", "dosage_form": "Injection", "file": "pfizer-inc-penicillin-g-benzathine-injection-60793-702-10.md", "generated": true, "generic_name": "Penicillin G Benzathine Injection", "harvested": "2026-09-01", "id": "pfizer-inc-penicillin-g-benzathine-injection-60793-702-10", "initial_posting_date": "04/26/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "60793-702-10", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-11", "related_info": "Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/26/2023\", \"package_ndc\": \"60793-702-10\", \"generic_name\": \"Penicillin G Benzathine Injection\", \"related_info_link\": \"https://www.fda.gov/media/190713/download\", \"contact_info\": \"800-533-4535\", \"availability\": \"Limited Availability\", \"related_info\": \"Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Penicillin%20G%20Benzathine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-14", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "60793-702-10 \u00b7 Penicillin G Benzathine Injection \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0071-0527-23\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 5 mg (NDC 0071-0527-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 5 mg (NDC 0071-0527-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 5 mg (NDC 0071-0527-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 5 mg (NDC 0071-0527-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 5 mg (NDC 0071-0527-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 5 mg (NDC 0071-0527-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"0071-0527-23\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "pfizer-inc-quinapril-hydrochloride-tablet-0071-0527-23.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "pfizer-inc-quinapril-hydrochloride-tablet-0071-0527-23", "initial_posting_date": "01/19/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0071-0527-23", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 5 mg (NDC 0071-0527-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 5 mg (NDC 0071-0527-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 5 mg (NDC 0071-0527-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 5 mg (NDC 0071-0527-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 5 mg (NDC 0071-0527-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 5 mg (NDC 0071-0527-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"0071-0527-23\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0071-0527-23 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0071-0530-23\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 10 mg (NDC 0071-0530-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 10 mg (NDC 0071-0530-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 10 mg (NDC 0071-0530-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 10 mg (NDC 0071-0530-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 10 mg (NDC 0071-0530-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 10 mg (NDC 0071-0530-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"0071-0530-23\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "pfizer-inc-quinapril-hydrochloride-tablet-0071-0530-23.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "pfizer-inc-quinapril-hydrochloride-tablet-0071-0530-23", "initial_posting_date": "01/19/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0071-0530-23", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 10 mg (NDC 0071-0530-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 10 mg (NDC 0071-0530-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 10 mg (NDC 0071-0530-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 10 mg (NDC 0071-0530-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 10 mg (NDC 0071-0530-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 10 mg (NDC 0071-0530-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"0071-0530-23\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0071-0530-23 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0071-0532-23\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 20 mg (NDC 0071-0532-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 20 mg (NDC 0071-0532-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 20 mg (NDC 0071-0532-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 20 mg (NDC 0071-0532-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 20 mg (NDC 0071-0532-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 20 mg (NDC 0071-0532-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"0071-0532-23\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "pfizer-inc-quinapril-hydrochloride-tablet-0071-0532-23.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "pfizer-inc-quinapril-hydrochloride-tablet-0071-0532-23", "initial_posting_date": "01/19/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0071-0532-23", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 20 mg (NDC 0071-0532-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 20 mg (NDC 0071-0532-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 20 mg (NDC 0071-0532-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 20 mg (NDC 0071-0532-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 20 mg (NDC 0071-0532-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 20 mg (NDC 0071-0532-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"0071-0532-23\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0071-0532-23 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0071-0535-23\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 40 mg (NDC 0071-0535-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 40 mg (NDC 0071-0535-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 40 mg (NDC 0071-0535-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 40 mg (NDC 0071-0535-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 40 mg (NDC 0071-0535-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 40 mg (NDC 0071-0535-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"0071-0535-23\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "pfizer-inc-quinapril-hydrochloride-tablet-0071-0535-23.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "pfizer-inc-quinapril-hydrochloride-tablet-0071-0535-23", "initial_posting_date": "01/19/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0071-0535-23", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 40 mg (NDC 0071-0535-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 40 mg (NDC 0071-0535-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 40 mg (NDC 0071-0535-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 40 mg (NDC 0071-0535-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 40 mg (NDC 0071-0535-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accupril, Tablet, 40 mg (NDC 0071-0535-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"0071-0535-23\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0071-0535-23 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0071-0220-23\n\n**Generic name:** Quinapril/Hydrochlorothiazide Tablet\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"0071-0220-23\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "pfizer-inc-quinapril-hydrochlorothiazide-tablet-0071-0220-23.md", "generated": true, "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "harvested": "2026-09-01", "id": "pfizer-inc-quinapril-hydrochlorothiazide-tablet-0071-0220-23", "initial_posting_date": "01/19/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0071-0220-23", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"0071-0220-23\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0071-0220-23 \u00b7 Quinapril/Hydrochlorothiazide Tablet \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0071-0222-23\n\n**Generic name:** Quinapril/Hydrochlorothiazide Tablet\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"0071-0222-23\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "pfizer-inc-quinapril-hydrochlorothiazide-tablet-0071-0222-23.md", "generated": true, "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "harvested": "2026-09-01", "id": "pfizer-inc-quinapril-hydrochlorothiazide-tablet-0071-0222-23", "initial_posting_date": "01/19/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0071-0222-23", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"0071-0222-23\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0071-0222-23 \u00b7 Quinapril/Hydrochlorothiazide Tablet \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0071-0223-23\n\n**Generic name:** Quinapril/Hydrochlorothiazide Tablet\n\n**Manufacturer:** Pfizer Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"0071-0223-23\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "pfizer-inc-quinapril-hydrochlorothiazide-tablet-0071-0223-23.md", "generated": true, "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "harvested": "2026-09-01", "id": "pfizer-inc-quinapril-hydrochlorothiazide-tablet-0071-0223-23", "initial_posting_date": "01/19/2023", "manufacturer_name": "Pfizer Inc.", "package_ndc": "0071-0223-23", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)\", \"company_name\": \"Pfizer Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"0071-0223-23\", \"generic_name\": \"Quinapril/Hydrochlorothiazide Tablet\", \"contact_info\": \"800-533-4535\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Pfizer%20Inc.%22+AND+generic_name%3A%22Quinapril/Hydrochlorothiazide%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "0071-0223-23 \u00b7 Quinapril/Hydrochlorothiazide Tablet \u00b7 Pfizer Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 66794-160-02\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Piramal Critical Care Inc.\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** On allocation\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"66794-160-02\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-414-1901\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Piramal%20Critical%20Care%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "piramal-critical-care-inc-morphine-sulfate-injection-66794-160-02.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "piramal-critical-care-inc-morphine-sulfate-injection-66794-160-02", "initial_posting_date": "10/31/2017", "manufacturer_name": "Piramal Critical Care Inc.", "package_ndc": "66794-160-02", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "On allocation", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"66794-160-02\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-414-1901\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Piramal%20Critical%20Care%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "66794-160-02 \u00b7 Morphine Sulfate Injection \u00b7 Piramal Critical Care Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 66794-162-02\n\n**Generic name:** Morphine Sulfate Injection\n\n**Manufacturer:** Piramal Critical Care Inc.\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/31/2017\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3227\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"66794-162-02\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-414-1901\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Piramal%20Critical%20Care%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3227", "dosage_form": "Injection", "file": "piramal-critical-care-inc-morphine-sulfate-injection-66794-162-02.md", "generated": true, "generic_name": "Morphine Sulfate Injection", "harvested": "2026-09-01", "id": "piramal-critical-care-inc-morphine-sulfate-injection-66794-162-02", "initial_posting_date": "10/31/2017", "manufacturer_name": "Piramal Critical Care Inc.", "package_ndc": "66794-162-02", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02)\", \"company_name\": \"Piramal Critical Care Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/31/2017\", \"package_ndc\": \"66794-162-02\", \"generic_name\": \"Morphine Sulfate Injection\", \"contact_info\": \"800-414-1901\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Piramal%20Critical%20Care%20Inc.%22+AND+generic_name%3A%22Morphine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "66794-162-02 \u00b7 Morphine Sulfate Injection \u00b7 Piramal Critical Care Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 66794-228-41\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Piramal Critical Care Inc.\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** On allocation\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"66794-228-41\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"800-414-1901\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Piramal%20Critical%20Care%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "piramal-critical-care-inc-rocuronium-bromide-injection-66794-228-41.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "piramal-critical-care-inc-rocuronium-bromide-injection-66794-228-41", "initial_posting_date": "02/15/2023", "manufacturer_name": "Piramal Critical Care Inc.", "package_ndc": "66794-228-41", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "On allocation", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"66794-228-41\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"800-414-1901\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Piramal%20Critical%20Care%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "66794-228-41 \u00b7 Rocuronium Bromide Injection \u00b7 Piramal Critical Care Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 66794-229-41\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Piramal Critical Care Inc.\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** On allocation\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"66794-229-41\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"800-414-1901\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Piramal%20Critical%20Care%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "piramal-critical-care-inc-rocuronium-bromide-injection-66794-229-41.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "piramal-critical-care-inc-rocuronium-bromide-injection-66794-229-41", "initial_posting_date": "02/15/2023", "manufacturer_name": "Piramal Critical Care Inc.", "package_ndc": "66794-229-41", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)\", \"company_name\": \"Piramal Critical Care Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "On allocation", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"66794-229-41\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"800-414-1901\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Piramal%20Critical%20Care%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "66794-229-41 \u00b7 Rocuronium Bromide Injection \u00b7 Piramal Critical Care Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43547-406-10\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Prinston Pharmaceutical, Inc.\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Solco Healthcare\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 07/01/2026\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"43547-406-10\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"For orders, Solco Healthcare 866-931-9829\", \"availability\": \"Available\", \"related_info\": \"Marketed by Solco Healthcare\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "prinston-pharmaceutical-inc-clonazepam-tablet-43547-406-10.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "prinston-pharmaceutical-inc-clonazepam-tablet-43547-406-10", "initial_posting_date": "03/10/2023", "manufacturer_name": "Prinston Pharmaceutical, Inc.", "package_ndc": "43547-406-10", "quote_dosage_form": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "related_info": "Marketed by Solco Healthcare", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"43547-406-10\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"For orders, Solco Healthcare 866-931-9829\", \"availability\": \"Available\", \"related_info\": \"Marketed by Solco Healthcare\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "43547-406-10 \u00b7 Clonazepam Tablet \u00b7 Prinston Pharmaceutical, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43547-406-11\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Prinston Pharmaceutical, Inc.\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Solco Healthcare\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 07/01/2026\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"43547-406-11\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"For orders, Solco Healthcare 866-931-9829\", \"availability\": \"Available\", \"related_info\": \"Marketed by Solco Healthcare\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "prinston-pharmaceutical-inc-clonazepam-tablet-43547-406-11.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "prinston-pharmaceutical-inc-clonazepam-tablet-43547-406-11", "initial_posting_date": "03/10/2023", "manufacturer_name": "Prinston Pharmaceutical, Inc.", "package_ndc": "43547-406-11", "quote_dosage_form": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "related_info": "Marketed by Solco Healthcare", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"43547-406-11\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"For orders, Solco Healthcare 866-931-9829\", \"availability\": \"Available\", \"related_info\": \"Marketed by Solco Healthcare\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "43547-406-11 \u00b7 Clonazepam Tablet \u00b7 Prinston Pharmaceutical, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43547-406-50\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Prinston Pharmaceutical, Inc.\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Solco Healthcare\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 07/01/2026\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"43547-406-50\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"For orders, Solco Healthcare 866-931-9829\", \"availability\": \"Available\", \"related_info\": \"Marketed by Solco Healthcare\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "prinston-pharmaceutical-inc-clonazepam-tablet-43547-406-50.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "prinston-pharmaceutical-inc-clonazepam-tablet-43547-406-50", "initial_posting_date": "03/10/2023", "manufacturer_name": "Prinston Pharmaceutical, Inc.", "package_ndc": "43547-406-50", "quote_dosage_form": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 43547-406-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "related_info": "Marketed by Solco Healthcare", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"43547-406-50\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"For orders, Solco Healthcare 866-931-9829\", \"availability\": \"Available\", \"related_info\": \"Marketed by Solco Healthcare\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "43547-406-50 \u00b7 Clonazepam Tablet \u00b7 Prinston Pharmaceutical, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43547-407-10\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Prinston Pharmaceutical, Inc.\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Solco Healthcare\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 07/01/2026\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"43547-407-10\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"For orders, Solco Healthcare 866-931-9829\", \"availability\": \"Available\", \"related_info\": \"Marketed by Solco Healthcare\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "prinston-pharmaceutical-inc-clonazepam-tablet-43547-407-10.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "prinston-pharmaceutical-inc-clonazepam-tablet-43547-407-10", "initial_posting_date": "03/10/2023", "manufacturer_name": "Prinston Pharmaceutical, Inc.", "package_ndc": "43547-407-10", "quote_dosage_form": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "related_info": "Marketed by Solco Healthcare", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"43547-407-10\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"For orders, Solco Healthcare 866-931-9829\", \"availability\": \"Available\", \"related_info\": \"Marketed by Solco Healthcare\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "43547-407-10 \u00b7 Clonazepam Tablet \u00b7 Prinston Pharmaceutical, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43547-407-11\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Prinston Pharmaceutical, Inc.\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Solco Healthcare\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 07/01/2026\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"43547-407-11\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"For orders, Solco Healthcare 866-931-9829\", \"availability\": \"Available\", \"related_info\": \"Marketed by Solco Healthcare\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "prinston-pharmaceutical-inc-clonazepam-tablet-43547-407-11.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "prinston-pharmaceutical-inc-clonazepam-tablet-43547-407-11", "initial_posting_date": "03/10/2023", "manufacturer_name": "Prinston Pharmaceutical, Inc.", "package_ndc": "43547-407-11", "quote_dosage_form": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-11)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "related_info": "Marketed by Solco Healthcare", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"43547-407-11\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"For orders, Solco Healthcare 866-931-9829\", \"availability\": \"Available\", \"related_info\": \"Marketed by Solco Healthcare\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "43547-407-11 \u00b7 Clonazepam Tablet \u00b7 Prinston Pharmaceutical, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43547-407-50\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Prinston Pharmaceutical, Inc.\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Solco Healthcare\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 07/01/2026\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"43547-407-50\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"For orders, Solco Healthcare 866-931-9829\", \"availability\": \"Available\", \"related_info\": \"Marketed by Solco Healthcare\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "prinston-pharmaceutical-inc-clonazepam-tablet-43547-407-50.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "prinston-pharmaceutical-inc-clonazepam-tablet-43547-407-50", "initial_posting_date": "03/10/2023", "manufacturer_name": "Prinston Pharmaceutical, Inc.", "package_ndc": "43547-407-50", "quote_dosage_form": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 43547-407-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "related_info": "Marketed by Solco Healthcare", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"43547-407-50\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"For orders, Solco Healthcare 866-931-9829\", \"availability\": \"Available\", \"related_info\": \"Marketed by Solco Healthcare\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "43547-407-50 \u00b7 Clonazepam Tablet \u00b7 Prinston Pharmaceutical, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43547-408-10\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Prinston Pharmaceutical, Inc.\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Solco Healthcare\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 07/01/2026\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"43547-408-10\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"For orders, Solco Healthcare 866-931-9829\", \"availability\": \"Available\", \"related_info\": \"Marketed by Solco Healthcare\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "prinston-pharmaceutical-inc-clonazepam-tablet-43547-408-10.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "prinston-pharmaceutical-inc-clonazepam-tablet-43547-408-10", "initial_posting_date": "03/10/2023", "manufacturer_name": "Prinston Pharmaceutical, Inc.", "package_ndc": "43547-408-10", "quote_dosage_form": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-10)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "related_info": "Marketed by Solco Healthcare", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"43547-408-10\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"For orders, Solco Healthcare 866-931-9829\", \"availability\": \"Available\", \"related_info\": \"Marketed by Solco Healthcare\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "43547-408-10 \u00b7 Clonazepam Tablet \u00b7 Prinston Pharmaceutical, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 43547-408-50\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Prinston Pharmaceutical, Inc.\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Solco Healthcare\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 07/01/2026\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"43547-408-50\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"For orders, Solco Healthcare 866-931-9829\", \"availability\": \"Available\", \"related_info\": \"Marketed by Solco Healthcare\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "prinston-pharmaceutical-inc-clonazepam-tablet-43547-408-50.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "prinston-pharmaceutical-inc-clonazepam-tablet-43547-408-50", "initial_posting_date": "03/10/2023", "manufacturer_name": "Prinston Pharmaceutical, Inc.", "package_ndc": "43547-408-50", "quote_dosage_form": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 43547-408-50)\", \"company_name\": \"Prinston Pharmaceutical, Inc.\", \"status\": \"Current\"", "related_info": "Marketed by Solco Healthcare", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"43547-408-50\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"For orders, Solco Healthcare 866-931-9829\", \"availability\": \"Available\", \"related_info\": \"Marketed by Solco Healthcare\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Prinston%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "43547-408-50 \u00b7 Clonazepam Tablet \u00b7 Prinston Pharmaceutical, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 42858-161-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Rhodes Pharmaceuticals L.P.\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/24/2026\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"42858-161-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-827-0616\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rhodes%20Pharmaceuticals%20L.P.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "rhodes-pharmaceuticals-l-p-lisdexamfetamine-dimesylate-capsule-42858-161-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "rhodes-pharmaceuticals-l-p-lisdexamfetamine-dimesylate-capsule-42858-161-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Rhodes Pharmaceuticals L.P.", "package_ndc": "42858-161-01", "quote_dosage_form": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"42858-161-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-827-0616\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rhodes%20Pharmaceuticals%20L.P.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "42858-161-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Rhodes Pharmaceuticals L.P. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 42858-162-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Rhodes Pharmaceuticals L.P.\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/24/2026\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"42858-162-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-827-0616\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rhodes%20Pharmaceuticals%20L.P.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "rhodes-pharmaceuticals-l-p-lisdexamfetamine-dimesylate-capsule-42858-162-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "rhodes-pharmaceuticals-l-p-lisdexamfetamine-dimesylate-capsule-42858-162-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Rhodes Pharmaceuticals L.P.", "package_ndc": "42858-162-01", "quote_dosage_form": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"42858-162-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-827-0616\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rhodes%20Pharmaceuticals%20L.P.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "42858-162-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Rhodes Pharmaceuticals L.P. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 42858-163-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Rhodes Pharmaceuticals L.P.\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/24/2026\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"42858-163-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-827-0616\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rhodes%20Pharmaceuticals%20L.P.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "rhodes-pharmaceuticals-l-p-lisdexamfetamine-dimesylate-capsule-42858-163-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "rhodes-pharmaceuticals-l-p-lisdexamfetamine-dimesylate-capsule-42858-163-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Rhodes Pharmaceuticals L.P.", "package_ndc": "42858-163-01", "quote_dosage_form": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"42858-163-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-827-0616\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rhodes%20Pharmaceuticals%20L.P.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "42858-163-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Rhodes Pharmaceuticals L.P. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 42858-164-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Rhodes Pharmaceuticals L.P.\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/24/2026\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"42858-164-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-827-0616\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rhodes%20Pharmaceuticals%20L.P.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "rhodes-pharmaceuticals-l-p-lisdexamfetamine-dimesylate-capsule-42858-164-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "rhodes-pharmaceuticals-l-p-lisdexamfetamine-dimesylate-capsule-42858-164-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Rhodes Pharmaceuticals L.P.", "package_ndc": "42858-164-01", "quote_dosage_form": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"42858-164-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-827-0616\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rhodes%20Pharmaceuticals%20L.P.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "42858-164-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Rhodes Pharmaceuticals L.P. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 42858-165-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Rhodes Pharmaceuticals L.P.\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/24/2026\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"42858-165-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-827-0616\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rhodes%20Pharmaceuticals%20L.P.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "rhodes-pharmaceuticals-l-p-lisdexamfetamine-dimesylate-capsule-42858-165-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "rhodes-pharmaceuticals-l-p-lisdexamfetamine-dimesylate-capsule-42858-165-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Rhodes Pharmaceuticals L.P.", "package_ndc": "42858-165-01", "quote_dosage_form": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"42858-165-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-827-0616\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rhodes%20Pharmaceuticals%20L.P.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "42858-165-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Rhodes Pharmaceuticals L.P. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 42858-166-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Rhodes Pharmaceuticals L.P.\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/24/2026\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"42858-166-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-827-0616\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rhodes%20Pharmaceuticals%20L.P.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "rhodes-pharmaceuticals-l-p-lisdexamfetamine-dimesylate-capsule-42858-166-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "rhodes-pharmaceuticals-l-p-lisdexamfetamine-dimesylate-capsule-42858-166-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Rhodes Pharmaceuticals L.P.", "package_ndc": "42858-166-01", "quote_dosage_form": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"42858-166-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-827-0616\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rhodes%20Pharmaceuticals%20L.P.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "42858-166-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Rhodes Pharmaceuticals L.P. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 42858-167-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Rhodes Pharmaceuticals L.P.\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 01/11/2024\n\n**Last update date:** 06/24/2026\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 964\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/11/2024\", \"package_ndc\": \"42858-167-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-827-0616\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rhodes%20Pharmaceuticals%20L.P.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "964", "dosage_form": "Capsule", "file": "rhodes-pharmaceuticals-l-p-lisdexamfetamine-dimesylate-capsule-42858-167-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "rhodes-pharmaceuticals-l-p-lisdexamfetamine-dimesylate-capsule-42858-167-01", "initial_posting_date": "01/11/2024", "manufacturer_name": "Rhodes Pharmaceuticals L.P.", "package_ndc": "42858-167-01", "quote_dosage_form": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/24/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)\", \"company_name\": \"Rhodes Pharmaceuticals L.P.\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"01/11/2024\", \"package_ndc\": \"42858-167-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"888-827-0616\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rhodes%20Pharmaceuticals%20L.P.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "42858-167-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Rhodes Pharmaceuticals L.P. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 16571-600-96\n\n**Generic name:** Cromolyn Sodium Concentrate\n\n**Manufacturer:** Rising Pharma Holdings, Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/03/2023\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1033\n\n**Dosage form:** Concentrate\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Pulmonary/Allergy\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/03/2023\", \"package_ndc\": \"16571-600-96\", \"generic_name\": \"Cromolyn Sodium Concentrate\", \"contact_info\": \"(201) 961-9000 or contact@risingpharma.com\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rising%20Pharma%20Holdings,%20Inc.%22+AND+generic_name%3A%22Cromolyn%20Sodium%20Concentrate%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1033", "dosage_form": "Concentrate", "file": "rising-pharma-holdings-inc-cromolyn-sodium-concentrate-16571-600-96.md", "generated": true, "generic_name": "Cromolyn Sodium Concentrate", "harvested": "2026-09-01", "id": "rising-pharma-holdings-inc-cromolyn-sodium-concentrate-16571-600-96", "initial_posting_date": "11/03/2023", "manufacturer_name": "Rising Pharma Holdings, Inc.", "package_ndc": "16571-600-96", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Pulmonary/Allergy\" ], \"dosage_form\": \"Concentrate\", \"presentation\": \"Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/03/2023\", \"package_ndc\": \"16571-600-96\", \"generic_name\": \"Cromolyn Sodium Concentrate\", \"contact_info\": \"(201) 961-9000 or contact@risingpharma.com\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rising%20Pharma%20Holdings,%20Inc.%22+AND+generic_name%3A%22Cromolyn%20Sodium%20Concentrate%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Pulmonary/Allergy", "title": "16571-600-96 \u00b7 Cromolyn Sodium Concentrate \u00b7 Rising Pharma Holdings, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0378-4415-01\n\n**Generic name:** Flurazepam Hydrochloride Capsule\n\n**Manufacturer:** Rising Pharma Holdings, Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility.\n\n**Initial posting date:** 08/03/2022\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"\n\n**Days in shortage:** 1490\n\n**Reason for shortage:** Regulatory delay\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"08/03/2022\", \"package_ndc\": \"0378-4415-01\", \"generic_name\": \"Flurazepam Hydrochloride Capsule\", \"contact_info\": \"1-844-874-7464\", \"availability\": \"Unavailable\", \"related_info\": \"Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rising%20Pharma%20Holdings,%20Inc.%22+AND+generic_name%3A%22Flurazepam%20Hydrochloride%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1490", "dosage_form": "Capsule", "file": "rising-pharma-holdings-inc-flurazepam-hydrochloride-capsule-0378-4415-01.md", "generated": true, "generic_name": "Flurazepam Hydrochloride Capsule", "harvested": "2026-09-01", "id": "rising-pharma-holdings-inc-flurazepam-hydrochloride-capsule-0378-4415-01", "initial_posting_date": "08/03/2022", "manufacturer_name": "Rising Pharma Holdings, Inc.", "package_ndc": "0378-4415-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"", "related_info": "Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility.", "shortage_reason": "Regulatory delay", "source_quote": "\"initial_posting_date\": \"08/03/2022\", \"package_ndc\": \"0378-4415-01\", \"generic_name\": \"Flurazepam Hydrochloride Capsule\", \"contact_info\": \"1-844-874-7464\", \"availability\": \"Unavailable\", \"related_info\": \"Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rising%20Pharma%20Holdings,%20Inc.%22+AND+generic_name%3A%22Flurazepam%20Hydrochloride%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "0378-4415-01 \u00b7 Flurazepam Hydrochloride Capsule \u00b7 Rising Pharma Holdings, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0378-4430-01\n\n**Generic name:** Flurazepam Hydrochloride Capsule\n\n**Manufacturer:** Rising Pharma Holdings, Inc.\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility.\n\n**Initial posting date:** 08/03/2022\n\n**Last update date:** 08/24/2026\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"\n\n**Days in shortage:** 1490\n\n**Reason for shortage:** Regulatory delay\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"08/03/2022\", \"package_ndc\": \"0378-4430-01\", \"generic_name\": \"Flurazepam Hydrochloride Capsule\", \"contact_info\": \"1-844-874-7464\", \"availability\": \"Unavailable\", \"related_info\": \"Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rising%20Pharma%20Holdings,%20Inc.%22+AND+generic_name%3A%22Flurazepam%20Hydrochloride%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1490", "dosage_form": "Capsule", "file": "rising-pharma-holdings-inc-flurazepam-hydrochloride-capsule-0378-4430-01.md", "generated": true, "generic_name": "Flurazepam Hydrochloride Capsule", "harvested": "2026-09-01", "id": "rising-pharma-holdings-inc-flurazepam-hydrochloride-capsule-0378-4430-01", "initial_posting_date": "08/03/2022", "manufacturer_name": "Rising Pharma Holdings, Inc.", "package_ndc": "0378-4430-01", "quote_dosage_form": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/24/2026\", \"therapeutic_category\": [ \"Neurology\", \"Other\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)\", \"company_name\": \"Rising Pharma Holdings, Inc.\", \"shortage_reason\": \"Regulatory delay\", \"status\": \"Current\"", "related_info": "Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility.", "shortage_reason": "Regulatory delay", "source_quote": "\"initial_posting_date\": \"08/03/2022\", \"package_ndc\": \"0378-4430-01\", \"generic_name\": \"Flurazepam Hydrochloride Capsule\", \"contact_info\": \"1-844-874-7464\", \"availability\": \"Unavailable\", \"related_info\": \"Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rising%20Pharma%20Holdings,%20Inc.%22+AND+generic_name%3A%22Flurazepam%20Hydrochloride%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "0378-4430-01 \u00b7 Flurazepam Hydrochloride Capsule \u00b7 Rising Pharma Holdings, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/24/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72888-152-00\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Rubicon Research Private Limited\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Advagen Pharma Ltd.\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 06/01/2026\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-152-00\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "rubicon-research-private-limited-clonazepam-tablet-72888-152-00.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "rubicon-research-private-limited-clonazepam-tablet-72888-152-00", "initial_posting_date": "03/10/2023", "manufacturer_name": "Rubicon Research Private Limited", "package_ndc": "72888-152-00", "quote_dosage_form": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "related_info": "Marketed by Advagen Pharma Ltd.", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-152-00\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "72888-152-00 \u00b7 Clonazepam Tablet \u00b7 Rubicon Research Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72888-152-01\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Rubicon Research Private Limited\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Advagen Pharma Ltd.\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 06/01/2026\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-152-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "rubicon-research-private-limited-clonazepam-tablet-72888-152-01.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "rubicon-research-private-limited-clonazepam-tablet-72888-152-01", "initial_posting_date": "03/10/2023", "manufacturer_name": "Rubicon Research Private Limited", "package_ndc": "72888-152-01", "quote_dosage_form": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "related_info": "Marketed by Advagen Pharma Ltd.", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-152-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "72888-152-01 \u00b7 Clonazepam Tablet \u00b7 Rubicon Research Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72888-152-05\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Rubicon Research Private Limited\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Advagen Pharma Ltd.\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 06/01/2026\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-152-05\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "rubicon-research-private-limited-clonazepam-tablet-72888-152-05.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "rubicon-research-private-limited-clonazepam-tablet-72888-152-05", "initial_posting_date": "03/10/2023", "manufacturer_name": "Rubicon Research Private Limited", "package_ndc": "72888-152-05", "quote_dosage_form": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "related_info": "Marketed by Advagen Pharma Ltd.", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-152-05\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "72888-152-05 \u00b7 Clonazepam Tablet \u00b7 Rubicon Research Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72888-152-30\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Rubicon Research Private Limited\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Advagen Pharma Ltd.\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 06/01/2026\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-152-30\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "rubicon-research-private-limited-clonazepam-tablet-72888-152-30.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "rubicon-research-private-limited-clonazepam-tablet-72888-152-30", "initial_posting_date": "03/10/2023", "manufacturer_name": "Rubicon Research Private Limited", "package_ndc": "72888-152-30", "quote_dosage_form": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 72888-152-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "related_info": "Marketed by Advagen Pharma Ltd.", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-152-30\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "72888-152-30 \u00b7 Clonazepam Tablet \u00b7 Rubicon Research Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72888-153-00\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Rubicon Research Private Limited\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Advagen Pharma Ltd.\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 06/01/2026\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-153-00\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "rubicon-research-private-limited-clonazepam-tablet-72888-153-00.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "rubicon-research-private-limited-clonazepam-tablet-72888-153-00", "initial_posting_date": "03/10/2023", "manufacturer_name": "Rubicon Research Private Limited", "package_ndc": "72888-153-00", "quote_dosage_form": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-00)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "related_info": "Marketed by Advagen Pharma Ltd.", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-153-00\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "72888-153-00 \u00b7 Clonazepam Tablet \u00b7 Rubicon Research Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72888-153-01\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Rubicon Research Private Limited\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Advagen Pharma Ltd.\n\n**Initial posting date:** 03/27/2023\n\n**Last update date:** 06/01/2026\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 1254\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/27/2023\", \"package_ndc\": \"72888-153-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1254", "dosage_form": "Tablet", "file": "rubicon-research-private-limited-clonazepam-tablet-72888-153-01.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "rubicon-research-private-limited-clonazepam-tablet-72888-153-01", "initial_posting_date": "03/27/2023", "manufacturer_name": "Rubicon Research Private Limited", "package_ndc": "72888-153-01", "quote_dosage_form": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "related_info": "Marketed by Advagen Pharma Ltd.", "source_quote": "\"initial_posting_date\": \"03/27/2023\", \"package_ndc\": \"72888-153-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "72888-153-01 \u00b7 Clonazepam Tablet \u00b7 Rubicon Research Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72888-153-05\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Rubicon Research Private Limited\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Advagen Pharma Ltd.\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 06/01/2026\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-153-05\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "rubicon-research-private-limited-clonazepam-tablet-72888-153-05.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "rubicon-research-private-limited-clonazepam-tablet-72888-153-05", "initial_posting_date": "03/10/2023", "manufacturer_name": "Rubicon Research Private Limited", "package_ndc": "72888-153-05", "quote_dosage_form": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "related_info": "Marketed by Advagen Pharma Ltd.", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-153-05\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "72888-153-05 \u00b7 Clonazepam Tablet \u00b7 Rubicon Research Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72888-153-30\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Rubicon Research Private Limited\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Advagen Pharma Ltd.\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 06/01/2026\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-153-30\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "rubicon-research-private-limited-clonazepam-tablet-72888-153-30.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "rubicon-research-private-limited-clonazepam-tablet-72888-153-30", "initial_posting_date": "03/10/2023", "manufacturer_name": "Rubicon Research Private Limited", "package_ndc": "72888-153-30", "quote_dosage_form": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 72888-153-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "related_info": "Marketed by Advagen Pharma Ltd.", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-153-30\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "72888-153-30 \u00b7 Clonazepam Tablet \u00b7 Rubicon Research Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72888-154-01\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Rubicon Research Private Limited\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Advagen Pharma Ltd.\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 06/01/2026\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-154-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "rubicon-research-private-limited-clonazepam-tablet-72888-154-01.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "rubicon-research-private-limited-clonazepam-tablet-72888-154-01", "initial_posting_date": "03/10/2023", "manufacturer_name": "Rubicon Research Private Limited", "package_ndc": "72888-154-01", "quote_dosage_form": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-01)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "related_info": "Marketed by Advagen Pharma Ltd.", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-154-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "72888-154-01 \u00b7 Clonazepam Tablet \u00b7 Rubicon Research Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72888-154-05\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Rubicon Research Private Limited\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Advagen Pharma Ltd.\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 06/01/2026\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-154-05\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "rubicon-research-private-limited-clonazepam-tablet-72888-154-05.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "rubicon-research-private-limited-clonazepam-tablet-72888-154-05", "initial_posting_date": "03/10/2023", "manufacturer_name": "Rubicon Research Private Limited", "package_ndc": "72888-154-05", "quote_dosage_form": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-05)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "related_info": "Marketed by Advagen Pharma Ltd.", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-154-05\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "72888-154-05 \u00b7 Clonazepam Tablet \u00b7 Rubicon Research Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72888-154-30\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Rubicon Research Private Limited\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Marketed by Advagen Pharma Ltd.\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 06/01/2026\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-154-30\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "rubicon-research-private-limited-clonazepam-tablet-72888-154-30.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "rubicon-research-private-limited-clonazepam-tablet-72888-154-30", "initial_posting_date": "03/10/2023", "manufacturer_name": "Rubicon Research Private Limited", "package_ndc": "72888-154-30", "quote_dosage_form": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/01/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 72888-154-30)\", \"company_name\": \"Rubicon Research Private Limited\", \"status\": \"Current\"", "related_info": "Marketed by Advagen Pharma Ltd.", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"72888-154-30\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"sales@advagenpharma.com\", \"availability\": \"Available\", \"related_info\": \"Marketed by Advagen Pharma Ltd.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Rubicon%20Research%20Private%20Limited%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "72888-154-30 \u00b7 Clonazepam Tablet \u00b7 Rubicon Research Private Limited \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 25021-321-04\n\n**Generic name:** Bumetanide Injection\n\n**Manufacturer:** Sagent Pharmaceuticals\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/31/2018\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 3135\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/31/2018\", \"package_ndc\": \"25021-321-04\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3135", "dosage_form": "Injection", "file": "sagent-pharmaceuticals-bumetanide-injection-25021-321-04.md", "generated": true, "generic_name": "Bumetanide Injection", "harvested": "2026-09-01", "id": "sagent-pharmaceuticals-bumetanide-injection-25021-321-04", "initial_posting_date": "01/31/2018", "manufacturer_name": "Sagent Pharmaceuticals", "package_ndc": "25021-321-04", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"01/31/2018\", \"package_ndc\": \"25021-321-04\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "25021-321-04 \u00b7 Bumetanide Injection \u00b7 Sagent Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 25021-321-10\n\n**Generic name:** Bumetanide Injection\n\n**Manufacturer:** Sagent Pharmaceuticals\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/31/2018\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 3135\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/31/2018\", \"package_ndc\": \"25021-321-10\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3135", "dosage_form": "Injection", "file": "sagent-pharmaceuticals-bumetanide-injection-25021-321-10.md", "generated": true, "generic_name": "Bumetanide Injection", "harvested": "2026-09-01", "id": "sagent-pharmaceuticals-bumetanide-injection-25021-321-10", "initial_posting_date": "01/31/2018", "manufacturer_name": "Sagent Pharmaceuticals", "package_ndc": "25021-321-10", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"01/31/2018\", \"package_ndc\": \"25021-321-10\", \"generic_name\": \"Bumetanide Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Bumetanide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "25021-321-10 \u00b7 Bumetanide Injection \u00b7 Sagent Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 25021-115-02\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Sagent Pharmaceuticals\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Selling through remaining short-dated inventory (Dec 2026), API not available, Exiting product line\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"25021-115-02\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Limited Availability\", \"related_info\": \"Selling through remaining short-dated inventory (Dec 2026), API not available, Exiting product line\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "sagent-pharmaceuticals-clindamycin-phosphate-injection-25021-115-02.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "sagent-pharmaceuticals-clindamycin-phosphate-injection-25021-115-02", "initial_posting_date": "03/21/2023", "manufacturer_name": "Sagent Pharmaceuticals", "package_ndc": "25021-115-02", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Selling through remaining short-dated inventory (Dec 2026), API not available, Exiting product line", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"25021-115-02\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Limited Availability\", \"related_info\": \"Selling through remaining short-dated inventory (Dec 2026), API not available, Exiting product line\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "25021-115-02 \u00b7 Clindamycin Phosphate Injection \u00b7 Sagent Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 25021-115-04\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Sagent Pharmaceuticals\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"25021-115-04\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "sagent-pharmaceuticals-clindamycin-phosphate-injection-25021-115-04.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "sagent-pharmaceuticals-clindamycin-phosphate-injection-25021-115-04", "initial_posting_date": "03/21/2023", "manufacturer_name": "Sagent Pharmaceuticals", "package_ndc": "25021-115-04", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"25021-115-04\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "25021-115-04 \u00b7 Clindamycin Phosphate Injection \u00b7 Sagent Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 25021-115-06\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Sagent Pharmaceuticals\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Selling through remaining short-dated inventory (Dec 2026), API not available, Exiting product line\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"25021-115-06\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Limited Availability\", \"related_info\": \"Selling through remaining short-dated inventory (Dec 2026), API not available, Exiting product line\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "sagent-pharmaceuticals-clindamycin-phosphate-injection-25021-115-06.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "sagent-pharmaceuticals-clindamycin-phosphate-injection-25021-115-06", "initial_posting_date": "03/21/2023", "manufacturer_name": "Sagent Pharmaceuticals", "package_ndc": "25021-115-06", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Selling through remaining short-dated inventory (Dec 2026), API not available, Exiting product line", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"25021-115-06\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Limited Availability\", \"related_info\": \"Selling through remaining short-dated inventory (Dec 2026), API not available, Exiting product line\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "25021-115-06 \u00b7 Clindamycin Phosphate Injection \u00b7 Sagent Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 25021-700-01\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Sagent Pharmaceuticals\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: late September 2026\n\n**Initial posting date:** 03/26/2018\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 3081\n\n**Reason for shortage:** Delay in shipping of the drug\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/26/2018\", \"package_ndc\": \"25021-700-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: late September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3081", "dosage_form": "Injection", "file": "sagent-pharmaceuticals-ketorolac-tromethamine-injection-25021-700-01.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "sagent-pharmaceuticals-ketorolac-tromethamine-injection-25021-700-01", "initial_posting_date": "03/26/2018", "manufacturer_name": "Sagent Pharmaceuticals", "package_ndc": "25021-700-01", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Delay in shipping of the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: late September 2026", "shortage_reason": "Delay in shipping of the drug", "source_quote": "\"initial_posting_date\": \"03/26/2018\", \"package_ndc\": \"25021-700-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: late September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "25021-700-01 \u00b7 Ketorolac Tromethamine Injection \u00b7 Sagent Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 25021-701-01\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Sagent Pharmaceuticals\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/26/2018\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 3081\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/26/2018\", \"package_ndc\": \"25021-701-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3081", "dosage_form": "Injection", "file": "sagent-pharmaceuticals-ketorolac-tromethamine-injection-25021-701-01.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "sagent-pharmaceuticals-ketorolac-tromethamine-injection-25021-701-01", "initial_posting_date": "03/26/2018", "manufacturer_name": "Sagent Pharmaceuticals", "package_ndc": "25021-701-01", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/26/2018\", \"package_ndc\": \"25021-701-01\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "25021-701-01 \u00b7 Ketorolac Tromethamine Injection \u00b7 Sagent Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 25021-701-02\n\n**Generic name:** Ketorolac Tromethamine Injection\n\n**Manufacturer:** Sagent Pharmaceuticals\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/26/2018\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 3081\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/26/2018\", \"package_ndc\": \"25021-701-02\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3081", "dosage_form": "Injection", "file": "sagent-pharmaceuticals-ketorolac-tromethamine-injection-25021-701-02.md", "generated": true, "generic_name": "Ketorolac Tromethamine Injection", "harvested": "2026-09-01", "id": "sagent-pharmaceuticals-ketorolac-tromethamine-injection-25021-701-02", "initial_posting_date": "03/26/2018", "manufacturer_name": "Sagent Pharmaceuticals", "package_ndc": "25021-701-02", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/26/2018\", \"package_ndc\": \"25021-701-02\", \"generic_name\": \"Ketorolac Tromethamine Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Ketorolac%20Tromethamine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "25021-701-02 \u00b7 Ketorolac Tromethamine Injection \u00b7 Sagent Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 25021-820-05\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Sagent Pharmaceuticals\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: November 2026\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"25021-820-05\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: November 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "sagent-pharmaceuticals-methylprednisolone-acetate-injection-25021-820-05.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "sagent-pharmaceuticals-methylprednisolone-acetate-injection-25021-820-05", "initial_posting_date": "12/15/2021", "manufacturer_name": "Sagent Pharmaceuticals", "package_ndc": "25021-820-05", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: November 2026", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"25021-820-05\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: November 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "25021-820-05 \u00b7 Methylprednisolone Acetate Injection \u00b7 Sagent Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 25021-820-10\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Sagent Pharmaceuticals\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: November 2026\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"25021-820-10\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: November 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "sagent-pharmaceuticals-methylprednisolone-acetate-injection-25021-820-10.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "sagent-pharmaceuticals-methylprednisolone-acetate-injection-25021-820-10", "initial_posting_date": "12/15/2021", "manufacturer_name": "Sagent Pharmaceuticals", "package_ndc": "25021-820-10", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: November 2026", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"25021-820-10\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: November 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "25021-820-10 \u00b7 Methylprednisolone Acetate Injection \u00b7 Sagent Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 25021-821-05\n\n**Generic name:** Methylprednisolone Acetate Injection\n\n**Manufacturer:** Sagent Pharmaceuticals\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: November 2026, Product on hand is 8-12 months of dating prior to expiry\n\n**Initial posting date:** 12/15/2021\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1721\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"25021-821-05\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: November 2026, Product on hand is 8-12 months of dating prior to expiry\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1721", "dosage_form": "Injection", "file": "sagent-pharmaceuticals-methylprednisolone-acetate-injection-25021-821-05.md", "generated": true, "generic_name": "Methylprednisolone Acetate Injection", "harvested": "2026-09-01", "id": "sagent-pharmaceuticals-methylprednisolone-acetate-injection-25021-821-05", "initial_posting_date": "12/15/2021", "manufacturer_name": "Sagent Pharmaceuticals", "package_ndc": "25021-821-05", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Estimated recovery: November 2026, Product on hand is 8-12 months of dating prior to expiry", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"12/15/2021\", \"package_ndc\": \"25021-821-05\", \"generic_name\": \"Methylprednisolone Acetate Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: November 2026, Product on hand is 8-12 months of dating prior to expiry\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Methylprednisolone%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "25021-821-05 \u00b7 Methylprednisolone Acetate Injection \u00b7 Sagent Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 25021-687-05\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Sagent Pharmaceuticals\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"25021-687-05\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "sagent-pharmaceuticals-rocuronium-bromide-injection-25021-687-05.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "sagent-pharmaceuticals-rocuronium-bromide-injection-25021-687-05", "initial_posting_date": "02/15/2023", "manufacturer_name": "Sagent Pharmaceuticals", "package_ndc": "25021-687-05", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)\", \"company_name\": \"Sagent Pharmaceuticals\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"25021-687-05\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"866-625-1618\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sagent%20Pharmaceuticals%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "25021-687-05 \u00b7 Rocuronium Bromide Injection \u00b7 Sagent Pharmaceuticals \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0185-0842-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Sandoz Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0185-0842-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "sandoz-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0185-0842-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "sandoz-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0185-0842-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Sandoz Inc.", "package_ndc": "0185-0842-01", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0185-0842-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0185-0842-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Sandoz Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0185-0853-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Sandoz Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0185-0853-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "sandoz-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0185-0853-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "sandoz-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0185-0853-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Sandoz Inc.", "package_ndc": "0185-0853-01", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0185-0853-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0185-0853-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Sandoz Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0185-2098-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Sandoz Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0185-2098-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "sandoz-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0185-2098-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "sandoz-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0185-2098-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Sandoz Inc.", "package_ndc": "0185-2098-01", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0185-2098-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0185-2098-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Sandoz Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0185-2099-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Sandoz Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0185-2099-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "sandoz-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0185-2099-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "sandoz-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0185-2099-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Sandoz Inc.", "package_ndc": "0185-2099-01", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0185-2099-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0185-2099-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Sandoz Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0781-3288-09\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Sandoz Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0781-3288-09\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "sandoz-inc-clindamycin-phosphate-injection-0781-3288-09.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "sandoz-inc-clindamycin-phosphate-injection-0781-3288-09", "initial_posting_date": "03/21/2023", "manufacturer_name": "Sandoz Inc.", "package_ndc": "0781-3288-09", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0781-3288-09\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0781-3288-09 \u00b7 Clindamycin Phosphate Injection \u00b7 Sandoz Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0781-3289-09\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Sandoz Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0781-3289-09\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "sandoz-inc-clindamycin-phosphate-injection-0781-3289-09.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "sandoz-inc-clindamycin-phosphate-injection-0781-3289-09", "initial_posting_date": "03/21/2023", "manufacturer_name": "Sandoz Inc.", "package_ndc": "0781-3289-09", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0781-3289-09\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0781-3289-09 \u00b7 Clindamycin Phosphate Injection \u00b7 Sandoz Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0781-3290-09\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Sandoz Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0781-3290-09\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "sandoz-inc-clindamycin-phosphate-injection-0781-3290-09.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "sandoz-inc-clindamycin-phosphate-injection-0781-3290-09", "initial_posting_date": "03/21/2023", "manufacturer_name": "Sandoz Inc.", "package_ndc": "0781-3290-09", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"0781-3290-09\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0781-3290-09 \u00b7 Clindamycin Phosphate Injection \u00b7 Sandoz Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72572-074-24\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Sandoz Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Civica Label\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"72572-074-24\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\", \"related_info\": \"Civica Label\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "sandoz-inc-clindamycin-phosphate-injection-72572-074-24.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "sandoz-inc-clindamycin-phosphate-injection-72572-074-24", "initial_posting_date": "03/21/2023", "manufacturer_name": "Sandoz Inc.", "package_ndc": "72572-074-24", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Civica Label", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"72572-074-24\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\", \"related_info\": \"Civica Label\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "72572-074-24 \u00b7 Clindamycin Phosphate Injection \u00b7 Sandoz Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 72572-076-24\n\n**Generic name:** Clindamycin Phosphate Injection\n\n**Manufacturer:** Sandoz Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Civica Label\n\n**Initial posting date:** 03/21/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1260\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"72572-076-24\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\", \"related_info\": \"Civica Label\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1260", "dosage_form": "Injection", "file": "sandoz-inc-clindamycin-phosphate-injection-72572-076-24.md", "generated": true, "generic_name": "Clindamycin Phosphate Injection", "harvested": "2026-09-01", "id": "sandoz-inc-clindamycin-phosphate-injection-72572-076-24", "initial_posting_date": "03/21/2023", "manufacturer_name": "Sandoz Inc.", "package_ndc": "72572-076-24", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Civica Label", "source_quote": "\"initial_posting_date\": \"03/21/2023\", \"package_ndc\": \"72572-076-24\", \"generic_name\": \"Clindamycin Phosphate Injection\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\", \"related_info\": \"Civica Label\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Clindamycin%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "72572-076-24 \u00b7 Clindamycin Phosphate Injection \u00b7 Sandoz Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0781-3220-92\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Sandoz Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"0781-3220-92\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "sandoz-inc-rocuronium-bromide-injection-0781-3220-92.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "sandoz-inc-rocuronium-bromide-injection-0781-3220-92", "initial_posting_date": "02/15/2023", "manufacturer_name": "Sandoz Inc.", "package_ndc": "0781-3220-92", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"0781-3220-92\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0781-3220-92 \u00b7 Rocuronium Bromide Injection \u00b7 Sandoz Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0781-3220-95\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** Sandoz Inc.\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"0781-3220-95\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "sandoz-inc-rocuronium-bromide-injection-0781-3220-95.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "sandoz-inc-rocuronium-bromide-injection-0781-3220-95", "initial_posting_date": "02/15/2023", "manufacturer_name": "Sandoz Inc.", "package_ndc": "0781-3220-95", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)\", \"company_name\": \"Sandoz Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-08", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"0781-3220-95\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"800-525-8747\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sandoz%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Anesthesia", "title": "0781-3220-95 \u00b7 Rocuronium Bromide Injection \u00b7 Sandoz Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0068-0597-01\n\n**Generic name:** Rifampin Injection\n\n**Manufacturer:** Sanofi-Aventis U.S. LLC\n\n> \"update_date\": \"06/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifadin, Injection, 600 mg (NDC 0068-0597-01)\", \"company_name\": \"Sanofi-Aventis U.S. LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifadin, Injection, 600 mg (NDC 0068-0597-01)\", \"company_name\": \"Sanofi-Aventis U.S. LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 02/17/2021\n\n**Last update date:** 06/22/2026\n\n> \"update_date\": \"06/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifadin, Injection, 600 mg (NDC 0068-0597-01)\", \"company_name\": \"Sanofi-Aventis U.S. LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 2022\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"06/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifadin, Injection, 600 mg (NDC 0068-0597-01)\", \"company_name\": \"Sanofi-Aventis U.S. LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifadin, Injection, 600 mg (NDC 0068-0597-01)\", \"company_name\": \"Sanofi-Aventis U.S. LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"06/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifadin, Injection, 600 mg (NDC 0068-0597-01)\", \"company_name\": \"Sanofi-Aventis U.S. LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/17/2021\", \"package_ndc\": \"0068-0597-01\", \"generic_name\": \"Rifampin Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Rifampin%20Injection&st=d\", \"contact_info\": \"800-633-1610\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sanofi-Aventis%20U.S.%20LLC%22+AND+generic_name%3A%22Rifampin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2022", "dosage_form": "Injection", "file": "sanofi-aventis-u-s-llc-rifampin-injection-0068-0597-01.md", "generated": true, "generic_name": "Rifampin Injection", "harvested": "2026-09-01", "id": "sanofi-aventis-u-s-llc-rifampin-injection-0068-0597-01", "initial_posting_date": "02/17/2021", "manufacturer_name": "Sanofi-Aventis U.S. LLC", "package_ndc": "0068-0597-01", "quote_dosage_form": "\"update_date\": \"06/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifadin, Injection, 600 mg (NDC 0068-0597-01)\", \"company_name\": \"Sanofi-Aventis U.S. LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifadin, Injection, 600 mg (NDC 0068-0597-01)\", \"company_name\": \"Sanofi-Aventis U.S. LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifadin, Injection, 600 mg (NDC 0068-0597-01)\", \"company_name\": \"Sanofi-Aventis U.S. LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifadin, Injection, 600 mg (NDC 0068-0597-01)\", \"company_name\": \"Sanofi-Aventis U.S. LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifadin, Injection, 600 mg (NDC 0068-0597-01)\", \"company_name\": \"Sanofi-Aventis U.S. LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/22/2026\", \"therapeutic_category\": [ \"Anti-Infective\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rifadin, Injection, 600 mg (NDC 0068-0597-01)\", \"company_name\": \"Sanofi-Aventis U.S. LLC\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"02/17/2021\", \"package_ndc\": \"0068-0597-01\", \"generic_name\": \"Rifampin Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Rifampin%20Injection&st=d\", \"contact_info\": \"800-633-1610\", \"availability\": \"Unavailable\", \"related_info\": \"Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sanofi-Aventis%20U.S.%20LLC%22+AND+generic_name%3A%22Rifampin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "0068-0597-01 \u00b7 Rifampin Injection \u00b7 Sanofi-Aventis U.S. LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/22/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 43547-602-10\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Solco Healthcare US, LLC\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** On allocation\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/29/2026\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"43547-602-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-931-9829\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "solco-healthcare-us-llc-lisdexamfetamine-dimesylate-capsule-43547-602-10.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "solco-healthcare-us-llc-lisdexamfetamine-dimesylate-capsule-43547-602-10", "initial_posting_date": "07/14/2023", "manufacturer_name": "Solco Healthcare US, LLC", "package_ndc": "43547-602-10", "quote_dosage_form": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "On allocation", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"43547-602-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-931-9829\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "43547-602-10 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Solco Healthcare US, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/29/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 43547-603-10\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Solco Healthcare US, LLC\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** On allocation\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/29/2026\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"43547-603-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-931-9829\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "solco-healthcare-us-llc-lisdexamfetamine-dimesylate-capsule-43547-603-10.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "solco-healthcare-us-llc-lisdexamfetamine-dimesylate-capsule-43547-603-10", "initial_posting_date": "07/14/2023", "manufacturer_name": "Solco Healthcare US, LLC", "package_ndc": "43547-603-10", "quote_dosage_form": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "On allocation", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"43547-603-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-931-9829\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "43547-603-10 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Solco Healthcare US, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/29/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 43547-604-10\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Solco Healthcare US, LLC\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** On allocation\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/29/2026\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"43547-604-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-931-9829\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "solco-healthcare-us-llc-lisdexamfetamine-dimesylate-capsule-43547-604-10.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "solco-healthcare-us-llc-lisdexamfetamine-dimesylate-capsule-43547-604-10", "initial_posting_date": "07/14/2023", "manufacturer_name": "Solco Healthcare US, LLC", "package_ndc": "43547-604-10", "quote_dosage_form": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "On allocation", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"43547-604-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-931-9829\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "43547-604-10 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Solco Healthcare US, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/29/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 43547-605-10\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Solco Healthcare US, LLC\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** On allocation\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/29/2026\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"43547-605-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-931-9829\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "solco-healthcare-us-llc-lisdexamfetamine-dimesylate-capsule-43547-605-10.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "solco-healthcare-us-llc-lisdexamfetamine-dimesylate-capsule-43547-605-10", "initial_posting_date": "07/14/2023", "manufacturer_name": "Solco Healthcare US, LLC", "package_ndc": "43547-605-10", "quote_dosage_form": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "On allocation", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"43547-605-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-931-9829\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "43547-605-10 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Solco Healthcare US, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/29/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 43547-606-10\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Solco Healthcare US, LLC\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** On allocation\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/29/2026\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"43547-606-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-931-9829\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "solco-healthcare-us-llc-lisdexamfetamine-dimesylate-capsule-43547-606-10.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "solco-healthcare-us-llc-lisdexamfetamine-dimesylate-capsule-43547-606-10", "initial_posting_date": "07/14/2023", "manufacturer_name": "Solco Healthcare US, LLC", "package_ndc": "43547-606-10", "quote_dosage_form": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "On allocation", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"43547-606-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-931-9829\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "43547-606-10 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Solco Healthcare US, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/29/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 43547-607-10\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Solco Healthcare US, LLC\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** On allocation\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/29/2026\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"43547-607-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-931-9829\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "solco-healthcare-us-llc-lisdexamfetamine-dimesylate-capsule-43547-607-10.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "solco-healthcare-us-llc-lisdexamfetamine-dimesylate-capsule-43547-607-10", "initial_posting_date": "07/14/2023", "manufacturer_name": "Solco Healthcare US, LLC", "package_ndc": "43547-607-10", "quote_dosage_form": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "On allocation", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"43547-607-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-931-9829\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "43547-607-10 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Solco Healthcare US, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/29/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 43547-608-10\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Solco Healthcare US, LLC\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** On allocation\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/29/2026\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"43547-608-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-931-9829\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "solco-healthcare-us-llc-lisdexamfetamine-dimesylate-capsule-43547-608-10.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "solco-healthcare-us-llc-lisdexamfetamine-dimesylate-capsule-43547-608-10", "initial_posting_date": "07/14/2023", "manufacturer_name": "Solco Healthcare US, LLC", "package_ndc": "43547-608-10", "quote_dosage_form": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "On allocation", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"43547-608-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"866-931-9829\", \"availability\": \"Limited Availability\", \"related_info\": \"On allocation\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "43547-608-10 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Solco Healthcare US, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/29/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 43547-410-09\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Solco Healthcare US, LLC\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Not available. Long-term backorder for all NDCs. No estimated release date at this time.\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 06/29/2026\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"43547-410-09\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-931-9829\", \"availability\": \"Unavailable\", \"related_info\": \"Not available. Long-term backorder for all NDCs. No estimated release date at this time.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "solco-healthcare-us-llc-quinapril-hydrochloride-tablet-43547-410-09.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "solco-healthcare-us-llc-quinapril-hydrochloride-tablet-43547-410-09", "initial_posting_date": "01/19/2023", "manufacturer_name": "Solco Healthcare US, LLC", "package_ndc": "43547-410-09", "quote_dosage_form": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Not available. Long-term backorder for all NDCs. No estimated release date at this time.", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"43547-410-09\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-931-9829\", \"availability\": \"Unavailable\", \"related_info\": \"Not available. Long-term backorder for all NDCs. No estimated release date at this time.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "43547-410-09 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Solco Healthcare US, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/29/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 43547-411-09\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Solco Healthcare US, LLC\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Not available. Long-term backorder for all NDCs. No estimated release date at this time.\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 06/29/2026\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"43547-411-09\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-931-9829\", \"availability\": \"Unavailable\", \"related_info\": \"Not available. Long-term backorder for all NDCs. No estimated release date at this time.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "solco-healthcare-us-llc-quinapril-hydrochloride-tablet-43547-411-09.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "solco-healthcare-us-llc-quinapril-hydrochloride-tablet-43547-411-09", "initial_posting_date": "01/19/2023", "manufacturer_name": "Solco Healthcare US, LLC", "package_ndc": "43547-411-09", "quote_dosage_form": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Not available. Long-term backorder for all NDCs. No estimated release date at this time.", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"43547-411-09\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-931-9829\", \"availability\": \"Unavailable\", \"related_info\": \"Not available. Long-term backorder for all NDCs. No estimated release date at this time.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "43547-411-09 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Solco Healthcare US, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/29/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 43547-412-09\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Solco Healthcare US, LLC\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Not available. Long-term backorder for all NDCs. No estimated release date at this time.\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 06/29/2026\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"43547-412-09\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-931-9829\", \"availability\": \"Unavailable\", \"related_info\": \"Not available. Long-term backorder for all NDCs. No estimated release date at this time.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "solco-healthcare-us-llc-quinapril-hydrochloride-tablet-43547-412-09.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "solco-healthcare-us-llc-quinapril-hydrochloride-tablet-43547-412-09", "initial_posting_date": "01/19/2023", "manufacturer_name": "Solco Healthcare US, LLC", "package_ndc": "43547-412-09", "quote_dosage_form": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Not available. Long-term backorder for all NDCs. No estimated release date at this time.", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"43547-412-09\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-931-9829\", \"availability\": \"Unavailable\", \"related_info\": \"Not available. Long-term backorder for all NDCs. No estimated release date at this time.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "43547-412-09 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Solco Healthcare US, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/29/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 43547-413-09\n\n**Generic name:** Quinapril Hydrochloride Tablet\n\n**Manufacturer:** Solco Healthcare US, LLC\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Not available. Long-term backorder for all NDCs. No estimated release date at this time.\n\n**Initial posting date:** 01/19/2023\n\n**Last update date:** 06/29/2026\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Days in shortage:** 1321\n\n**Reason for shortage:** Shortage of an active ingredient\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n**Therapeutic category:** Cardiovascular\n\n> \"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"43547-413-09\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-931-9829\", \"availability\": \"Unavailable\", \"related_info\": \"Not available. Long-term backorder for all NDCs. No estimated release date at this time.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1321", "dosage_form": "Tablet", "file": "solco-healthcare-us-llc-quinapril-hydrochloride-tablet-43547-413-09.md", "generated": true, "generic_name": "Quinapril Hydrochloride Tablet", "harvested": "2026-09-01", "id": "solco-healthcare-us-llc-quinapril-hydrochloride-tablet-43547-413-09", "initial_posting_date": "01/19/2023", "manufacturer_name": "Solco Healthcare US, LLC", "package_ndc": "43547-413-09", "quote_dosage_form": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/29/2026\", \"therapeutic_category\": [ \"Cardiovascular\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)\", \"company_name\": \"Solco Healthcare US, LLC\", \"shortage_reason\": \"Shortage of an active ingredient\", \"status\": \"Current\"", "related_info": "Not available. Long-term backorder for all NDCs. No estimated release date at this time.", "shortage_reason": "Shortage of an active ingredient", "source_quote": "\"initial_posting_date\": \"01/19/2023\", \"package_ndc\": \"43547-413-09\", \"generic_name\": \"Quinapril Hydrochloride Tablet\", \"contact_info\": \"866-931-9829\", \"availability\": \"Unavailable\", \"related_info\": \"Not available. Long-term backorder for all NDCs. No estimated release date at this time.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Solco%20Healthcare%20US,%20LLC%22+AND+generic_name%3A%22Quinapril%20Hydrochloride%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Cardiovascular", "title": "43547-413-09 \u00b7 Quinapril Hydrochloride Tablet \u00b7 Solco Healthcare US, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/29/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-481-10\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"70069-481-10\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-atropine-sulfate-injection-70069-481-10.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-atropine-sulfate-injection-70069-481-10", "initial_posting_date": "01/01/2012", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-481-10", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"70069-481-10\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-481-10 \u00b7 Atropine Sulfate Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-631-25\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-631-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-631-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-631-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-631-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-631-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"70069-631-25\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-atropine-sulfate-injection-70069-631-25.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-atropine-sulfate-injection-70069-631-25", "initial_posting_date": "01/01/2012", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-631-25", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-631-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-631-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-631-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-631-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-631-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"70069-631-25\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-631-25 \u00b7 Atropine Sulfate Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-641-25\n\n**Generic name:** Atropine Sulfate Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 70069-641-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 70069-641-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 01/01/2012\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 70069-641-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 5357\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 70069-641-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 70069-641-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"70069-641-25\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "5357", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-atropine-sulfate-injection-70069-641-25.md", "generated": true, "generic_name": "Atropine Sulfate Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-atropine-sulfate-injection-70069-641-25", "initial_posting_date": "01/01/2012", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-641-25", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 70069-641-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 70069-641-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 70069-641-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 70069-641-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Atropine Sulfate, Injection, 1 mg/1 mL (NDC 70069-641-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"01/01/2012\", \"package_ndc\": \"70069-641-25\", \"generic_name\": \"Atropine Sulfate Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Atropine%20Sulfate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-641-25 \u00b7 Atropine Sulfate Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-752-01\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"70069-752-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-bupivacaine-hydrochloride-injection-70069-752-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-bupivacaine-hydrochloride-injection-70069-752-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-752-01", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"70069-752-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-752-01 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-752-10\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"70069-752-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-bupivacaine-hydrochloride-injection-70069-752-10.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-bupivacaine-hydrochloride-injection-70069-752-10", "initial_posting_date": "02/20/2018", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-752-10", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"70069-752-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-752-10 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-752-25\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"70069-752-25\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-bupivacaine-hydrochloride-injection-70069-752-25.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-bupivacaine-hydrochloride-injection-70069-752-25", "initial_posting_date": "02/20/2018", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-752-25", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"70069-752-25\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-752-25 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-753-01\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"70069-753-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-bupivacaine-hydrochloride-injection-70069-753-01.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-bupivacaine-hydrochloride-injection-70069-753-01", "initial_posting_date": "02/20/2018", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-753-01", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"70069-753-01\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-753-01 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-753-10\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"70069-753-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-bupivacaine-hydrochloride-injection-70069-753-10.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-bupivacaine-hydrochloride-injection-70069-753-10", "initial_posting_date": "02/20/2018", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-753-10", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"70069-753-10\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-753-10 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-753-25\n\n**Generic name:** Bupivacaine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/20/2018\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3115\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"70069-753-25\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3115", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-bupivacaine-hydrochloride-injection-70069-753-25.md", "generated": true, "generic_name": "Bupivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-bupivacaine-hydrochloride-injection-70069-753-25", "initial_posting_date": "02/20/2018", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-753-25", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/20/2018\", \"package_ndc\": \"70069-753-25\", \"generic_name\": \"Bupivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Bupivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-753-25 \u00b7 Bupivacaine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-021-25\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"70069-021-25\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"732-554-1019\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-dexamethasone-sodium-phosphate-injection-70069-021-25.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-dexamethasone-sodium-phosphate-injection-70069-021-25", "initial_posting_date": "02/08/2019", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-021-25", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"70069-021-25\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"732-554-1019\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Dermatology", "title": "70069-021-25 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-025-10\n\n**Generic name:** Dexamethasone Sodium Phosphate Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/08/2019\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2762\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Dermatology\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"70069-025-10\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2762", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-dexamethasone-sodium-phosphate-injection-70069-025-10.md", "generated": true, "generic_name": "Dexamethasone Sodium Phosphate Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-dexamethasone-sodium-phosphate-injection-70069-025-10", "initial_posting_date": "02/08/2019", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-025-10", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Dermatology\", \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Hematology\", \"Neurology\", \"Oncology\", \"Ophthalmology\", \"Other\", \"Pulmonary/Allergy\", \"Rheumatology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/08/2019\", \"package_ndc\": \"70069-025-10\", \"generic_name\": \"Dexamethasone Sodium Phosphate Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Dexamethasone%20Sodium%20Phosphate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Dermatology", "title": "70069-025-10 \u00b7 Dexamethasone Sodium Phosphate Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-758-04\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-758-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-758-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-758-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-758-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-758-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"70069-758-04\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-dexmedetomidine-hydrochloride-injection-70069-758-04.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-dexmedetomidine-hydrochloride-injection-70069-758-04", "initial_posting_date": "04/10/2020", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-758-04", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-758-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-758-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-758-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-758-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-758-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"70069-758-04\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-758-04 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-759-04\n\n**Generic name:** Dexmedetomidine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-759-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-759-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 04/10/2020\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-759-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 2335\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-759-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-759-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"70069-759-04\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2335", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-dexmedetomidine-hydrochloride-injection-70069-759-04.md", "generated": true, "generic_name": "Dexmedetomidine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-dexmedetomidine-hydrochloride-injection-70069-759-04", "initial_posting_date": "04/10/2020", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-759-04", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-759-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-759-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-759-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-759-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-759-04)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"04/10/2020\", \"package_ndc\": \"70069-759-04\", \"generic_name\": \"Dexmedetomidine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Dexmedetomidine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-759-04 \u00b7 Dexmedetomidine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-061-10\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-061-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1019\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-061-10.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-061-10", "initial_posting_date": "03/23/2018", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-061-10", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-061-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1019\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-061-10 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-061-25\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-061-25\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1019\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-061-25.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-061-25", "initial_posting_date": "03/23/2018", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-061-25", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-061-25\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1019\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-061-25 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-062-10\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-062-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1019\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-062-10.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-062-10", "initial_posting_date": "03/23/2018", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-062-10", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-062-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1019\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-062-10 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-062-25\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-062-25\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1019\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-062-25.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-062-25", "initial_posting_date": "03/23/2018", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-062-25", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-062-25\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1019\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-062-25 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-063-25\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-063-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-063-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-063-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-063-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-063-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-063-25\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-063-25.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-063-25", "initial_posting_date": "03/23/2018", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-063-25", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-063-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-063-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-063-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-063-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-063-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-063-25\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-063-25 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-064-01\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-064-01\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1019\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-064-01.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-064-01", "initial_posting_date": "03/23/2018", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-064-01", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-064-01\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1019\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-064-01 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-064-10\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-064-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1019\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-064-10.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-064-10", "initial_posting_date": "03/23/2018", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-064-10", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-064-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1019\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-064-10 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-064-25\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-064-25\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1019\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-064-25.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-064-25", "initial_posting_date": "03/23/2018", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-064-25", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-064-25\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1019\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-064-25 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-067-10\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-067-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-067-10.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-067-10", "initial_posting_date": "03/23/2018", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-067-10", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-10)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-067-10\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-067-10 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-067-25\n\n**Generic name:** Ropivacaine Hydrochloride Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/23/2018\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3084\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-067-25\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3084", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-067-25.md", "generated": true, "generic_name": "Ropivacaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-ropivacaine-hydrochloride-injection-70069-067-25", "initial_posting_date": "03/23/2018", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-067-25", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"03/23/2018\", \"package_ndc\": \"70069-067-25\", \"generic_name\": \"Ropivacaine Hydrochloride Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Ropivacaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Anesthesia", "title": "70069-067-25 \u00b7 Ropivacaine Hydrochloride Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-047-25\n\n**Generic name:** Sodium Acetate Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/03/2016\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3863\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"70069-047-25\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3863", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-sodium-acetate-injection-70069-047-25.md", "generated": true, "generic_name": "Sodium Acetate Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-sodium-acetate-injection-70069-047-25", "initial_posting_date": "02/03/2016", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-047-25", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"70069-047-25\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "70069-047-25 \u00b7 Sodium Acetate Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 70069-048-20\n\n**Generic name:** Sodium Acetate Injection\n\n**Manufacturer:** Somerset Therapeutics, LLC\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/03/2016\n\n**Last update date:** 07/20/2026\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 3863\n\n**Dosage form:** Injection\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Endocrinology/Metabolism\n\n> \"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"70069-048-20\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3863", "dosage_form": "Injection", "file": "somerset-therapeutics-llc-sodium-acetate-injection-70069-048-20.md", "generated": true, "generic_name": "Sodium Acetate Injection", "harvested": "2026-09-01", "id": "somerset-therapeutics-llc-sodium-acetate-injection-70069-048-20", "initial_posting_date": "02/03/2016", "manufacturer_name": "Somerset Therapeutics, LLC", "package_ndc": "70069-048-20", "quote_dosage_form": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"07/20/2026\", \"therapeutic_category\": [ \"Endocrinology/Metabolism\", \"Gastroenterology\", \"Pediatric\", \"Total Parenteral Nutrition\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20)\", \"company_name\": \"Somerset Therapeutics, LLC\", \"status\": \"Current\"", "rechecked": "2026-09-15", "source_quote": "\"initial_posting_date\": \"02/03/2016\", \"package_ndc\": \"70069-048-20\", \"generic_name\": \"Sodium Acetate Injection\", \"contact_info\": \"732-554-1037\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Somerset%20Therapeutics,%20LLC%22+AND+generic_name%3A%22Sodium%20Acetate%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-18", "status": "Current", "therapeutic_category": "Endocrinology/Metabolism", "title": "70069-048-20 \u00b7 Sodium Acetate Injection \u00b7 Somerset Therapeutics, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "07/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0406-8884-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** SpecGx LLC\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0406-8884-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "specgx-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0406-8884-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "specgx-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0406-8884-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "SpecGx LLC", "package_ndc": "0406-8884-01", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0406-8884-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0406-8884-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 SpecGx LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0406-8885-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** SpecGx LLC\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0406-8885-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "specgx-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0406-8885-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "specgx-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0406-8885-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "SpecGx LLC", "package_ndc": "0406-8885-01", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0406-8885-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0406-8885-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 SpecGx LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0406-8891-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** SpecGx LLC\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0406-8891-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-325-8888\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "specgx-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0406-8891-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "specgx-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0406-8891-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "SpecGx LLC", "package_ndc": "0406-8891-01", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0406-8891-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-325-8888\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0406-8891-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 SpecGx LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0406-8892-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** SpecGx LLC\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0406-8892-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-325-8888\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "specgx-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0406-8892-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "specgx-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0406-8892-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "SpecGx LLC", "package_ndc": "0406-8892-01", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0406-8892-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-325-8888\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0406-8892-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 SpecGx LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0406-8893-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** SpecGx LLC\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0406-8893-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "specgx-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0406-8893-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "specgx-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0406-8893-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "SpecGx LLC", "package_ndc": "0406-8893-01", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0406-8893-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0406-8893-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 SpecGx LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0406-8894-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** SpecGx LLC\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0406-8894-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-325-8888\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "specgx-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0406-8894-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "specgx-llc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0406-8894-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "SpecGx LLC", "package_ndc": "0406-8894-01", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)\", \"company_name\": \"SpecGx LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0406-8894-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-325-8888\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0406-8894-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 SpecGx LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0406-5111-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** SpecGx LLC\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0406-5111-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "specgx-llc-lisdexamfetamine-dimesylate-capsule-0406-5111-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "specgx-llc-lisdexamfetamine-dimesylate-capsule-0406-5111-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "SpecGx LLC", "package_ndc": "0406-5111-01", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0406-5111-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0406-5111-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 SpecGx LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0406-5112-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** SpecGx LLC\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0406-5112-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "specgx-llc-lisdexamfetamine-dimesylate-capsule-0406-5112-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "specgx-llc-lisdexamfetamine-dimesylate-capsule-0406-5112-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "SpecGx LLC", "package_ndc": "0406-5112-01", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0406-5112-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0406-5112-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 SpecGx LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0406-5113-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** SpecGx LLC\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0406-5113-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "specgx-llc-lisdexamfetamine-dimesylate-capsule-0406-5113-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "specgx-llc-lisdexamfetamine-dimesylate-capsule-0406-5113-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "SpecGx LLC", "package_ndc": "0406-5113-01", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0406-5113-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0406-5113-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 SpecGx LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0406-5114-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** SpecGx LLC\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0406-5114-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "specgx-llc-lisdexamfetamine-dimesylate-capsule-0406-5114-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "specgx-llc-lisdexamfetamine-dimesylate-capsule-0406-5114-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "SpecGx LLC", "package_ndc": "0406-5114-01", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0406-5114-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0406-5114-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 SpecGx LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0406-5115-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** SpecGx LLC\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0406-5115-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "specgx-llc-lisdexamfetamine-dimesylate-capsule-0406-5115-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "specgx-llc-lisdexamfetamine-dimesylate-capsule-0406-5115-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "SpecGx LLC", "package_ndc": "0406-5115-01", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0406-5115-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0406-5115-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 SpecGx LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0406-5116-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** SpecGx LLC\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0406-5116-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "specgx-llc-lisdexamfetamine-dimesylate-capsule-0406-5116-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "specgx-llc-lisdexamfetamine-dimesylate-capsule-0406-5116-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "SpecGx LLC", "package_ndc": "0406-5116-01", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0406-5116-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0406-5116-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 SpecGx LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0406-5117-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** SpecGx LLC\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/20/2026\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0406-5117-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "specgx-llc-lisdexamfetamine-dimesylate-capsule-0406-5117-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "specgx-llc-lisdexamfetamine-dimesylate-capsule-0406-5117-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "SpecGx LLC", "package_ndc": "0406-5117-01", "quote_dosage_form": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/20/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)\", \"company_name\": \"SpecGx LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0406-5117-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-325-8888\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SpecGx%20LLC%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0406-5117-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 SpecGx LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/20/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 65282-1605-1\n\n**Generic name:** Lidocaine Hydrochloride Injection\n\n**Manufacturer:** Spectra Medical Devices, LLC\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)\", \"company_name\": \"Spectra Medical Devices, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)\", \"company_name\": \"Spectra Medical Devices, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 06/14/2018\n\n**Last update date:** 05/15/2026\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)\", \"company_name\": \"Spectra Medical Devices, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 3001\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)\", \"company_name\": \"Spectra Medical Devices, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)\", \"company_name\": \"Spectra Medical Devices, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)\", \"company_name\": \"Spectra Medical Devices, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/14/2018\", \"package_ndc\": \"65282-1605-1\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"978-657-0889 ext. 5231\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Spectra%20Medical%20Devices,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3001", "dosage_form": "Injection", "file": "spectra-medical-devices-llc-lidocaine-hydrochloride-injection-65282-1605-1.md", "generated": true, "generic_name": "Lidocaine Hydrochloride Injection", "harvested": "2026-09-01", "id": "spectra-medical-devices-llc-lidocaine-hydrochloride-injection-65282-1605-1", "initial_posting_date": "06/14/2018", "manufacturer_name": "Spectra Medical Devices, LLC", "package_ndc": "65282-1605-1", "quote_dosage_form": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)\", \"company_name\": \"Spectra Medical Devices, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)\", \"company_name\": \"Spectra Medical Devices, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)\", \"company_name\": \"Spectra Medical Devices, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)\", \"company_name\": \"Spectra Medical Devices, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)\", \"company_name\": \"Spectra Medical Devices, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"05/15/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)\", \"company_name\": \"Spectra Medical Devices, LLC\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"06/14/2018\", \"package_ndc\": \"65282-1605-1\", \"generic_name\": \"Lidocaine Hydrochloride Injection\", \"contact_info\": \"978-657-0889 ext. 5231\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Spectra%20Medical%20Devices,%20LLC%22+AND+generic_name%3A%22Lidocaine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "65282-1605-1 \u00b7 Lidocaine Hydrochloride Injection \u00b7 Spectra Medical Devices, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "05/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 21586-011-02\n\n**Generic name:** Cefotaxime Sodium Powder, for Solution\n\n**Manufacturer:** SteriMax, Inc.\n\n> \"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/17/2015\n\n**Last update date:** 06/15/2026\n\n> \"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 4214\n\n**Dosage form:** Powder, For Solution\n\n> \"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/17/2015\", \"package_ndc\": \"21586-011-02\", \"generic_name\": \"Cefotaxime Sodium Powder, for Solution\", \"related_info_link\": \"https://www.fda.gov/media/193116/download?attachment\", \"contact_info\": \"800-881-3550\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SteriMax,%20Inc.%22+AND+generic_name%3A%22Cefotaxime%20Sodium%20Powder,%20for%20Solution%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "4214", "dosage_form": "Powder, For Solution", "file": "sterimax-inc-cefotaxime-sodium-powder-for-solution-21586-011-02.md", "generated": true, "generic_name": "Cefotaxime Sodium Powder, for Solution", "harvested": "2026-09-01", "id": "sterimax-inc-cefotaxime-sodium-powder-for-solution-21586-011-02", "initial_posting_date": "02/17/2015", "manufacturer_name": "SteriMax, Inc.", "package_ndc": "21586-011-02", "quote_dosage_form": "\"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"02/17/2015\", \"package_ndc\": \"21586-011-02\", \"generic_name\": \"Cefotaxime Sodium Powder, for Solution\", \"related_info_link\": \"https://www.fda.gov/media/193116/download?attachment\", \"contact_info\": \"800-881-3550\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SteriMax,%20Inc.%22+AND+generic_name%3A%22Cefotaxime%20Sodium%20Powder,%20for%20Solution%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "21586-011-02 \u00b7 Cefotaxime Sodium Powder, for Solution \u00b7 SteriMax, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 21586-012-02\n\n**Generic name:** Cefotaxime Sodium Powder, for Solution\n\n**Manufacturer:** SteriMax, Inc.\n\n> \"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 02/17/2015\n\n**Last update date:** 06/15/2026\n\n> \"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 4214\n\n**Dosage form:** Powder, For Solution\n\n> \"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anti-Infective\n\n> \"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/17/2015\", \"package_ndc\": \"21586-012-02\", \"generic_name\": \"Cefotaxime Sodium Powder, for Solution\", \"related_info_link\": \"https://www.fda.gov/media/193116/download?attachment\", \"contact_info\": \"800-881-3550\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SteriMax,%20Inc.%22+AND+generic_name%3A%22Cefotaxime%20Sodium%20Powder,%20for%20Solution%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "4214", "dosage_form": "Powder, For Solution", "file": "sterimax-inc-cefotaxime-sodium-powder-for-solution-21586-012-02.md", "generated": true, "generic_name": "Cefotaxime Sodium Powder, for Solution", "harvested": "2026-09-01", "id": "sterimax-inc-cefotaxime-sodium-powder-for-solution-21586-012-02", "initial_posting_date": "02/17/2015", "manufacturer_name": "SteriMax, Inc.", "package_ndc": "21586-012-02", "quote_dosage_form": "\"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/15/2026\", \"therapeutic_category\": [ \"Anti-Infective\", \"Pediatric\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"02/17/2015\", \"package_ndc\": \"21586-012-02\", \"generic_name\": \"Cefotaxime Sodium Powder, for Solution\", \"related_info_link\": \"https://www.fda.gov/media/193116/download?attachment\", \"contact_info\": \"800-881-3550\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SteriMax,%20Inc.%22+AND+generic_name%3A%22Cefotaxime%20Sodium%20Powder,%20for%20Solution%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anti-Infective", "title": "21586-012-02 \u00b7 Cefotaxime Sodium Powder, for Solution \u00b7 SteriMax, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/15/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 21586-211-02\n\n**Generic name:** Ifosfamide Injection\n\n**Manufacturer:** SteriMax, Inc.\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/1 (NDC 21586-211-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/1 (NDC 21586-211-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** To place an order, please contact GlobalRX at info@globalrx.com or (919) 245-8418\n\n**Initial posting date:** 06/12/2026\n\n**Last update date:** 09/08/2026\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/1 (NDC 21586-211-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 90\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/1 (NDC 21586-211-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/1 (NDC 21586-211-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"21586-211-02\", \"generic_name\": \"Ifosfamide Injection\", \"related_info_link\": \"https://www.fda.gov/media/194567/download\", \"contact_info\": \"877-373-4657\", \"availability\": \"Available\", \"related_info\": \"To place an order, please contact GlobalRX at info@globalrx.com or (919) 245-8418\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SteriMax,%20Inc.%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "90", "dosage_form": "Injection", "file": "sterimax-inc-ifosfamide-injection-21586-211-02.md", "generated": true, "generic_name": "Ifosfamide Injection", "harvested": "2026-09-10", "id": "sterimax-inc-ifosfamide-injection-21586-211-02", "initial_posting_date": "06/12/2026", "manufacturer_name": "SteriMax, Inc.", "package_ndc": "21586-211-02", "quote_dosage_form": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/1 (NDC 21586-211-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/1 (NDC 21586-211-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/1 (NDC 21586-211-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/1 (NDC 21586-211-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/08/2026\", \"therapeutic_category\": [ \"Oncology\", \"Pediatric\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Ifosfamide, Injection, 1 g/1 (NDC 21586-211-02)\", \"company_name\": \"SteriMax, Inc.\", \"status\": \"Current\"", "related_info": "To place an order, please contact GlobalRX at info@globalrx.com or (919) 245-8418", "source_quote": "\"initial_posting_date\": \"06/12/2026\", \"package_ndc\": \"21586-211-02\", \"generic_name\": \"Ifosfamide Injection\", \"related_info_link\": \"https://www.fda.gov/media/194567/download\", \"contact_info\": \"877-373-4657\", \"availability\": \"Available\", \"related_info\": \"To place an order, please contact GlobalRX at info@globalrx.com or (919) 245-8418\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22SteriMax,%20Inc.%22+AND+generic_name%3A%22Ifosfamide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-13", "status": "Current", "therapeutic_category": "Oncology", "title": "21586-211-02 \u00b7 Ifosfamide Injection \u00b7 SteriMax, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/08/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 57664-046-88\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-046-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-818-4555\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-capsule-57664-046-88.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-capsule-57664-046-88", "initial_posting_date": "07/14/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "57664-046-88", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-046-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-818-4555\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57664-046-88 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 57664-048-88\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-048-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-818-4555\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-capsule-57664-048-88.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-capsule-57664-048-88", "initial_posting_date": "07/14/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "57664-048-88", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-048-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-818-4555\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57664-048-88 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 57664-049-88\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-049-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-818-4555\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-capsule-57664-049-88.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-capsule-57664-049-88", "initial_posting_date": "07/14/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "57664-049-88", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-049-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-818-4555\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57664-049-88 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 57664-050-88\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-050-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-818-4555\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-capsule-57664-050-88.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-capsule-57664-050-88", "initial_posting_date": "07/14/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "57664-050-88", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-050-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-818-4555\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57664-050-88 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 57664-051-88\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-051-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-818-4555\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-capsule-57664-051-88.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-capsule-57664-051-88", "initial_posting_date": "07/14/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "57664-051-88", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-051-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-818-4555\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57664-051-88 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 57664-052-88\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-052-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-818-4555\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-capsule-57664-052-88.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-capsule-57664-052-88", "initial_posting_date": "07/14/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "57664-052-88", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-052-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-818-4555\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57664-052-88 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 57664-083-88\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-083-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"800-818-4555\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-tablet-chewable-57664-083-88.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-tablet-chewable-57664-083-88", "initial_posting_date": "07/14/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "57664-083-88", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-083-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"800-818-4555\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57664-083-88 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 57664-084-88\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-084-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"800-818-4555\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-tablet-chewable-57664-084-88.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-tablet-chewable-57664-084-88", "initial_posting_date": "07/14/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "57664-084-88", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-084-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"800-818-4555\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57664-084-88 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 57664-085-88\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-085-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"800-818-4555\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-tablet-chewable-57664-085-88.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-tablet-chewable-57664-085-88", "initial_posting_date": "07/14/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "57664-085-88", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-085-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"800-818-4555\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57664-085-88 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 57664-086-88\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-086-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"800-818-4555\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-tablet-chewable-57664-086-88.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-tablet-chewable-57664-086-88", "initial_posting_date": "07/14/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "57664-086-88", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-086-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"800-818-4555\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57664-086-88 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 57664-087-88\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-087-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"800-818-4555\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-tablet-chewable-57664-087-88.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-tablet-chewable-57664-087-88", "initial_posting_date": "07/14/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "57664-087-88", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-087-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"800-818-4555\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57664-087-88 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 57664-088-88\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-088-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"800-818-4555\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-tablet-chewable-57664-088-88.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-lisdexamfetamine-dimesylate-tablet-chewable-57664-088-88", "initial_posting_date": "07/14/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "57664-088-88", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"57664-088-88\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"800-818-4555\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57664-088-88 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 57664-606-88\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Currently not marketed\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"57664-606-88\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-818-4555\", \"availability\": \"Unavailable\", \"related_info\": \"Currently not marketed\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "sun-pharmaceutical-industries-inc-methylphenidate-hydrochloride-tablet-extended-release-57664-606-88.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-methylphenidate-hydrochloride-tablet-extended-release-57664-606-88", "initial_posting_date": "07/26/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "57664-606-88", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Currently not marketed", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"57664-606-88\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-818-4555\", \"availability\": \"Unavailable\", \"related_info\": \"Currently not marketed\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57664-606-88 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 57664-607-88\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Currently not marketed\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"57664-607-88\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-818-4555\", \"availability\": \"Unavailable\", \"related_info\": \"Currently not marketed\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "sun-pharmaceutical-industries-inc-methylphenidate-hydrochloride-tablet-extended-release-57664-607-88.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-methylphenidate-hydrochloride-tablet-extended-release-57664-607-88", "initial_posting_date": "07/26/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "57664-607-88", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Currently not marketed", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"57664-607-88\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-818-4555\", \"availability\": \"Unavailable\", \"related_info\": \"Currently not marketed\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57664-607-88 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 57664-608-88\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Currently not marketed\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"57664-608-88\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-818-4555\", \"availability\": \"Unavailable\", \"related_info\": \"Currently not marketed\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "sun-pharmaceutical-industries-inc-methylphenidate-hydrochloride-tablet-extended-release-57664-608-88.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-methylphenidate-hydrochloride-tablet-extended-release-57664-608-88", "initial_posting_date": "07/26/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "57664-608-88", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Currently not marketed", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"57664-608-88\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-818-4555\", \"availability\": \"Unavailable\", \"related_info\": \"Currently not marketed\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57664-608-88 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 57664-609-88\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Currently not marketed\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"57664-609-88\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-818-4555\", \"availability\": \"Unavailable\", \"related_info\": \"Currently not marketed\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "sun-pharmaceutical-industries-inc-methylphenidate-hydrochloride-tablet-extended-release-57664-609-88.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-methylphenidate-hydrochloride-tablet-extended-release-57664-609-88", "initial_posting_date": "07/26/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "57664-609-88", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Currently not marketed", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"57664-609-88\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-818-4555\", \"availability\": \"Unavailable\", \"related_info\": \"Currently not marketed\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57664-609-88 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 45567-0060-1\n\n**Generic name:** Technetium TC-99M Pyrophosphate Kit Injection\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 12/27/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 979\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Medical Imaging\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/27/2023\", \"package_ndc\": \"45567-0060-1\", \"generic_name\": \"Technetium TC-99M Pyrophosphate Kit Injection\", \"contact_info\": \"800-818-4555\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Technetium%20TC-99M%20Pyrophosphate%20Kit%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "979", "dosage_form": "Injection", "file": "sun-pharmaceutical-industries-inc-technetium-tc-99m-pyrophosphate-kit-injection-45567-0060-1.md", "generated": true, "generic_name": "Technetium TC-99M Pyrophosphate Kit Injection", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-technetium-tc-99m-pyrophosphate-kit-injection-45567-0060-1", "initial_posting_date": "12/27/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "45567-0060-1", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"12/27/2023\", \"package_ndc\": \"45567-0060-1\", \"generic_name\": \"Technetium TC-99M Pyrophosphate Kit Injection\", \"contact_info\": \"800-818-4555\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Technetium%20TC-99M%20Pyrophosphate%20Kit%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Medical Imaging", "title": "45567-0060-1 \u00b7 Technetium TC-99M Pyrophosphate Kit Injection \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 45567-0060-2\n\n**Generic name:** Technetium TC-99M Pyrophosphate Kit Injection\n\n**Manufacturer:** Sun Pharmaceutical Industries, Inc.\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 12/27/2023\n\n**Last update date:** 08/05/2026\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 979\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Medical Imaging\n\n> \"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/27/2023\", \"package_ndc\": \"45567-0060-2\", \"generic_name\": \"Technetium TC-99M Pyrophosphate Kit Injection\", \"contact_info\": \"800-818-4555\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Technetium%20TC-99M%20Pyrophosphate%20Kit%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "979", "dosage_form": "Injection", "file": "sun-pharmaceutical-industries-inc-technetium-tc-99m-pyrophosphate-kit-injection-45567-0060-2.md", "generated": true, "generic_name": "Technetium TC-99M Pyrophosphate Kit Injection", "harvested": "2026-09-01", "id": "sun-pharmaceutical-industries-inc-technetium-tc-99m-pyrophosphate-kit-injection-45567-0060-2", "initial_posting_date": "12/27/2023", "manufacturer_name": "Sun Pharmaceutical Industries, Inc.", "package_ndc": "45567-0060-2", "quote_dosage_form": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/05/2026\", \"therapeutic_category\": [ \"Medical Imaging\" ], \"dosage_form\": \"Injection\", \"presentation\": \"CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)\", \"company_name\": \"Sun Pharmaceutical Industries, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"12/27/2023\", \"package_ndc\": \"45567-0060-2\", \"generic_name\": \"Technetium TC-99M Pyrophosphate Kit Injection\", \"contact_info\": \"800-818-4555\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sun%20Pharmaceutical%20Industries,%20Inc.%22+AND+generic_name%3A%22Technetium%20TC-99M%20Pyrophosphate%20Kit%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Medical Imaging", "title": "45567-0060-2 \u00b7 Technetium TC-99M Pyrophosphate Kit Injection \u00b7 Sun Pharmaceutical Industries, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/05/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 11534-190-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Sunrise Pharmaceutical, Inc.\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/16/2026\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"11534-190-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"732-382-6085 Monday to Friday 9 am to 3:45 pm\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sunrise%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "sunrise-pharmaceutical-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-11534-190-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "sunrise-pharmaceutical-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-11534-190-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Sunrise Pharmaceutical, Inc.", "package_ndc": "11534-190-01", "quote_dosage_form": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"11534-190-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"732-382-6085 Monday to Friday 9 am to 3:45 pm\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sunrise%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "11534-190-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Sunrise Pharmaceutical, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/16/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 11534-191-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Sunrise Pharmaceutical, Inc.\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/16/2026\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"11534-191-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"732-382-6085 Monday to Friday 9 am to 3:45 pm\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sunrise%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "sunrise-pharmaceutical-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-11534-191-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "sunrise-pharmaceutical-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-11534-191-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Sunrise Pharmaceutical, Inc.", "package_ndc": "11534-191-01", "quote_dosage_form": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"11534-191-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"732-382-6085 Monday to Friday 9 am to 3:45 pm\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sunrise%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "11534-191-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Sunrise Pharmaceutical, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/16/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 11534-192-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Sunrise Pharmaceutical, Inc.\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/16/2026\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"11534-192-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"732-382-6085 Monday to Friday 9 am to 3:45 pm\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sunrise%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "sunrise-pharmaceutical-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-11534-192-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "sunrise-pharmaceutical-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-11534-192-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Sunrise Pharmaceutical, Inc.", "package_ndc": "11534-192-01", "quote_dosage_form": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"11534-192-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"732-382-6085 Monday to Friday 9 am to 3:45 pm\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sunrise%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "11534-192-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Sunrise Pharmaceutical, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/16/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 11534-193-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Sunrise Pharmaceutical, Inc.\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/16/2026\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"11534-193-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"732-382-6085 Monday to Friday 9 am to 3:45 pm\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sunrise%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "sunrise-pharmaceutical-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-11534-193-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "sunrise-pharmaceutical-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-11534-193-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Sunrise Pharmaceutical, Inc.", "package_ndc": "11534-193-01", "quote_dosage_form": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"11534-193-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"732-382-6085 Monday to Friday 9 am to 3:45 pm\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sunrise%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "11534-193-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Sunrise Pharmaceutical, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/16/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 11534-194-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Sunrise Pharmaceutical, Inc.\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/16/2026\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"11534-194-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"732-382-6085 Monday to Friday 9 am to 3:45 pm\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sunrise%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "sunrise-pharmaceutical-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-11534-194-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "sunrise-pharmaceutical-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-11534-194-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Sunrise Pharmaceutical, Inc.", "package_ndc": "11534-194-01", "quote_dosage_form": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"11534-194-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"732-382-6085 Monday to Friday 9 am to 3:45 pm\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sunrise%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "11534-194-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Sunrise Pharmaceutical, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/16/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 11534-195-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Sunrise Pharmaceutical, Inc.\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/16/2026\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"11534-195-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"732-382-6085 Monday to Friday 9 am to 3:45 pm\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sunrise%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "sunrise-pharmaceutical-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-11534-195-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "sunrise-pharmaceutical-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-11534-195-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Sunrise Pharmaceutical, Inc.", "package_ndc": "11534-195-01", "quote_dosage_form": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"11534-195-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"732-382-6085 Monday to Friday 9 am to 3:45 pm\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sunrise%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "11534-195-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Sunrise Pharmaceutical, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/16/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 11534-196-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Sunrise Pharmaceutical, Inc.\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/16/2026\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"11534-196-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"732-382-6085 Monday to Friday 9 am to 3:45 pm\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sunrise%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "sunrise-pharmaceutical-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-11534-196-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "sunrise-pharmaceutical-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-11534-196-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Sunrise Pharmaceutical, Inc.", "package_ndc": "11534-196-01", "quote_dosage_form": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/16/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)\", \"company_name\": \"Sunrise Pharmaceutical, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"11534-196-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"732-382-6085 Monday to Friday 9 am to 3:45 pm\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Sunrise%20Pharmaceutical,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "11534-196-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Sunrise Pharmaceutical, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/16/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59417-101-10\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Takeda Pharmaceuticals USA Inc.\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 10 mg (NDC 59417-101-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 10 mg (NDC 59417-101-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/23/2026\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 10 mg (NDC 59417-101-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 10 mg (NDC 59417-101-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 10 mg (NDC 59417-101-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-101-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-59417-101-10.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-59417-101-10", "initial_posting_date": "07/14/2023", "manufacturer_name": "Takeda Pharmaceuticals USA Inc.", "package_ndc": "59417-101-10", "quote_dosage_form": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 10 mg (NDC 59417-101-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 10 mg (NDC 59417-101-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 10 mg (NDC 59417-101-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 10 mg (NDC 59417-101-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 10 mg (NDC 59417-101-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-101-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Psychiatry", "title": "59417-101-10 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Takeda Pharmaceuticals USA Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/23/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59417-102-10\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Takeda Pharmaceuticals USA Inc.\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 20 mg (NDC 59417-102-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 20 mg (NDC 59417-102-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/23/2026\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 20 mg (NDC 59417-102-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 20 mg (NDC 59417-102-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 20 mg (NDC 59417-102-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-102-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-59417-102-10.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-59417-102-10", "initial_posting_date": "07/14/2023", "manufacturer_name": "Takeda Pharmaceuticals USA Inc.", "package_ndc": "59417-102-10", "quote_dosage_form": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 20 mg (NDC 59417-102-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 20 mg (NDC 59417-102-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 20 mg (NDC 59417-102-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 20 mg (NDC 59417-102-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 20 mg (NDC 59417-102-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-102-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Psychiatry", "title": "59417-102-10 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Takeda Pharmaceuticals USA Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/23/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59417-103-10\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Takeda Pharmaceuticals USA Inc.\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 30 mg (NDC 59417-103-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 30 mg (NDC 59417-103-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/23/2026\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 30 mg (NDC 59417-103-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 30 mg (NDC 59417-103-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 30 mg (NDC 59417-103-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-103-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-59417-103-10.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-59417-103-10", "initial_posting_date": "07/14/2023", "manufacturer_name": "Takeda Pharmaceuticals USA Inc.", "package_ndc": "59417-103-10", "quote_dosage_form": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 30 mg (NDC 59417-103-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 30 mg (NDC 59417-103-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 30 mg (NDC 59417-103-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 30 mg (NDC 59417-103-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 30 mg (NDC 59417-103-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-103-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Psychiatry", "title": "59417-103-10 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Takeda Pharmaceuticals USA Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/23/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59417-104-10\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Takeda Pharmaceuticals USA Inc.\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 40 mg (NDC 59417-104-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 40 mg (NDC 59417-104-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/23/2026\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 40 mg (NDC 59417-104-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 40 mg (NDC 59417-104-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 40 mg (NDC 59417-104-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-104-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-59417-104-10.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-59417-104-10", "initial_posting_date": "07/14/2023", "manufacturer_name": "Takeda Pharmaceuticals USA Inc.", "package_ndc": "59417-104-10", "quote_dosage_form": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 40 mg (NDC 59417-104-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 40 mg (NDC 59417-104-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 40 mg (NDC 59417-104-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 40 mg (NDC 59417-104-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 40 mg (NDC 59417-104-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-104-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Psychiatry", "title": "59417-104-10 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Takeda Pharmaceuticals USA Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/23/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59417-105-10\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Takeda Pharmaceuticals USA Inc.\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 50 mg (NDC 59417-105-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 50 mg (NDC 59417-105-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/23/2026\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 50 mg (NDC 59417-105-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 50 mg (NDC 59417-105-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 50 mg (NDC 59417-105-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-105-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-59417-105-10.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-59417-105-10", "initial_posting_date": "07/14/2023", "manufacturer_name": "Takeda Pharmaceuticals USA Inc.", "package_ndc": "59417-105-10", "quote_dosage_form": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 50 mg (NDC 59417-105-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 50 mg (NDC 59417-105-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 50 mg (NDC 59417-105-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 50 mg (NDC 59417-105-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 50 mg (NDC 59417-105-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-105-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Psychiatry", "title": "59417-105-10 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Takeda Pharmaceuticals USA Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/23/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59417-106-10\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Takeda Pharmaceuticals USA Inc.\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 60 mg (NDC 59417-106-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 60 mg (NDC 59417-106-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/23/2026\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 60 mg (NDC 59417-106-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 60 mg (NDC 59417-106-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 60 mg (NDC 59417-106-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-106-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-59417-106-10.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-59417-106-10", "initial_posting_date": "07/14/2023", "manufacturer_name": "Takeda Pharmaceuticals USA Inc.", "package_ndc": "59417-106-10", "quote_dosage_form": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 60 mg (NDC 59417-106-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 60 mg (NDC 59417-106-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 60 mg (NDC 59417-106-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 60 mg (NDC 59417-106-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 60 mg (NDC 59417-106-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-106-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Psychiatry", "title": "59417-106-10 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Takeda Pharmaceuticals USA Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/23/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59417-107-10\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Takeda Pharmaceuticals USA Inc.\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 70 mg (NDC 59417-107-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 70 mg (NDC 59417-107-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/23/2026\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 70 mg (NDC 59417-107-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 70 mg (NDC 59417-107-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 70 mg (NDC 59417-107-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-107-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-59417-107-10.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-59417-107-10", "initial_posting_date": "07/14/2023", "manufacturer_name": "Takeda Pharmaceuticals USA Inc.", "package_ndc": "59417-107-10", "quote_dosage_form": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 70 mg (NDC 59417-107-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 70 mg (NDC 59417-107-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 70 mg (NDC 59417-107-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 70 mg (NDC 59417-107-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Vyvanse, Capsule, 70 mg (NDC 59417-107-10)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-107-10\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Psychiatry", "title": "59417-107-10 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Takeda Pharmaceuticals USA Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/23/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59417-115-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Takeda Pharmaceuticals USA Inc.\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/23/2026\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-115-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-tablet-chewable-59417-115-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-tablet-chewable-59417-115-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Takeda Pharmaceuticals USA Inc.", "package_ndc": "59417-115-01", "quote_dosage_form": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-115-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Psychiatry", "title": "59417-115-01 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Takeda Pharmaceuticals USA Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/23/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59417-116-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Takeda Pharmaceuticals USA Inc.\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/23/2026\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-116-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-tablet-chewable-59417-116-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-tablet-chewable-59417-116-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Takeda Pharmaceuticals USA Inc.", "package_ndc": "59417-116-01", "quote_dosage_form": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-116-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Psychiatry", "title": "59417-116-01 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Takeda Pharmaceuticals USA Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/23/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59417-117-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Takeda Pharmaceuticals USA Inc.\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/23/2026\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-117-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-tablet-chewable-59417-117-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-tablet-chewable-59417-117-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Takeda Pharmaceuticals USA Inc.", "package_ndc": "59417-117-01", "quote_dosage_form": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-117-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Psychiatry", "title": "59417-117-01 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Takeda Pharmaceuticals USA Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/23/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59417-118-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Takeda Pharmaceuticals USA Inc.\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/23/2026\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-118-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-tablet-chewable-59417-118-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-tablet-chewable-59417-118-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Takeda Pharmaceuticals USA Inc.", "package_ndc": "59417-118-01", "quote_dosage_form": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-118-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Psychiatry", "title": "59417-118-01 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Takeda Pharmaceuticals USA Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/23/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59417-119-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Takeda Pharmaceuticals USA Inc.\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/23/2026\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-119-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-tablet-chewable-59417-119-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-tablet-chewable-59417-119-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Takeda Pharmaceuticals USA Inc.", "package_ndc": "59417-119-01", "quote_dosage_form": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-119-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Psychiatry", "title": "59417-119-01 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Takeda Pharmaceuticals USA Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/23/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 59417-120-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Tablet, Chewable\n\n**Manufacturer:** Takeda Pharmaceuticals USA Inc.\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 06/23/2026\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Tablet, Chewable\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-120-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Tablet, Chewable", "file": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-tablet-chewable-59417-120-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "harvested": "2026-09-01", "id": "takeda-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-tablet-chewable-59417-120-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Takeda Pharmaceuticals USA Inc.", "package_ndc": "59417-120-01", "quote_dosage_form": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet, Chewable\", \"presentation\": \"Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)\", \"company_name\": \"Takeda Pharmaceuticals USA Inc.\", \"status\": \"Current\"", "rechecked": "2026-09-16", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"59417-120-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Tablet, Chewable\", \"contact_info\": \"877-TAKEDA-7 (1-877-825-3327)\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Tablet,%20Chewable%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-19", "status": "Current", "therapeutic_category": "Psychiatry", "title": "59417-120-01 \u00b7 Lisdexamfetamine Dimesylate Tablet, Chewable \u00b7 Takeda Pharmaceuticals USA Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/23/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0555-0775-02\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0775-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0775-02.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0775-02", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0555-0775-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0775-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0555-0775-02 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0555-0776-02\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0776-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0776-02.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0776-02", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0555-0776-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0776-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0555-0776-02 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0555-0777-02\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: September 2026\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1422\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0777-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1422", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0777-02-2.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-03", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0777-02-2", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0555-0777-02", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: September 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0777-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0555-0777-02 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0555-0777-02\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0777-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0777-02.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0777-02", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0555-0777-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0777-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0555-0777-02 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0555-0971-02\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0971-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0971-02.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0971-02", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0555-0971-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0971-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0555-0971-02 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0555-0972-02\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0972-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0972-02.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0972-02", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0555-0972-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0972-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0555-0972-02 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0555-0973-02\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1422\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0973-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1422", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0973-02-2.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-03", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0973-02-2", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0555-0973-02", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0973-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0555-0973-02 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0555-0973-02\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0973-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0973-02.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0973-02", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0555-0973-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0973-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0555-0973-02 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0555-0974-02\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0974-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0974-02.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-0555-0974-02", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0555-0974-02", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"0555-0974-02\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0555-0974-02 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 57844-105-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"57844-105-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-57844-105-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-57844-105-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "57844-105-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"57844-105-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57844-105-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 57844-110-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"57844-110-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-57844-110-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-57844-110-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "57844-110-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"57844-110-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57844-110-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 57844-112-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1422\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"57844-112-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1422", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-57844-112-01-2.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-03", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-57844-112-01-2", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "57844-112-01", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"57844-112-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57844-112-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 57844-112-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"57844-112-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-57844-112-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-57844-112-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "57844-112-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"57844-112-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57844-112-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 57844-115-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"57844-115-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-57844-115-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-57844-115-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "57844-115-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"57844-115-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57844-115-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 57844-117-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"57844-117-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-57844-117-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-57844-117-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "57844-117-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"57844-117-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57844-117-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 57844-120-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"57844-120-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-57844-120-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-57844-120-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "57844-120-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"57844-120-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57844-120-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 57844-130-01\n\n**Generic name:** Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 10/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1420\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"57844-130-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1420", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-57844-130-01.md", "generated": true, "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-amphetamine-aspartate-monohydrate-amphetamine-sulfate-dextroamphetamine-sacchara-57844-130-01", "initial_posting_date": "10/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "57844-130-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"10/12/2022\", \"package_ndc\": \"57844-130-01\", \"generic_name\": \"Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "57844-130-01 \u00b7 Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 68001-313-56\n\n**Generic name:** Azacitidine Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 68001-313-56)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 68001-313-56)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 12/22/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 68001-313-56)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 2079\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 68001-313-56)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 68001-313-56)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 68001-313-56)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"12/22/2020\", \"package_ndc\": \"68001-313-56\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2079", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-azacitidine-injection-68001-313-56.md", "generated": true, "generic_name": "Azacitidine Injection", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-azacitidine-injection-68001-313-56", "initial_posting_date": "12/22/2020", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "68001-313-56", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 68001-313-56)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 68001-313-56)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 68001-313-56)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 68001-313-56)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 68001-313-56)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Azacitidine, Injection, 100 mg (NDC 68001-313-56)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"12/22/2020\", \"package_ndc\": \"68001-313-56\", \"generic_name\": \"Azacitidine Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Azacitidine%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "68001-313-56 \u00b7 Azacitidine Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0703-4239-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: December 2028\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0703-4239-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: December 2028\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-carboplatin-injection-0703-4239-01.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-carboplatin-injection-0703-4239-01", "initial_posting_date": "04/28/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-4239-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: December 2028", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0703-4239-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: December 2028\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Oncology", "title": "0703-4239-01 \u00b7 Carboplatin Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0703-4244-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: January 2027\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1228\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0703-4244-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: January 2027\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1228", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-carboplatin-injection-0703-4244-01-2.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-07", "id": "teva-pharmaceuticals-usa-inc-carboplatin-injection-0703-4244-01-2", "initial_posting_date": "04/28/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-4244-01", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: January 2027", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0703-4244-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: January 2027\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Oncology", "title": "0703-4244-01 \u00b7 Carboplatin Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0703-4244-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0703-4244-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-carboplatin-injection-0703-4244-01.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-carboplatin-injection-0703-4244-01", "initial_posting_date": "04/28/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-4244-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0703-4244-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "0703-4244-01 \u00b7 Carboplatin Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0703-4246-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: September 2026\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1228\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0703-4246-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1228", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-carboplatin-injection-0703-4246-01-2.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-07", "id": "teva-pharmaceuticals-usa-inc-carboplatin-injection-0703-4246-01-2", "initial_posting_date": "04/28/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-4246-01", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: September 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0703-4246-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Oncology", "title": "0703-4246-01 \u00b7 Carboplatin Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0703-4246-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: September 2026\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0703-4246-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-carboplatin-injection-0703-4246-01.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-carboplatin-injection-0703-4246-01", "initial_posting_date": "04/28/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-4246-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: September 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0703-4246-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "0703-4246-01 \u00b7 Carboplatin Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0703-4248-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: March 2027\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1228\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0703-4248-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: March 2027\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1228", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-carboplatin-injection-0703-4248-01-2.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-07", "id": "teva-pharmaceuticals-usa-inc-carboplatin-injection-0703-4248-01-2", "initial_posting_date": "04/28/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-4248-01", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: March 2027", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0703-4248-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: March 2027\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Oncology", "title": "0703-4248-01 \u00b7 Carboplatin Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0703-4248-01\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: February 2027\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0703-4248-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: February 2027\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-carboplatin-injection-0703-4248-01.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-carboplatin-injection-0703-4248-01", "initial_posting_date": "04/28/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-4248-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: February 2027", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"0703-4248-01\", \"generic_name\": \"Carboplatin Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: February 2027\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "0703-4248-01 \u00b7 Carboplatin Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0093-0832-01\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"0093-0832-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-clonazepam-tablet-0093-0832-01.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-clonazepam-tablet-0093-0832-01", "initial_posting_date": "03/10/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0093-0832-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"0093-0832-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "0093-0832-01 \u00b7 Clonazepam Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0093-0832-05\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"0093-0832-05\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-clonazepam-tablet-0093-0832-05.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-clonazepam-tablet-0093-0832-05", "initial_posting_date": "03/10/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0093-0832-05", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"0093-0832-05\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "0093-0832-05 \u00b7 Clonazepam Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0093-3212-01\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated supply: August 2026\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"0093-3212-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated supply: August 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-clonazepam-tablet-0093-3212-01.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-clonazepam-tablet-0093-3212-01", "initial_posting_date": "03/10/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0093-3212-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated supply: August 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"0093-3212-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated supply: August 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "0093-3212-01 \u00b7 Clonazepam Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0093-3212-05\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"0093-3212-05\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-clonazepam-tablet-0093-3212-05.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-clonazepam-tablet-0093-3212-05", "initial_posting_date": "03/10/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0093-3212-05", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"0093-3212-05\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "0093-3212-05 \u00b7 Clonazepam Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0093-3213-01\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"0093-3213-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-clonazepam-tablet-0093-3213-01.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-clonazepam-tablet-0093-3213-01", "initial_posting_date": "03/10/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0093-3213-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"0093-3213-01\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "0093-3213-01 \u00b7 Clonazepam Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0093-3213-05\n\n**Generic name:** Clonazepam Tablet\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/10/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1271\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Neurology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"0093-3213-05\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1271", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-clonazepam-tablet-0093-3213-05.md", "generated": true, "generic_name": "Clonazepam Tablet", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-clonazepam-tablet-0093-3213-05", "initial_posting_date": "03/10/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0093-3213-05", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Neurology\", \"Pediatric\", \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/10/2023\", \"package_ndc\": \"0093-3213-05\", \"generic_name\": \"Clonazepam Tablet\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Clonazepam%20Tablet%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Neurology", "title": "0093-3213-05 \u00b7 Clonazepam Tablet \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0703-0018-01\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/01/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3226\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0703-0018-01\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3226", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-hydromorphone-hydrochloride-injection-0703-0018-01.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-hydromorphone-hydrochloride-injection-0703-0018-01", "initial_posting_date": "11/01/2017", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-0018-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0703-0018-01\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0703-0018-01 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0703-0110-03\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/01/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3226\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0703-0110-03\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3226", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-hydromorphone-hydrochloride-injection-0703-0110-03.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-hydromorphone-hydrochloride-injection-0703-0110-03", "initial_posting_date": "11/01/2017", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-0110-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0703-0110-03\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0703-0110-03 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0703-0113-03\n\n**Generic name:** Hydromorphone Hydrochloride Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/01/2017\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 3226\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0703-0113-03\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "3226", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-hydromorphone-hydrochloride-injection-0703-0113-03.md", "generated": true, "generic_name": "Hydromorphone Hydrochloride Injection", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-hydromorphone-hydrochloride-injection-0703-0113-03", "initial_posting_date": "11/01/2017", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-0113-03", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/01/2017\", \"package_ndc\": \"0703-0113-03\", \"generic_name\": \"Hydromorphone Hydrochloride Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydromorphone%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "0703-0113-03 \u00b7 Hydromorphone Hydrochloride Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0591-2888-30\n\n**Generic name:** Hydroxocobalamin Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: September 2026\n\n**Initial posting date:** 11/04/2024\n\n**Last update date:** 08/04/2026\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 666\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Other\n\n> \"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/04/2024\", \"package_ndc\": \"0591-2888-30\", \"generic_name\": \"Hydroxocobalamin Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydroxocobalamin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "666", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-hydroxocobalamin-injection-0591-2888-30.md", "generated": true, "generic_name": "Hydroxocobalamin Injection", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-hydroxocobalamin-injection-0591-2888-30", "initial_posting_date": "11/04/2024", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0591-2888-30", "quote_dosage_form": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/04/2026\", \"therapeutic_category\": [ \"Other\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: September 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"11/04/2024\", \"package_ndc\": \"0591-2888-30\", \"generic_name\": \"Hydroxocobalamin Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Hydroxocobalamin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Other", "title": "0591-2888-30 \u00b7 Hydroxocobalamin Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/04/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0480-3564-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0480-3564-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "teva-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0480-3564-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0480-3564-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0480-3564-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0480-3564-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0480-3564-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0480-3565-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0480-3565-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "teva-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0480-3565-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0480-3565-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0480-3565-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0480-3565-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0480-3565-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0480-3566-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0480-3566-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "teva-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0480-3566-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0480-3566-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0480-3566-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0480-3566-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0480-3566-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0480-3567-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0480-3567-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "teva-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0480-3567-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0480-3567-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0480-3567-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0480-3567-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0480-3567-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0480-3568-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0480-3568-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "teva-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0480-3568-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0480-3568-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0480-3568-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0480-3568-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0480-3568-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0480-3569-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0480-3569-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "teva-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0480-3569-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0480-3569-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0480-3569-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0480-3569-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0480-3569-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0480-3570-01\n\n**Generic name:** Lisdexamfetamine Dimesylate Capsule\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/14/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1145\n\n**Dosage form:** Capsule\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0480-3570-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1145", "dosage_form": "Capsule", "file": "teva-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0480-3570-01.md", "generated": true, "generic_name": "Lisdexamfetamine Dimesylate Capsule", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-lisdexamfetamine-dimesylate-capsule-0480-3570-01", "initial_posting_date": "07/14/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0480-3570-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Capsule\", \"presentation\": \"Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/14/2023\", \"package_ndc\": \"0480-3570-01\", \"generic_name\": \"Lisdexamfetamine Dimesylate Capsule\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "0480-3570-01 \u00b7 Lisdexamfetamine Dimesylate Capsule \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 0703-3671-01\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1270\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0703-3671-01\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1270", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0703-3671-01-2.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-03", "id": "teva-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0703-3671-01-2", "initial_posting_date": "03/13/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-3671-01", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0703-3671-01\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0703-3671-01 \u00b7 Methotrexate Sodium Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0703-3671-01\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1268\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0703-3671-01\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1268", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0703-3671-01.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0703-3671-01", "initial_posting_date": "03/13/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-3671-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0703-3671-01\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0703-3671-01 \u00b7 Methotrexate Sodium Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0703-3675-01\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: December 2026\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1270\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0703-3675-01\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: December 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1270", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0703-3675-01-2.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-03", "id": "teva-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0703-3675-01-2", "initial_posting_date": "03/13/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-3675-01", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: December 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0703-3675-01\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: December 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0703-3675-01 \u00b7 Methotrexate Sodium Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0703-3675-01\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: December 2026\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1268\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0703-3675-01\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: December 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1268", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0703-3675-01.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0703-3675-01", "initial_posting_date": "03/13/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-3675-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: December 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0703-3675-01\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: December 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0703-3675-01 \u00b7 Methotrexate Sodium Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 0703-3678-01\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1270\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0703-3678-01\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1270", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0703-3678-01-2.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-03", "id": "teva-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0703-3678-01-2", "initial_posting_date": "03/13/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-3678-01", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0703-3678-01\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0703-3678-01 \u00b7 Methotrexate Sodium Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0703-3678-01\n\n**Generic name:** Methotrexate Sodium Injection\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: October 2026\n\n**Initial posting date:** 03/13/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1268\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Rheumatology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0703-3678-01\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1268", "dosage_form": "Injection", "file": "teva-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0703-3678-01.md", "generated": true, "generic_name": "Methotrexate Sodium Injection", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-methotrexate-sodium-injection-0703-3678-01", "initial_posting_date": "03/13/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-3678-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Rheumatology\", \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: October 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"03/13/2023\", \"package_ndc\": \"0703-3678-01\", \"generic_name\": \"Methotrexate Sodium Injection\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: October 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methotrexate%20Sodium%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Rheumatology", "title": "0703-3678-01 \u00b7 Methotrexate Sodium Injection \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 62037-725-01\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: September 2026\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62037-725-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-methylphenidate-hydrochloride-tablet-extended-release-62037-725-01.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-methylphenidate-hydrochloride-tablet-extended-release-62037-725-01", "initial_posting_date": "07/26/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "62037-725-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: September 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62037-725-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "62037-725-01 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 62037-726-01\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: September 2026\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62037-726-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: September 2026\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-methylphenidate-hydrochloride-tablet-extended-release-62037-726-01.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-methylphenidate-hydrochloride-tablet-extended-release-62037-726-01", "initial_posting_date": "07/26/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "62037-726-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: September 2026", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62037-726-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: September 2026\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "62037-726-01 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62037-727-01\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 09/01/2026\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1135\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62037-727-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1135", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-methylphenidate-hydrochloride-tablet-extended-release-62037-727-01-2.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-03", "id": "teva-pharmaceuticals-usa-inc-methylphenidate-hydrochloride-tablet-extended-release-62037-727-01-2", "initial_posting_date": "07/26/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "62037-727-01", "quote_dosage_form": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"09/01/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62037-727-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-06", "status": "Current", "therapeutic_category": "Psychiatry", "title": "62037-727-01 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "09/01/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 62037-727-01\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62037-727-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-methylphenidate-hydrochloride-tablet-extended-release-62037-727-01.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-methylphenidate-hydrochloride-tablet-extended-release-62037-727-01", "initial_posting_date": "07/26/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "62037-727-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62037-727-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-545-8800\", \"availability\": \"Limited Availability\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "62037-727-01 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 62037-734-01\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62037-734-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "teva-pharmaceuticals-usa-inc-methylphenidate-hydrochloride-tablet-extended-release-62037-734-01.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-methylphenidate-hydrochloride-tablet-extended-release-62037-734-01", "initial_posting_date": "07/26/2023", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "62037-734-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"62037-734-01\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-545-8800\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "62037-734-01 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 0703-4636-01\n\n**Generic name:** Streptozocin Powder, For Solution\n\n**Manufacturer:** Teva Pharmaceuticals USA, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 07/12/2022\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Days in shortage:** 1512\n\n**Reason for shortage:** Other\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Dosage form:** Powder, For Solution\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/12/2022\", \"package_ndc\": \"0703-4636-01\", \"generic_name\": \"Streptozocin Powder, For Solution\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Streptozocin%20Powder,%20For%20Solution%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1512", "dosage_form": "Powder, For Solution", "file": "teva-pharmaceuticals-usa-inc-streptozocin-powder-for-solution-0703-4636-01.md", "generated": true, "generic_name": "Streptozocin Powder, For Solution", "harvested": "2026-09-01", "id": "teva-pharmaceuticals-usa-inc-streptozocin-powder-for-solution-0703-4636-01", "initial_posting_date": "07/12/2022", "manufacturer_name": "Teva Pharmaceuticals USA, Inc.", "package_ndc": "0703-4636-01", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Powder, For Solution\", \"presentation\": \"Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)\", \"company_name\": \"Teva Pharmaceuticals USA, Inc.\", \"shortage_reason\": \"Other\", \"status\": \"Current\"", "rechecked": "2026-09-08", "related_info": "Estimated recovery: TBD", "shortage_reason": "Other", "source_quote": "\"initial_posting_date\": \"07/12/2022\", \"package_ndc\": \"0703-4636-01\", \"generic_name\": \"Streptozocin Powder, For Solution\", \"contact_info\": \"800-545-8800\", \"availability\": \"Unavailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teva%20Pharmaceuticals%20USA,%20Inc.%22+AND+generic_name%3A%22Streptozocin%20Powder,%20For%20Solution%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-11", "status": "Current", "therapeutic_category": "Oncology", "title": "0703-4636-01 \u00b7 Streptozocin Powder, For Solution \u00b7 Teva Pharmaceuticals USA, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 60505-6282-1\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Teyro Labs\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"60505-6282-1\", \"generic_name\": \"Carboplatin Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Carboplatin%20Injection&st=d\", \"contact_info\": \"Apotex Inc.: 800-706-5575\", \"availability\": \"Unavailable\", \"related_info\": \"Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teyro%20Labs%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "teyro-labs-carboplatin-injection-60505-6282-1.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "teyro-labs-carboplatin-injection-60505-6282-1", "initial_posting_date": "04/28/2023", "manufacturer_name": "Teyro Labs", "package_ndc": "60505-6282-1", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"60505-6282-1\", \"generic_name\": \"Carboplatin Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Carboplatin%20Injection&st=d\", \"contact_info\": \"Apotex Inc.: 800-706-5575\", \"availability\": \"Unavailable\", \"related_info\": \"Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teyro%20Labs%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "60505-6282-1 \u00b7 Carboplatin Injection \u00b7 Teyro Labs \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 60505-6282-3\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Teyro Labs\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"60505-6282-3\", \"generic_name\": \"Carboplatin Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Carboplatin%20Injection&st=d\", \"contact_info\": \"Apotex Inc.: 800-706-5575\", \"availability\": \"Unavailable\", \"related_info\": \"Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teyro%20Labs%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "teyro-labs-carboplatin-injection-60505-6282-3.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "teyro-labs-carboplatin-injection-60505-6282-3", "initial_posting_date": "04/28/2023", "manufacturer_name": "Teyro Labs", "package_ndc": "60505-6282-3", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"60505-6282-3\", \"generic_name\": \"Carboplatin Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Carboplatin%20Injection&st=d\", \"contact_info\": \"Apotex Inc.: 800-706-5575\", \"availability\": \"Unavailable\", \"related_info\": \"Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teyro%20Labs%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "60505-6282-3 \u00b7 Carboplatin Injection \u00b7 Teyro Labs \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 60505-6282-6\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Teyro Labs\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"60505-6282-6\", \"generic_name\": \"Carboplatin Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Carboplatin%20Injection&st=d\", \"contact_info\": \"Apotex Inc.: 800-706-5575\", \"availability\": \"Unavailable\", \"related_info\": \"Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teyro%20Labs%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "teyro-labs-carboplatin-injection-60505-6282-6.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "teyro-labs-carboplatin-injection-60505-6282-6", "initial_posting_date": "04/28/2023", "manufacturer_name": "Teyro Labs", "package_ndc": "60505-6282-6", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"60505-6282-6\", \"generic_name\": \"Carboplatin Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Carboplatin%20Injection&st=d\", \"contact_info\": \"Apotex Inc.: 800-706-5575\", \"availability\": \"Unavailable\", \"related_info\": \"Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teyro%20Labs%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "60505-6282-6 \u00b7 Carboplatin Injection \u00b7 Teyro Labs \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unavailable", "body": "**Package NDC:** 60505-6282-7\n\n**Generic name:** Carboplatin Injection\n\n**Manufacturer:** Teyro Labs\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Availability now:** Unavailable\n\n**FDA note:** Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug\n\n**Initial posting date:** 04/28/2023\n\n**Last update date:** 08/18/2026\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1222\n\n**Reason for shortage:** Discontinuation of the manufacture of the drug\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Oncology\n\n> \"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"60505-6282-7\", \"generic_name\": \"Carboplatin Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Carboplatin%20Injection&st=d\", \"contact_info\": \"Apotex Inc.: 800-706-5575\", \"availability\": \"Unavailable\", \"related_info\": \"Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teyro%20Labs%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1222", "dosage_form": "Injection", "file": "teyro-labs-carboplatin-injection-60505-6282-7.md", "generated": true, "generic_name": "Carboplatin Injection", "harvested": "2026-09-01", "id": "teyro-labs-carboplatin-injection-60505-6282-7", "initial_posting_date": "04/28/2023", "manufacturer_name": "Teyro Labs", "package_ndc": "60505-6282-7", "quote_dosage_form": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/18/2026\", \"therapeutic_category\": [ \"Oncology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)\", \"company_name\": \"Teyro Labs\", \"shortage_reason\": \"Discontinuation of the manufacture of the drug\", \"status\": \"Current\"", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug", "shortage_reason": "Discontinuation of the manufacture of the drug", "source_quote": "\"initial_posting_date\": \"04/28/2023\", \"package_ndc\": \"60505-6282-7\", \"generic_name\": \"Carboplatin Injection\", \"related_info_link\": \"https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Carboplatin%20Injection&st=d\", \"contact_info\": \"Apotex Inc.: 800-706-5575\", \"availability\": \"Unavailable\", \"related_info\": \"Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Teyro%20Labs%22+AND+generic_name%3A%22Carboplatin%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Oncology", "title": "60505-6282-7 \u00b7 Carboplatin Injection \u00b7 Teyro Labs \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/18/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 13811-700-30\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Trigen Laboratories, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Allocation to current contracted customers\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"13811-700-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Limited Availability\", \"related_info\": \"Allocation to current contracted customers\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Trigen%20Laboratories,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "trigen-laboratories-llc-methylphenidate-hydrochloride-tablet-extended-release-13811-700-30.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "trigen-laboratories-llc-methylphenidate-hydrochloride-tablet-extended-release-13811-700-30", "initial_posting_date": "07/26/2023", "manufacturer_name": "Trigen Laboratories, LLC", "package_ndc": "13811-700-30", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Allocation to current contracted customers", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"13811-700-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Limited Availability\", \"related_info\": \"Allocation to current contracted customers\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Trigen%20Laboratories,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "13811-700-30 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Trigen Laboratories, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 13811-706-10\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Trigen Laboratories, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Allocation to current contracted customers\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"13811-706-10\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Limited Availability\", \"related_info\": \"Allocation to current contracted customers\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Trigen%20Laboratories,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "trigen-laboratories-llc-methylphenidate-hydrochloride-tablet-extended-release-13811-706-10.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "trigen-laboratories-llc-methylphenidate-hydrochloride-tablet-extended-release-13811-706-10", "initial_posting_date": "07/26/2023", "manufacturer_name": "Trigen Laboratories, LLC", "package_ndc": "13811-706-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Allocation to current contracted customers", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"13811-706-10\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Limited Availability\", \"related_info\": \"Allocation to current contracted customers\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Trigen%20Laboratories,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "13811-706-10 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Trigen Laboratories, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 13811-707-10\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Trigen Laboratories, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Allocation to current contracted customers\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"13811-707-10\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Limited Availability\", \"related_info\": \"Allocation to current contracted customers\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Trigen%20Laboratories,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "trigen-laboratories-llc-methylphenidate-hydrochloride-tablet-extended-release-13811-707-10.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "trigen-laboratories-llc-methylphenidate-hydrochloride-tablet-extended-release-13811-707-10", "initial_posting_date": "07/26/2023", "manufacturer_name": "Trigen Laboratories, LLC", "package_ndc": "13811-707-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Allocation to current contracted customers", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"13811-707-10\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Limited Availability\", \"related_info\": \"Allocation to current contracted customers\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Trigen%20Laboratories,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "13811-707-10 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Trigen Laboratories, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 13811-708-10\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Trigen Laboratories, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Allocation to current contracted customers\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"13811-708-10\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Limited Availability\", \"related_info\": \"Allocation to current contracted customers\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Trigen%20Laboratories,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "trigen-laboratories-llc-methylphenidate-hydrochloride-tablet-extended-release-13811-708-10.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "trigen-laboratories-llc-methylphenidate-hydrochloride-tablet-extended-release-13811-708-10", "initial_posting_date": "07/26/2023", "manufacturer_name": "Trigen Laboratories, LLC", "package_ndc": "13811-708-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Allocation to current contracted customers", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"13811-708-10\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Limited Availability\", \"related_info\": \"Allocation to current contracted customers\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Trigen%20Laboratories,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "13811-708-10 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Trigen Laboratories, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 13811-709-10\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Trigen Laboratories, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Allocation to current contracted customers\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"13811-709-10\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Limited Availability\", \"related_info\": \"Allocation to current contracted customers\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Trigen%20Laboratories,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "trigen-laboratories-llc-methylphenidate-hydrochloride-tablet-extended-release-13811-709-10.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "trigen-laboratories-llc-methylphenidate-hydrochloride-tablet-extended-release-13811-709-10", "initial_posting_date": "07/26/2023", "manufacturer_name": "Trigen Laboratories, LLC", "package_ndc": "13811-709-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Allocation to current contracted customers", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"13811-709-10\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Limited Availability\", \"related_info\": \"Allocation to current contracted customers\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Trigen%20Laboratories,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "13811-709-10 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Trigen Laboratories, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 13811-710-30\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Trigen Laboratories, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Allocation to current contracted customers\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"13811-710-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Limited Availability\", \"related_info\": \"Allocation to current contracted customers\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Trigen%20Laboratories,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "trigen-laboratories-llc-methylphenidate-hydrochloride-tablet-extended-release-13811-710-30.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "trigen-laboratories-llc-methylphenidate-hydrochloride-tablet-extended-release-13811-710-30", "initial_posting_date": "07/26/2023", "manufacturer_name": "Trigen Laboratories, LLC", "package_ndc": "13811-710-30", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Allocation to current contracted customers", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"13811-710-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Limited Availability\", \"related_info\": \"Allocation to current contracted customers\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Trigen%20Laboratories,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "13811-710-30 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Trigen Laboratories, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Limited Availability", "body": "**Package NDC:** 13811-711-30\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Trigen Laboratories, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Limited Availability\n\n**FDA note:** Allocation to current contracted customers\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"13811-711-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Limited Availability\", \"related_info\": \"Allocation to current contracted customers\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Trigen%20Laboratories,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "trigen-laboratories-llc-methylphenidate-hydrochloride-tablet-extended-release-13811-711-30.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "trigen-laboratories-llc-methylphenidate-hydrochloride-tablet-extended-release-13811-711-30", "initial_posting_date": "07/26/2023", "manufacturer_name": "Trigen Laboratories, LLC", "package_ndc": "13811-711-30", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)\", \"company_name\": \"Trigen Laboratories, LLC\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Allocation to current contracted customers", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"13811-711-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Limited Availability\", \"related_info\": \"Allocation to current contracted customers\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Trigen%20Laboratories,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "13811-711-30 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Trigen Laboratories, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 68025-084-30\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Vertical Pharmaceuticals, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-084-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-084-30.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-084-30", "initial_posting_date": "07/26/2023", "manufacturer_name": "Vertical Pharmaceuticals, LLC", "package_ndc": "68025-084-30", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-084-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "68025-084-30 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Vertical Pharmaceuticals, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 68025-088-30\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Vertical Pharmaceuticals, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-088-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-088-30.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-088-30", "initial_posting_date": "07/26/2023", "manufacturer_name": "Vertical Pharmaceuticals, LLC", "package_ndc": "68025-088-30", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-088-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "68025-088-30 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Vertical Pharmaceuticals, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 68025-089-30\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Vertical Pharmaceuticals, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-089-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-089-30.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-089-30", "initial_posting_date": "07/26/2023", "manufacturer_name": "Vertical Pharmaceuticals, LLC", "package_ndc": "68025-089-30", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-089-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "68025-089-30 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Vertical Pharmaceuticals, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 68025-095-10\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Vertical Pharmaceuticals, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-095-10\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-095-10.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-095-10", "initial_posting_date": "07/26/2023", "manufacturer_name": "Vertical Pharmaceuticals, LLC", "package_ndc": "68025-095-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-095-10\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "68025-095-10 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Vertical Pharmaceuticals, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 68025-095-30\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Vertical Pharmaceuticals, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-095-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-095-30.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-095-30", "initial_posting_date": "07/26/2023", "manufacturer_name": "Vertical Pharmaceuticals, LLC", "package_ndc": "68025-095-30", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-095-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "68025-095-30 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Vertical Pharmaceuticals, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 68025-096-10\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Vertical Pharmaceuticals, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-096-10\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-096-10.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-096-10", "initial_posting_date": "07/26/2023", "manufacturer_name": "Vertical Pharmaceuticals, LLC", "package_ndc": "68025-096-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-096-10\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "68025-096-10 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Vertical Pharmaceuticals, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 68025-096-30\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Vertical Pharmaceuticals, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-096-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-096-30.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-096-30", "initial_posting_date": "07/26/2023", "manufacturer_name": "Vertical Pharmaceuticals, LLC", "package_ndc": "68025-096-30", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-096-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "68025-096-30 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Vertical Pharmaceuticals, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 68025-097-10\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Vertical Pharmaceuticals, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-097-10\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-097-10.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-097-10", "initial_posting_date": "07/26/2023", "manufacturer_name": "Vertical Pharmaceuticals, LLC", "package_ndc": "68025-097-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-097-10\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "68025-097-10 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Vertical Pharmaceuticals, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 68025-097-30\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Vertical Pharmaceuticals, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-097-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-097-30.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-097-30", "initial_posting_date": "07/26/2023", "manufacturer_name": "Vertical Pharmaceuticals, LLC", "package_ndc": "68025-097-30", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-097-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "68025-097-30 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Vertical Pharmaceuticals, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 68025-098-10\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Vertical Pharmaceuticals, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-098-10\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-098-10.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-098-10", "initial_posting_date": "07/26/2023", "manufacturer_name": "Vertical Pharmaceuticals, LLC", "package_ndc": "68025-098-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-098-10\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "68025-098-10 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Vertical Pharmaceuticals, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 68025-098-30\n\n**Generic name:** Methylphenidate Hydrochloride Tablet, Extended Release\n\n**Manufacturer:** Vertical Pharmaceuticals, LLC\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 07/26/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Days in shortage:** 1133\n\n**Dosage form:** Tablet\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n**Therapeutic category:** Psychiatry\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-098-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1133", "dosage_form": "Tablet", "file": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-098-30.md", "generated": true, "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "harvested": "2026-09-01", "id": "vertical-pharmaceuticals-llc-methylphenidate-hydrochloride-tablet-extended-release-68025-098-30", "initial_posting_date": "07/26/2023", "manufacturer_name": "Vertical Pharmaceuticals, LLC", "package_ndc": "68025-098-30", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Psychiatry\" ], \"dosage_form\": \"Tablet\", \"presentation\": \"Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)\", \"company_name\": \"Vertical Pharmaceuticals, LLC\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"07/26/2023\", \"package_ndc\": \"68025-098-30\", \"generic_name\": \"Methylphenidate Hydrochloride Tablet, Extended Release\", \"contact_info\": \"800-541-4802\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Vertical%20Pharmaceuticals,%20LLC%22+AND+generic_name%3A%22Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Psychiatry", "title": "68025-098-30 \u00b7 Methylphenidate Hydrochloride Tablet, Extended Release \u00b7 Vertical Pharmaceuticals, LLC \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 44567-610-10\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** WG Critical Care\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Please check wholesalers and distributors for inventory.\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"44567-610-10\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-493-0861\", \"availability\": \"Available\", \"related_info\": \"Please check wholesalers and distributors for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22WG%20Critical%20Care%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "wg-critical-care-midazolam-hydrochloride-injection-44567-610-10.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "wg-critical-care-midazolam-hydrochloride-injection-44567-610-10", "initial_posting_date": "04/02/2020", "manufacturer_name": "WG Critical Care", "package_ndc": "44567-610-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"", "related_info": "Please check wholesalers and distributors for inventory.", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"44567-610-10\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-493-0861\", \"availability\": \"Available\", \"related_info\": \"Please check wholesalers and distributors for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22WG%20Critical%20Care%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "44567-610-10 \u00b7 Midazolam Hydrochloride Injection \u00b7 WG Critical Care \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 44567-611-10\n\n**Generic name:** Midazolam Hydrochloride Injection\n\n**Manufacturer:** WG Critical Care\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Please check wholesalers and distributors for inventory.\n\n**Initial posting date:** 04/02/2020\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"\n\n**Days in shortage:** 2343\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"44567-611-10\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-493-0861\", \"availability\": \"Available\", \"related_info\": \"Please check wholesalers and distributors for inventory.\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22WG%20Critical%20Care%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "2343", "dosage_form": "Injection", "file": "wg-critical-care-midazolam-hydrochloride-injection-44567-611-10.md", "generated": true, "generic_name": "Midazolam Hydrochloride Injection", "harvested": "2026-09-01", "id": "wg-critical-care-midazolam-hydrochloride-injection-44567-611-10", "initial_posting_date": "04/02/2020", "manufacturer_name": "WG Critical Care", "package_ndc": "44567-611-10", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\", \"Neurology\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)\", \"company_name\": \"WG Critical Care\", \"status\": \"Current\"", "related_info": "Please check wholesalers and distributors for inventory.", "source_quote": "\"initial_posting_date\": \"04/02/2020\", \"package_ndc\": \"44567-611-10\", \"generic_name\": \"Midazolam Hydrochloride Injection\", \"contact_info\": \"888-493-0861\", \"availability\": \"Available\", \"related_info\": \"Please check wholesalers and distributors for inventory.\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22WG%20Critical%20Care%22+AND+generic_name%3A%22Midazolam%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "44567-611-10 \u00b7 Midazolam Hydrochloride Injection \u00b7 WG Critical Care \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 39822-5525-3\n\n**Generic name:** Promethazine Hydrochloride Injection\n\n**Manufacturer:** XGen Pharmaceuticals DJB, Inc.\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**Initial posting date:** 11/21/2023\n\n**Last update date:** 06/23/2026\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1015\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"39822-5525-3\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"866-390-4411\", \"availability\": \"Available\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22XGen%20Pharmaceuticals%20DJB,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1015", "dosage_form": "Injection", "file": "xgen-pharmaceuticals-djb-inc-promethazine-hydrochloride-injection-39822-5525-3.md", "generated": true, "generic_name": "Promethazine Hydrochloride Injection", "harvested": "2026-09-01", "id": "xgen-pharmaceuticals-djb-inc-promethazine-hydrochloride-injection-39822-5525-3", "initial_posting_date": "11/21/2023", "manufacturer_name": "XGen Pharmaceuticals DJB, Inc.", "package_ndc": "39822-5525-3", "quote_dosage_form": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"", "source_quote": "\"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"39822-5525-3\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"866-390-4411\", \"availability\": \"Available\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22XGen%20Pharmaceuticals%20DJB,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "39822-5525-3 \u00b7 Promethazine Hydrochloride Injection \u00b7 XGen Pharmaceuticals DJB, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/23/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Unvailable", "body": "**Package NDC:** 39822-5550-6\n\n**Generic name:** Promethazine Hydrochloride Injection\n\n**Manufacturer:** XGen Pharmaceuticals DJB, Inc.\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Availability now:** Unvailable\n\n**FDA note:** Estimated recovery: TBD\n\n**Initial posting date:** 11/21/2023\n\n**Last update date:** 06/23/2026\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Days in shortage:** 1015\n\n**Reason for shortage:** Demand increase for the drug\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Dosage form:** Injection\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n**Therapeutic category:** Analgesia/Addiction\n\n> \"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"39822-5550-6\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"866-390-4411\", \"availability\": \"Unvailable\", \"related_info\": \"Estimated recovery: TBD\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22XGen%20Pharmaceuticals%20DJB,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1015", "dosage_form": "Injection", "file": "xgen-pharmaceuticals-djb-inc-promethazine-hydrochloride-injection-39822-5550-6.md", "generated": true, "generic_name": "Promethazine Hydrochloride Injection", "harvested": "2026-09-01", "id": "xgen-pharmaceuticals-djb-inc-promethazine-hydrochloride-injection-39822-5550-6", "initial_posting_date": "11/21/2023", "manufacturer_name": "XGen Pharmaceuticals DJB, Inc.", "package_ndc": "39822-5550-6", "quote_dosage_form": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_shortage_reason": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"06/23/2026\", \"therapeutic_category\": [ \"Analgesia/Addiction\", \"Gastroenterology\", \"Other\", \"Pulmonary/Allergy\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"shortage_reason\": \"Demand increase for the drug\", \"status\": \"Current\"", "related_info": "Estimated recovery: TBD", "shortage_reason": "Demand increase for the drug", "source_quote": "\"initial_posting_date\": \"11/21/2023\", \"package_ndc\": \"39822-5550-6\", \"generic_name\": \"Promethazine Hydrochloride Injection\", \"contact_info\": \"866-390-4411\", \"availability\": \"Unvailable\", \"related_info\": \"Estimated recovery: TBD\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22XGen%20Pharmaceuticals%20DJB,%20Inc.%22+AND+generic_name%3A%22Promethazine%20Hydrochloride%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Analgesia/Addiction", "title": "39822-5550-6 \u00b7 Promethazine Hydrochloride Injection \u00b7 XGen Pharmaceuticals DJB, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "06/23/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 39822-4200-2\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** XGen Pharmaceuticals DJB, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Tamarang is the application holder and X-Gen is the distributor/labeler\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"39822-4200-2\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"866-390-4411\", \"availability\": \"Available\", \"related_info\": \"Tamarang is the application holder and X-Gen is the distributor/labeler\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22XGen%20Pharmaceuticals%20DJB,%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "xgen-pharmaceuticals-djb-inc-rocuronium-bromide-injection-39822-4200-2.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "xgen-pharmaceuticals-djb-inc-rocuronium-bromide-injection-39822-4200-2", "initial_posting_date": "02/15/2023", "manufacturer_name": "XGen Pharmaceuticals DJB, Inc.", "package_ndc": "39822-4200-2", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"", "related_info": "Tamarang is the application holder and X-Gen is the distributor/labeler", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"39822-4200-2\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"866-390-4411\", \"availability\": \"Available\", \"related_info\": \"Tamarang is the application holder and X-Gen is the distributor/labeler\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22XGen%20Pharmaceuticals%20DJB,%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "39822-4200-2 \u00b7 Rocuronium Bromide Injection \u00b7 XGen Pharmaceuticals DJB, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}
{"asset": "drug-shortage-duration-tracker", "availability": "Available", "body": "**Package NDC:** 39822-4200-6\n\n**Generic name:** Rocuronium Bromide Injection\n\n**Manufacturer:** XGen Pharmaceuticals DJB, Inc.\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"\n\n**Status:** Current\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"\n\n**Availability now:** Available\n\n**FDA note:** Tamarang is the application holder and X-Gen is the distributor/labeler\n\n**Initial posting date:** 02/15/2023\n\n**Last update date:** 08/17/2026\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"\n\n**Days in shortage:** 1294\n\n**Dosage form:** Injection\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"\n\n**Therapeutic category:** Anesthesia\n\n> \"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"\n\n> \"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"39822-4200-6\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"866-390-4411\", \"availability\": \"Available\", \"related_info\": \"Tamarang is the application holder and X-Gen is the distributor/labeler\"\n\nSource: <https://api.fda.gov/drug/shortages.json?search=company_name%3A%22XGen%20Pharmaceuticals%20DJB,%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000>\n", "days_in_shortage": "1294", "dosage_form": "Injection", "file": "xgen-pharmaceuticals-djb-inc-rocuronium-bromide-injection-39822-4200-6.md", "generated": true, "generic_name": "Rocuronium Bromide Injection", "harvested": "2026-09-01", "id": "xgen-pharmaceuticals-djb-inc-rocuronium-bromide-injection-39822-4200-6", "initial_posting_date": "02/15/2023", "manufacturer_name": "XGen Pharmaceuticals DJB, Inc.", "package_ndc": "39822-4200-6", "quote_dosage_form": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"", "quote_manufacturer_name": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"", "quote_status": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"", "quote_therapeutic_category": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"", "quote_update_date": "\"update_date\": \"08/17/2026\", \"therapeutic_category\": [ \"Anesthesia\" ], \"dosage_form\": \"Injection\", \"presentation\": \"Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)\", \"company_name\": \"XGen Pharmaceuticals DJB, Inc.\", \"status\": \"Current\"", "related_info": "Tamarang is the application holder and X-Gen is the distributor/labeler", "source_quote": "\"initial_posting_date\": \"02/15/2023\", \"package_ndc\": \"39822-4200-6\", \"generic_name\": \"Rocuronium Bromide Injection\", \"contact_info\": \"866-390-4411\", \"availability\": \"Available\", \"related_info\": \"Tamarang is the application holder and X-Gen is the distributor/labeler\"", "sources": ["https://api.fda.gov/drug/shortages.json?search=company_name%3A%22XGen%20Pharmaceuticals%20DJB,%20Inc.%22+AND+generic_name%3A%22Rocuronium%20Bromide%20Injection%22+AND+status%3A%22Current%22&limit=1000"], "stale_after": "2026-09-04", "status": "Current", "therapeutic_category": "Anesthesia", "title": "39822-4200-6 \u00b7 Rocuronium Bromide Injection \u00b7 XGen Pharmaceuticals DJB, Inc. \u2014 FDA drug shortage duration tracker", "type": "duration-tracking", "update_date": "08/17/2026", "verified": false}